No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, 1e9hA, 1.0000, 0.00, 1.000, 295, 295, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
2, 1h27A, 0.9954, 0.43, 1.000, 296, 295, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
3, 1h26A, 0.9947, 0.47, 1.000, 296, 295, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
4, 1pkdA, 0.9944, 0.48, 1.000, 296, 295, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
5, 2wmbA, 0.9934, 0.52, 1.000, 296, 295, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
6, 1p5eA, 0.9930, 0.56, 1.000, 296, 295, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
7, 2cciA, 0.9927, 0.55, 1.000, 296, 295, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
8, 4cfmA, 0.9925, 0.58, 1.000, 296, 295, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
9, 4cfvA, 0.9924, 0.61, 0.993, 300, 295, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
10, 2wmaA, 0.9917, 0.63, 1.000, 296, 295, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
11, 1e9hC, 0.9916, 0.59, 1.000, 296, 295, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
12, 1pkdC, 0.9901, 0.64, 1.000, 296, 295, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
13, 1h1rA, 0.9900, 0.70, 1.000, 296, 295, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
14, 4cfwC, 0.9896, 0.67, 1.000, 297, 295, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
15, 1h1qA, 0.9895, 0.71, 1.000, 296, 295, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
16, 2g9xA, 0.9894, 0.70, 0.993, 298, 295, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
17, 4eooC, 0.9890, 0.68, 0.997, 297, 295, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
18, 2uzdC, 0.9889, 0.68, 1.000, 295, 295, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
19, 1gy3C, 0.9885, 0.68, 1.000, 295, 295, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
20, 1h1sA, 0.9883, 0.74, 1.000, 296, 295, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
21, 5lqeC, 0.9882, 0.75, 1.000, 296, 295, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
22, 1gy3A, 0.9882, 0.70, 1.000, 295, 295, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
23, 5nevC, 0.9880, 0.74, 1.000, 296, 295, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
24, 1jstA, 0.9879, 0.73, 1.000, 297, 295, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
25, 4cfuA, 0.9878, 0.48, 0.993, 299, 293, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
26, 3bhvA, 0.9878, 0.48, 0.993, 297, 293, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
27, 3ddpA, 0.9877, 0.75, 1.000, 297, 295, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
28, 2iw8A, 0.9877, 0.76, 0.983, 297, 295, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
29, 1h28C, 0.9876, 0.72, 1.000, 296, 295, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
30, 1h28A, 0.9876, 0.71, 1.000, 296, 295, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
31, 5cyiA, 0.9874, 0.85, 1.000, 298, 295, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
32, 5cyiC, 0.9872, 0.79, 1.000, 296, 295, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
33, 4bcnA, 0.9872, 0.50, 1.000, 296, 293, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
34, 4eomA, 0.9871, 0.57, 0.983, 296, 293, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
35, 3dogA, 0.9871, 0.67, 0.993, 297, 294, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
36, 1oi9A, 0.9871, 0.68, 1.000, 295, 294, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
37, 2cjmC, 0.9870, 0.63, 1.000, 294, 294, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
38, 1qmzA, 0.9870, 0.73, 1.000, 296, 295, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
39, 4cfwA, 0.9869, 0.89, 1.000, 299, 295, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
40, 1jstC, 0.9869, 0.76, 1.000, 297, 295, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
41, 4bcpA, 0.9868, 0.87, 0.993, 298, 295, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
42, 1qmzC, 0.9867, 0.74, 1.000, 296, 295, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
43, 2uzeA, 0.9866, 0.79, 1.000, 295, 295, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
44, 2cciC, 0.9864, 0.75, 1.000, 296, 295, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
45, 2c6tC, 0.9863, 0.77, 1.000, 295, 295, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
46, 1h1qC, 0.9862, 0.81, 1.000, 296, 295, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
47, 4eoqA, 0.9858, 0.41, 0.993, 295, 292, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
48, 4bcoA, 0.9858, 0.89, 0.993, 298, 295, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
49, 3bhtA, 0.9858, 0.58, 0.993, 297, 293, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
50, 2uzbA, 0.9858, 0.78, 1.000, 295, 295, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
51, 2uzeC, 0.9856, 0.82, 1.000, 295, 295, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
52, 4cfxA, 0.9855, 0.91, 1.000, 298, 295, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
53, 2uzlA, 0.9855, 0.82, 1.000, 295, 295, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
54, 3my5A, 0.9854, 0.43, 0.993, 296, 292, CDK2/CYCLINA IN COMPLEX WITH DRB
55, 1h25A, 0.9854, 0.43, 1.000, 293, 292, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
56, 2uzlC, 0.9853, 0.82, 1.000, 295, 295, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
57, 1h24A, 0.9853, 0.43, 1.000, 293, 292, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
58, 1oiyC, 0.9852, 0.84, 1.000, 296, 295, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
59, 1h1rC, 0.9852, 0.83, 1.000, 296, 295, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
60, 3tnwA, 0.9849, 0.46, 1.000, 295, 292, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
61, 5nevA, 0.9847, 0.74, 1.000, 295, 294, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
62, 3bhuA, 0.9847, 0.62, 0.993, 297, 293, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
63, 1h1sC, 0.9846, 0.85, 1.000, 296, 295, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
64, 1p5eC, 0.9845, 0.85, 1.000, 296, 295, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
65, 5lqeA, 0.9839, 0.77, 0.997, 295, 294, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
66, 4bcmA, 0.9839, 0.50, 1.000, 295, 292, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
67, 4bcmC, 0.9835, 0.65, 1.000, 294, 293, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
68, 3ddqA, 0.9835, 0.68, 0.993, 296, 293, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
69, 5lmkA, 0.9833, 0.69, 0.993, 296, 293, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
70, 4bcnC, 0.9831, 0.66, 1.000, 295, 293, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
71, 4eooA, 0.9824, 0.41, 0.997, 294, 291, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
72, 2cchA, 0.9824, 0.98, 1.000, 296, 295, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
73, 4cfnA, 0.9821, 0.60, 1.000, 296, 292, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
74, 4eopC, 0.9813, 0.95, 0.997, 296, 295, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
75, 4cfxC, 0.9809, 0.98, 1.000, 298, 295, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
76, 4cfnC, 0.9807, 0.77, 1.000, 296, 293, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
77, 2bkzC, 0.9807, 0.87, 0.983, 298, 294, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
78, 3f5xC, 0.9806, 0.87, 0.980, 298, 294, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
79, 2wxvC, 0.9805, 0.87, 0.983, 299, 294, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
80, 4ii5C, 0.9804, 1.00, 1.000, 295, 295, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
81, 4ii5A, 0.9804, 1.00, 1.000, 295, 295, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
82, 1oguA, 0.9804, 0.68, 0.993, 296, 292, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
83, 1oiuA, 0.9803, 0.69, 0.993, 296, 292, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
84, 4i3zC, 0.9802, 1.01, 1.000, 295, 295, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
85, 4i3zA, 0.9802, 1.01, 1.000, 295, 295, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
86, 4eojA, 0.9798, 0.53, 0.983, 295, 291, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
87, 1oiyA, 0.9798, 0.69, 1.000, 293, 292, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
88, 2c4gC, 0.9797, 0.90, 0.983, 300, 294, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
89, 4eoiC, 0.9796, 0.99, 0.993, 296, 295, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
90, 1vywC, 0.9796, 0.90, 0.983, 299, 294, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
91, 4eosC, 0.9791, 0.99, 1.000, 296, 295, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
92, 2wihC, 0.9791, 0.91, 0.983, 299, 294, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
93, 2iw6C, 0.9790, 0.90, 0.997, 295, 294, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
94, 4eokC, 0.9789, 0.99, 0.990, 299, 295, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
95, 5if1C, 0.9786, 0.93, 0.980, 296, 294, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
96, 2wpaC, 0.9786, 0.92, 0.983, 299, 294, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
97, 2cchC, 0.9785, 1.08, 1.000, 296, 295, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
98, 2c6tA, 0.9785, 1.00, 1.000, 295, 295, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
99, 1ol1A, 0.9785, 0.93, 0.983, 296, 294, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
100, 2uueC, 0.9784, 0.94, 0.983, 296, 294, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
101, 2x1nA, 0.9783, 0.95, 0.983, 296, 294, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
102, 1h24C, 0.9782, 0.70, 1.000, 293, 292, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
103, 2uzdA, 0.9781, 1.00, 1.000, 295, 295, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
104, 2uueA, 0.9781, 0.96, 0.983, 296, 294, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
105, 1okwA, 0.9781, 0.95, 0.983, 296, 294, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
106, 1finA, 0.9781, 0.93, 0.980, 298, 294, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
107, 2whbA, 0.9780, 0.96, 0.983, 296, 294, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
108, 2bpmC, 0.9780, 0.94, 0.983, 299, 294, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
109, 2v22A, 0.9779, 0.96, 0.983, 296, 294, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
110, 2i40C, 0.9779, 0.95, 0.983, 296, 294, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
111, 2c5oA, 0.9779, 0.96, 0.983, 296, 294, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
112, 2x1nC, 0.9778, 0.96, 0.983, 296, 294, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
113, 2c5xA, 0.9777, 0.95, 0.983, 296, 294, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
114, 2c5oC, 0.9777, 0.97, 0.983, 296, 294, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
115, 4eolC, 0.9776, 1.03, 0.990, 299, 295, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
116, 3ddpC, 0.9776, 1.05, 0.997, 298, 295, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
117, 3f5xA, 0.9774, 0.87, 0.980, 297, 293, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
118, 2iw6A, 0.9774, 0.65, 0.997, 292, 291, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
119, 2c5vA, 0.9774, 0.98, 0.983, 296, 294, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
120, 1ol2A, 0.9774, 0.96, 0.983, 296, 294, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
121, 4eonC, 0.9773, 1.04, 0.990, 298, 295, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
122, 2iw9A, 0.9773, 0.68, 0.990, 293, 291, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
123, 3tnwC, 0.9771, 0.65, 0.997, 291, 291, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
124, 1fvvC, 0.9771, 0.97, 0.983, 298, 294, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
125, 3qhrC, 0.9770, 1.11, 0.997, 297, 295, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
126, 3qhrA, 0.9770, 1.11, 0.997, 297, 295, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
127, 2v22C, 0.9770, 0.98, 0.983, 296, 294, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
128, 1ol1C, 0.9769, 0.98, 0.980, 296, 294, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
129, 1okwC, 0.9769, 0.98, 0.983, 296, 294, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
130, 2uzbC, 0.9768, 0.74, 1.000, 292, 292, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
131, 2bkzA, 0.9768, 1.09, 0.983, 302, 294, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
132, 2c5vC, 0.9767, 0.99, 0.983, 296, 294, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
133, 2bpmA, 0.9767, 1.06, 0.980, 302, 294, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
134, 1vywA, 0.9767, 1.07, 0.980, 302, 294, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
135, 2wfyC, 0.9764, 0.99, 0.983, 296, 294, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
136, 1oi9C, 0.9764, 1.04, 1.000, 296, 295, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
137, 2c4gA, 0.9763, 1.06, 0.980, 301, 294, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
138, 3qhwA, 0.9761, 1.14, 1.000, 297, 295, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
139, 2whbC, 0.9761, 1.01, 0.983, 296, 294, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
140, 2wevA, 0.9760, 1.01, 0.983, 296, 294, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
141, 1urcA, 0.9760, 1.01, 0.983, 296, 294, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
142, 2wxvA, 0.9759, 1.08, 0.980, 302, 294, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
143, 1finC, 0.9759, 0.99, 0.980, 298, 294, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
144, 2wihA, 0.9758, 1.10, 0.980, 302, 294, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
145, 2wpaA, 0.9757, 1.10, 0.980, 302, 294, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
146, 4eorA, 0.9756, 0.73, 0.993, 293, 291, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
147, 3qhwC, 0.9755, 1.16, 1.000, 297, 295, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
148, 5if1A, 0.9754, 1.08, 0.980, 298, 294, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
149, 2c5nA, 0.9754, 1.03, 0.983, 296, 294, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
150, 2c5xC, 0.9753, 1.02, 0.983, 296, 294, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
151, 4eonA, 0.9752, 1.19, 0.990, 299, 295, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
152, 4bckA, 0.9749, 1.07, 1.000, 298, 295, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
153, 4eosA, 0.9748, 0.86, 1.000, 296, 292, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
154, 2c5nC, 0.9748, 1.09, 0.983, 296, 294, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
155, 1urcC, 0.9748, 1.06, 0.983, 296, 294, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
156, 2wevC, 0.9746, 1.07, 0.976, 296, 294, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
157, 2wfyA, 0.9745, 0.95, 0.983, 295, 293, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
158, 4eopA, 0.9740, 0.99, 0.997, 297, 293, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
159, 1ol2C, 0.9738, 1.06, 0.976, 296, 294, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
160, 1h27C, 0.9733, 0.64, 1.000, 291, 290, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
161, 1fvvA, 0.9733, 1.10, 0.983, 298, 294, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
162, 1okvC, 0.9728, 1.08, 0.976, 296, 294, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
163, 1okvA, 0.9718, 1.01, 0.983, 295, 293, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
164, 4eoiA, 0.9710, 0.88, 0.993, 294, 291, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
165, 4fx3C, 0.9709, 1.18, 0.980, 298, 294, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
166, 4fx3A, 0.9708, 1.16, 0.980, 298, 294, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
167, 3eidA, 0.9694, 0.91, 0.979, 292, 291, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
168, 1h1pA, 0.9691, 1.20, 1.000, 296, 295, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
169, 3ej1A, 0.9680, 0.96, 0.983, 295, 291, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
170, 3ej1C, 0.9679, 0.96, 0.983, 294, 291, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
171, 3eocC, 0.9671, 0.97, 0.983, 293, 291, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
172, 3eocA, 0.9665, 0.99, 0.983, 295, 291, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
173, 2wipC, 0.9658, 0.82, 0.983, 292, 289, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
174, 4eolA, 0.9655, 1.13, 0.986, 294, 292, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
175, 4eokA, 0.9653, 1.01, 0.990, 293, 291, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
176, 2i40A, 0.9646, 0.93, 0.983, 291, 290, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
177, 1h1pC, 0.9645, 1.30, 0.997, 296, 295, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
178, 4bckC, 0.9625, 1.01, 1.000, 293, 291, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
179, 5uq2A, 0.9621, 1.49, 1.000, 296, 295, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
180, 3eidC, 0.9621, 1.07, 0.976, 290, 290, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
181, 2wipA, 0.9620, 1.04, 0.979, 297, 289, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
182, 4bcqC, 0.9608, 1.05, 0.997, 292, 291, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
183, 2cjmA, 0.9596, 0.54, 1.000, 285, 285, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
184, 1w98A, 0.9544, 1.21, 1.000, 297, 289, THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
185, 5l2wA, 0.9541, 1.24, 1.000, 297, 289, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK2/CYCLINE AND DINACICLIB.
186, 2jgzA, 0.9529, 1.00, 1.000, 288, 287, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
187, 4bcqA, 0.9518, 1.15, 0.997, 292, 289, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
188, 4nstC, 0.9458, 1.69, 0.429, 317, 294, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
189, 1fq1B, 0.9438, 1.56, 0.976, 295, 292, CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2
190, 4nstA, 0.9435, 1.74, 0.425, 322, 294, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
191, 5acbC, 0.9421, 1.71, 0.432, 324, 294, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
192, 5uq1A, 0.9417, 1.38, 0.997, 288, 287, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
193, 4cxaA, 0.9404, 1.72, 0.422, 329, 294, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
194, 6b3eA, 0.9398, 1.78, 0.422, 309, 294, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLINK IN COMPLEX WITH AN INHIBITOR
195, 5efqC, 0.9396, 1.80, 0.435, 325, 294, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
196, 1f5qA, 0.9392, 1.75, 0.979, 296, 290, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
197, 4un0C, 0.9386, 1.72, 0.433, 308, 293, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
198, 5uq1C, 0.9385, 1.48, 1.000, 289, 288, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
199, 5efqA, 0.9385, 1.86, 0.429, 321, 294, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
200, 4imyE, 0.9382, 1.82, 0.403, 313, 293, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
201, 5acbD, 0.9378, 1.64, 0.435, 319, 292, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
202, 6b3eC, 0.9350, 1.83, 0.422, 307, 294, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLINK IN COMPLEX WITH AN INHIBITOR
203, 4cxaC, 0.9321, 1.76, 0.433, 330, 291, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
204, 4imyA, 0.9303, 2.06, 0.401, 314, 294, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
205, 3miaA, 0.9290, 2.10, 0.401, 324, 294, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB
206, 1h25C, 0.9287, 0.68, 1.000, 278, 277, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
207, 1unlA, 0.9277, 1.73, 0.597, 292, 288, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
208, 3mi9A, 0.9276, 2.12, 0.401, 328, 294, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB
209, 1jsuA, 0.9267, 1.65, 0.950, 285, 282, P27(KIP1)/CYCLIN A/CDK2 COMPLEX
210, 4ec8A, 0.9257, 2.03, 0.408, 325, 294, STRUCTURE OF FULL LENGTH CDK9 IN COMPLEX WITH CYCLINT AND DRB
211, 4imyC, 0.9253, 1.90, 0.400, 310, 290, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
212, 4bchA, 0.9247, 2.04, 0.403, 308, 293, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
213, 3lq5A, 0.9247, 1.93, 0.395, 307, 291, STRUCTURE OF CDK9/CYCLINT IN COMPLEX WITH S-CR8
214, 4or5F, 0.9243, 2.15, 0.405, 324, 294, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
215, 4bcgA, 0.9240, 2.08, 0.406, 312, 293, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
216, 3o0gA, 0.9227, 1.72, 0.601, 289, 286, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
217, 3my1A, 0.9212, 2.15, 0.401, 314, 294, STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB
218, 4or5A, 0.9207, 2.20, 0.401, 319, 294, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
219, 4eojC, 0.9191, 1.15, 0.968, 282, 278, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
220, 4bcjA, 0.9185, 2.18, 0.403, 309, 293, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
221, 4bciA, 0.9184, 2.06, 0.405, 308, 291, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
222, 4krcA, 0.9182, 1.86, 0.569, 297, 288, CRYSTAL STRUCTURE OF PHO85-PCL10-ATP-GAMMA-S COMPLEX
223, 4ogrA, 0.9181, 2.17, 0.401, 314, 294, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
224, 4ec9A, 0.9174, 1.89, 0.406, 306, 288, CRYSTAL STRUCTURE OF FULL-LENGTH CDK9 IN COMPLEX WITH CYCLIN T
225, 4bcfA, 0.9168, 2.15, 0.404, 307, 292, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
226, 4krdA, 0.9158, 1.79, 0.573, 294, 286, CRYSTAL STRUCTURE OF PHO85-PCL10 COMPLEX
227, 3tn8A, 0.9155, 2.20, 0.405, 304, 291, CDK9/CYCLIN T IN COMPLEX WITH CAN508
228, 1f5qC, 0.9155, 1.47, 0.972, 288, 281, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
229, 1ungA, 0.9151, 1.75, 0.588, 288, 284, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
230, 4ogrI, 0.9128, 2.26, 0.401, 318, 294, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
231, 1unlB, 0.9123, 1.97, 0.597, 292, 288, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
232, 3blrA, 0.9118, 2.01, 0.410, 300, 288, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH FLAVOPIRIDOL
233, 4yc3A, 0.9116, 2.01, 0.656, 295, 285, CDK1/CYCLINB1/CKS2 APO
234, 3blqA, 0.9109, 1.69, 0.413, 295, 283, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH ATP
235, 4ogrE, 0.9085, 2.22, 0.388, 310, 291, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
236, 5l1zA, 0.9081, 2.22, 0.388, 310, 291, TAR COMPLEX WITH HIV-1 TAT-AFF4-P-TEFB
237, 4eoqC, 0.9068, 0.76, 0.996, 275, 271, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
238, 1j1cA, 0.9054, 2.10, 0.322, 354, 286, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
239, 3zuvC, 0.9051, 1.87, 0.377, 357, 284, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
240, 4eomC, 0.9050, 0.81, 0.985, 275, 271, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
241, 1j1bA, 0.9048, 2.11, 0.322, 354, 286, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
242, 3i4bB, 0.9043, 2.00, 0.323, 347, 285, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
243, 3zuvA, 0.9032, 1.91, 0.377, 357, 284, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
244, 4cfuC, 0.9031, 0.64, 1.000, 272, 269, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
245, 2pk9A, 0.9030, 1.73, 0.562, 287, 281, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
246, 3i4bA, 0.9026, 2.03, 0.323, 359, 285, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
247, 3tniA, 0.9025, 1.94, 0.408, 297, 284, STRUCTURE OF CDK9/CYCLIN T F241L
248, 1j1cB, 0.9025, 2.02, 0.323, 364, 285, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
249, 5xs2A, 0.9020, 2.11, 0.377, 366, 289, CDK8-CYCC IN COMPLEX WITH COMPOUND 17:3-CHLORO-4-(4-PYRIDYL)-1H- PYRROLE-2-CARBOXAMIDE
250, 2g9xC, 0.9015, 0.93, 0.996, 274, 271, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
251, 3bhvC, 0.9013, 0.71, 1.000, 271, 269, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
252, 2erkA, 0.9013, 2.05, 0.379, 351, 285, PHOSPHORYLATED MAP KINASE ERK2
253, 1j1bB, 0.9009, 2.05, 0.323, 364, 285, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
254, 3blhA, 0.9007, 1.63, 0.414, 291, 280, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1
255, 4ic7A, 0.9006, 1.99, 0.391, 355, 284, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
256, 5v60A, 0.9003, 2.09, 0.375, 347, 285, PHOSPHO-ERK2 BOUND TO AMP-PCP
257, 4acgB, 0.9001, 2.08, 0.326, 350, 285, GSK3B IN COMPLEX WITH INHIBITOR
258, 5a14A, 0.9000, 2.00, 0.975, 284, 281, HUMAN CDK2 WITH TYPE II INHIBITOR
259, 1q41B, 0.9000, 2.07, 0.323, 343, 285, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
260, 3bhtC, 0.8998, 0.75, 1.000, 270, 269, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
261, 4acgA, 0.8990, 2.08, 0.323, 350, 285, GSK3B IN COMPLEX WITH INHIBITOR
262, 4achB, 0.8984, 2.09, 0.323, 350, 285, GSK3B IN COMPLEX WITH INHIBITOR
263, 5v61A, 0.8983, 1.99, 0.373, 348, 284, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP2
264, 4b7tA, 0.8981, 2.10, 0.323, 350, 285, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE AND LEUCETTINE L4
265, 5v62A, 0.8980, 1.99, 0.373, 349, 284, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP3
266, 4nm0A, 0.8979, 2.09, 0.323, 356, 285, CRYSTAL STRUCTURE OF PEPTIDE INHIBITOR-FREE GSK-3/AXIN COMPLEX
267, 4acdA, 0.8979, 2.12, 0.323, 350, 285, GSK3B IN COMPLEX WITH INHIBITOR
268, 4accA, 0.8979, 2.12, 0.323, 350, 285, GSK3B IN COMPLEX WITH INHIBITOR
269, 1h8fB, 0.8978, 2.11, 0.326, 350, 285, GLYCOGEN SYNTHASE KINASE 3 BETA.
270, 4acdB, 0.8977, 2.10, 0.323, 350, 285, GSK3B IN COMPLEX WITH INHIBITOR
271, 4achA, 0.8976, 2.13, 0.323, 350, 285, GSK3B IN COMPLEX WITH INHIBITOR
272, 1oguC, 0.8976, 0.86, 1.000, 272, 269, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
273, 1h8fA, 0.8975, 2.12, 0.326, 352, 285, GLYCOGEN SYNTHASE KINASE 3 BETA.
274, 4accB, 0.8971, 2.10, 0.323, 350, 285, GSK3B IN COMPLEX WITH INHIBITOR
275, 5hlnA, 0.8970, 2.10, 0.323, 346, 285, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
276, 3pupB, 0.8969, 2.07, 0.324, 347, 284, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
277, 4nm5A, 0.8968, 2.14, 0.323, 361, 285, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 C-MOTIF
278, 3pupA, 0.8968, 2.07, 0.324, 346, 284, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
279, 3bhuC, 0.8967, 0.88, 1.000, 271, 269, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
280, 4nm3A, 0.8966, 2.11, 0.323, 357, 285, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED N- TERMINAL AUTO-INHIBITORY PS9 PEPTIDE
281, 1o9uA, 0.8966, 2.11, 0.323, 349, 285, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE
282, 4ic7D, 0.8965, 2.07, 0.394, 353, 284, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
283, 5hq0A, 0.8964, 2.12, 0.655, 292, 284, TERNARY COMPLEX OF HUMAN PROTEINS CDK1 CYCLIN B AND CKS2 BOUND TO AN INHIBITOR
284, 4y72A, 0.8964, 2.12, 0.655, 292, 284, HUMAN CDK1/CYCLINB1/CKS2 WITH INHIBITOR
285, 5f94A, 0.8962, 2.11, 0.323, 346, 285, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
286, 3pxzA, 0.8962, 2.26, 0.965, 302, 284, CDK2 TERNARY COMPLEX WITH JWS648 AND ANS
287, 4ptcA, 0.8960, 2.11, 0.323, 342, 285, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
288, 2jldB, 0.8960, 2.20, 0.323, 349, 285, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
289, 5f94B, 0.8959, 2.12, 0.323, 349, 285, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
290, 4nu1A, 0.8959, 2.24, 0.322, 356, 286, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED N-TERMINAL AUTO-INHIBITORY PS9 PEPTIDE
291, 3zu7A, 0.8959, 2.13, 0.372, 344, 285, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE MAP KINASE ERK2
292, 1h4lB, 0.8957, 1.44, 0.596, 278, 275, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
293, 3sayB, 0.8956, 2.13, 0.323, 347, 285, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
294, 2jldA, 0.8956, 2.09, 0.324, 349, 284, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
295, 3pxfA, 0.8955, 2.25, 0.961, 302, 284, CDK2 IN COMPLEX WITH TWO MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
296, 1r0eB, 0.8953, 2.12, 0.323, 344, 285, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
297, 4nm7A, 0.8952, 2.14, 0.323, 355, 285, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 E-MOTIF
298, 3sayA, 0.8952, 2.04, 0.325, 347, 283, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
299, 3m1sB, 0.8951, 2.24, 0.323, 349, 285, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
300, 4bcoC, 0.8950, 0.84, 1.000, 269, 268, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
301, 5kpkB, 0.8949, 2.19, 0.326, 344, 285, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0209
302, 5lqfA, 0.8948, 2.00, 0.667, 287, 282, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
303, 1r0eA, 0.8945, 2.13, 0.323, 344, 285, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
304, 4ez7A, 0.8944, 2.17, 0.975, 302, 283, CDK2 IN COMPLEX WITH STAUROSPORINE AND 2 MOLECULES OF 8-ANILINO-1- NAPHTHALENE SULFONIC ACID
305, 1h4lA, 0.8944, 1.46, 0.596, 278, 275, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
306, 4ptcB, 0.8942, 2.15, 0.323, 347, 285, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
307, 5kpmA, 0.8941, 2.14, 0.323, 344, 285, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD3731
308, 4pteB, 0.8941, 2.16, 0.323, 347, 285, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
309, 3zrkB, 0.8940, 2.25, 0.322, 348, 286, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
310, 4eorC, 0.8939, 0.96, 0.959, 270, 269, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
311, 2o5kA, 0.8936, 2.33, 0.321, 350, 287, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A BENZOIMIDAZOL INHIBITOR
312, 5hlnB, 0.8934, 2.16, 0.323, 346, 285, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
313, 4pteA, 0.8933, 2.04, 0.325, 341, 283, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
314, 3sd0B, 0.8933, 2.18, 0.323, 349, 285, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
315, 3m1sA, 0.8932, 2.09, 0.325, 348, 283, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
316, 2gphA, 0.8929, 2.19, 0.375, 345, 285, DOCKING MOTIF INTERACTIONS IN THE MAP KINASE ERK2
317, 5airA, 0.8924, 2.00, 0.333, 353, 282, STRUCTURAL ANALYSIS OF MOUSE GSK3BETA FUSED WITH LRP6 PEPTIDE.
318, 1q5kA, 0.8924, 2.05, 0.330, 345, 282, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
319, 3sd0A, 0.8921, 2.19, 0.323, 350, 285, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
320, 3zrlB, 0.8917, 2.29, 0.322, 347, 286, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
321, 5kpkA, 0.8916, 2.23, 0.323, 346, 285, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0209
322, 4bcpC, 0.8916, 0.69, 1.000, 267, 266, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
323, 1uv5A, 0.8915, 2.21, 0.326, 348, 285, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3 -OXIME
324, 3erkA, 0.8914, 2.16, 0.372, 350, 285, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/SB220025
325, 3zdiA, 0.8913, 2.21, 0.323, 348, 285, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE AND INHIBITOR 7D
326, 5f95A, 0.8912, 2.03, 0.330, 345, 282, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
327, 4j71A, 0.8912, 2.19, 0.323, 347, 285, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
328, 2ojjA, 0.8912, 2.22, 0.368, 344, 285, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-N-(1-(3- CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
329, 1pyxA, 0.8912, 1.98, 0.331, 343, 281, GSK-3 BETA COMPLEXED WITH AMP-PNP
330, 5hbjA, 0.8911, 2.04, 0.382, 342, 283, CDK8-CYCC IN COMPLEX WITH 8-[2-AMINO-3-CHLORO-5-(1-METHYL-1H-INDAZOL- 5-YL)-PYRIDIN-4-YL]-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
331, 4iz5A, 0.8910, 2.03, 0.375, 347, 283, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
332, 4iz5D, 0.8909, 2.03, 0.375, 347, 283, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
333, 4iz5B, 0.8909, 2.03, 0.375, 347, 283, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
334, 3zrmB, 0.8909, 2.30, 0.322, 347, 286, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
335, 4iz5C, 0.8908, 2.03, 0.375, 347, 283, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
336, 5nhlA, 0.8906, 2.22, 0.375, 345, 285, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
337, 4iz7A, 0.8906, 2.10, 0.375, 344, 283, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
338, 2ojiA, 0.8905, 2.21, 0.368, 344, 285, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
339, 4cfmC, 0.8900, 0.64, 1.000, 266, 265, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
340, 3my5C, 0.8900, 0.63, 1.000, 266, 265, CDK2/CYCLINA IN COMPLEX WITH DRB
341, 5hd7A, 0.8899, 2.22, 0.372, 347, 285, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT MUTANT SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
342, 1unhB, 0.8898, 1.41, 0.590, 276, 273, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
343, 5nhpA, 0.8897, 2.24, 0.375, 338, 285, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
344, 3f88A, 0.8897, 2.12, 0.325, 340, 283, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
345, 5lqfD, 0.8896, 1.92, 0.664, 285, 280, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
346, 2iw9C, 0.8896, 0.90, 0.996, 268, 267, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
347, 4crlA, 0.8895, 2.18, 0.379, 339, 285, CRYSTAL STRUCTURE OF HUMAN CDK8-CYCLIN C IN COMPLEX WITH CORTISTATIN A
348, 3f88B, 0.8894, 2.15, 0.325, 340, 283, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
349, 5byyA, 0.8892, 1.98, 0.389, 338, 280, ERK5 IN COMPLEX WITH SMALL MOLECULE
350, 5kpmB, 0.8891, 2.21, 0.323, 345, 285, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD3731
351, 5nhvA, 0.8890, 2.23, 0.375, 345, 285, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
352, 4xrlA, 0.8890, 2.17, 0.373, 337, 284, CRYSTAL STRUCTURE AT ROOM TEMPERATURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
353, 3q3bB, 0.8890, 1.96, 0.332, 341, 280, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
354, 3q3bA, 0.8890, 2.03, 0.331, 344, 281, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
355, 1erkA, 0.8890, 2.16, 0.377, 357, 284, STRUCTURE OF SIGNAL-REGULATED KINASE
356, 4izaA, 0.8888, 2.20, 0.377, 346, 284, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
357, 4s34A, 0.8887, 2.22, 0.372, 343, 285, ERK2 (I84A) IN COMPLEX WITH AMP-PNP
358, 6g93A, 0.8886, 2.09, 0.371, 343, 283, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
359, 5ke0A, 0.8886, 2.26, 0.375, 340, 285, DISCOVERY OF 1-1H-PYRAZOLO 43-C PYRIDINE-6-YL UREA INHIBITORS OF EXTRACELLULAR SIGNAL REGULATED KINASE ERK FOR THE TREATMENT OF CANCERS
360, 4erkA, 0.8886, 2.22, 0.372, 350, 285, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/OLOMOUCINE
361, 1h26C, 0.8886, 0.80, 1.000, 267, 266, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
362, 6b8jA, 0.8884, 2.34, 0.323, 344, 285, CO-STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE BETA WITH A SELECTIVE (5-IMIDAZOL-2-YL-4-PHENYLPYRIMIDIN-2-YL)[2-(2-PYRIDYLAMINO) ETHYL]AMINE INHIBITOR
363, 1unhA, 0.8884, 1.45, 0.593, 276, 273, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
364, 5hbeA, 0.8883, 2.30, 0.371, 344, 286, CDK8-CYCC IN COMPLEX WITH 8-[3-CHLORO-5-(1-METHYL-22-DIOXO-2 3- DIHYDRO-1H-2L6-BENZO[C]ISOTHIAZOL-5-YL)-PYRIDIN- 4-YL]-1-OXA-38- DIAZA-SPIRO[4.5]DECAN-2-ONE
365, 5byzA, 0.8882, 2.10, 0.397, 348, 282, ERK5 IN COMPLEX WITH SMALL MOLECULE
366, 6gdqA, 0.8881, 2.22, 0.373, 339, 284, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
367, 4qteA, 0.8881, 2.27, 0.372, 348, 285, STRUCTURE OF ERK2 IN COMPLEX WITH VTX-11E 4-{2-[(2-CHLORO-4- FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-4-YL}-N-[(1S)-1-(3- CHLOROPHENYL)-2-HYDROXYETHYL]-1H-PYRROLE-2-CARBOXAMIDE
368, 4fv3A, 0.8881, 2.23, 0.373, 346, 284, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK6
369, 3zrkA, 0.8881, 2.18, 0.320, 345, 284, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
370, 4s2zA, 0.8880, 2.24, 0.372, 346, 285, ERK2 INTRINSICALLY ACTIVE MUTANT R65S
371, 4qyyA, 0.8880, 2.26, 0.375, 337, 285, DISCOVERY OF NOVEL DUAL MECHANISM ERK INHIBITORS BY AFFINITY SELECTION SCREENING OF AN INACTIVE KINASE STATE
372, 2ojgA, 0.8880, 2.26, 0.368, 337, 285, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH NN-DIMETHYL-4-(4- PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
373, 5nhfA, 0.8879, 2.20, 0.373, 339, 284, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
374, 4qtbA, 0.8879, 2.24, 0.379, 351, 285, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
375, 1golA, 0.8879, 2.18, 0.373, 357, 284, COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52
376, 4fv2A, 0.8878, 2.22, 0.373, 344, 284, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK5
377, 5airB, 0.8877, 2.13, 0.329, 361, 283, STRUCTURAL ANALYSIS OF MOUSE GSK3BETA FUSED WITH LRP6 PEPTIDE.
378, 5idpA, 0.8874, 2.22, 0.358, 342, 285, CDK8-CYCC IN COMPLEX WITH (3-AMINO-1H-INDAZOL-5-YL)-[(S)-2-(4-FLUORO- PHENYL)-PIPERIDIN-1-YL]-METHANONE
379, 4s33A, 0.8874, 2.26, 0.372, 347, 285, ERK2 R65S MUTANT COMPLEXED WITH AMP-PNP
380, 1pyxB, 0.8874, 1.97, 0.333, 338, 279, GSK-3 BETA COMPLEXED WITH AMP-PNP
381, 4j71B, 0.8872, 2.23, 0.323, 347, 285, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
382, 6g9aA, 0.8870, 2.13, 0.371, 341, 283, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
383, 1q3wB, 0.8870, 2.00, 0.332, 341, 280, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
384, 5i5zA, 0.8869, 2.27, 0.368, 345, 285, CDK8-CYCC IN COMPLEX WITH 8-(1-METHYL-22-DIOXO-23-DIHYDRO-1H-2L6- BENZO[C]ISOTHIAZOL-5-YL)-[16]NAPHTHYRIDINE-2-CARBOXYLIC ACID METHYLAMIDE
385, 4zzmA, 0.8869, 2.19, 0.373, 344, 284, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
386, 4gt3A, 0.8869, 2.20, 0.373, 347, 284, ATP-BOUND FORM OF THE ERK2 KINASE
387, 5nhhA, 0.8868, 2.28, 0.375, 348, 285, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
388, 5hd4A, 0.8868, 2.27, 0.375, 347, 285, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT WILD TYPE SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
389, 5nhoA, 0.8867, 2.22, 0.380, 343, 284, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
390, 5umoA, 0.8864, 2.25, 0.372, 347, 285, STRUCTURE OF EXTRACELLULAR SIGNAL-REGULATED KINASE
391, 5icpA, 0.8862, 2.34, 0.371, 343, 286, CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-CHLORO-PHENYL)-PYRROLIDIN-1-YL]- (5-METHYL-IMIDAZO[51-B][134]THIADIAZOL-2-YL)-METHANONE
392, 5ceiA, 0.8862, 2.36, 0.360, 345, 286, CRYSTAL STRUCTURE OF CDK8:CYCLIN C COMPLEX WITH COMPOUND 22
393, 3zrlA, 0.8862, 2.21, 0.320, 345, 284, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
394, 3gb2A, 0.8862, 2.10, 0.333, 340, 282, GSK3BETA INHIBITOR COMPLEX
395, 4un0D, 0.8861, 1.52, 0.442, 276, 274, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
396, 3du8A, 0.8861, 1.97, 0.333, 336, 279, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
397, 6g9hA, 0.8860, 2.23, 0.373, 343, 284, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
398, 6g8xA, 0.8860, 2.22, 0.373, 338, 284, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
399, 4fuxA, 0.8860, 2.21, 0.373, 342, 284, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E75
400, 1q3dB, 0.8860, 2.09, 0.332, 339, 280, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
401, 5xqxA, 0.8859, 1.95, 0.384, 340, 281, HUMAN CDK8-CYCC IN COMPLEX WITH COMPOUND 4: N-METHYL-4-(4-PYRIDYL)-1H- PYRROLE-2-CARBOXAMIDE
402, 4g6nA, 0.8859, 2.22, 0.370, 341, 284, CRYSTAL STRUCTURE OF THE ERK2
403, 6g9mA, 0.8858, 2.24, 0.373, 341, 284, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
404, 4s31A, 0.8858, 2.27, 0.372, 347, 285, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 1 WTERK2 AT 1.45A
405, 6gn1A, 0.8857, 2.18, 0.323, 339, 282, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3B) IN COMPLEX WITH PIK-75 
406, 4zzoA, 0.8856, 2.20, 0.377, 339, 284, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
407, 3zrmA, 0.8855, 2.22, 0.320, 344, 284, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
408, 6g91A, 0.8853, 2.23, 0.373, 344, 284, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
409, 5oy4A, 0.8853, 2.31, 0.323, 349, 285, GSK3BETA COMPLEX WITH N-(6-(34-DIHYDROXYPHENYL)-1H-PYRAZOLO[34- B]PYRIDIN-3-YL)ACETAMIDE
410, 4s32A, 0.8853, 2.28, 0.372, 346, 285, CRYSTAL STRUCTURE OF ERK2 AMP-PNP COMPLEX
411, 3du8B, 0.8853, 1.99, 0.333, 339, 279, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
412, 6gn1B, 0.8852, 2.19, 0.323, 339, 282, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3B) IN COMPLEX WITH PIK-75 
413, 2ow3B, 0.8851, 2.32, 0.323, 351, 285, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
414, 5bnjA, 0.8850, 2.24, 0.366, 343, 284, CDK8/CYCC IN COMPLEX WITH 8-{3-CHLORO-5-[4-(1-METHYL-1H-PYRAZOL-4-YL)- PHENYL]-PYRIDIN- 4-YL}-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
415, 4qtbB, 0.8850, 2.29, 0.379, 348, 285, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
416, 5nguA, 0.8849, 2.24, 0.377, 339, 284, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
417, 3pxqA, 0.8849, 2.18, 0.993, 298, 280, CDK2 IN COMPLEX WITH 3 MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
418, 3nizA, 0.8849, 2.25, 0.601, 288, 281, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH ADP BOUND.
419, 2wmbC, 0.8849, 0.80, 1.000, 266, 265, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
420, 2pmiC, 0.8849, 1.72, 0.564, 285, 275, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
421, 1q3wA, 0.8848, 2.11, 0.327, 344, 281, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
422, 4s30A, 0.8847, 2.24, 0.370, 342, 284, ERK2 INTRINSICALLY ACTIVE MUTANT (I84A)
423, 4j1rC, 0.8847, 2.32, 0.323, 344, 285, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
424, 1i09B, 0.8846, 2.04, 0.332, 341, 280, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
425, 4j1rD, 0.8845, 2.32, 0.323, 345, 285, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
426, 4mygA, 0.8844, 2.17, 0.388, 335, 281, MAPK13 ACTIVE FORM
427, 4j1rA, 0.8844, 2.32, 0.323, 343, 285, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
428, 4fv1A, 0.8844, 2.27, 0.373, 342, 284, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK4
429, 3r63A, 0.8844, 2.28, 0.372, 347, 285, STRUCTURE OF ERK2 (SPE) MUTANT (S246E)
430, 2ow3A, 0.8844, 2.32, 0.326, 346, 285, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
431, 4xj0A, 0.8843, 2.20, 0.375, 345, 283, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
432, 6g9dA, 0.8842, 2.25, 0.373, 345, 284, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
433, 4cfvC, 0.8841, 0.59, 0.996, 264, 263, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
434, 6g9nA, 0.8840, 2.27, 0.373, 344, 284, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
435, 4nifB, 0.8840, 2.13, 0.372, 349, 282, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
436, 4gvaA, 0.8840, 2.21, 0.373, 345, 284, ADP-BOUND FORM OF THE ERK2 KINASE
437, 4f7sA, 0.8840, 2.38, 0.364, 339, 286, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN THE DMG-IN CONFORMATION
438, 1ykrA, 0.8840, 2.47, 0.990, 298, 288, CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINE INHIBITOR
439, 4nifE, 0.8839, 2.13, 0.372, 348, 282, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
440, 6g97A, 0.8837, 2.18, 0.371, 344, 283, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
441, 4afjB, 0.8837, 2.20, 0.326, 346, 282, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
442, 4h3qA, 0.8836, 2.27, 0.377, 352, 284, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
443, 3dogC, 0.8836, 0.87, 0.996, 267, 265, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
444, 4zznA, 0.8835, 2.24, 0.373, 338, 284, HUMAN ERK2 IN COMPLEX WITH AN INHIBITOR
445, 6g92A, 0.8834, 2.25, 0.370, 343, 284, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
446, 5nhjA, 0.8834, 2.22, 0.373, 345, 284, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
447, 1tvoA, 0.8834, 2.30, 0.368, 350, 285, THE STRUCTURE OF ERK2 IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
448, 4fmqA, 0.8833, 2.27, 0.378, 350, 283, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
449, 3qyzA, 0.8833, 2.25, 0.373, 339, 284, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
450, 4xozA, 0.8832, 2.22, 0.373, 341, 284, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
451, 5o7iA, 0.8831, 2.05, 0.400, 340, 280, ERK5 IN COMPLEX WITH A PYRROLE INHIBITOR 
452, 4e7wA, 0.8830, 2.41, 0.354, 359, 285, STRUCTURE OF GSK3 FROM USTILAGO MAYDIS
453, 3f7zB, 0.8830, 2.12, 0.324, 339, 281, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
454, 5hlpA, 0.8828, 2.14, 0.331, 337, 281, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
455, 5oy4B, 0.8826, 2.34, 0.323, 353, 285, GSK3BETA COMPLEX WITH N-(6-(34-DIHYDROXYPHENYL)-1H-PYRAZOLO[34- B]PYRIDIN-3-YL)ACETAMIDE
456, 4qnyB, 0.8826, 2.32, 0.320, 339, 284, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
457, 5lcjA, 0.8825, 2.26, 0.373, 345, 284, IN-GEL ACTIVITY-BASED PROTEIN PROFILING OF A CLICKABLE COVALENT ERK 1/2 INHIBITOR
458, 2zoqA, 0.8825, 2.26, 0.387, 351, 284, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
459, 6ge0A, 0.8824, 2.24, 0.375, 343, 283, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
460, 5aikA, 0.8824, 1.83, 0.332, 344, 277, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
461, 4qp1A, 0.8824, 2.29, 0.373, 342, 284, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
462, 2z7lA, 0.8822, 2.19, 0.369, 329, 282, UNPHOSPHORYLATED MITOGEN ACTIVATED PROTEIN KINASE ERK2 IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN 2-YL]AMINO}PHENYL)ACETIC ACID
463, 5hnbA, 0.8821, 2.34, 0.365, 342, 285, CDK8-CYCC IN COMPLEX WITH [6-HYDROXY-3-(3-METHYL-BENZYL)-1H-INDAZOL-5- YL]-((S)-3-HYDROXY-PYRROLIDIN-1-YL)-METHANONE
464, 3eb0A, 0.8820, 2.18, 0.352, 311, 281, CRYSTAL STRUCTURE OF CGD4_240 FROM CRYPTOSPORIDIUM PARVUM IN COMPLEX WITH INDIRUBIN E804
465, 3anrC, 0.8820, 1.85, 0.332, 337, 277, HUMAN DYRK1A/HARMINE COMPLEX
466, 1q3dA, 0.8820, 2.06, 0.333, 339, 279, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
467, 3qywA, 0.8819, 2.26, 0.377, 340, 284, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
468, 4qpaB, 0.8818, 2.24, 0.378, 345, 283, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
469, 5u6iA, 0.8817, 2.22, 0.367, 339, 283, DISCOVERY OF MLI-2 AN ORALLY AVAILABLE AND SELECTIVE LRRK2 INHIBITOR THAT REDUCES BRAIN KINASE ACTIVITY
470, 4xneA, 0.8817, 2.21, 0.375, 344, 283, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
471, 2b53A, 0.8816, 2.40, 0.965, 294, 284, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN- 234325
472, 6g9kA, 0.8814, 2.25, 0.375, 343, 283, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
473, 3anrB, 0.8814, 1.85, 0.332, 342, 277, HUMAN DYRK1A/HARMINE COMPLEX
474, 4xrjA, 0.8812, 2.21, 0.375, 344, 283, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
475, 3anrA, 0.8812, 1.85, 0.336, 342, 277, HUMAN DYRK1A/HARMINE COMPLEX
476, 2wmaC, 0.8812, 0.81, 0.992, 265, 264, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
477, 5aikB, 0.8811, 1.84, 0.332, 342, 277, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
478, 3py3A, 0.8811, 1.92, 0.381, 355, 278, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38ALPHA MAP KINASE
479, 4j1rB, 0.8810, 2.25, 0.329, 346, 283, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
480, 1xo2B, 0.8810, 2.06, 0.488, 289, 283, CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR FISETIN
481, 4qp1B, 0.8809, 2.24, 0.371, 343, 283, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
482, 4zsjA, 0.8808, 2.31, 0.397, 344, 282, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
483, 4g6oA, 0.8808, 2.19, 0.374, 339, 281, CRYSTAL STRUCTURE OF THE ERK2
484, 4afjA, 0.8808, 2.15, 0.324, 342, 281, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
485, 3anqC, 0.8807, 1.86, 0.336, 340, 277, HUMAN DYRK1A/INHIBITOR COMPLEX
486, 3anqA, 0.8807, 1.85, 0.336, 342, 277, HUMAN DYRK1A/INHIBITOR COMPLEX
487, 5a3xA, 0.8806, 1.86, 0.332, 342, 277, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
488, 3ddqC, 0.8806, 0.86, 0.992, 266, 264, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
489, 3anqB, 0.8806, 1.87, 0.332, 343, 277, HUMAN DYRK1A/INHIBITOR COMPLEX
490, 1q4lA, 0.8806, 1.99, 0.335, 342, 278, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
491, 1oiuC, 0.8806, 0.87, 1.000, 265, 264, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
492, 4kd1A, 0.8804, 2.55, 0.990, 298, 288, CDK2 IN COMPLEX WITH DINACICLIB
493, 4g6lA, 0.8804, 2.16, 0.365, 336, 282, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN THE DMG-IN CONFORMATION
494, 2zoqB, 0.8803, 2.27, 0.380, 351, 284, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
495, 1q41A, 0.8801, 2.00, 0.335, 339, 278, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
496, 4xp3A, 0.8799, 2.31, 0.373, 339, 284, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
497, 4xp2A, 0.8797, 2.32, 0.373, 337, 284, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
498, 4iz7C, 0.8797, 2.17, 0.379, 340, 280, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
499, 4iq6B, 0.8797, 1.98, 0.336, 332, 277, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
500, 5kplB, 0.8796, 2.12, 0.332, 339, 280, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0705
501, 5aikC, 0.8796, 1.87, 0.329, 342, 277, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
502, 4zsgA, 0.8796, 2.32, 0.390, 347, 282, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
503, 1pmeA, 0.8795, 2.18, 0.370, 333, 281, STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MAP KINASE
504, 2b54A, 0.8792, 2.76, 0.972, 298, 288, HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH DIN- 232305
505, 5a4tA, 0.8791, 1.83, 0.337, 341, 276, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
506, 4fv0A, 0.8791, 2.20, 0.372, 341, 282, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK3
507, 2f49A, 0.8791, 2.17, 0.389, 335, 280, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
508, 5lmkC, 0.8790, 0.91, 1.000, 265, 264, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
509, 5lckA, 0.8789, 2.27, 0.375, 345, 283, A CLICKABLE COVALENT ERK 1/2 INHIBITOR
510, 4ptgA, 0.8789, 1.98, 0.339, 333, 277, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
511, 5a4eD, 0.8788, 1.84, 0.333, 331, 276, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
512, 5a3xB, 0.8788, 1.89, 0.329, 340, 277, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
513, 5aikD, 0.8787, 1.83, 0.333, 342, 276, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
514, 1wzyA, 0.8787, 2.35, 0.372, 350, 285, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A PYRAZOLOPYRIDAZINE DERIVATIVE
515, 5uq3A, 0.8785, 1.46, 0.989, 270, 269, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1-P27 TERNARY COMPLEX
516, 5fgkA, 0.8785, 1.92, 0.385, 331, 278, CDK8-CYCC IN COMPLEX WITH 8-[3-(3-AMINO-1H-INDAZOL-6-YL)-5-CHLORO- PYRIDINE-4-YL]-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
517, 5a3xC, 0.8785, 1.88, 0.329, 333, 277, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
518, 6g9jA, 0.8784, 2.25, 0.376, 347, 282, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
519, 4h3pA, 0.8782, 2.29, 0.379, 342, 282, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
520, 6gdmA, 0.8781, 2.23, 0.372, 341, 282, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
521, 5a3xD, 0.8781, 1.84, 0.330, 331, 276, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
522, 1buhA, 0.8781, 2.18, 0.964, 287, 279, CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1
523, 2pmiA, 0.8780, 1.73, 0.560, 284, 273, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
524, 1q5kB, 0.8777, 2.11, 0.337, 344, 279, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
525, 5a4lA, 0.8776, 1.86, 0.337, 341, 276, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
526, 4qnyA, 0.8776, 2.34, 0.322, 333, 283, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
527, 3anrD, 0.8775, 1.81, 0.338, 340, 275, HUMAN DYRK1A/HARMINE COMPLEX
528, 5a4lD, 0.8774, 1.81, 0.331, 334, 275, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
529, 4zslA, 0.8774, 2.31, 0.399, 341, 281, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
530, 5a4qA, 0.8773, 1.86, 0.341, 341, 276, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
531, 3r83A, 0.8773, 2.41, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-92
532, 3tnhA, 0.8772, 2.03, 0.424, 288, 276, CDK9/CYCLIN T IN COMPLEX WITH CAN508
533, 5a54A, 0.8771, 1.87, 0.337, 341, 276, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
534, 3eb0C, 0.8771, 2.10, 0.348, 310, 279, CRYSTAL STRUCTURE OF CGD4_240 FROM CRYPTOSPORIDIUM PARVUM IN COMPLEX WITH INDIRUBIN E804
535, 5a4tD, 0.8770, 1.80, 0.335, 332, 275, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
536, 4mygB, 0.8770, 2.05, 0.391, 335, 279, MAPK13 ACTIVE FORM
537, 4gcjA, 0.8770, 2.42, 0.996, 304, 285, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
538, 5a54D, 0.8769, 1.82, 0.331, 334, 275, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
539, 5a4qD, 0.8768, 1.82, 0.331, 334, 275, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
540, 3sa0A, 0.8768, 2.33, 0.371, 354, 283, COMPLEX OF ERK2 WITH NORATHYRIOL
541, 4fv7A, 0.8767, 2.23, 0.372, 342, 282, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E94
542, 2iw8C, 0.8767, 0.97, 0.989, 265, 264, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
543, 5a4tB, 0.8766, 1.87, 0.330, 339, 276, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
544, 4nctA, 0.8766, 1.86, 0.333, 341, 276, HUMAN DYRK1A IN COMPLEX WITH PKC412
545, 3qqlA, 0.8765, 2.40, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR L3
546, 3anqD, 0.8764, 1.82, 0.335, 334, 275, HUMAN DYRK1A/INHIBITOR COMPLEX
547, 5aneA, 0.8763, 2.41, 0.989, 294, 284, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-METHOXY-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
548, 4nctD, 0.8763, 1.86, 0.333, 331, 276, HUMAN DYRK1A IN COMPLEX WITH PKC412
549, 2fa2A, 0.8763, 2.21, 0.389, 333, 280, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
550, 4zxtA, 0.8761, 2.34, 0.371, 348, 283, COMPLEX OF ERK2 WITH CATECHOL
551, 3f7zA, 0.8761, 2.09, 0.324, 339, 278, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
552, 1gngA, 0.8761, 2.45, 0.323, 348, 285, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
553, 5a4qB, 0.8758, 1.87, 0.337, 335, 276, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
554, 4n0sA, 0.8757, 2.27, 0.372, 348, 282, COMPLEX OF ERK2 WITH CAFFEIC ACID
555, 5nzzG, 0.8756, 2.18, 0.372, 342, 277, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
556, 5idnA, 0.8756, 2.05, 0.384, 336, 279, CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-CHLORO-PHENYL)-PYRROLIDIN-1-YL]- (3-METHYL-1H-PYRAZOLO[34-B]PYRIDIN-5-YL)-METHANONE
557, 5a4lB, 0.8756, 1.89, 0.333, 339, 276, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
558, 3juhA, 0.8756, 2.41, 0.306, 334, 284, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
559, 5anjA, 0.8755, 2.60, 0.986, 291, 286, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH N-(9H-PURIN-6-YL) THIOPHENE-2-CARBOXAMIDE  PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
560, 3r8pA, 0.8755, 2.40, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-6
561, 2f49B, 0.8755, 2.22, 0.389, 337, 280, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
562, 5a54B, 0.8753, 1.89, 0.337, 339, 276, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
563, 4f6wA, 0.8753, 1.87, 0.379, 330, 277, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 1 (N-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-4-[2-({[3-TERT-BUTYL- 1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]CARBAMOYL}AMINO)ETHYL]PIPERAZINE- 1-CARBOXAMIDE)
564, 5a4eA, 0.8751, 1.89, 0.341, 341, 276, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
565, 5hlpB, 0.8750, 2.12, 0.331, 335, 278, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
566, 5nzzE, 0.8749, 2.04, 0.373, 343, 276, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
567, 4qp3A, 0.8748, 2.16, 0.380, 339, 279, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
568, 6dcgA, 0.8747, 2.23, 0.379, 326, 280, DISCOVERY OF MK-8353: AN ORALLY BIOAVAILABLE DUAL MECHANISM ERK INHIBITOR FOR ONCOLOGY 
569, 5m4cA, 0.8747, 2.31, 0.301, 329, 282, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER LOW-SALT CONDITIONS
570, 3h30A, 0.8747, 2.34, 0.300, 333, 283, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
571, 2jd5B, 0.8747, 2.18, 0.306, 360, 281, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
572, 1jwhA, 0.8746, 2.18, 0.299, 336, 281, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
573, 3py1A, 0.8745, 2.55, 0.965, 302, 285, CDK2 TERNARY COMPLEX WITH SU9516 AND ANS
574, 1pw2A, 0.8745, 2.45, 0.989, 294, 284, APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2
575, 3pj8A, 0.8743, 2.42, 0.993, 288, 283, STRUCTURE OF CDK2 IN COMPLEX WITH A PYRAZOLO[43-D]PYRIMIDINE BIOISOSTERE OF ROSCOVITINE.
576, 5kplA, 0.8741, 2.14, 0.335, 339, 278, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0705
577, 3o71A, 0.8741, 2.24, 0.374, 340, 281, CRYSTAL STRUCTURE OF ERK2/DCC PEPTIDE COMPLEX
578, 4lynA, 0.8739, 2.59, 0.996, 287, 285, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH (2S)-N-(5-(((5-TERT-BUTYL-13-OXAZOL-2-YL)METHYL)SULFANYL)-13- THIAZOL-2-YL)-2-PHENYLPROPANAMIDE
579, 4gsbA, 0.8739, 2.18, 0.371, 343, 280, MONOCLINIC CRYSTAL FORM OF THE APO-ERK2
580, 4nctB, 0.8738, 1.94, 0.333, 333, 276, HUMAN DYRK1A IN COMPLEX WITH PKC412
581, 2y9qA, 0.8738, 2.25, 0.374, 349, 281, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
582, 2b9iA, 0.8738, 2.21, 0.389, 338, 280, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM MSG5
583, 1q99B, 0.8738, 2.20, 0.302, 364, 281, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
584, 3nszA, 0.8737, 2.17, 0.300, 327, 280, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH AMPPN
585, 5hbhA, 0.8736, 2.09, 0.382, 336, 280, CDK8-CYCC IN COMPLEX WITH 5-{5-CHLORO-4-[1-(2-METHOXY-ETHYL)-18- DIAZA-SPIRO[4.5]DEC-8-YL]-PYRIDIN-3-YL}-1-METHYL-13-DIHYDRO- BENZO[C]ISOTHIAZOLE 22-DIOXIDE
586, 2exmA, 0.8735, 2.69, 0.990, 298, 287, HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE
587, 4xp0A, 0.8734, 2.32, 0.379, 336, 282, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
588, 4qp6A, 0.8734, 2.10, 0.381, 339, 278, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
589, 4b99A, 0.8734, 2.10, 0.399, 335, 276, CRYSTAL STRUCTURE OF MAPK7 (ERK5) WITH INHIBITOR
590, 3teiA, 0.8732, 2.23, 0.376, 339, 279, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
591, 2wo6A, 0.8732, 2.02, 0.336, 344, 277, HUMAN DUAL-SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A IN COMPLEX WITH A CONSENSUS SUBSTRATE PEPTIDE
592, 1q97B, 0.8732, 2.21, 0.306, 361, 281, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
593, 5a4tC, 0.8731, 1.92, 0.335, 332, 275, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
594, 1q8zB, 0.8730, 2.20, 0.302, 364, 281, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
595, 4qp2A, 0.8729, 2.11, 0.381, 336, 278, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
596, 2clxA, 0.8729, 2.41, 0.989, 293, 283, 4-ARYLAZO-35-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY CRYSTAL STRUCTURE IN COMPLEX WITH CDK2 SELECTIVITY AND CELLULAR EFFECTS
597, 1hckA, 0.8729, 2.48, 0.989, 294, 284, HUMAN CYCLIN-DEPENDENT KINASE 2
598, 6ft7B, 0.8728, 2.46, 0.280, 356, 282, CRYSTAL STRUCTURE OF CLK3 IN COMPLEX WITH COMPOUND 8A 
599, 2fa2B, 0.8728, 2.26, 0.389, 332, 280, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
600, 4n4sA, 0.8727, 2.18, 0.381, 342, 281, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
601, 3w8lA, 0.8727, 2.25, 0.302, 326, 281, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
602, 3juhB, 0.8727, 2.46, 0.306, 334, 284, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
603, 3c9wA, 0.8727, 2.05, 0.384, 336, 276, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
604, 5nzzF, 0.8726, 2.02, 0.375, 341, 275, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
605, 5wp1A, 0.8725, 2.30, 0.372, 340, 282, COMPLEX OF ERK2 WITH 5;7-DIHYDROXYCHROMONE 
606, 1hclA, 0.8725, 2.49, 0.989, 294, 284, HUMAN CYCLIN-DEPENDENT KINASE 2
607, 5osjA, 0.8724, 2.47, 0.979, 292, 284, CDK2(WT) WITH COVALENT ADDUCT AT C177
608, 1v0oA, 0.8724, 1.88, 0.610, 276, 272, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
609, 3r7yA, 0.8723, 2.48, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-88
610, 6ft7A, 0.8721, 2.45, 0.280, 356, 282, CRYSTAL STRUCTURE OF CLK3 IN COMPLEX WITH COMPOUND 8A 
611, 4qtaA, 0.8721, 2.00, 0.382, 335, 275, STRUCTURE OF HUMAN ERK2 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
612, 4nctC, 0.8721, 1.88, 0.331, 339, 275, HUMAN DYRK1A IN COMPLEX WITH PKC412
613, 3c9wB, 0.8719, 2.06, 0.384, 336, 276, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
614, 4ifcA, 0.8717, 2.06, 0.302, 327, 278, CRYSTAL STRUCTURE OF ADP-BOUND HUMAN PRPF4B KINASE DOMAIN
615, 5g6vB, 0.8716, 2.20, 0.529, 302, 278, CRYSTAL STRUCTURE OF THE PCTAIRE1 KINASE IN COMPLEX WITH INHIBITOR
616, 3r71A, 0.8716, 2.49, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-162
617, 3rm6A, 0.8715, 2.45, 0.972, 293, 283, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-80
618, 2fysA, 0.8714, 2.33, 0.372, 348, 282, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
619, 5nqcA, 0.8713, 2.39, 0.300, 331, 283, CK2ALPHA IN COMPLEX WITH NMR154
620, 5a4qC, 0.8713, 1.93, 0.335, 332, 275, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
621, 3qx2A, 0.8713, 2.47, 0.982, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-190
622, 5k5nA, 0.8712, 2.09, 0.332, 331, 277, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
623, 3rpoA, 0.8712, 2.49, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-156
624, 5a4eB, 0.8711, 2.10, 0.337, 322, 276, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
625, 4ianA, 0.8710, 2.07, 0.302, 321, 278, CRYSTAL STRUCTURE OF APO HUMAN PRPF4B KINASE DOMAIN
626, 1wccA, 0.8710, 2.32, 0.996, 283, 281, SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY
627, 1q4lB, 0.8710, 2.08, 0.326, 337, 276, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
628, 6fyrA, 0.8709, 2.43, 0.280, 355, 282, X-RAY STRUCTURE OF CLK3-KD(GP-[275-632]; NON-PHOS.)/CPD-2 AT 1.42A 
629, 5a4lC, 0.8709, 1.95, 0.335, 332, 275, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
630, 4md9P, 0.8709, 2.40, 0.298, 328, 282, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
631, 4dglC, 0.8707, 2.25, 0.292, 334, 281, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
632, 5a54C, 0.8706, 1.96, 0.338, 332, 275, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
633, 4erwA, 0.8706, 2.46, 0.986, 292, 282, CDK2 IN COMPLEX WITH STAUROSPORINE
634, 3qxoA, 0.8706, 2.46, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-84
635, 2b9hA, 0.8706, 2.21, 0.387, 337, 279, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM STE7
636, 5ooiB, 0.8705, 2.40, 0.301, 325, 282, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
637, 6cpwA, 0.8704, 2.30, 0.379, 328, 280, DISCOVERY OF 3(S)-THIOMETHYL PYRROLIDINE ERK INHIBITORS FOR ONCOLOGY 
638, 1pxjA, 0.8704, 2.51, 0.989, 294, 284, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE
639, 4qp8B, 0.8703, 2.14, 0.383, 337, 277, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
640, 4izaC, 0.8703, 2.05, 0.380, 335, 276, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
641, 2b9jA, 0.8703, 2.22, 0.391, 337, 279, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM FAR1
642, 2a0cX, 0.8702, 2.47, 0.989, 294, 284, HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II A NOVEL 269- TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE INHIBITOR
643, 4f7nA, 0.8701, 2.04, 0.383, 334, 277, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 11 (1- [3-TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-(5- HYDROXYPENTYL)UREA)
644, 3kxhA, 0.8701, 2.37, 0.301, 326, 282, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR (2-DYMETHYLAMMINO-4567-TETRABROMOBENZOIMIDAZOL-1YL- ACETIC ACID (K66)
645, 4ylkA, 0.8700, 2.08, 0.339, 341, 277, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-CHLORO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLONE-6-CARBOXYLIC ACID INHIBITOR 5S
646, 4qp2B, 0.8700, 2.00, 0.389, 329, 275, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
647, 3lfnA, 0.8700, 2.25, 1.000, 285, 280, CRYSTAL STRUCTURE OF CDK2 WITH SAR57 AN AMINOINDAZOLE TYPE INHIBITOR
648, 2eu9A, 0.8700, 2.45, 0.280, 345, 282, CRYSTAL STRUCTURE OF CLK3
649, 4ifcB, 0.8699, 2.05, 0.300, 329, 277, CRYSTAL STRUCTURE OF ADP-BOUND HUMAN PRPF4B KINASE DOMAIN
650, 2ds1A, 0.8699, 2.37, 0.932, 290, 280, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
651, 4yllA, 0.8698, 2.08, 0.339, 340, 277, CRYSTAL STRUCTURE OF DYRK1AA IN COMPLEX WITH 10-BROMO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLONE-6-CARBOXYLIC ACID INHIBITOR 5T
652, 4o6eA, 0.8697, 2.08, 0.382, 328, 275, DISCOVERY OF 5678-TETRAHYDROPYRIDO[34-D]PYRIMIDINE INHIBITORS OF ERK2
653, 4ijpB, 0.8697, 2.09, 0.302, 333, 278, CRYSTAL STRUCTURE OF HUMAN PRPF4B KINASE DOMAIN IN COMPLEX WITH 4-{5- [(2-CHLORO-PYRIDIN-4-YLMETHYL)-CARBAMOYL]-THIOPHEN-2-YL}- BENZO[B]THIOPHENE-2-CARBOXYLIC ACID AMINE
654, 3qtwA, 0.8697, 2.45, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-13
655, 2jd5A, 0.8697, 2.18, 0.305, 353, 279, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
656, 5xvuA, 0.8696, 2.20, 0.315, 321, 279, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
657, 2oxyA, 0.8696, 2.37, 0.306, 327, 281, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
658, 3r1qA, 0.8695, 2.44, 0.982, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-102
659, 1q8zA, 0.8694, 2.23, 0.300, 354, 280, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
660, 4h3pD, 0.8693, 2.22, 0.381, 338, 278, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
661, 3qx4A, 0.8693, 2.46, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-78
662, 1q99A, 0.8693, 2.23, 0.300, 354, 280, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
663, 1q97A, 0.8692, 2.13, 0.306, 351, 278, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
664, 1gngB, 0.8692, 2.50, 0.323, 355, 285, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
665, 3r6xA, 0.8689, 2.49, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-158
666, 1pxoA, 0.8689, 2.58, 0.989, 294, 284, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YL]-(3-NITRO-PHENYL)-AMINE
667, 1oirA, 0.8689, 2.22, 0.968, 286, 278, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
668, 1j91B, 0.8689, 2.49, 0.300, 327, 283, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
669, 3raiA, 0.8688, 2.50, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-160
670, 3r7vA, 0.8688, 2.48, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-9
671, 1pxiA, 0.8688, 2.53, 0.989, 294, 284, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(25-DICHLORO-THIOPHEN-3-YL)-PYRIMIDIN-2- YLAMINE
672, 3pxrA, 0.8687, 2.49, 0.989, 294, 284, APO CDK2 CRYSTALLIZED FROM JEFFAMINE
673, 3qzhA, 0.8685, 2.47, 0.982, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-124
674, 5xvuB, 0.8684, 2.22, 0.315, 321, 279, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
675, 4grbA, 0.8684, 2.26, 0.300, 327, 280, CASEIN KINASE 2 (CK2) BOUND TO INHIBITOR
676, 5xvuC, 0.8683, 2.26, 0.307, 321, 280, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
677, 4md9K, 0.8682, 2.41, 0.298, 328, 282, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
678, 4fuyA, 0.8682, 2.15, 0.379, 329, 277, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK2
679, 3qwjA, 0.8682, 2.47, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-142
680, 2zjwA, 0.8682, 2.32, 0.302, 332, 281, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH ELLAGIC ACID
681, 5n1vA, 0.8681, 2.45, 0.301, 331, 282, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
682, 4md9E, 0.8681, 2.42, 0.298, 329, 282, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
683, 2oxyB, 0.8681, 2.41, 0.298, 327, 282, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
684, 2c5yA, 0.8681, 2.39, 0.989, 290, 281, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
685, 4mq1B, 0.8680, 2.01, 0.333, 340, 276, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
686, 3r73A, 0.8680, 2.48, 0.951, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-164
687, 3qwkA, 0.8680, 2.48, 0.989, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-150
688, 4qp4A, 0.8679, 2.25, 0.381, 337, 278, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
689, 5m4fA, 0.8678, 2.42, 0.301, 330, 282, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER LOW-SALT CONDITIONS
690, 4qp9A, 0.8678, 2.09, 0.380, 335, 276, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-PROPYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
691, 4qp7A, 0.8678, 2.18, 0.379, 337, 277, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
692, 2wo6B, 0.8678, 2.03, 0.333, 339, 276, HUMAN DUAL-SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A IN COMPLEX WITH A CONSENSUS SUBSTRATE PEPTIDE
693, 5b0xA, 0.8677, 2.43, 0.301, 329, 282, CRYSTAL STRUCTURE OF THE CK2A/BENZOIC ACID DERIVATIVE COMPLEX
694, 3r28A, 0.8676, 2.60, 0.944, 294, 285, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-140
695, 3qziA, 0.8676, 2.48, 0.979, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-126
696, 2xnbA, 0.8676, 2.74, 0.990, 296, 286, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
697, 4md9G, 0.8675, 2.33, 0.299, 329, 281, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
698, 1q8yA, 0.8675, 2.21, 0.305, 351, 279, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
699, 1b38A, 0.8675, 2.39, 0.971, 290, 280, HUMAN CYCLIN-DEPENDENT KINASE 2
700, 5n1vB, 0.8674, 2.45, 0.301, 331, 282, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
701, 4xj0B, 0.8674, 2.20, 0.381, 338, 278, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
702, 4mq1D, 0.8674, 1.97, 0.335, 336, 275, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
703, 3royA, 0.8674, 2.49, 0.951, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-154
704, 3r1yA, 0.8674, 2.54, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-134
705, 3r1sA, 0.8674, 2.51, 0.982, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-127
706, 4f6uA, 0.8673, 2.06, 0.383, 334, 277, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 5 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-[3-(MORPHOLIN-4-YL) PROPYL]UREA)
707, 5clpB, 0.8671, 2.32, 0.302, 327, 281, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
708, 4md9L, 0.8670, 2.47, 0.298, 328, 282, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
709, 4ianB, 0.8670, 2.15, 0.302, 319, 278, CRYSTAL STRUCTURE OF APO HUMAN PRPF4B KINASE DOMAIN
710, 3ofmA, 0.8670, 2.44, 0.306, 325, 281, STRUCTURE OF A HUMAN CK2ALPHA PRIME THE PARALOG ISOFORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM HOMO SAPIENS
711, 5ooiA, 0.8669, 2.45, 0.301, 329, 282, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
712, 3r7eA, 0.8669, 2.53, 0.982, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-67
713, 2fysB, 0.8669, 2.40, 0.381, 338, 281, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
714, 5osmA, 0.8668, 2.34, 0.954, 292, 280, CDK2(F80C C177A) WITH COVALENT ADDUCT AT C80
715, 3tiyA, 0.8668, 2.49, 0.982, 293, 283, CDK2 IN COMPLEX WITH NSC 35676
716, 2no3A, 0.8668, 2.26, 0.364, 357, 280, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
717, 5mmrA, 0.8667, 2.26, 0.300, 326, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
718, 5g6vA, 0.8667, 2.32, 0.530, 308, 279, CRYSTAL STRUCTURE OF THE PCTAIRE1 KINASE IN COMPLEX WITH INHIBITOR
719, 3rniA, 0.8667, 2.63, 0.982, 294, 285, CDK2 IN COMPLEX WITH INHIBITOR RC-3-86
720, 3qzfA, 0.8667, 2.55, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-52
721, 3lfqA, 0.8667, 2.28, 0.968, 289, 279, CRYSTAL STRUCTURE OF CDK2 WITH SAR60 AN AMINOINDAZOLE TYPE INHIBITOR
722, 1ds5B, 0.8667, 2.44, 0.301, 328, 282, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
723, 3ns9A, 0.8666, 2.32, 0.986, 289, 279, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR BS-194
724, 2xmyA, 0.8666, 2.61, 0.982, 295, 285, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
725, 2vx3B, 0.8666, 2.06, 0.333, 340, 276, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
726, 1aq1A, 0.8666, 1.89, 0.971, 277, 273, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE
727, 5cx9A, 0.8665, 2.36, 0.302, 328, 281, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
728, 3lfsA, 0.8665, 2.36, 0.964, 290, 280, CRYSTAL STRUCTURE OF CDK2 WITH SAR37 AN AMINOINDAZOLE TYPE INHIBITOR
729, 2vx3D, 0.8664, 2.04, 0.333, 342, 276, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
730, 5modA, 0.8663, 2.28, 0.300, 327, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
731, 5ctpB, 0.8663, 2.35, 0.302, 327, 281, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
732, 5ct0A, 0.8663, 2.26, 0.296, 326, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
733, 4f7lA, 0.8663, 1.90, 0.382, 328, 275, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 2 (TERT- BUTYL [3-({[3-TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5- YL]CARBAMOYL}AMINO)PROPYL]CARBAMATE)
734, 4au8B, 0.8663, 2.04, 0.600, 277, 275, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
735, 3wikA, 0.8663, 2.28, 0.307, 334, 280, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND10 COMPLEX
736, 4looA, 0.8662, 2.19, 0.383, 349, 277, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (MONOCLINIC CRYSTAL FORM)
737, 3qrtA, 0.8662, 2.47, 0.940, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC2-55
738, 2eufB, 0.8662, 1.89, 0.505, 282, 273, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991
739, 2b9fA, 0.8662, 2.40, 0.389, 337, 280, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED FUS3
740, 4mq1A, 0.8661, 2.03, 0.333, 345, 276, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
741, 5cu2A, 0.8660, 2.35, 0.302, 328, 281, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
742, 4qp3B, 0.8660, 2.13, 0.388, 331, 276, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
743, 3rk9A, 0.8660, 2.55, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-74
744, 3h30B, 0.8660, 2.46, 0.300, 333, 283, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
745, 1j91A, 0.8660, 2.46, 0.306, 327, 281, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
746, 5csvA, 0.8659, 2.33, 0.304, 327, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 6 BOUND
747, 4md8G, 0.8659, 2.48, 0.298, 332, 282, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
748, 4ijpA, 0.8659, 2.18, 0.302, 330, 278, CRYSTAL STRUCTURE OF HUMAN PRPF4B KINASE DOMAIN IN COMPLEX WITH 4-{5- [(2-CHLORO-PYRIDIN-4-YLMETHYL)-CARBAMOYL]-THIOPHEN-2-YL}- BENZO[B]THIOPHENE-2-CARBOXYLIC ACID AMINE
749, 3fwqB, 0.8659, 2.54, 0.299, 334, 284, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
750, 1howA, 0.8659, 2.32, 0.307, 346, 280, THE X-RAY CRYSTAL STRUCTURE OF SKY1P AN SR PROTEIN KINASE IN YEAST
751, 6gmdB, 0.8658, 2.27, 0.296, 326, 280, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3 
752, 4yljB, 0.8658, 2.10, 0.332, 347, 277, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
753, 5oueA, 0.8657, 2.37, 0.302, 328, 281, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 20
754, 5os7A, 0.8657, 2.27, 0.296, 326, 280, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 4
755, 4qp6B, 0.8657, 2.15, 0.388, 334, 276, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
756, 4mq2B, 0.8657, 2.06, 0.337, 338, 276, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
757, 3rm7A, 0.8657, 2.57, 0.986, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-91
758, 1pjkA, 0.8657, 2.36, 0.299, 331, 281, CRYSTAL STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
759, 5mp8A, 0.8656, 2.24, 0.297, 325, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
760, 5cu0A, 0.8656, 2.27, 0.300, 327, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
761, 4qpaA, 0.8656, 2.16, 0.384, 331, 276, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
762, 2vtoA, 0.8656, 2.25, 0.982, 283, 278, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
763, 4md9F, 0.8655, 2.36, 0.299, 327, 281, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
764, 4md8E, 0.8655, 2.48, 0.298, 332, 282, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
765, 3uliA, 0.8655, 2.39, 0.975, 286, 281, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) BOUND TO AZABENZIMIDAZOLE DERIVATIVE
766, 5mmfA, 0.8654, 2.28, 0.300, 326, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
767, 4rj3A, 0.8654, 2.31, 0.964, 287, 279, CDK2 WITH EGFR INHIBITOR COMPOUND 8
768, 3rkbA, 0.8654, 2.55, 0.989, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR RC-2-73
769, 3qqfA, 0.8654, 2.58, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR L1
770, 3q9wA, 0.8653, 2.43, 0.306, 328, 281, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 8.5
771, 5jq5A, 0.8652, 2.21, 0.964, 287, 277, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0942
772, 5cu4A, 0.8652, 2.35, 0.311, 327, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
773, 3rk7A, 0.8652, 2.57, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-71
774, 2vx3A, 0.8652, 2.12, 0.332, 346, 277, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
775, 5oulA, 0.8651, 2.39, 0.302, 327, 281, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 9
776, 5k5nB, 0.8651, 2.17, 0.331, 334, 275, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
777, 5cspA, 0.8651, 2.33, 0.304, 327, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
778, 4ez3A, 0.8651, 2.65, 0.986, 294, 284, CDK2 IN COMPLEX WITH NSC 134199
779, 3rk5A, 0.8651, 2.58, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-72
780, 4mq1C, 0.8650, 2.01, 0.335, 328, 275, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
781, 2r3fA, 0.8650, 2.41, 0.943, 290, 280, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
782, 1h01A, 0.8650, 2.27, 0.968, 286, 278, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
783, 4md8H, 0.8649, 2.49, 0.298, 331, 282, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
784, 4fklA, 0.8649, 2.42, 0.943, 290, 280, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
785, 4ek3A, 0.8649, 2.38, 0.961, 287, 279, CRYSTAL STRUCTURE OF APO CDK2
786, 3q9yA, 0.8649, 2.38, 0.302, 327, 281, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 8.5
787, 1na7A, 0.8649, 2.35, 0.299, 326, 281, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2
788, 5hvyA, 0.8648, 2.27, 0.379, 335, 277, CDK8/CYCC IN COMPLEX WITH COMPOUND 20
789, 3c13A, 0.8648, 2.44, 0.306, 328, 281, LOW PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
790, 1h07A, 0.8648, 2.36, 0.975, 285, 279, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
791, 1ds5C, 0.8648, 2.46, 0.301, 328, 282, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
792, 4yu2D, 0.8647, 2.13, 0.336, 346, 277, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
793, 4md9M, 0.8647, 2.49, 0.298, 331, 282, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
794, 4ek4A, 0.8647, 2.37, 0.946, 287, 279, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
795, 3owjA, 0.8647, 2.50, 0.298, 328, 282, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A PYRIDOCARBAZOLE DERIVATIVE INHIBITOR
796, 2vtmA, 0.8647, 2.40, 0.975, 290, 280, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
797, 5otlB, 0.8646, 2.31, 0.300, 326, 280, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 29
798, 5mo8A, 0.8646, 2.30, 0.300, 325, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
799, 4rllA, 0.8646, 2.48, 0.298, 329, 282, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
800, 3owlA, 0.8646, 2.47, 0.294, 330, 282, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
801, 3bqcA, 0.8646, 2.45, 0.306, 328, 281, HIGH PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
802, 2f2cB, 0.8646, 1.79, 0.494, 280, 271, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLINWITH THE INHIBITOR AMINOPURVALANOL
803, 2b52A, 0.8646, 2.22, 0.986, 283, 278, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH- 042562
804, 4yljD, 0.8645, 2.11, 0.332, 347, 277, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
805, 4md7H, 0.8645, 2.43, 0.306, 330, 281, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
806, 4ib5C, 0.8645, 2.51, 0.298, 332, 282, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
807, 4anmA, 0.8645, 2.46, 0.301, 328, 282, COMPLEX OF CK2 WITH A CDC7 INHIBITOR
808, 3wblA, 0.8645, 2.30, 0.993, 283, 279, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR
809, 2c6lA, 0.8645, 2.50, 0.957, 291, 281, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
810, 1h0vA, 0.8645, 2.44, 0.961, 288, 281, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R)-PYRROLIDINO-5 -YL]METHOXYPURINE
811, 4nh1B, 0.8644, 2.48, 0.301, 332, 282, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
812, 4iirB, 0.8644, 2.04, 0.302, 327, 275, CRYSTAL STRUCTURE OF AMPPNP-BOUND HUMAN PRPF4B KINASE DOMAIN
813, 1zoeA, 0.8644, 2.47, 0.298, 325, 282, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
814, 1gz8A, 0.8644, 2.40, 0.989, 290, 280, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3 -METHYL-2 -OXO)BUTOXYPURINE
815, 4nh1A, 0.8643, 2.49, 0.301, 330, 282, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
816, 2vx3C, 0.8642, 2.10, 0.333, 338, 276, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
817, 1pxpA, 0.8642, 2.59, 0.989, 294, 284, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- N N -DIMETHYL-BENZENE-14-DIAMINE
818, 1lp4A, 0.8642, 2.45, 0.301, 327, 282, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 WITH MG-AMPPNP
819, 6fyiA, 0.8641, 2.48, 0.286, 336, 280, X-RAY STRUCTURE OF CLK2-KD(130-496)/TG003 AT 2.6A 
820, 5motA, 0.8641, 2.35, 0.304, 328, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0627 BOUND
821, 5mmrB, 0.8641, 2.25, 0.297, 325, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
822, 5cvhA, 0.8641, 2.35, 0.296, 327, 280, CRYSTAL STRUCTURE OF CK2ALPHA
823, 4md7G, 0.8641, 2.44, 0.306, 332, 281, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
824, 4f70A, 0.8641, 2.02, 0.385, 327, 275, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 4 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-[2-(MORPHOLIN-4-YL) ETHYL]UREA)
825, 3wowA, 0.8641, 2.33, 0.299, 334, 281, CRYSTAL STRUCTURE OF HUMAN CK2A WITH AMPPNP
826, 3wilA, 0.8641, 2.37, 0.302, 331, 281, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND3 COMPLEX
827, 3r9dA, 0.8641, 2.62, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-135
828, 1dayA, 0.8641, 2.43, 0.310, 327, 281, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-GMPPNP
829, 5t31B, 0.8640, 2.28, 0.335, 333, 278, EXPLOITING AN ASP-GLU SWITCH IN GLYCOGEN SYNTHASE KINASE 3 TO DESIGN PARALOG SELECTIVE INHIBITORS FOR USE IN ACUTE MYELOID LEUKEMIA
830, 5oo0A, 0.8640, 2.38, 0.982, 288, 280, CDK2(WT) COVALENT ADDUCT WITH D28 AT C177
831, 4yu2B, 0.8640, 2.13, 0.332, 347, 277, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
832, 4iirA, 0.8640, 2.09, 0.304, 325, 276, CRYSTAL STRUCTURE OF AMPPNP-BOUND HUMAN PRPF4B KINASE DOMAIN
833, 4f7jA, 0.8640, 2.05, 0.389, 326, 275, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 3 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-(2-HYDROXYETHYL) UREA)
834, 3qxpA, 0.8640, 2.46, 0.979, 294, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
835, 3qu0A, 0.8640, 2.57, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-38
836, 2vtlA, 0.8640, 2.40, 0.961, 290, 280, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
837, 5otoA, 0.8639, 2.31, 0.300, 327, 280, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 30
838, 5moeA, 0.8639, 2.28, 0.297, 325, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
839, 3axwA, 0.8639, 2.50, 0.301, 329, 282, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA COMPLEXED WITH A POTENT INHIBITOR
840, 5mo7A, 0.8638, 2.31, 0.300, 327, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
841, 4md7E, 0.8638, 2.49, 0.301, 332, 282, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
842, 2gmxA, 0.8638, 2.26, 0.358, 357, 279, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
843, 1ckpA, 0.8638, 2.22, 0.968, 279, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B
844, 6fylA, 0.8637, 2.46, 0.282, 340, 280, X-RAY STRUCTURE OF CLK2-KD(136-496)/CX-4945 AT 1.95A 
845, 5otzA, 0.8637, 2.40, 0.302, 327, 281, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 1
846, 5oslA, 0.8637, 2.39, 0.302, 328, 281, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 7
847, 5orkA, 0.8637, 2.29, 0.297, 324, 279, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 6
848, 5oniA, 0.8637, 2.42, 0.299, 334, 281, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
849, 5cu0B, 0.8637, 2.31, 0.296, 325, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
850, 3kxnA, 0.8637, 2.45, 0.301, 327, 282, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR TETRAIODOBENZIMIDAZOLE (K88)
851, 1lr4A, 0.8637, 2.47, 0.301, 327, 282, ROOM TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
852, 5mpjA, 0.8636, 2.36, 0.300, 326, 280, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
853, 4yu2A, 0.8636, 2.20, 0.331, 348, 278, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
854, 4md8F, 0.8636, 2.50, 0.298, 332, 282, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
855, 6fykB, 0.8635, 2.48, 0.286, 349, 280, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
856, 5ot5A, 0.8635, 2.33, 0.300, 326, 280, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 24
857, 5os8A, 0.8635, 2.40, 0.302, 327, 281, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 11
858, 1ds5A, 0.8635, 2.47, 0.301, 328, 282, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
859, 6fypA, 0.8634, 2.48, 0.285, 348, 281, X-RAY STRUCTURE OF CLK3-KD(GP-[275-632]; NON-PHOS.)/CX-4945 AT 2.29A 
860, 5cquA, 0.8634, 2.39, 0.299, 328, 281, MONOCLINIC COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
861, 4ek5A, 0.8634, 2.35, 0.978, 289, 279, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
862, 2a4lA, 0.8634, 2.27, 0.957, 286, 276, HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE
863, 5oquA, 0.8633, 2.31, 0.297, 324, 279, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 5
864, 5mo5A, 0.8633, 2.27, 0.301, 326, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
865, 3r8zA, 0.8633, 2.46, 0.989, 290, 283, CDK2 IN COMPLEX WITH INHIBITOR RC-1-136
866, 2r3rA, 0.8633, 2.41, 0.961, 290, 280, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
867, 1b39A, 0.8633, 2.45, 0.943, 290, 280, HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160
868, 5n9kA, 0.8632, 2.47, 0.306, 329, 281, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF107 (5)
869, 4yu2C, 0.8632, 2.16, 0.332, 346, 277, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
870, 3qtzA, 0.8632, 2.57, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-36
871, 2no3B, 0.8632, 2.35, 0.361, 357, 280, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
872, 1dawA, 0.8632, 2.46, 0.301, 327, 282, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-AMPPNP
873, 4ux9A, 0.8631, 2.21, 0.366, 343, 276, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
874, 3qruA, 0.8631, 2.56, 0.940, 295, 285, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-12
875, 3mb6A, 0.8631, 2.50, 0.306, 329, 281, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (CPA)
876, 2vtsA, 0.8631, 2.12, 0.989, 282, 276, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
877, 1ds5D, 0.8631, 2.48, 0.301, 328, 282, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
878, 4mq2D, 0.8630, 2.08, 0.333, 329, 276, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
879, 3qtqA, 0.8630, 2.61, 0.982, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-1-137
880, 1y8yA, 0.8630, 2.51, 0.989, 292, 282, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
881, 5t1hA, 0.8629, 2.51, 0.301, 331, 282, CRYSTAL STRUCTURE OF CK2
882, 5mowA, 0.8629, 2.30, 0.297, 328, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
883, 5mo7B, 0.8629, 2.28, 0.301, 325, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
884, 4yljC, 0.8629, 2.15, 0.332, 346, 277, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
885, 3qqkA, 0.8629, 2.58, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR L4
886, 2c69A, 0.8629, 2.57, 0.943, 292, 282, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
887, 5othA, 0.8628, 2.34, 0.300, 326, 280, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 26
888, 3at2A, 0.8628, 2.37, 0.299, 334, 281, CRYSTAL STRUCTURE OF CK2ALPHA
889, 2uzoA, 0.8628, 2.51, 0.975, 290, 282, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
890, 6gmdA, 0.8627, 2.28, 0.297, 325, 279, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3 
891, 5otdA, 0.8627, 2.32, 0.300, 327, 280, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 25
892, 5os7B, 0.8627, 2.28, 0.297, 325, 279, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 4
893, 5iexA, 0.8627, 2.52, 0.989, 285, 282, CRYSTAL STRUCTURE OF (RS)-S-{4-[(5-BROMO-4-{[(2R3R)-2-HYDROXY-1- METHYLPROPYL]OXY}- PYRIMIDIN-2-YL)AMINO]PHENYL}-S- CYCLOPROPYLSULFOXIMIDE BOUND TO CDK2
894, 4ux9C, 0.8627, 2.18, 0.364, 333, 275, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
895, 4jqeA, 0.8627, 2.53, 0.277, 369, 282, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH AMPPN
896, 3pe2A, 0.8627, 2.40, 0.299, 327, 281, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR CX-5011
897, 2r3oA, 0.8627, 2.36, 0.961, 289, 279, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
898, 2r3hA, 0.8627, 2.36, 0.964, 289, 279, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
899, 4fkuA, 0.8626, 2.65, 0.986, 293, 283, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
900, 3pwdA, 0.8626, 2.49, 0.301, 327, 282, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH NBC (Z1)
901, 3iggA, 0.8626, 2.47, 0.943, 290, 280, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFQ WITH CDK-2
902, 2qc6A, 0.8626, 2.49, 0.301, 326, 282, PROTEIN KINASE CK2 IN COMPLEX WITH DBC
903, 2pvrA, 0.8626, 2.41, 0.299, 328, 281, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (C- TERMINAL DELETION MUTANT 1-335) IN COMPLEX WITH TWO SULFATE IONS
904, 5modB, 0.8625, 2.30, 0.297, 324, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
905, 4azeB, 0.8625, 2.16, 0.336, 345, 277, HUMAN DYRK1A IN COMPLEX WITH LEUCETTINE L41
906, 3owkA, 0.8625, 2.53, 0.298, 330, 282, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
907, 5oumA, 0.8624, 2.33, 0.300, 326, 280, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 21
908, 5ievA, 0.8624, 2.41, 0.996, 284, 280, CRYSTAL STRUCTURE OF BAY 1000394 (RONICICLIB) BOUND TO CDK2
909, 4fkvA, 0.8624, 2.22, 1.000, 282, 278, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
910, 2oxxA, 0.8624, 2.50, 0.301, 325, 282, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
911, 4azeA, 0.8623, 2.17, 0.336, 348, 277, HUMAN DYRK1A IN COMPLEX WITH LEUCETTINE L41
912, 3e3bX, 0.8623, 2.47, 0.306, 334, 281, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2ALPHA PRIME WITH A POTENT INDAZOLE-DERIVATIVE INHIBITOR
913, 2c6kA, 0.8623, 2.54, 0.989, 292, 282, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
914, 6fykA, 0.8622, 2.60, 0.281, 349, 281, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
915, 5orhB, 0.8622, 2.28, 0.297, 325, 279, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 2
916, 5mo6B, 0.8622, 2.29, 0.297, 324, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
917, 4dgoA, 0.8622, 2.49, 0.301, 325, 282, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH TYRPHOSTIN AG99
918, 3vudA, 0.8622, 2.41, 0.357, 355, 280, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
919, 5oueB, 0.8621, 2.30, 0.297, 326, 279, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 20
920, 5orjA, 0.8621, 2.32, 0.297, 325, 279, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3
921, 5h8bA, 0.8621, 2.53, 0.301, 331, 282, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
922, 5cu3A, 0.8621, 2.30, 0.301, 325, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
923, 4md7F, 0.8621, 2.51, 0.301, 332, 282, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
924, 3pvgA, 0.8621, 2.50, 0.301, 326, 282, CRYSTAL STRUCTURE OF Z. MAYS CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMO-1-CARBOXYMETHYLBENZIMIDAZOLE (K68)
925, 3mtlA, 0.8621, 2.10, 0.504, 294, 276, CRYSTAL STRUCTURE OF THE PCTAIRE1 KINASE IN COMPLEX WITH INDIRUBIN E804
926, 2v0dA, 0.8621, 2.57, 0.957, 292, 282, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
927, 2c68A, 0.8621, 2.56, 0.943, 290, 282, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
928, 1y91A, 0.8621, 2.17, 0.989, 286, 277, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
929, 1q8yB, 0.8621, 2.25, 0.306, 357, 278, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
930, 5oquB, 0.8620, 2.30, 0.297, 324, 279, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 5
931, 5mo5B, 0.8620, 2.30, 0.297, 325, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
932, 4ubaB, 0.8620, 2.41, 0.299, 333, 281, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
933, 4azeC, 0.8620, 2.17, 0.336, 348, 277, HUMAN DYRK1A IN COMPLEX WITH LEUCETTINE L41
934, 3u87A, 0.8620, 2.53, 0.301, 329, 282, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
935, 3s2pA, 0.8620, 2.23, 0.968, 279, 277, CRYSTAL STRUCTURE OF CDK2 WITH A 2-AMINOPYRIMIDINE COMPOUND
936, 3ql8A, 0.8620, 2.60, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-260
937, 2oxdA, 0.8620, 2.49, 0.301, 325, 282, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE K17 K22 AND K32 INHIBITORS
938, 5unpB, 0.8619, 2.46, 0.287, 347, 279, STRUCTURE OF CDC2-LIKE KINASE 2 (CLK2) IN COMPLEX WITH COMPOUND T-025 [N2-METHYL-N4-(PYRIMIDIN-2-YLMETHYL)-5-(QUINOLIN-6-YL)-7H-PYRROLO[2; 3-D]PYRIMIDINE-2;4-DIAMINE] 
939, 5unpA, 0.8619, 2.46, 0.287, 347, 279, STRUCTURE OF CDC2-LIKE KINASE 2 (CLK2) IN COMPLEX WITH COMPOUND T-025 [N2-METHYL-N4-(PYRIMIDIN-2-YLMETHYL)-5-(QUINOLIN-6-YL)-7H-PYRROLO[2; 3-D]PYRIMIDINE-2;4-DIAMINE] 
940, 5ctpA, 0.8619, 2.29, 0.297, 324, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
941, 4xoyA, 0.8619, 2.24, 0.385, 326, 275, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
942, 3w55A, 0.8619, 2.13, 0.373, 335, 276, THE STRUCTURE OF ERK2 IN COMPLEX WITH FR148083
943, 1v0oB, 0.8619, 1.92, 0.615, 274, 270, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
944, 1m2rA, 0.8619, 2.53, 0.301, 327, 282, CRYSTAL STRUCTURE OF 58-DI-AMINO-14-DI-HYDROXY- ANTHRAQUINONE/CK2 KINASE COMPLEX
945, 5ts8A, 0.8618, 2.40, 0.306, 332, 281, Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 56-DIBROMOBENZOTRIAZOLE
946, 5owlB, 0.8618, 2.52, 0.301, 332, 282, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
947, 5mo6A, 0.8618, 2.29, 0.301, 325, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
948, 5mmfB, 0.8618, 2.30, 0.297, 325, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
949, 5cshA, 0.8618, 2.30, 0.297, 324, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
950, 4mq2C, 0.8618, 2.12, 0.333, 339, 276, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
951, 4au8A, 0.8618, 1.95, 0.596, 276, 272, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
952, 3vuiA, 0.8618, 2.33, 0.358, 355, 279, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
953, 3vuhA, 0.8618, 2.43, 0.357, 355, 280, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M3 IN MAP KINASE JNK1
954, 3rpvA, 0.8618, 2.60, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-88
955, 2w1hA, 0.8618, 2.44, 0.957, 283, 280, FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4-YL UREA (AT9283) A MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY
956, 2h96A, 0.8618, 2.34, 0.362, 358, 279, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
957, 5mohA, 0.8617, 2.30, 0.301, 326, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0583 BOUND.
958, 3vugA, 0.8617, 2.27, 0.363, 356, 278, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
959, 1pxlA, 0.8617, 2.44, 0.943, 290, 280, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- (4-TRIFLUOROMETHYL-PHENYL)-AMINE
960, 6eiiB, 0.8616, 2.31, 0.301, 326, 279, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 18
961, 4md9H, 0.8616, 2.51, 0.298, 328, 282, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
962, 3rjcA, 0.8616, 2.63, 0.986, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR L4-12
963, 2c6oA, 0.8616, 2.56, 0.943, 290, 282, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
964, 5h8gA, 0.8615, 2.20, 0.307, 324, 277, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7B
965, 3u4uA, 0.8615, 2.35, 0.300, 327, 280, CASEIN KINASE 2 IN COMPLEX WITH AZ-INHIBITOR
966, 3pe1A, 0.8615, 2.42, 0.299, 327, 281, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-4945
967, 4mq2A, 0.8614, 2.17, 0.332, 343, 277, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
968, 3kxgA, 0.8614, 2.51, 0.301, 326, 282, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 34567-PENTABROMO-1H-INDAZOLE (K64)
969, 1zohA, 0.8614, 2.50, 0.301, 326, 282, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
970, 1m2pA, 0.8614, 2.51, 0.301, 325, 282, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO- ANTHRAQUINONE/CK2 KINASE COMPLEX
971, 3pzhA, 0.8613, 2.50, 0.301, 327, 282, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH EMODIN AT 1.92 A RESOLUTION
972, 2vtpA, 0.8613, 2.28, 0.982, 281, 277, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
973, 5ct0B, 0.8612, 2.30, 0.297, 326, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
974, 3q04A, 0.8612, 2.51, 0.301, 328, 282, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 8.5
975, 2vtrA, 0.8612, 2.46, 0.946, 290, 280, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
976, 5oumB, 0.8611, 2.31, 0.297, 326, 279, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 21
977, 5movA, 0.8611, 2.30, 0.306, 325, 278, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0633 BOUND
978, 5k4jA, 0.8611, 2.21, 1.000, 282, 277, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH COMPOUND 22
979, 5ieyA, 0.8611, 2.50, 0.993, 286, 281, CRYSTAL STRUCTURE OF A CDK INHIBITOR BOUND TO CDK2
980, 3ti1A, 0.8611, 2.64, 0.989, 294, 284, CDK2 IN COMPLEX WITH SUNITINIB
981, 5ot6A, 0.8610, 2.37, 0.300, 327, 280, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 19
982, 1lpuA, 0.8610, 2.51, 0.298, 327, 282, LOW TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
983, 5orhA, 0.8609, 2.32, 0.297, 324, 279, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 2
984, 5cx9B, 0.8609, 2.31, 0.297, 325, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
985, 4dgnA, 0.8609, 2.51, 0.301, 325, 282, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR LUTEOLIN
986, 3r8uA, 0.8609, 2.64, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-1-132
987, 2pvnA, 0.8609, 2.51, 0.298, 327, 282, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
988, 1pf8A, 0.8609, 2.77, 1.000, 298, 286, CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH A NUCLEOSIDE INHIBITOR
989, 1om1A, 0.8609, 2.51, 0.301, 325, 282, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH IQA
990, 5n9nA, 0.8608, 2.52, 0.301, 329, 282, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF85 (4A)
991, 5cvfA, 0.8608, 2.33, 0.301, 325, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
992, 3r0tA, 0.8608, 2.44, 0.299, 327, 281, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-5279
993, 2r3pA, 0.8608, 2.41, 0.989, 289, 279, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
994, 6eiiA, 0.8607, 2.33, 0.301, 326, 279, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 18
995, 4yljA, 0.8607, 2.18, 0.332, 346, 277, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
996, 3v3vA, 0.8607, 2.42, 0.366, 351, 279, STRUCTURAL AND FUNCTIONAL ANALYSIS OF QUERCETAGETIN A NATURAL JNK1 INHIBITOR
997, 1h0wA, 0.8606, 2.41, 0.975, 283, 280, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[CYCLOHEX-3-ENYL]METHOXYPURINE
998, 4fkiA, 0.8605, 2.23, 0.986, 287, 277, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
999, 2c6mA, 0.8605, 2.60, 0.957, 290, 282, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
1000, 1cm8B, 0.8605, 2.13, 0.366, 327, 273, PHOSPHORYLATED MAP KINASE P38-GAMMA
1001, 1cm8A, 0.8605, 2.13, 0.366, 327, 273, PHOSPHORYLATED MAP KINASE P38-GAMMA
1002, 5ouuB, 0.8604, 2.34, 0.297, 325, 279, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 22
1003, 4dgmA, 0.8604, 2.52, 0.301, 326, 282, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR APIGENIN
1004, 6fykC, 0.8603, 2.59, 0.286, 349, 280, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
1005, 5oniB, 0.8603, 2.42, 0.295, 334, 281, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
1006, 5buiA, 0.8603, 2.24, 0.375, 338, 277, ERK2 COMPLEXED WITH 2-PYRIDIYL TETRAHYDROAZAINDAZOLE
1007, 4ptgB, 0.8603, 2.01, 0.335, 332, 272, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
1008, 4n4sB, 0.8603, 2.14, 0.379, 337, 277, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
1009, 3vukA, 0.8603, 2.28, 0.363, 355, 278, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M5 IN MAP KINASE JNK1
1010, 3kxmA, 0.8603, 2.52, 0.301, 326, 282, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR K74
1011, 2r3gA, 0.8603, 2.34, 0.953, 287, 277, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1012, 2pvmA, 0.8603, 2.52, 0.298, 327, 282, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1013, 5owhA, 0.8602, 2.36, 0.304, 334, 280, HIGH SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3-AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
1014, 4f6sA, 0.8602, 2.17, 0.388, 328, 276, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 7 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]UREA)
1015, 3qtxA, 0.8602, 2.76, 0.982, 294, 285, CDK2 IN COMPLEX WITH INHIBITOR RC-2-35
1016, 5mo8B, 0.8601, 2.33, 0.301, 324, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1017, 5h8eA, 0.8601, 2.55, 0.301, 331, 282, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
1018, 3rpsA, 0.8601, 2.40, 0.304, 334, 280, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
1019, 3qa0B, 0.8601, 2.50, 0.306, 330, 281, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
1020, 3i60A, 0.8601, 2.00, 0.384, 335, 271, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-4-(2-(2-CHLOROPHENYLAMINO)-5- METHYLPYRIMIDIN-4-YL)-N-(2-HYDROXY-1-PHENYLETHYL)-1H-PYRROLE-2- CARBOXAMIDE
1021, 3fwqA, 0.8601, 2.70, 0.299, 334, 284, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
1022, 1w8cA, 0.8601, 2.45, 0.975, 290, 280, CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H- PURIN-2-YLAMINE AND MONOMERIC CDK2
1023, 1jamA, 0.8601, 2.52, 0.301, 327, 282, CRYSTAL STRUCTURE OF APO-FORM OF Z. MAYS CK2 PROTEIN KINASE ALPHA SUBUNIT
1024, 5nzzH, 0.8600, 1.96, 0.380, 335, 271, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
1025, 3q9xB, 0.8600, 2.49, 0.306, 330, 281, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
1026, 3ngaA, 0.8600, 2.55, 0.298, 331, 282, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
1027, 1zogA, 0.8600, 2.52, 0.301, 325, 282, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES
1028, 5cu6A, 0.8599, 2.47, 0.295, 327, 281, CRYSTAL STRUCTURE OF CK2ALPHA
1029, 5cu2B, 0.8599, 2.32, 0.297, 325, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
1030, 4fbxA, 0.8599, 2.38, 0.304, 333, 280, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT CRYSTALLIZED IN THE PRESENCE OF A BISUBSTRATE INHIBITOR
1031, 3fz1A, 0.8599, 2.30, 0.982, 284, 278, CRYSTAL STRUCTURE OF A BENZTHIOPHENE INHIBITOR BOUND TO HUMAN CYCLIN-DEPENDENT KINASE-2 (CDK-2)
1032, 5otyA, 0.8597, 2.47, 0.302, 327, 281, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712
1033, 5f95B, 0.8597, 2.08, 0.333, 338, 273, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
1034, 5cu3B, 0.8597, 2.34, 0.301, 324, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
1035, 2pvjA, 0.8597, 2.53, 0.294, 326, 282, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1036, 2c6iA, 0.8596, 2.61, 0.986, 292, 282, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
1037, 1jsvA, 0.8596, 2.31, 0.986, 287, 277, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL) AMINO]BENZENESULFONAMIDE
1038, 5n9lA, 0.8595, 2.54, 0.301, 329, 282, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE DIBENZOFURAN INHIBITOR TF (4B)
1039, 5mowB, 0.8595, 2.34, 0.297, 324, 279, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1040, 5cqwA, 0.8595, 2.57, 0.298, 331, 282, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
1041, 3u87B, 0.8595, 2.57, 0.301, 329, 282, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
1042, 5orjB, 0.8594, 2.35, 0.297, 324, 279, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3
1043, 2w17A, 0.8594, 2.12, 0.960, 278, 275, CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE COMPOUND (S)-8B
1044, 3r8lA, 0.8593, 2.64, 0.972, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR L3-4
1045, 3be9A, 0.8593, 2.53, 0.294, 327, 282, STRUCTURE-BASED DESIGN AND SYNTHESIS OF NOVEL MACROCYCLIC PYRAZOLO[15-A] [135]TRIAZINE COMPOUNDS AS POTENT INHIBITORS OF PROTEIN KINASE CK2 AND THEIR ANTICANCER ACTIVITIES
1046, 2r64A, 0.8593, 2.28, 0.982, 279, 277, CRYSTAL STRUCTURE OF A 3-AMINOINDAZOLE COMPOUND WITH CDK2
1047, 2pvkA, 0.8593, 2.53, 0.298, 327, 282, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1048, 1e1vA, 0.8592, 2.51, 0.943, 290, 280, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058
1049, 3r9hA, 0.8591, 2.70, 0.986, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-142
1050, 3mb7A, 0.8591, 2.58, 0.298, 330, 282, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (AMR)
1051, 1ungB, 0.8591, 1.50, 0.585, 268, 265, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1052, 5orkB, 0.8590, 2.32, 0.295, 323, 278, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 6
1053, 5k4iA, 0.8590, 1.98, 0.382, 336, 272, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH COMPOUND 22
1054, 4kwpA, 0.8590, 2.53, 0.298, 329, 282, CRYSTAL STRUCTURE OF HUMAN CK2-ALPHA IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR (K164) AT 1.25 A RESOLUTION
1055, 5mpjB, 0.8589, 2.36, 0.301, 324, 279, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
1056, 5cvhB, 0.8589, 2.37, 0.297, 324, 279, CRYSTAL STRUCTURE OF CK2ALPHA
1057, 3s0oA, 0.8589, 2.63, 0.936, 293, 283, CDK2 IN COMPLEX WITH INHIBITOR RC-1-138
1058, 3l1sB, 0.8589, 2.09, 0.332, 330, 271, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
1059, 5otrA, 0.8588, 2.48, 0.302, 327, 281, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 14
1060, 3u9cA, 0.8588, 2.53, 0.302, 331, 281, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
1061, 3qa0A, 0.8588, 2.59, 0.301, 330, 282, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
1062, 2r3iA, 0.8588, 2.44, 0.989, 289, 279, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1063, 5kwhA, 0.8586, 2.59, 0.301, 331, 282, CRYSTAL STRUCTURE OF CK2
1064, 3s00A, 0.8586, 2.66, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR L4-14
1065, 3qtuA, 0.8586, 2.61, 0.940, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-2-132
1066, 3ngaB, 0.8586, 2.58, 0.298, 331, 282, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
1067, 2vv9A, 0.8585, 2.19, 0.989, 279, 276, CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE
1068, 2bhhA, 0.8585, 1.93, 0.974, 274, 272, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE
1069, 5m56B, 0.8584, 2.65, 0.305, 328, 282, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
1070, 3ig7A, 0.8584, 2.23, 0.996, 278, 276, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFP WITH CDK-2
1071, 6ehkA, 0.8583, 2.49, 0.302, 327, 281, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712 AND COMPOUND 37
1072, 5t31A, 0.8583, 2.29, 0.330, 334, 276, EXPLOITING AN ASP-GLU SWITCH IN GLYCOGEN SYNTHASE KINASE 3 TO DESIGN PARALOG SELECTIVE INHIBITORS FOR USE IN ACUTE MYELOID LEUKEMIA
1073, 5m56A, 0.8583, 2.57, 0.301, 331, 282, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
1074, 5moeB, 0.8582, 2.31, 0.295, 323, 278, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1075, 3nwwA, 0.8582, 2.14, 0.383, 339, 274, P38 ALPHA KINASE COMPLEXED WITH A 2-AMINOTHIAZOL-5-YL-PYRIMIDINE BASED INHIBITOR
1076, 2pvlA, 0.8582, 2.55, 0.298, 327, 282, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1077, 3qqjA, 0.8581, 2.68, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR L2
1078, 2pvhA, 0.8581, 2.56, 0.294, 327, 282, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1079, 4fkgA, 0.8580, 2.23, 0.986, 286, 276, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
1080, 3tizA, 0.8580, 2.60, 0.982, 293, 283, CDK2 IN COMPLEX WITH NSC 111848
1081, 3rgfA, 0.8579, 2.13, 0.371, 321, 275, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC
1082, 3o17A, 0.8579, 2.44, 0.364, 357, 280, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
1083, 3l1sA, 0.8579, 1.97, 0.333, 336, 270, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
1084, 3fl5A, 0.8579, 2.56, 0.301, 324, 282, PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR QUINALIZARIN
1085, 5x8iB, 0.8578, 2.47, 0.287, 327, 279, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH COMPOUND 25
1086, 5ku8A, 0.8578, 2.55, 0.302, 328, 281, CRYSTAL STRUCTURE OF CK2
1087, 1fvtA, 0.8578, 2.34, 0.982, 282, 278, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR
1088, 1e1xA, 0.8578, 2.51, 0.989, 290, 280, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027
1089, 5omyA, 0.8577, 2.40, 0.304, 332, 280, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
1090, 5myvB, 0.8577, 2.27, 0.291, 349, 278, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
1091, 5larA, 0.8576, 2.55, 0.379, 350, 282, CRYSTAL STRUCTURE OF P38 ALPHA MAPK14 IN COMPLEX WITH VPC00628
1092, 3sqqA, 0.8576, 2.35, 0.986, 288, 279, CDK2 IN COMPLEX WITH INHIBITOR RC-3-96
1093, 6fyvA, 0.8575, 2.46, 0.272, 329, 279, X-RAY STRUCTURE OF CLK4-KD(146-480)/CX-4945 AT 2.46A 
1094, 5x8iA, 0.8574, 2.47, 0.287, 328, 279, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH COMPOUND 25
1095, 3warA, 0.8574, 2.47, 0.299, 334, 281, CRYSTAL STRUCTURE OF HUMAN CK2A
1096, 3u9cB, 0.8574, 2.53, 0.306, 331, 281, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
1097, 4fkwA, 0.8572, 2.28, 1.000, 280, 277, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1098, 5otdB, 0.8571, 2.37, 0.301, 324, 279, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 25
1099, 5h8bB, 0.8571, 2.60, 0.301, 331, 282, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
1100, 4qp8A, 0.8571, 2.38, 0.383, 335, 277, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
1101, 4ewqA, 0.8570, 2.28, 0.372, 346, 274, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A PYRIDAZINE BASED INHIBITOR
1102, 3nr9C, 0.8570, 2.51, 0.287, 347, 279, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
1103, 3at3A, 0.8570, 2.47, 0.302, 332, 281, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVATIVE
1104, 2w06A, 0.8570, 2.38, 0.982, 282, 278, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5C
1105, 1pxnA, 0.8570, 2.65, 0.951, 294, 283, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5-YL)- PYRIMIDIN-2-YLAMINO]-PHENOL
1106, 5othB, 0.8569, 2.39, 0.301, 324, 279, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 26
1107, 5cs6A, 0.8569, 2.54, 0.300, 327, 280, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
1108, 5cqwB, 0.8569, 2.60, 0.301, 331, 282, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
1109, 5t1hB, 0.8568, 2.61, 0.301, 331, 282, CRYSTAL STRUCTURE OF CK2
1110, 5mhqA, 0.8568, 2.42, 0.950, 291, 278, CCT068127 IN COMPLEX WITH CDK2
1111, 4ubaA, 0.8568, 2.47, 0.299, 333, 281, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
1112, 2f9gA, 0.8568, 2.23, 0.393, 332, 275, CRYSTAL STRUCTURE OF FUS3 PHOSPHORYLATED ON TYR182
1113, 5ot6B, 0.8567, 2.37, 0.301, 326, 279, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 19
1114, 5mxxA, 0.8567, 2.30, 0.295, 361, 278, CRYSTAL STRUCTURE OF HUMAN SR PROTEIN KINASE 1 (SRPK1) IN COMPLEX WITH COMPOUND 1
1115, 4ux9B, 0.8567, 2.21, 0.359, 327, 273, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
1116, 3le6A, 0.8567, 2.26, 0.960, 283, 275, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A PYRAZOLOBENZODIAZEPINE INHIBITOR
1117, 5ot5B, 0.8566, 2.39, 0.297, 325, 279, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 24
1118, 2uznA, 0.8566, 2.16, 0.989, 279, 275, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
1119, 5otoB, 0.8565, 2.37, 0.297, 324, 279, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 30
1120, 5mp8B, 0.8565, 2.28, 0.300, 323, 277, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1121, 5h8eB, 0.8565, 2.62, 0.301, 331, 282, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
1122, 5m4uA, 0.8564, 2.56, 0.302, 332, 281, ORTHORHOMBIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
1123, 5cvgA, 0.8563, 2.31, 0.310, 326, 277, CRYSTAL STRUCTURE OF CK2ALPHA WITH A NOVEL CLOSED CONFORMATION OF THE AD LOOP
1124, 4fi1A, 0.8563, 2.62, 0.277, 371, 282, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
1125, 3r7iA, 0.8563, 2.45, 0.964, 282, 279, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-74
1126, 3at4A, 0.8563, 2.49, 0.302, 331, 281, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVERTIVE
1127, 4rlkA, 0.8562, 2.57, 0.301, 327, 282, CRYSTAL STRUCTURE OF Z. MAYS CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
1128, 3q9xA, 0.8562, 2.61, 0.301, 330, 282, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
1129, 3nr9A, 0.8562, 2.60, 0.286, 341, 280, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
1130, 2g01A, 0.8562, 2.50, 0.357, 355, 280, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
1131, 5ci6B, 0.8561, 2.20, 0.361, 350, 274, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
1132, 4mwhA, 0.8561, 2.59, 0.277, 371, 282, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
1133, 4lfiA, 0.8561, 2.61, 0.277, 370, 282, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1134, 1pxkA, 0.8561, 2.57, 0.961, 290, 280, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)PYRIMIDIN-2-YL]- N -HYDROXYIMINOFORMAMIDE
1135, 4qp7B, 0.8558, 2.30, 0.384, 335, 276, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
1136, 4gubA, 0.8558, 2.51, 0.299, 329, 281, CASEIN KINASE II BOUND TO INHIBITOR
1137, 2r3mA, 0.8558, 2.09, 0.971, 278, 274, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1138, 4lfiB, 0.8557, 2.62, 0.277, 371, 282, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1139, 4aguC, 0.8556, 2.08, 0.397, 278, 272, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1140, 3w8lB, 0.8556, 2.51, 0.302, 326, 281, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
1141, 5lxdA, 0.8555, 2.33, 0.302, 385, 278, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 1610 (COMPOUND 2)
1142, 4qp4B, 0.8555, 2.36, 0.383, 335, 277, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
1143, 5lxdB, 0.8554, 2.33, 0.302, 385, 278, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 1610 (COMPOUND 2)
1144, 5kwhB, 0.8554, 2.62, 0.301, 331, 282, CRYSTAL STRUCTURE OF CK2
1145, 3rawA, 0.8554, 2.53, 0.286, 351, 280, CRYSTAL STRUCTURE OF HUMAN CDC-LIKE KINASE 3 ISOFORM IN COMPLEX WITH LEUCETTINE L41
1146, 1di8A, 0.8554, 2.42, 1.000, 283, 278, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-67-DIMETHOXYQUINAZOLINE
1147, 3rawB, 0.8553, 2.63, 0.285, 349, 281, CRYSTAL STRUCTURE OF HUMAN CDC-LIKE KINASE 3 ISOFORM IN COMPLEX WITH LEUCETTINE L41
1148, 2r3qA, 0.8553, 2.32, 0.986, 286, 276, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1149, 5ouuA, 0.8552, 2.31, 0.303, 324, 277, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 22
1150, 4fv6A, 0.8552, 1.88, 0.383, 332, 269, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E57
1151, 3qqgA, 0.8552, 2.71, 0.986, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR L2-5
1152, 2wu6A, 0.8552, 2.59, 0.285, 350, 281, CRYSTAL STRUCTURE OF THE HUMAN CLK3 IN COMPLEX WITH DKI
1153, 5myvC, 0.8551, 2.31, 0.295, 348, 278, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
1154, 3r7uA, 0.8550, 2.47, 0.964, 282, 279, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-75
1155, 1m2qA, 0.8550, 2.65, 0.301, 327, 282, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO-XANTEN-9- ONE/CK2 KINASE COMPLEX
1156, 5lxcB, 0.8549, 2.40, 0.302, 385, 278, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 5372 (COMPOUND 1)
1157, 5lxcA, 0.8549, 2.25, 0.304, 383, 276, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 5372 (COMPOUND 1)
1158, 3rpsB, 0.8549, 2.45, 0.304, 334, 280, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
1159, 2w05A, 0.8549, 2.13, 0.989, 276, 273, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5B
1160, 2vtaA, 0.8549, 2.30, 0.989, 278, 276, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1161, 2h96B, 0.8549, 2.54, 0.354, 357, 280, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
1162, 1f0qA, 0.8549, 2.64, 0.298, 329, 282, CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT OF PROTEIN KINASE CK2 IN COMPLEX WITH THE NUCLEOTIDE COMPETITIVE INHIBITOR EMODIN
1163, 3q9zB, 0.8548, 2.58, 0.306, 332, 281, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
1164, 1w0xC, 0.8548, 2.45, 0.982, 280, 278, CRYSTAL STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE.
1165, 4fkjA, 0.8547, 2.18, 0.989, 278, 275, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
1166, 5j1wB, 0.8545, 2.57, 0.283, 337, 279, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
1167, 3unkA, 0.8545, 2.80, 0.986, 295, 285, CDK2 IN COMPLEX WITH INHIBITOR YL5-083
1168, 3dt1A, 0.8545, 2.44, 0.380, 356, 276, P38 COMPLEXED WITH A QUINAZOLINE INHIBITOR
1169, 1ke6A, 0.8545, 2.33, 0.986, 280, 277, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4- [2-(7-OXO-67-DIHYDRO-8H-[13]THIAZOLO[54-E]INDOL-8- YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
1170, 3r9oA, 0.8544, 2.52, 0.989, 282, 279, CDK2 IN COMPLEX WITH INHIBITOR RC-2-143
1171, 3mvlA, 0.8544, 2.11, 0.385, 339, 273, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
1172, 1ke7A, 0.8544, 2.45, 0.982, 281, 278, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(22- DIOXIDO-13-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5- (13-OXAZOL-5-YL)-13-DIHYDRO-2H-INDOL-2-ONE
1173, 4yc6E, 0.8543, 2.69, 0.653, 285, 277, CDK1/CKS1
1174, 4ek6A, 0.8543, 2.14, 0.993, 278, 274, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
1175, 3hl7A, 0.8543, 2.10, 0.386, 336, 272, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH SD-0006
1176, 5oyfA, 0.8542, 2.56, 0.302, 327, 281, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 31
1177, 4yc6G, 0.8542, 2.57, 0.652, 285, 276, CDK1/CKS1
1178, 4ib5A, 0.8542, 2.57, 0.306, 331, 281, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1179, 4aa4A, 0.8542, 2.61, 0.385, 347, 278, P38ALPHA MAP KINASE BOUND TO CMPD 22
1180, 2wu7A, 0.8542, 2.63, 0.281, 348, 281, CRYSTAL STRUCTURE OF THE HUMAN CLK3 IN COMPLEX WITH V25
1181, 5otiA, 0.8541, 2.54, 0.302, 327, 281, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 27
1182, 5ku8B, 0.8541, 2.64, 0.301, 331, 282, CRYSTAL STRUCTURE OF CK2
1183, 3r8vA, 0.8541, 2.79, 0.986, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR RC-1-135
1184, 2vthA, 0.8541, 2.31, 0.989, 278, 276, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN
1185, 1jwhB, 0.8541, 2.50, 0.299, 335, 281, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
1186, 5cshB, 0.8540, 2.30, 0.301, 323, 276, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
1187, 5aniA, 0.8538, 2.29, 0.964, 280, 276, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-CHLORO-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1188, 4fkqA, 0.8538, 2.51, 0.975, 283, 280, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1189, 1dm2A, 0.8538, 2.03, 0.967, 274, 272, HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE
1190, 5oszA, 0.8537, 2.57, 0.302, 327, 281, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 23
1191, 3hllA, 0.8537, 1.99, 0.378, 337, 270, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH PH-797804
1192, 3ezvA, 0.8537, 2.13, 0.978, 277, 274, CDK-2 WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
1193, 2ozaB, 0.8537, 2.36, 0.385, 340, 275, STRUCTURE OF P38ALPHA COMPLEX
1194, 2j9mA, 0.8536, 2.06, 0.982, 275, 273, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE
1195, 1jowB, 0.8536, 1.73, 0.493, 277, 268, CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN CDK6 AND A VIRAL CYCLIN
1196, 1h08A, 0.8535, 2.39, 0.996, 283, 277, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
1197, 3nieA, 0.8534, 2.65, 0.396, 369, 280, CRYSTAL STRUCTURE OF PF11_0147
1198, 5clpA, 0.8533, 2.33, 0.304, 322, 276, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
1199, 4fv8A, 0.8533, 1.91, 0.387, 333, 269, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E63
1200, 6ehuA, 0.8532, 2.56, 0.302, 327, 281, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
1201, 1ke8A, 0.8532, 2.41, 0.982, 282, 278, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO- 12-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(13- THIAZOL-2-YL)BENZENESULFONAMIDE
1202, 4yc6A, 0.8531, 2.58, 0.652, 285, 276, CDK1/CKS1
1203, 3qzgA, 0.8531, 2.76, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-76
1204, 5owlA, 0.8530, 2.70, 0.301, 331, 282, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
1205, 3nr9B, 0.8530, 2.62, 0.287, 347, 279, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
1206, 2vtiA, 0.8530, 2.40, 0.982, 280, 277, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1207, 1g5sA, 0.8530, 2.05, 0.985, 275, 272, CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717
1208, 4yc6C, 0.8529, 2.77, 0.655, 285, 278, CDK1/CKS1
1209, 3qqhA, 0.8528, 2.73, 0.989, 294, 284, CDK2 IN COMPLEX WITH INHIBITOR L2-2
1210, 3amyA, 0.8528, 2.11, 0.305, 318, 272, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH APIGENIN
1211, 4fkrA, 0.8526, 2.40, 0.986, 282, 278, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1212, 1pxmA, 0.8526, 2.56, 0.975, 290, 280, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL
1213, 4ib5B, 0.8524, 2.74, 0.298, 329, 282, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1214, 4fa2A, 0.8524, 2.04, 0.385, 339, 270, HUMAN P38 ALPHA MITOGEN-ACTIVATED KINASE IN COMPLEX WITH SB239063
1215, 5y9mA, 0.8522, 2.34, 0.292, 320, 277, CRYSTAL STRUCTURE OF CK2A2 FORM 3 
1216, 4f9wA, 0.8522, 2.07, 0.384, 336, 271, HUMAN P38ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
1217, 1h00A, 0.8522, 2.18, 0.978, 278, 274, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
1218, 6ft9B, 0.8520, 2.61, 0.287, 337, 279, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
1219, 6fyoA, 0.8519, 2.65, 0.287, 331, 279, X-RAY STRUCTURE OF CLK1-KD(148-484)/CPD-2 AT 2.32A 
1220, 4iq6A, 0.8519, 2.02, 0.338, 324, 269, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
1221, 4f9yA, 0.8518, 2.12, 0.382, 339, 272, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
1222, 3bx5A, 0.8518, 2.30, 0.387, 338, 274, P38 ALPHA MAP KINASE COMPLEXED WITH BMS-640994
1223, 5otqA, 0.8517, 2.60, 0.302, 327, 281, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 33
1224, 5jq8A, 0.8517, 2.12, 0.985, 278, 273, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0943
1225, 4zthA, 0.8517, 2.15, 0.384, 339, 271, STRUCTURE OF HUMAN P38AMAPK-ARYLPYRIDAZINYLPYRIDINE FRAGMENT COMPLEX USED IN INHIBITOR DISCOVERY
1226, 4ek8A, 0.8517, 2.26, 0.989, 280, 275, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1227, 3o2mA, 0.8517, 2.30, 0.366, 358, 276, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
1228, 2balA, 0.8516, 2.18, 0.386, 337, 272, P38ALPHA MAP KINASE BOUND TO PYRAZOLOAMINE
1229, 4ub7A, 0.8515, 2.58, 0.293, 334, 280, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26) SHOWING AN EXTREME DISTORTION OF THE ATP-BINDING LOOP COMBINED WITH A PI-HALOGEN BOND
1230, 4bzdA, 0.8515, 2.21, 0.923, 277, 274, STRUCTURE OF CDK2 IN COMPLEX WITH A BENZIMIDAZOPYRIMIDINE
1231, 3py0A, 0.8515, 2.70, 0.951, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR SU9516
1232, 6g33C, 0.8514, 2.60, 0.287, 336, 279, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
1233, 5lw1H, 0.8514, 2.41, 0.344, 355, 276, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1234, 2gmxB, 0.8514, 2.33, 0.361, 357, 277, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
1235, 5lw1B, 0.8513, 2.42, 0.344, 355, 276, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1236, 3pxyA, 0.8513, 2.76, 0.951, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR JWS648
1237, 3kf7A, 0.8513, 2.08, 0.376, 337, 271, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A TRIAZOLOPYRIMIDINE COMPOUND
1238, 1ke5A, 0.8513, 2.50, 0.996, 281, 278, CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO-12-DIHYDRO-3H- INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
1239, 6ft8A, 0.8512, 2.65, 0.287, 338, 279, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 8G 
1240, 5j1vB, 0.8512, 2.52, 0.288, 337, 278, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
1241, 4fktA, 0.8512, 2.24, 0.989, 278, 275, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1242, 2btsA, 0.8512, 2.07, 0.971, 274, 272, STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032
1243, 2vtqA, 0.8511, 2.01, 0.989, 274, 271, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1244, 1z57A, 0.8511, 2.65, 0.287, 333, 279, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH 10Z-HYMENIALDISINE
1245, 4aacA, 0.8510, 2.50, 0.389, 350, 275, P38ALPHA MAP KINASE BOUND TO CMPD 29
1246, 1ke9A, 0.8510, 2.40, 1.000, 281, 277, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4- ({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2- OXO-23-DIHYDRO-1H-INDOLE
1247, 5xyyA, 0.8509, 2.52, 0.384, 350, 276, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
1248, 2r3kA, 0.8509, 2.19, 0.985, 277, 274, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1249, 1vyzA, 0.8509, 2.25, 0.993, 279, 274, STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227
1250, 6eq9A, 0.8507, 2.46, 0.355, 350, 276, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AMP-PCP 
1251, 2x7gA, 0.8507, 2.35, 0.285, 344, 277, STRUCTURE OF HUMAN SERINE-ARGININE-RICH PROTEIN-SPECIFIC KINASE 2 (SRPK2) BOUND TO PURVALANOL B
1252, 3rocA, 0.8506, 2.12, 0.376, 337, 271, CRYSTAL STRUCTURE OF HUMAN P38 ALPHA COMPLEXED WITH A PYRIMIDINONE COMPOUND
1253, 3o2mB, 0.8506, 2.39, 0.365, 358, 277, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
1254, 4fksA, 0.8505, 2.19, 0.989, 275, 274, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1255, 3rzbA, 0.8505, 2.53, 0.982, 282, 278, CDK2 IN COMPLEX WITH INHIBITOR RC-2-23
1256, 5j1wA, 0.8504, 2.61, 0.287, 338, 279, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
1257, 3n9xB, 0.8504, 2.73, 0.409, 374, 281, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
1258, 2vu3A, 0.8504, 2.11, 0.993, 285, 272, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1259, 3o17B, 0.8503, 2.39, 0.365, 357, 277, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
1260, 5y9mX, 0.8502, 2.34, 0.293, 319, 276, CRYSTAL STRUCTURE OF CK2A2 FORM 3 
1261, 4fkpA, 0.8501, 2.24, 0.989, 279, 275, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1262, 1ywrA, 0.8501, 2.22, 0.388, 338, 273, CRYSTAL STRUCTURE ANALYSIS OF INACTIVE P38 KINASE DOMAIN IN COMPLEX WITH A MONOCYCLIC PYRAZOLONE INHIBITOR
1263, 1oukA, 0.8501, 2.48, 0.385, 348, 275, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR
1264, 3q9zA, 0.8499, 2.70, 0.298, 332, 282, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
1265, 5m4iA, 0.8497, 2.55, 0.294, 331, 279, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
1266, 4i5hA, 0.8497, 2.09, 0.381, 335, 270, CRYSTAL STRUCTURE OF A DOUBLE MUTANT RAT ERK2 COMPLEXED WITH A TYPE II QUINAZOLINE INHIBITOR
1267, 2vtnA, 0.8496, 2.13, 0.985, 274, 272, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1268, 4aguA, 0.8493, 2.17, 0.399, 277, 271, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1269, 3gfeA, 0.8493, 2.61, 0.379, 352, 277, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR
1270, 5yf9B, 0.8492, 2.32, 0.291, 319, 275, CRYSTAL STRUCTURE OF CK2A2 FORM-2 
1271, 5lw1E, 0.8491, 2.44, 0.344, 355, 276, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1272, 5anoA, 0.8489, 2.23, 0.978, 277, 274, CRYSTAL STRUCTURE OF CDK2 PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1273, 2vtjA, 0.8489, 2.22, 0.993, 276, 274, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1274, 4dglD, 0.8488, 2.69, 0.301, 328, 282, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
1275, 2r3jA, 0.8487, 2.23, 0.985, 278, 274, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1276, 3ocgA, 0.8486, 2.14, 0.376, 336, 271, P38 ALPHA KINASE COMPLEXED WITH A 5-AMINO-PYRAZOLE BASED INHIBITOR
1277, 4ehvA, 0.8485, 2.25, 0.380, 337, 271, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F10 AND RL87
1278, 3v6rA, 0.8485, 2.46, 0.350, 349, 277, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1279, 3mvlB, 0.8485, 2.22, 0.385, 339, 273, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
1280, 3bv2A, 0.8485, 2.22, 0.380, 337, 271, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 30
1281, 3begA, 0.8485, 2.39, 0.285, 348, 277, CRYSTAL STRUCTURE OF SR PROTEIN KINASE 1 COMPLEXED TO ITS SUBSTRATE ASF/SF2
1282, 2gtnA, 0.8485, 2.12, 0.381, 337, 270, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-951717
1283, 6ft9A, 0.8484, 2.73, 0.286, 336, 280, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
1284, 1giiA, 0.8484, 2.48, 0.971, 279, 277, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
1285, 5yf9X, 0.8483, 2.32, 0.295, 319, 275, CRYSTAL STRUCTURE OF CK2A2 FORM-2 
1286, 4lopB, 0.8483, 2.25, 0.363, 350, 273, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1287, 3qtrA, 0.8483, 2.52, 0.978, 282, 278, CDK2 IN COMPLEX WITH INHIBITOR RC-1-148
1288, 3oz6A, 0.8483, 2.62, 0.372, 343, 277, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
1289, 2b55A, 0.8483, 2.24, 0.996, 276, 273, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH INDENOPYRAXOLE DIN-101312
1290, 1ouyA, 0.8483, 2.50, 0.385, 350, 275, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROPYRIDO- PYRIMIDINE INHIBITOR
1291, 4aa5A, 0.8482, 2.32, 0.392, 340, 273, P38ALPHA MAP KINASE BOUND TO CMPD 33
1292, 2ghmA, 0.8482, 2.17, 0.384, 336, 271, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-895449
1293, 4acmA, 0.8481, 2.25, 0.971, 277, 274, CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL] SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE
1294, 3nieB, 0.8481, 2.66, 0.398, 367, 279, CRYSTAL STRUCTURE OF PF11_0147
1295, 3i5zA, 0.8480, 2.02, 0.388, 331, 268, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-N-(2-HYDROXY-1-PHENYLETHYL)-4- (5-METHYL-2-(PHENYLAMINO)PYRIMIDIN-4-YL)-1H-PYRROLE-2-CARBOXAMIDE
1296, 4kinB, 0.8479, 2.35, 0.383, 341, 274, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1297, 3od6X, 0.8479, 2.45, 0.357, 344, 277, CRYSTAL STRUCTURE OF P38ALPHA Y323T ACTIVE MUTANT
1298, 5otlA, 0.8478, 2.34, 0.302, 320, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 29
1299, 5bveA, 0.8477, 1.84, 0.383, 330, 266, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
1300, 3o0gB, 0.8477, 1.42, 0.590, 264, 261, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
1301, 1yw2A, 0.8477, 2.09, 0.381, 341, 270, MUTATED MUS MUSCULUS P38 KINASE (MP38)
1302, 1i09A, 0.8477, 2.07, 0.342, 338, 269, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
1303, 6ehuB, 0.8476, 2.66, 0.302, 327, 281, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
1304, 4nj3A, 0.8476, 2.21, 0.993, 277, 273, MODULATING THE INTERACTION BETWEEN CDK2 AND CYCLIN A WITH A QUINOLINE- BASED INHIBITOR
1305, 4loqB, 0.8476, 2.22, 0.363, 351, 273, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1306, 3lltA, 0.8476, 2.49, 0.265, 341, 275, CRYSTAL STRUCTURE OF PF14_0431 KINASE DOMAIN.
1307, 3lhjA, 0.8475, 2.49, 0.369, 341, 274, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR.
1308, 3u8wA, 0.8474, 2.61, 0.379, 349, 277, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A TRIAZOLOPYRIDAZINONE INHIBITOR
1309, 3ds6D, 0.8474, 2.55, 0.384, 349, 276, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1310, 3bv3A, 0.8473, 2.23, 0.380, 338, 271, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 2
1311, 1m7qA, 0.8472, 2.49, 0.385, 348, 275, CRYSTAL STRUCTURE OF P38 MAP KINASE IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
1312, 3e7oA, 0.8471, 2.42, 0.342, 342, 275, CRYSTAL STRUCTURE OF JNK2
1313, 4fv5A, 0.8470, 2.03, 0.384, 330, 268, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK9
1314, 3unjA, 0.8470, 2.78, 0.951, 294, 283, CDK2 IN COMPLEX WITH INHIBITOR YL1-038-31
1315, 5j1vA, 0.8469, 2.66, 0.287, 338, 279, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
1316, 4loqA, 0.8469, 2.22, 0.363, 352, 273, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1317, 4lopD, 0.8468, 2.42, 0.375, 351, 275, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1318, 4loqD, 0.8467, 2.24, 0.363, 351, 273, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1319, 2vttA, 0.8466, 2.05, 0.989, 272, 270, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1320, 3s3iA, 0.8464, 2.52, 0.380, 349, 276, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1321, 2duvA, 0.8464, 2.03, 1.000, 272, 270, STRUCTURE OF CDK2 WITH A 3-HYDROXYCHROMONES
1322, 1gihA, 0.8464, 2.31, 0.989, 276, 274, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
1323, 4kipA, 0.8462, 2.28, 0.375, 337, 272, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
1324, 4eh2A, 0.8462, 2.11, 0.372, 337, 269, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F1 AND RL87
1325, 3sw4A, 0.8462, 2.41, 0.986, 279, 276, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1326, 3queA, 0.8462, 2.15, 0.381, 343, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH SKEPINONE-L
1327, 3hp2A, 0.8462, 2.17, 0.381, 341, 270, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIDINONE COMPOUND
1328, 3ezrA, 0.8462, 2.07, 0.985, 273, 271, CDK-2 WITH INDAZOLE INHIBITOR 17 BOUND AT ITS ACTIVE SITE
1329, 5bvdA, 0.8461, 1.87, 0.383, 330, 266, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
1330, 5andA, 0.8461, 2.27, 0.963, 273, 273, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 2-IMIDAZOL-1-YL-1H- BENZIMIDAZOLE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1331, 4o2zA, 0.8461, 2.38, 0.342, 363, 272, CRYSTAL STRUCTURE OF MPK3 FROM LEISHMANIA DONOVANI LDBPK_100540 IN THE PRESENCE OF NVP-BBT594
1332, 3n9xA, 0.8461, 2.73, 0.411, 374, 280, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
1333, 3fklA, 0.8460, 2.30, 0.386, 344, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO9552
1334, 4fv9A, 0.8458, 2.02, 0.384, 331, 268, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E71
1335, 2r3nA, 0.8458, 2.17, 0.993, 275, 272, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1336, 2lgcA, 0.8458, 2.43, 0.385, 359, 273, JOINT NMR AND X-RAY REFINEMENT REVEALS THE STRUCTURE OF A NOVEL DIBENZO[AD]CYCLOHEPTENONE INHIBITOR/P38 MAP KINASE COMPLEX IN SOLUTION
1337, 3v6sA, 0.8457, 2.56, 0.353, 349, 278, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1338, 3rahA, 0.8457, 2.61, 0.924, 282, 278, CDK2 IN COMPLEX WITH INHIBITOR RC-2-22
1339, 2qkrA, 0.8457, 2.07, 0.577, 273, 267, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH INDIRUBIN 3 -MONOXIME BOUND
1340, 4lopA, 0.8456, 2.43, 0.375, 351, 275, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1341, 4fv4A, 0.8456, 2.12, 0.384, 329, 268, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK7
1342, 3qtsA, 0.8456, 2.63, 0.978, 282, 279, CDK2 IN COMPLEX WITH INHIBITOR RC-2-12
1343, 2zb0A, 0.8456, 2.57, 0.384, 349, 276, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
1344, 2r3lA, 0.8454, 2.21, 0.985, 275, 273, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1345, 4wuaA, 0.8453, 2.46, 0.285, 344, 277, CRYSTAL STRUCTURE OF HUMAN SRPK1 COMPLEXED TO AN INHIBITOR SRPIN340
1346, 3mptA, 0.8453, 2.37, 0.377, 347, 273, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A PYRROLE-2- CARBOXAMIDE INHIBITOR
1347, 2btrA, 0.8452, 2.09, 0.996, 275, 271, STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873
1348, 4f9aC, 0.8451, 2.62, 0.266, 317, 278, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND NUCLEOTIDE
1349, 3ds6A, 0.8450, 2.51, 0.362, 343, 276, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1350, 5ankA, 0.8448, 2.18, 0.974, 273, 271, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 246-TRIOXO-1- PHENYL-HEXAHYDROPYRIMIDINE-5-CARBOXAMIDE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1351, 3rprA, 0.8448, 2.62, 0.924, 282, 278, CDK2 IN COMPLEX WITH INHIBITOR RC-2-49
1352, 3rmfA, 0.8448, 2.34, 0.975, 278, 275, CDK2 IN COMPLEX WITH INHIBITOR RC-2-33
1353, 4f9aA, 0.8447, 2.63, 0.266, 315, 278, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND NUCLEOTIDE
1354, 4r3cA, 0.8446, 2.03, 0.377, 335, 268, CRYSTAL STRUCTURE OF P38 ALPHA MAP KINASE IN COMPLEX WITH A NOVEL ISOFORM SELECTIVE DRUG CANDIDATE
1355, 4jr7A, 0.8446, 2.57, 0.274, 367, 277, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1356, 2bheA, 0.8446, 2.15, 0.967, 274, 272, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE
1357, 5ztnA, 0.8445, 2.35, 0.304, 395, 276, THE CRYSTAL STRUCTURE OF HUMAN DYRK2 IN COMPLEX WITH CURCUMIN 
1358, 2g01B, 0.8445, 2.60, 0.361, 356, 280, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
1359, 1wbpA, 0.8445, 2.46, 0.282, 350, 277, SRPK1 BOUND TO 9MER DOCKING MOTIF PEPTIDE
1360, 1v0pA, 0.8445, 2.62, 0.625, 277, 275, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
1361, 1r78A, 0.8445, 2.14, 0.989, 273, 271, CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR
1362, 1r3cA, 0.8445, 2.57, 0.384, 349, 276, THE STRUCTURE OF P38ALPHA C162S MUTANT
1363, 3rpyA, 0.8444, 2.32, 0.978, 277, 274, CDK2 IN COMPLEX WITH INHIBITOR RC-2-40
1364, 1wbwA, 0.8443, 2.55, 0.385, 351, 275, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1365, 5ztnB, 0.8442, 2.36, 0.304, 395, 276, THE CRYSTAL STRUCTURE OF HUMAN DYRK2 IN COMPLEX WITH CURCUMIN 
1366, 5m44A, 0.8442, 2.63, 0.301, 329, 279, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
1367, 4aguB, 0.8442, 2.22, 0.400, 276, 270, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1368, 3zyaA, 0.8442, 2.31, 0.373, 346, 271, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO- DIBENZOSUBERONE
1369, 5xv7A, 0.8440, 2.48, 0.282, 350, 277, SRPK1 IN COMPLEX WITH ALECTINIB
1370, 2ghlA, 0.8440, 2.21, 0.381, 334, 270, MUTANT MUS MUSCULUS P38 KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-874743
1371, 1w84A, 0.8439, 2.57, 0.384, 351, 276, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1372, 3o8pA, 0.8438, 2.18, 0.370, 336, 270, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1373, 1di9A, 0.8438, 2.57, 0.384, 348, 276, THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH 4-[3-METHYLSULFANYLANILINO]-67- DIMETHOXYQUINAZOLINE
1374, 3uvqA, 0.8437, 2.06, 0.381, 333, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOSUBERONE DERIVATIVE
1375, 3fmhA, 0.8437, 2.36, 0.382, 347, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((R)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
1376, 1urwA, 0.8437, 2.23, 0.911, 274, 271, CDK2 IN COMPLEX WITH AN IMIDAZO[12-B]PYRIDAZINE
1377, 4eh6A, 0.8436, 2.12, 0.369, 335, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F5 AND RL87
1378, 3r9nA, 0.8436, 2.67, 0.899, 282, 278, CDK2 IN COMPLEX WITH INHIBITOR RC-2-21
1379, 1oitA, 0.8436, 2.15, 0.974, 273, 270, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
1380, 5fp6A, 0.8435, 2.43, 0.978, 278, 276, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 3-(47-DICHLORO-1H-INDOL-3-YL)PROP-2-YN-1-OL (AT17833) IN AN ALTERNATE BINDING SITE.
1381, 3s1hA, 0.8435, 2.31, 0.974, 277, 274, CDK2 IN COMPLEX WITH INHIBITOR RC-2-39
1382, 6g33B, 0.8434, 2.79, 0.286, 337, 280, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
1383, 3e3pB, 0.8434, 2.53, 0.337, 337, 276, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
1384, 6gihA, 0.8433, 2.56, 0.306, 324, 278, CRYSTAL STRUCTURE OF CK2ALPHA WITH CAM187 BOUND 
1385, 5my8A, 0.8433, 2.51, 0.295, 355, 278, CRYSTAL STRUCTURE OF SRPK1 IN COMPLEX WITH SPHINX31
1386, 4ynoA, 0.8432, 2.49, 0.391, 342, 274, CRYSTAL STRUCTURE OF MAPK13 AT INACTIVE FORM
1387, 4kinC, 0.8431, 2.40, 0.376, 338, 274, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1388, 4eh7A, 0.8430, 2.19, 0.375, 337, 269, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F6 AND RL87
1389, 3gc9B, 0.8430, 2.43, 0.370, 339, 273, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
1390, 3gc8B, 0.8430, 2.42, 0.371, 346, 272, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
1391, 2vagA, 0.8429, 2.68, 0.285, 330, 277, CRYSTAL STRUCTURE OF DI-PHOSPHORYLATED HUMAN CLK1 IN COMPLEX WITH A NOVEL SUBSTITUTED INDOLE INHIBITOR
1392, 4kiqB, 0.8428, 2.30, 0.375, 338, 272, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
1393, 1w82A, 0.8428, 2.46, 0.381, 351, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1394, 4kiqC, 0.8427, 2.29, 0.375, 338, 272, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
1395, 3flyA, 0.8427, 2.43, 0.381, 347, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-ISOPROPYLAMINO-8-METHYL-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
1396, 3flwA, 0.8427, 2.43, 0.374, 345, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH PAMAPIMOD
1397, 3e3pA, 0.8427, 2.44, 0.342, 337, 275, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
1398, 3d7zA, 0.8427, 2.59, 0.385, 348, 275, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
1399, 5y86A, 0.8426, 2.53, 0.303, 391, 277, CRYSTAL STRUCTURE OF KINASE 
1400, 3rakA, 0.8426, 2.32, 0.974, 277, 274, CDK2 IN COMPLEX WITH INHIBITOR RC-2-32
1401, 3r8mA, 0.8426, 2.79, 0.968, 286, 281, CDK2 IN COMPLEX WITH INHIBITOR L3-3
1402, 3kvwA, 0.8426, 2.39, 0.304, 403, 276, CRYSTAL STRUCTURE OF DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 2 (DYRK2) IN COMPLEX WITH AN INDIRUBIN LIGAND
1403, 1wakA, 0.8426, 2.51, 0.282, 353, 277, X-RAY STRUCTURE OF SRPK1
1404, 1v0bA, 0.8426, 2.78, 0.621, 286, 277, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
1405, 4lopC, 0.8425, 2.08, 0.377, 341, 268, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
1406, 4eh8A, 0.8425, 2.13, 0.369, 336, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F7 AND RL87
1407, 3ralA, 0.8425, 2.34, 0.934, 277, 273, CDK2 IN COMPLEX WITH INHIBITOR RC-2-34
1408, 4f9bC, 0.8424, 2.68, 0.266, 316, 278, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
1409, 1bl6A, 0.8424, 2.52, 0.371, 351, 275, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB216995
1410, 5etcA, 0.8423, 2.59, 0.384, 355, 276, STRUCTURE OF INACTIVE MAPK14 WITH ORDERED ACTIVATION LOOP
1411, 5ax3A, 0.8423, 2.18, 0.383, 329, 269, CRYSTAL STRUCTURE OF ERK2 COMPLEXED WITH ALLOSTERIC AND ATP- COMPETITIVE INHIBITORS.
1412, 4f9bA, 0.8423, 2.66, 0.266, 318, 278, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
1413, 4ic8B, 0.8422, 2.59, 0.380, 336, 276, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
1414, 5ci6A, 0.8421, 2.19, 0.357, 335, 269, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
1415, 5bujA, 0.8421, 2.08, 0.381, 331, 268, ERK2 COMPLEXED WITH A N-H TETRAHYDROAZAINDAZOLE
1416, 4eh3A, 0.8421, 2.21, 0.375, 339, 269, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F2 AND RL87
1417, 3newA, 0.8421, 2.19, 0.378, 334, 270, P38-ALPHA COMPLEXED WITH COMPOUND 10
1418, 3itzA, 0.8421, 2.72, 0.379, 357, 277, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDAZINE INHIBITOR
1419, 2r7iB, 0.8421, 2.60, 0.292, 322, 277, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1420, 1v1kA, 0.8420, 2.31, 0.982, 277, 274, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
1421, 4azfA, 0.8419, 2.39, 0.304, 404, 276, HUMAN DYRK2 IN COMPLEX WITH LEUCETTINE L41
1422, 4kipB, 0.8418, 2.27, 0.387, 338, 271, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
1423, 4bghA, 0.8418, 2.31, 0.989, 275, 273, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PAN-CDK INHIBITOR
1424, 3sw7A, 0.8417, 2.35, 0.978, 278, 275, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1425, 3rp9A, 0.8416, 2.75, 0.397, 350, 277, CRYSTAL STRUCTURE OF THE APO MAPK FROM TOXOPLASMA GONDII 25.M01780 OR TGME49_007820
1426, 5bueA, 0.8415, 2.08, 0.381, 329, 268, ERK2 COMPLEXED WITH N-BENZYLPYRIDONE TETRAHYDROAZAINDAZOLE
1427, 3rinA, 0.8415, 2.74, 0.379, 349, 277, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1428, 3flzA, 0.8415, 2.44, 0.381, 347, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 8-METHYL-6-PHENOXY-2- (TETRAHYDRO-PYRAN-4-YLAMINO)-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
1429, 2fvdA, 0.8415, 2.07, 0.981, 284, 270, CYCLIN DEPENDENT KINASE 2 (CDK2) WITH DIAMINOPYRIMIDINE INHIBITOR
1430, 2r7iD, 0.8414, 2.61, 0.292, 322, 277, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1431, 3ds6B, 0.8412, 2.78, 0.380, 343, 279, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1432, 4kiqD, 0.8411, 2.32, 0.375, 338, 272, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
1433, 3nnwA, 0.8411, 2.49, 0.381, 349, 273, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP802
1434, 3qudA, 0.8410, 2.31, 0.380, 345, 271, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO-BENZOPHENONE
1435, 1wboA, 0.8410, 2.62, 0.384, 351, 276, FRAGMENT BASED P38 INHIBITORS
1436, 3k2lA, 0.8408, 2.53, 0.301, 402, 276, CRYSTAL STRUCTURE OF DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 2 (DYRK2)
1437, 3fmkA, 0.8408, 2.33, 0.382, 346, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((S)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
1438, 3e92A, 0.8408, 2.58, 0.387, 348, 274, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
1439, 1zz2A, 0.8407, 2.30, 0.386, 337, 272, TWO CLASSES OF P38ALPHA MAP KINASE INHIBITORS HAVING A COMMON DIPHENYLETHER CORE BUT EXHIBITING DIVERGENT BINDING MODES
1440, 3nnvA, 0.8406, 2.53, 0.380, 348, 274, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP437
1441, 2r7iA, 0.8406, 2.62, 0.292, 322, 277, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1442, 4y5hA, 0.8404, 2.46, 0.358, 349, 274, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1443, 4fkoA, 0.8404, 2.45, 0.975, 291, 276, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1444, 4f99A, 0.8404, 2.67, 0.266, 312, 278, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND NUCLEOTIDE
1445, 3iphA, 0.8399, 2.48, 0.382, 345, 272, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH A BIPHENYLAMIDE INHIBITOR
1446, 2rg6A, 0.8399, 2.24, 0.378, 335, 270, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11J
1447, 2pk9C, 0.8399, 1.58, 0.573, 266, 260, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
1448, 5cs6B, 0.8398, 2.26, 0.310, 316, 271, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
1449, 3mpaA, 0.8397, 1.99, 0.368, 331, 266, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1450, 3gc8A, 0.8397, 2.51, 0.371, 347, 272, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
1451, 2zb1A, 0.8397, 2.49, 0.371, 345, 272, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
1452, 1wbvA, 0.8397, 2.49, 0.381, 351, 273, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1453, 1p2aA, 0.8397, 2.04, 0.978, 271, 269, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A TRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR
1454, 3tg1A, 0.8396, 2.13, 0.375, 334, 269, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH A MAPK DOCKING PARTNER
1455, 3oz6B, 0.8396, 2.79, 0.394, 341, 277, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
1456, 4y46A, 0.8395, 2.46, 0.361, 340, 274, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1457, 3nnuA, 0.8395, 2.35, 0.384, 348, 271, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP1376
1458, 3gc9A, 0.8395, 2.41, 0.369, 335, 271, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
1459, 3ds6C, 0.8395, 2.53, 0.382, 349, 275, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
1460, 1zzlA, 0.8395, 2.66, 0.380, 351, 276, CRYSTAL STRUCTURE OF P38 WITH TRIAZOLOPYRIDINE
1461, 1bmkA, 0.8394, 2.70, 0.383, 351, 277, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655
1462, 4qtdA, 0.8393, 2.50, 0.350, 355, 274, STRUCTURE OF HUMAN JNK1 IN COMPLEX WITH SCH772984 AND THE AMPPNP- HYDROLYSED TRIPHOSPHATE REVEALING THE SECOND TYPE-I BINDING MODE
1463, 3mh1A, 0.8393, 2.24, 0.374, 337, 270, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1464, 1oveA, 0.8393, 2.75, 0.379, 349, 277, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROQUINOLINONE
1465, 5n66A, 0.8392, 2.12, 0.371, 332, 267, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9J
1466, 5myvA, 0.8392, 2.55, 0.291, 352, 278, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
1467, 4kinA, 0.8392, 2.47, 0.385, 338, 273, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1468, 4dljA, 0.8392, 2.16, 0.377, 336, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH RL163
1469, 3mvmB, 0.8392, 2.15, 0.372, 332, 269, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
1470, 4l8mA, 0.8391, 2.38, 0.381, 339, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOXEPINONE
1471, 1ob3A, 0.8391, 2.66, 0.625, 277, 275, STRUCTURE OF P. FALCIPARUM PFPK5
1472, 4awiA, 0.8390, 2.48, 0.349, 352, 272, HUMAN JNK1ALPHA KINASE WITH 4-PHENYL-7-AZAINDOLE IKK2 INHIBITOR.
1473, 6ft9C, 0.8389, 2.69, 0.288, 337, 278, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
1474, 5ekoA, 0.8389, 2.45, 0.381, 341, 273, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
1475, 5bvfA, 0.8386, 1.91, 0.379, 327, 264, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
1476, 4kkhA, 0.8386, 2.67, 0.362, 351, 276, THE CRYSTAL STRUCTURE OF INHIBITOR-BOUND JNK3
1477, 2yixA, 0.8386, 2.58, 0.382, 351, 275, TRIAZOLOPYRIDINE INHIBITORS OF P38
1478, 3gc7A, 0.8385, 2.71, 0.379, 349, 277, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH A DIHYDROQUINAZOLINONE
1479, 4kiqA, 0.8384, 2.33, 0.375, 338, 272, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
1480, 1ua2C, 0.8384, 2.17, 0.448, 286, 268, CRYSTAL STRUCTURE OF HUMAN CDK7
1481, 2r7iC, 0.8383, 2.61, 0.293, 321, 276, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1482, 1wbtA, 0.8383, 2.52, 0.381, 351, 273, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1483, 1bl7A, 0.8383, 2.61, 0.370, 351, 276, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB220025
1484, 4kkeA, 0.8382, 2.58, 0.364, 354, 275, THE CRYSTAL STRUCTURE OF AMP-BOUND JNK3
1485, 3obgA, 0.8382, 2.06, 0.382, 332, 267, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
1486, 4w4wA, 0.8381, 2.69, 0.362, 349, 276, JNK2/3 IN COMPLEX WITH N-(2-METHYLPYRIDIN-4-YL)-3-{4- [(PHENYLCARBAMOYL)AMINO]-1H-PYRAZOL-1-YL}BENZAMIDE
1487, 3hv4A, 0.8380, 2.45, 0.382, 339, 272, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
1488, 4eyjA, 0.8379, 2.32, 0.391, 338, 271, MAPK13 COMPLEX WITH INHIBITOR
1489, 4d1xA, 0.8379, 2.23, 0.933, 274, 270, CDK2 IN COMPLEX WITH LUCIFERIN
1490, 2onlB, 0.8379, 2.39, 0.386, 339, 272, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1491, 5myvD, 0.8377, 2.55, 0.282, 351, 277, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
1492, 1lewA, 0.8377, 2.37, 0.386, 341, 272, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS NUCLEAR SUBSTRATE MEF2A
1493, 2rg5A, 0.8376, 2.22, 0.379, 333, 269, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11B
1494, 1lezA, 0.8376, 2.42, 0.388, 343, 273, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS ACTIVATOR MKK3B
1495, 1a9uA, 0.8376, 2.57, 0.366, 351, 276, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB203580
1496, 2gtmA, 0.8375, 2.13, 0.386, 341, 267, MUTATED MOUSE P38 MAP KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-892579
1497, 3gcuA, 0.8374, 2.47, 0.382, 339, 272, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
1498, 1ua2D, 0.8374, 2.19, 0.448, 286, 268, CRYSTAL STRUCTURE OF HUMAN CDK7
1499, 3mh0A, 0.8373, 2.08, 0.378, 332, 267, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1500, 1ua2B, 0.8373, 2.21, 0.451, 286, 268, CRYSTAL STRUCTURE OF HUMAN CDK7
1501, 4eymA, 0.8371, 2.40, 0.390, 340, 272, MAPK13 COMPLEX WITH INHIBITOR
1502, 4eh4A, 0.8371, 2.20, 0.378, 337, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F3 AND RL87
1503, 2zazA, 0.8370, 2.47, 0.384, 345, 271, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH 4-ANILINO QUINOLINE INHIBITOR
1504, 4kkgA, 0.8368, 2.56, 0.361, 353, 274, CRYSTAL STRUCTURE OF APO AND AMP-BOUND JNK3
1505, 1wbsA, 0.8368, 2.55, 0.381, 351, 273, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
1506, 2onlA, 0.8366, 2.31, 0.387, 338, 271, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1507, 4e73A, 0.8365, 2.26, 0.346, 318, 269, CRYSTAL STRUCTURE OF JNK1BETA-JIP IN COMPLEX WITH AN AZAQUINOLONE INHBITOR
1508, 4ditA, 0.8365, 2.11, 0.338, 328, 266, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A IMIDAZOPYRIDINE INHIBITOR
1509, 1r39A, 0.8365, 2.52, 0.369, 345, 274, THE STRUCTURE OF P38ALPHA
1510, 1kv1A, 0.8365, 2.17, 0.386, 331, 267, P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1
1511, 5o90A, 0.8363, 2.26, 0.386, 330, 267, CRYSTAL STRUCTURE OF A P38ALPHA T185G MUTANT IN COMPLEX WITH TAB1 PEPTIDE.
1512, 4ka3A, 0.8363, 2.26, 0.374, 340, 270, STRUCTURE OF MAP KINASE IN COMPLEX WITH A DOCKING PEPTIDE
1513, 4h3bC, 0.8363, 2.46, 0.375, 351, 272, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
1514, 4h3bA, 0.8363, 2.46, 0.375, 351, 272, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
1515, 3mh3A, 0.8363, 2.19, 0.369, 334, 268, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1516, 4tyhB, 0.8362, 2.39, 0.385, 335, 270, TERNARY COMPLEX OF P38 AND MK2 WITH A P38 INHIBITOR
1517, 3hv5A, 0.8362, 2.49, 0.382, 339, 272, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
1518, 1w83A, 0.8361, 2.58, 0.381, 351, 273, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1519, 3hv3A, 0.8359, 2.22, 0.377, 335, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH RL49
1520, 2okrA, 0.8359, 2.41, 0.386, 339, 272, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1521, 5mz3A, 0.8358, 2.57, 0.381, 350, 273, P38 ALPHA MUTANT C162S IN COMPLEX WITH CMPD2 [N-(4-METHYL-3-(4455- TETRAMETHYL-132-DIOXABOROLAN-2-YL)PHENYL)-3-(TRIFLUOROMETHYL) BENZAMIDE]
1522, 4h36A, 0.8358, 2.35, 0.373, 353, 271, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH ATF2 PEPTIDE
1523, 1zyjA, 0.8356, 2.06, 0.372, 331, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1A
1524, 3k3iA, 0.8355, 2.18, 0.386, 332, 267, P38ALPHA BOUND TO NOVEL DGF-OUT COMPOUND PF-00215955
1525, 3cgfA, 0.8355, 2.62, 0.363, 346, 273, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
1526, 3pzeA, 0.8353, 2.50, 0.351, 347, 271, JNK1 IN COMPLEX WITH INHIBITOR
1527, 3nnxA, 0.8352, 2.15, 0.391, 336, 266, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38 ALPHA IN COMPLEX WITH DP802
1528, 3o8uA, 0.8351, 2.20, 0.371, 332, 267, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1529, 3fknA, 0.8351, 2.43, 0.376, 346, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO7125
1530, 2p33A, 0.8351, 2.65, 0.363, 332, 273, SYNTHESIS AND SAR OF AMINOPYRIMIDINES AS NOVEL C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
1531, 1w7hA, 0.8350, 2.69, 0.384, 351, 276, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1532, 3kq7A, 0.8349, 2.62, 0.380, 348, 274, STRUCTURE OF HUMAN P38ALPHA WITH N-[4-METHYL-3-(6-{[2-(1- METHYLPYRROLIDIN-2-YL)ETHYL]AMINO}PYRIDINE-3-AMIDO)PHENYL]- 2-(MORPHOLIN-4-YL)PYRIDINE-4-CARBOXAMIDE
1533, 3gcqA, 0.8349, 2.24, 0.377, 337, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH RL45
1534, 1gijA, 0.8349, 2.27, 0.930, 273, 270, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
1535, 3gc0A, 0.8348, 2.38, 0.550, 278, 271, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA IN COMPLEX WITH AMP
1536, 3cgoA, 0.8348, 2.35, 0.367, 332, 270, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
1537, 4g1wA, 0.8346, 2.27, 0.349, 322, 269, CRYSTAL STRUCTURE OF JNK1 IN COMPLEX WITH JIP1 PEPTIDE AND 7-FLUORO-3- [4-(2-HYDROXY-ETHANESULFONYL)-BENZYL]-4-OXO-1-PHENYL-14-DIHYDRO- QUINOLINE-2-CARBOXYLIC ACID METHYL ESTER
1538, 3p7bA, 0.8346, 2.17, 0.375, 332, 267, P38 INHIBITOR-BOUND
1539, 3npcA, 0.8346, 2.39, 0.359, 357, 270, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
1540, 3flsA, 0.8346, 2.33, 0.377, 343, 268, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((R)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
1541, 3p78A, 0.8345, 2.18, 0.378, 332, 267, P38 INHIBITOR-BOUND
1542, 3fskA, 0.8345, 2.37, 0.378, 342, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6257
1543, 3fmmA, 0.8345, 2.49, 0.382, 346, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6226
1544, 1pyeA, 0.8345, 1.85, 0.992, 266, 263, CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR
1545, 4kinD, 0.8344, 2.39, 0.380, 339, 271, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
1546, 3ptgA, 0.8344, 2.34, 0.374, 340, 270, DESIGN AND SYNTHESIS OF A NOVEL ORALLY EFFICACIOUS TRI-SUBSTITUTED THIOPHENE BASED JNK INHIBITOR
1547, 3mh2A, 0.8344, 2.00, 0.366, 330, 265, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1548, 3hp5A, 0.8344, 1.98, 0.375, 330, 264, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIMIDOPYRIDAZINONE COMPOUND
1549, 1yqjA, 0.8344, 2.66, 0.367, 356, 275, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH A SELECTIVE PYRIDAZINE INHIBITOR
1550, 1wbnA, 0.8344, 2.58, 0.381, 351, 273, FRAGMENT BASED P38 INHIBITORS
1551, 5awmA, 0.8343, 2.44, 0.336, 345, 271, THE CRYSTAL STRUCTURE OF JNK FROM DROSOPHILA MELANOGASTER REVEALS AN EVOLUTIONARILY CONSERVED TOPOLOGY WITH THAT OF MAMMALIAN JNK PROTEINS.
1552, 3ha8A, 0.8343, 2.55, 0.371, 342, 272, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/COMPOUND 14B
1553, 3e93A, 0.8343, 2.39, 0.385, 346, 270, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
1554, 6g33A, 0.8342, 2.66, 0.286, 335, 276, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
1555, 2xs0A, 0.8342, 2.29, 0.349, 346, 269, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
1556, 3flqA, 0.8341, 2.51, 0.376, 345, 271, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((S)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN
1557, 2i0hA, 0.8341, 2.80, 0.379, 349, 277, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH AN ARYLPYRIDAZINONE
1558, 1ukiA, 0.8341, 2.24, 0.364, 328, 269, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
1559, 1p38A, 0.8339, 2.76, 0.383, 351, 277, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTOMS RESOLUTION
1560, 3o8tA, 0.8337, 2.20, 0.375, 332, 267, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG-MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1561, 1jnkA, 0.8337, 2.55, 0.360, 346, 272, THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNP
1562, 6emhB, 0.8335, 2.51, 0.349, 344, 272, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR 
1563, 3p79A, 0.8334, 2.19, 0.375, 332, 267, P38 INHIBITOR-BOUND
1564, 5etaA, 0.8333, 2.15, 0.378, 336, 267, STRUCTURE OF MAPK14 WITH BOUND THE KIM DOMAIN OF THE TOXOPLASMA PROTEIN GRA24
1565, 5eknA, 0.8333, 2.29, 0.383, 336, 269, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
1566, 3p5kA, 0.8333, 2.19, 0.375, 332, 267, P38 INHIBITOR-BOUND
1567, 2y8oA, 0.8333, 2.39, 0.386, 339, 272, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A MAPK DOCKING PEPTIDE
1568, 2o0uA, 0.8333, 2.62, 0.363, 331, 273, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-{3-CYANO-6-[3-(1- PIPERIDINYL)PROPANOYL]-4567-TETRAHYDROTHIENO[23-C]PYRIDIN-2-YL}- 1-NAPHTHALENECARBOXAMIDE
1569, 3npcB, 0.8331, 2.31, 0.362, 356, 268, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
1570, 4x21A, 0.8328, 2.33, 0.364, 336, 269, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
1571, 4w4yA, 0.8328, 2.63, 0.353, 350, 275, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-METHYLPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1572, 2zdtA, 0.8328, 2.60, 0.360, 342, 272, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
1573, 5etiA, 0.8327, 2.64, 0.382, 355, 275, STRUCTURE OF DEAD KINASE MAPK14
1574, 4eh9A, 0.8327, 2.25, 0.380, 334, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F11 AND RL87
1575, 4dliA, 0.8327, 2.24, 0.378, 334, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH RL87
1576, 4yr8A, 0.8326, 2.22, 0.353, 320, 266, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1577, 4loqC, 0.8326, 2.07, 0.377, 337, 265, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
1578, 1pmnA, 0.8325, 2.60, 0.364, 344, 272, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE- PYRIMIDINE INHIBITOR
1579, 6emhA, 0.8324, 2.53, 0.349, 344, 272, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR 
1580, 4w4xA, 0.8322, 2.74, 0.351, 342, 276, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-FLUOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1581, 4w4vA, 0.8322, 2.67, 0.356, 342, 275, JNK2/3 IN COMPLEX WITH 3-(4-{[(2-CHLOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
1582, 3mvmA, 0.8322, 2.33, 0.390, 335, 269, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
1583, 3v6rB, 0.8318, 2.47, 0.357, 346, 272, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1584, 2i6lA, 0.8316, 2.44, 0.335, 292, 269, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
1585, 5d1jA, 0.8315, 1.94, 0.943, 265, 263, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH N-[5-[[[5-(11-DIMETHYLETHYL)-2-OXAZOLYL] METHYL]THIO]-2-THIAZOLYL]- 4-PIPERIDINECARBOXAMIDE (BMS-387032)
1586, 3fmjA, 0.8314, 2.38, 0.368, 344, 269, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 4-(5-METHYL-3-PHENYL- ISOXAZOL-4-YL)-PYRIMIDIN-2-YLAMINE
1587, 3fkoA, 0.8314, 2.43, 0.381, 343, 270, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3668
1588, 1wfcA, 0.8314, 2.53, 0.376, 340, 271, STRUCTURE OF APO UNPHOSPHORYLATED P38 MITOGEN ACTIVATED PROTEIN KINASE P38 (P38 MAP KINASE) THE MAMMALIAN HOMOLOGUE OF THE YEAST HOG1 PROTEIN
1589, 1ua2A, 0.8314, 2.28, 0.448, 286, 268, CRYSTAL STRUCTURE OF HUMAN CDK7
1590, 3hvcA, 0.8312, 1.94, 0.382, 327, 262, CRYSTAL STRUCTURE OF HUMAN P38ALPHA MAP KINASE
1591, 2okrD, 0.8312, 2.34, 0.385, 339, 270, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
1592, 3p4kA, 0.8311, 2.39, 0.384, 338, 271, THE THIRD CONFORMATION OF P38A MAP KINASE OBSERVED IN PHOSPHORYLATED P38A AND IN SOLUTION
1593, 3flnC, 0.8311, 2.25, 0.390, 343, 267, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH R1487
1594, 3c5uA, 0.8311, 2.41, 0.373, 338, 271, P38 ALPHA MAP KINASE COMPLEXED WITH A BENZOTHIAZOLE BASED INHIBITOR
1595, 5etaB, 0.8310, 2.18, 0.378, 335, 267, STRUCTURE OF MAPK14 WITH BOUND THE KIM DOMAIN OF THE TOXOPLASMA PROTEIN GRA24
1596, 2qd9A, 0.8310, 2.06, 0.381, 330, 265, P38 ALPHA MAP KINASE INHIBITOR BASED ON HETEROBICYCLIC SCAFFOLDS
1597, 4a9yA, 0.8309, 2.30, 0.381, 334, 268, P38ALPHA MAP KINASE BOUND TO CMPD 8
1598, 3pg1A, 0.8309, 2.23, 0.338, 341, 269, MAP KINASE LMAMPK10 FROM LEISHMANIA MAJOR (1.95 ANGS RESOLUTION)
1599, 2bakA, 0.8309, 2.30, 0.381, 334, 268, P38ALPHA MAP KINASE BOUND TO MPAQ
1600, 2gfsA, 0.8308, 2.61, 0.375, 344, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3201195
1601, 3p7cA, 0.8307, 2.24, 0.371, 332, 267, P38 INHIBITOR-BOUND
1602, 3gp0A, 0.8306, 2.13, 0.360, 333, 264, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 11 (P38 BETA) IN COMPLEX WITH NILOTINIB
1603, 5n68A, 0.8304, 2.06, 0.379, 328, 264, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9M
1604, 5uojA, 0.8301, 2.58, 0.374, 343, 273, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTROMS RESOLUTION
1605, 3oc1A, 0.8301, 2.20, 0.372, 330, 266, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
1606, 4u79A, 0.8300, 2.31, 0.364, 337, 269, CRYSTAL STRUCTURE OF HUMAN JNK3 IN COMPLEX WITH A BENZENESULFONAMIDE INHIBITOR.
1607, 3uvpA, 0.8300, 2.40, 0.356, 334, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZAMIDE SUBSTITUTED BENZOSUBERONE
1608, 3lffA, 0.8299, 2.40, 0.378, 335, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH RL166
1609, 3ttiA, 0.8297, 2.83, 0.361, 341, 274, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-930 AN ORALLY ACTIVE ANTI-FIBROTIC JNK INHIBITOR
1610, 3ctqA, 0.8297, 2.44, 0.381, 336, 270, STRUCTURE OF MAP KINASE P38 IN COMPLEX WITH A 1-O-TOLYL-12 3-TRIAZOLE-4-CARBOXAMIDE
1611, 2wajA, 0.8296, 2.49, 0.362, 348, 271, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH A 1-ARYL-34- DIHYDROISOQUINOLINE INHIBITOR
1612, 3objA, 0.8295, 2.44, 0.375, 332, 269, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
1613, 3gbzA, 0.8295, 2.37, 0.537, 274, 270, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA
1614, 2puuA, 0.8295, 2.16, 0.370, 330, 265, CRYSTAL STRUCTURE OF P38 COMPLEX WITH 1-(5-TERT-BUTYL-2-P- TOLYL-2H-PYRAZOL-3-YL)-3-[4-(6-MORPHOLIN-4-YLMETHYL- PYRIDIN-3-YL)NAPHTHALEN-1-YL]UREA
1615, 3hrbA, 0.8293, 2.67, 0.375, 344, 272, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1616, 1oz1A, 0.8293, 2.58, 0.391, 344, 271, P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4-AZAINDOLE INHIBITOR
1617, 5mtxA, 0.8291, 2.25, 0.373, 331, 268, DIBENZOOXEPINONE INHIBITOR 12B IN COMPLEX WITH P38 MAPK
1618, 4whzA, 0.8290, 2.95, 0.360, 342, 275, DESIGN AND SYNTHESIS OF HIGHLY POTENT AND ISOFORM SELECTIVE JNK3 INHIBITORS: SAR STUDIES ON AMINOPYRAZOLE DERIVATIVES
1619, 1ianA, 0.8290, 2.23, 0.385, 328, 265, HUMAN P38 MAP KINASE INHIBITOR COMPLEX
1620, 5angA, 0.8289, 2.17, 0.872, 268, 265, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 7-HYDROXY-4-( MORPHOLINOMETHYL)CHROMEN-2-ONE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1621, 3d83A, 0.8286, 2.63, 0.382, 347, 272, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
1622, 5o8uA, 0.8284, 2.15, 0.366, 331, 265, COVALENT INHIBITOR 4B BOUND TO THE LIPID POCKET OF P38ALPHA MUTANT S252C
1623, 5j1wC, 0.8284, 2.52, 0.298, 316, 272, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
1624, 3fmnA, 0.8284, 2.30, 0.375, 341, 267, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO2530
1625, 3ttjA, 0.8283, 2.61, 0.360, 333, 272, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-359 A JNK INHIBITOR FOR THE PREVENTION OF ISCHEMIA-REPERFUSION INJURY
1626, 4hysA, 0.8281, 2.22, 0.352, 321, 267, CRYSTAL STRUCTURE OF JNK1 IN COMPLEX WITH JIP1 PEPTIDE AND 4-(4- INDAZOL-1-YL-PYRIMIDIN-2-YLAMINO)-CYCLOHEXAN
1627, 3hegA, 0.8281, 2.27, 0.375, 333, 267, P38 IN COMPLEX WITH SORAFENIB
1628, 3hv6A, 0.8280, 2.19, 0.377, 331, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH RL39
1629, 5etfA, 0.8279, 2.46, 0.380, 338, 271, STRUCTURE OF DEAD KINASE MAPK14 WITH BOUND THE KIM DOMAIN OF MKK6
1630, 5n65A, 0.8277, 2.33, 0.372, 333, 269, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9H
1631, 4x21B, 0.8276, 2.31, 0.364, 336, 269, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
1632, 6eq9B, 0.8272, 2.27, 0.366, 332, 268, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AMP-PCP 
1633, 3g9nA, 0.8271, 2.70, 0.364, 346, 272, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-PHENYLINDOLIN-2-ONE
1634, 1oiqA, 0.8269, 1.99, 0.916, 264, 262, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
1635, 4yr8E, 0.8268, 2.29, 0.350, 317, 266, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1636, 6f5eB, 0.8267, 2.24, 0.362, 346, 265, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
1637, 5lenB, 0.8267, 2.24, 0.362, 346, 265, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX WITH JNK1A1 AND JIP1 PEPTIDE
1638, 3hv4B, 0.8267, 2.45, 0.385, 338, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
1639, 3fmlA, 0.8267, 2.43, 0.366, 342, 268, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6224
1640, 2ewaA, 0.8267, 2.12, 0.390, 330, 264, DUAL BINDING MODE OF PYRIDINYLIMIDAZOLE TO MAP KINASE P38
1641, 4h39A, 0.8266, 2.26, 0.367, 340, 267, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH JIP1 PEPTIDE
1642, 3g90X, 0.8266, 2.67, 0.358, 345, 271, JNK-3 BOUND TO (Z)-5-FLUORO-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL) METHYL)-3-(HYDROXYIMINO)INDOLIN-2-ONE
1643, 3mw1A, 0.8265, 2.48, 0.372, 342, 269, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1644, 6ekdA, 0.8264, 2.22, 0.365, 325, 266, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR 
1645, 4z9lA, 0.8262, 2.47, 0.363, 333, 270, THE STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE-PYRIMIDINE INHIBITOR
1646, 4f9cA, 0.8262, 2.75, 0.269, 306, 275, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND XL413
1647, 6cnhA, 0.8257, 2.07, 0.303, 321, 264, HUMAN PRPF4B IN COMPLEX WITH REBASTINIB
1648, 3hv5B, 0.8257, 2.47, 0.385, 339, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
1649, 3p7aA, 0.8254, 2.31, 0.375, 332, 267, P38 INHIBITOR-BOUND
1650, 3iw6A, 0.8253, 2.50, 0.374, 337, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZYLPIPERAZIN- PYRROL
1651, 5fp5A, 0.8252, 2.06, 0.955, 264, 264, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 4-FLUOROBENZOIC ACID (AT222) IN AN ALTERNATE BINDING SITE.
1652, 3v6sB, 0.8252, 2.33, 0.362, 340, 268, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
1653, 3gcuB, 0.8251, 2.47, 0.385, 337, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
1654, 1pmuA, 0.8251, 2.59, 0.357, 342, 272, THE CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PHENANTROLINE INHIBITOR
1655, 2zduA, 0.8250, 2.54, 0.363, 330, 270, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
1656, 4pniA, 0.8249, 2.18, 0.260, 492, 265, BOVINE G PROTEIN-COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH GSK2163632A
1657, 4fr4C, 0.8249, 2.07, 0.235, 344, 264, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
1658, 3eljA, 0.8249, 2.45, 0.357, 347, 269, JNK1 COMPLEXED WITH A BIS-ANILINO-PYRROLOPYRIMIDINE INHIBITOR.
1659, 4fr4A, 0.8248, 2.08, 0.235, 350, 264, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
1660, 3da6A, 0.8247, 2.61, 0.362, 328, 271, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-METHYL- 4-(3-(2-(METHYLAMINO)PYRIMIDIN-4-YL)PYRIDIN-2-YLOXY) NAPHTHALEN-1-YL)-1H-BENZO[D]IMIDAZOL-2-AMINE
1661, 4izyA, 0.8244, 2.28, 0.352, 322, 267, CRYSTAL STRUCTURE OF JNK1 IN COMPLEX WITH JIP1 PEPTIDE AND 4-{4-[4-(4- METHANESULFONYL-PIPERIDIN-1-YL)-INDOL-1-YL]-PYRIMIDIN-2-YLAMINO}- CYCLOHEXAN
1662, 3hv7A, 0.8244, 2.30, 0.385, 330, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH RL38
1663, 3zsiA, 0.8243, 2.18, 0.386, 326, 264, X-RAY STRUCTURE OF P38ALPHA BOUND TO VX-745
1664, 3iw7A, 0.8242, 2.53, 0.374, 335, 270, HUMAN P38 MAP KINASE IN COMPLEX WITH AN IMIDAZO-PYRIDINE
1665, 6emhC, 0.8241, 2.36, 0.354, 334, 268, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR 
1666, 4l7fA, 0.8241, 2.53, 0.353, 354, 269, CO-CRYSTAL STRUCTURE OF JNK1 AND AX13587
1667, 4fr4F, 0.8239, 2.09, 0.235, 346, 264, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
1668, 4hyuA, 0.8237, 2.10, 0.355, 322, 265, CRYSTAL STRUCTURE OF JNK1 IN COMPLEX WITH JIP1 PEPTIDE AND 4-{4-[4-(3- METHANESULFONYL-PROPOXY)-INDAZOL-1-YL]-PYRIMIDIN-2-YLAMINO}- CYCLOHEXAN
1669, 4fr4D, 0.8236, 2.10, 0.235, 346, 264, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
1670, 4fr4B, 0.8236, 2.09, 0.235, 350, 264, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
1671, 1pmvA, 0.8236, 2.77, 0.363, 347, 273, THE STRUCTURE OF JNK3 IN COMPLEX WITH A DIHYDROANTHRAPYRAZOLE INHIBITOR
1672, 4fr4E, 0.8234, 2.09, 0.235, 342, 264, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
1673, 2o2uA, 0.8230, 2.33, 0.363, 319, 267, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-CYANO-4567- TETRAHYDRO-1-BENZOTHIEN-2-YL)-2-FLUOROBENZAMIDE
1674, 3mgyA, 0.8229, 2.16, 0.371, 329, 264, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
1675, 3k3jA, 0.8229, 2.22, 0.379, 329, 264, P38ALPHA BOUND TO NOVEL DFG-OUT COMPOUND PF-00416121
1676, 3vulA, 0.8228, 2.26, 0.361, 344, 266, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
1677, 5n67A, 0.8222, 2.15, 0.382, 327, 262, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9L
1678, 4ux9D, 0.8219, 2.65, 0.349, 344, 272, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
1679, 6anlA, 0.8218, 2.53, 0.376, 338, 271, STRUCTURE-BASED DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF IMIDAZO[12-B]PYRIDAZINE-BASED P38 MAP KINASE INHIBITORS
1680, 3lfbA, 0.8216, 2.42, 0.362, 333, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH RL98
1681, 4wboA, 0.8215, 2.23, 0.258, 497, 264, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
1682, 4eh5A, 0.8215, 2.15, 0.378, 329, 262, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F4 AND RL87
1683, 4bgqA, 0.8215, 2.38, 0.386, 276, 267, CRYSTAL STRUCTURE OF THE HUMAN CDKL5 KINASE DOMAIN
1684, 3oefX, 0.8214, 2.54, 0.381, 334, 270, CRYSTAL STRUCTURE OF Y323F INACTIVE MUTANT OF P38ALPHA MAP KINASE
1685, 3fi4A, 0.8214, 2.33, 0.392, 339, 265, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO4499
1686, 3gcvA, 0.8213, 2.26, 0.370, 338, 265, HUMAN P38 MAP KINASE IN COMPLEX WITH RL62
1687, 5j1vC, 0.8211, 2.56, 0.296, 314, 270, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
1688, 3e7oB, 0.8211, 2.14, 0.350, 326, 263, CRYSTAL STRUCTURE OF JNK2
1689, 1ukhA, 0.8211, 2.11, 0.352, 321, 264, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
1690, 3uvrA, 0.8210, 2.51, 0.383, 331, 269, HUMAN P38 MAP KINASE IN COMPLEX WITH KM064
1691, 3fsfA, 0.8210, 2.40, 0.375, 340, 267, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 3-(26- DICHLORO-PHENYL)-7-[4-(2-DIETHYLAMINO-ETHOXY)-PHENYLAMINO]- 1-METHYL-34-DIHYDRO-1H-PYRIMIDO[45-D]PYRIMIDIN-2-ONE
1692, 1kv2A, 0.8208, 1.98, 0.388, 325, 260, HUMAN P38 MAP KINASE IN COMPLEX WITH BIRB 796
1693, 2baqA, 0.8206, 2.20, 0.397, 329, 262, P38ALPHA BOUND TO RO3201195
1694, 1blxA, 0.8206, 2.99, 0.453, 305, 274, P19INK4D/CDK6 COMPLEX
1695, 2hy81, 0.8204, 2.16, 0.298, 293, 262, PAK1 COMPLEX WITH ST2001
1696, 5o8vA, 0.8203, 2.14, 0.379, 328, 261, COVALENT INHIBITOR 4A BOUND TO THE LIPID POCKET OF P38ALPHA MUTANT S251C
1697, 3oy1A, 0.8203, 2.42, 0.365, 329, 266, HIGHLY SELECTIVE C-JUN N-TERMINAL KINASE (JNK) 2 AND 3 INHIBITORS WITH IN VITRO CNS-LIKE PHARMACOKINETIC PROPERTIES
1698, 2ok1A, 0.8203, 2.53, 0.358, 333, 268, CRYSTAL STRUCTURE OF JNK3 BOUND TO N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
1699, 3hubA, 0.8201, 2.55, 0.373, 335, 271, HUMAN P38 MAP KINASE IN COMPLEX WITH SCIOS-469
1700, 2acxA, 0.8200, 2.27, 0.272, 495, 265, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 6 BOUND TO AMPPNP
1701, 5tbeA, 0.8199, 2.29, 0.365, 332, 266, HUMAN P38ALPHA MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 2
1702, 4wboD, 0.8197, 2.27, 0.258, 491, 264, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
1703, 3gi3A, 0.8197, 2.28, 0.371, 330, 264, CRYSTAL STRUCTURE OF A N-PHENYL-N -NAPHTHYLUREA ANALOG IN COMPLEX WITH P38 MAP KINASE
1704, 3pg3A, 0.8196, 2.60, 0.376, 337, 271, HUMAN P38 MAP KINASE IN COMPLEX WITH RL182
1705, 3fc1X, 0.8196, 2.22, 0.369, 330, 263, CRYSTAL STRUCTURE OF P38 KINASE BOUND TO PYRIMIDO-PYRIDAZINONE INHIBITOR
1706, 4e6cA, 0.8195, 2.20, 0.377, 330, 265, P38A-PERIFOSINE COMPLEX
1707, 3iw5A, 0.8195, 2.49, 0.368, 336, 269, HUMAN P38 MAP KINASE IN COMPLEX WITH AN INDOLE DERIVATIVE
1708, 3rtpA, 0.8193, 2.23, 0.364, 331, 264, DESIGN AND SYNTHESIS OF BRAIN PENETRANT SELECTIVE JNK INHIBITORS WITH IMPROVED PHARMACOKINETIC PROPERTIES FOR THE PREVENTION OF NEURODEGENERATION
1709, 3hecA, 0.8193, 2.26, 0.367, 329, 264, P38 IN COMPLEX WITH IMATINIB
1710, 3zduA, 0.8191, 2.61, 0.349, 297, 272, CRYSTAL STRUCTURE OF THE HUMAN CDKL3 KINASE DOMAIN
1711, 4wboC, 0.8190, 2.32, 0.258, 481, 264, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
1712, 3c51A, 0.8190, 2.33, 0.258, 487, 264, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 3.55A
1713, 3coiA, 0.8189, 2.78, 0.391, 344, 274, CRYSTAL STRUCTURE OF P38DELTA KINASE
1714, 3lfeA, 0.8187, 2.43, 0.373, 334, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH RL116
1715, 3hucA, 0.8186, 2.58, 0.376, 337, 271, HUMAN P38 MAP KINASE IN COMPLEX WITH RL40
1716, 3fl4A, 0.8186, 2.40, 0.385, 339, 265, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO5634
1717, 3oxiA, 0.8184, 2.27, 0.370, 322, 265, DESIGN AND SYNTHESIS OF DISUBSTITUTED THIOPHENE AND THIAZOLE BASED INHIBITORS OF JNK FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
1718, 3l8xA, 0.8184, 2.20, 0.379, 326, 261, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-PYRIMIDINE BASED INHIBITOR
1719, 4aa0A, 0.8182, 2.29, 0.390, 328, 264, P38ALPHA MAP KINASE BOUND TO CMPD 2
1720, 3vumA, 0.8181, 2.34, 0.361, 347, 266, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M7 IN MAP KINASE JNK1
1721, 3fv8A, 0.8180, 2.44, 0.367, 331, 267, JNK3 BOUND TO PIPERAZINE AMIDE INHIBITOR SR2774.
1722, 4yhjB, 0.8175, 2.45, 0.272, 490, 265, STRUCTURE AND FUNCTION OF THE HYPERTENSION VARIANT A486V OF G PROTEIN- COUPLED RECEPTOR KINASE 4 (GRK4)
1723, 3zshA, 0.8175, 2.51, 0.372, 331, 269, X-RAY STRUCTURE OF P38ALPHA BOUND TO SCIO-469
1724, 5n64A, 0.8174, 2.20, 0.378, 329, 262, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9G
1725, 3t8oA, 0.8173, 2.35, 0.260, 493, 265, RHODOPSIN KINASE (GRK1) L166K MUTANT AT 2.5A RESOLUTION
1726, 1jvpP, 0.8172, 2.36, 0.970, 268, 265, CRYSTAL STRUCTURE OF HUMAN CDK2 (UNPHOSPHORYLATED) IN COMPLEX WITH PKF049-365
1727, 5n63A, 0.8171, 2.15, 0.377, 325, 260, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9C
1728, 5mtyA, 0.8171, 2.20, 0.369, 328, 263, DIBENZOSUBERONE INHIBITOR 8E IN COMPLEX WITH P38 MAPK
1729, 3q53A, 0.8170, 2.22, 0.294, 291, 262, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN IN COMPLEX WITH ATP
1730, 3lfaA, 0.8167, 2.41, 0.371, 333, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH DASATINIB
1731, 3lfcA, 0.8165, 2.53, 0.369, 334, 268, HUMAN P38 MAP KINASE IN COMPLEX WITH RL99
1732, 2excX, 0.8165, 2.49, 0.363, 335, 267, INHIBITOR COMPLEX OF JNK3
1733, 3kvxA, 0.8162, 2.36, 0.370, 327, 265, JNK3 BOUND TO AMINOPYRIMIDINE INHIBITOR SR-3562
1734, 2acxB, 0.8161, 2.23, 0.278, 492, 263, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 6 BOUND TO AMPPNP
1735, 4wboB, 0.8160, 2.34, 0.258, 495, 264, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
1736, 1g3nE, 0.8160, 2.71, 0.451, 293, 268, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
1737, 4d1zA, 0.8159, 1.96, 0.888, 258, 258, CDK2 IN COMPLEX WITH A LUCIFERIN DERIVATE
1738, 5tcoA, 0.8158, 2.24, 0.369, 327, 263, HUMAN P38 MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 1
1739, 3s4qA, 0.8156, 2.26, 0.375, 326, 261, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-TRIAZINE BASED INHIBITOR
1740, 5xyxA, 0.8152, 2.28, 0.378, 337, 262, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
1741, 6emhD, 0.8146, 2.41, 0.348, 331, 267, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR 
1742, 2b1pA, 0.8145, 2.58, 0.360, 331, 267, INHIBITOR COMPLEX OF JNK3
1743, 5dfpA, 0.8142, 2.25, 0.298, 292, 262, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND FRAX1036
1744, 4yhjA, 0.8142, 2.50, 0.272, 501, 265, STRUCTURE AND FUNCTION OF THE HYPERTENSION VARIANT A486V OF G PROTEIN- COUPLED RECEPTOR KINASE 4 (GRK4)
1745, 4ic8A, 0.8141, 2.43, 0.381, 325, 265, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
1746, 2yiwA, 0.8141, 1.97, 0.385, 325, 257, TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE
1747, 4eqcA, 0.8140, 2.28, 0.298, 296, 262, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN IN COMPLEX WITH FRAX597 INHIBITOR
1748, 3g9lX, 0.8138, 2.58, 0.361, 336, 266, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-STYRYLINDOLIN-2-ONE
1749, 3c50A, 0.8137, 2.46, 0.260, 499, 265, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 2.6A
1750, 4dawA, 0.8134, 2.30, 0.298, 293, 262, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH THE RUTHENIUM PHTHALIMIDE COMPLEX
1751, 1yhwA, 0.8132, 2.26, 0.298, 293, 262, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH ONE POINT MUTATIONS (K299R)
1752, 1v0pB, 0.8132, 2.12, 0.597, 258, 258, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
1753, 5wjjA, 0.8131, 2.58, 0.375, 338, 269, STRUCTURE-BASED DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF IMIDAZO[12-B]PYRIDAZINE-BASED P38 MAP KINASE INHIBITORS
1754, 1yhvA, 0.8130, 2.26, 0.298, 293, 262, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH TWO POINT MUTATIONS (K299R T423E)
1755, 3c50B, 0.8127, 2.43, 0.258, 496, 264, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 2.6A
1756, 3c4xA, 0.8122, 2.41, 0.258, 496, 264, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.9A
1757, 3q52A, 0.8120, 2.29, 0.294, 292, 262, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN
1758, 3iw8A, 0.8120, 2.57, 0.368, 334, 269, STRUCTURE OF INACTIVE HUMAN P38 MAP KINASE IN COMPLEX WITH A THIAZOLE-UREA
1759, 1g3nA, 0.8118, 2.83, 0.485, 293, 270, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
1760, 3c4wB, 0.8117, 2.37, 0.255, 518, 263, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.7A
1761, 4e5aX, 0.8116, 2.38, 0.386, 332, 264, THE W197A MUTANT OF P38A MAP KINASE
1762, 3c4wA, 0.8115, 2.42, 0.258, 494, 264, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.7A
1763, 3c4yA, 0.8114, 2.36, 0.260, 478, 265, CRYSTAL STRUCTURE OF APO FORM OF G PROTEIN COUPLED RECEPTOR KINASE 1 AT 7.51A
1764, 2yisA, 0.8113, 2.09, 0.384, 325, 258, TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE.
1765, 3qc9D, 0.8112, 2.50, 0.260, 486, 265, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
1766, 3qc9C, 0.8112, 2.50, 0.260, 482, 265, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
1767, 3qc9B, 0.8112, 2.50, 0.260, 481, 265, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
1768, 3qc9A, 0.8111, 2.50, 0.260, 486, 265, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
1769, 2xrwA, 0.8109, 2.38, 0.354, 348, 263, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
1770, 3ocbA, 0.8107, 2.33, 0.279, 315, 262, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
1771, 3l8sA, 0.8106, 2.52, 0.367, 334, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH CP-547632
1772, 1v0bB, 0.8106, 2.30, 0.609, 261, 261, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
1773, 5deyA, 0.8105, 2.30, 0.294, 295, 262, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
1774, 3fxzA, 0.8104, 2.32, 0.298, 292, 262, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX LAMBDA-FL172
1775, 3c4zA, 0.8102, 2.36, 0.259, 493, 263, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 1.84A
1776, 2y7jA, 0.8101, 2.23, 0.282, 284, 259, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1777, 3gcsA, 0.8100, 2.46, 0.375, 331, 267, HUMAN P38 MAP KINASE IN COMPLEX WITH SORAFENIB
1778, 3iw4C, 0.8098, 2.35, 0.270, 332, 263, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1779, 4e5bA, 0.8097, 2.21, 0.375, 324, 261, STRUCTURE OF P38A MAP KINASE WITHOUT BOG
1780, 3nyoB, 0.8095, 2.48, 0.277, 553, 264, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH AMP
1781, 5veeA, 0.8094, 2.40, 0.263, 289, 262, PAK4 KINASE DOMAIN IN COMPLEX WITH FRAX486
1782, 4tthB, 0.8094, 1.68, 0.510, 256, 253, CRYSTAL STRUCTURE OF A CDK6/VCYCLIN COMPLEX WITH INHIBITOR BOUND
1783, 4geoA, 0.8093, 2.26, 0.372, 326, 261, P38A MAP KINASE DEF-POCKET PENTA MUTANT (M194A L195A H228A I229A Y258A)
1784, 3gcpA, 0.8092, 2.71, 0.376, 337, 271, HUMAN P38 MAP KINASE IN COMPLEX WITH SB203580
1785, 2jedB, 0.8090, 2.41, 0.285, 320, 263, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
1786, 1u5rA, 0.8090, 2.28, 0.271, 308, 262, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1787, 3fi2A, 0.8087, 2.37, 0.361, 326, 263, CRYSTAL STRUCTURE OF JNK3 WITH AMINO-PYRAZOLE INHIBITOR SR- 3451
1788, 4yr8C, 0.8086, 2.41, 0.338, 318, 263, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
1789, 3ocbB, 0.8086, 2.29, 0.284, 319, 261, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
1790, 4l9iB, 0.8084, 2.34, 0.262, 493, 263, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH PAROXETINE
1791, 2y7jC, 0.8084, 2.28, 0.282, 284, 259, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1792, 2r9sB, 0.8083, 2.45, 0.364, 325, 264, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
1793, 3cqwA, 0.8081, 2.32, 0.284, 318, 261, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
1794, 5izjA, 0.8080, 2.21, 0.273, 328, 260, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1411
1795, 5dewA, 0.8079, 2.34, 0.294, 295, 262, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
1796, 3nynB, 0.8079, 2.41, 0.278, 553, 263, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH SANGIVAMYCIN
1797, 3c4xB, 0.8079, 2.40, 0.259, 475, 263, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.9A
1798, 3zsgA, 0.8078, 2.74, 0.376, 337, 271, X-RAY STRUCTURE OF P38ALPHA BOUND TO TAK-715
1799, 3zs5A, 0.8075, 2.76, 0.376, 340, 271, STRUCTURAL BASIS FOR KINASE SELECTIVITY OF THREE CLINICAL P38ALPHA INHIBITORS
1800, 3nyoA, 0.8075, 2.41, 0.278, 553, 263, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH AMP
1801, 6c0tA, 0.8074, 2.41, 0.228, 334, 263, CRYSTAL STRUCTURE OF CGMP-DEPENDENT PROTEIN KINASE IALPHA (PKG IALPHA) CATALYTIC DOMAIN BOUND WITH N46 
1802, 5izjB, 0.8074, 2.15, 0.273, 325, 260, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1411
1803, 1u5qA, 0.8071, 2.32, 0.271, 308, 262, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1804, 3uibA, 0.8069, 2.29, 0.341, 309, 258, MAP KINASE LMAMPK10 FROM LEISHMANIA MAJOR IN COMPLEX WITH SB203580
1805, 1ob3B, 0.8069, 2.08, 0.611, 258, 257, STRUCTURE OF P. FALCIPARUM PFPK5
1806, 2fslX, 0.8067, 2.41, 0.371, 332, 264, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327S) ACTIVATING MUTANT FORM-A
1807, 3iw4B, 0.8066, 2.40, 0.270, 325, 263, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1808, 3ow4A, 0.8064, 2.30, 0.280, 317, 261, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1809, 4ekkA, 0.8063, 2.31, 0.284, 318, 261, AKT1 WITH AMP-PNP
1810, 4e6aA, 0.8063, 2.25, 0.372, 324, 261, P38A-PIA23 COMPLEX
1811, 2jdoA, 0.8063, 2.31, 0.284, 314, 261, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1812, 2gcdA, 0.8059, 2.34, 0.271, 308, 262, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1813, 3nynA, 0.8058, 2.33, 0.279, 553, 262, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH SANGIVAMYCIN
1814, 2r9sA, 0.8058, 2.38, 0.366, 325, 262, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
1815, 3fy0A, 0.8057, 2.40, 0.298, 292, 262, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX DW1
1816, 2ou7A, 0.8056, 2.34, 0.252, 292, 262, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
1817, 4e8aA, 0.8053, 2.37, 0.376, 327, 263, THE CRYSTAL STRUCTURE OF P38A MAP KINASE IN COMPLEX WITH PIA24
1818, 2x39A, 0.8049, 2.33, 0.280, 316, 261, STRUCTURE OF 4-AMINO-N-(4-CHLOROBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE BOUND TO PKB
1819, 3iw4A, 0.8048, 2.44, 0.270, 330, 263, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1820, 3mvhA, 0.8046, 2.26, 0.285, 311, 260, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
1821, 6ccyA, 0.8044, 2.31, 0.280, 325, 261, CRYSTAL STRUCTURE OF AKT1 IN COMPLEX WITH A SELECTIVE INHIBITOR 
1822, 2owbA, 0.8043, 2.37, 0.252, 294, 262, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
1823, 1u5rB, 0.8041, 2.39, 0.271, 308, 262, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1824, 4wnkA, 0.8040, 2.32, 0.267, 499, 262, CRYSTAL STRUCTURE OF BOVINE G PROTEIN COUPLED-RECEPTOR KINASE 5 IN COMPLEX WITH CCG215022
1825, 2npqA, 0.8040, 2.35, 0.374, 326, 262, A NOVEL LIPID BINDING SITE IN THE P38 ALPHA MAP KINASE
1826, 2jedA, 0.8040, 2.41, 0.286, 324, 262, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
1827, 4j53A, 0.8039, 2.37, 0.252, 293, 262, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH TAK-960
1828, 3odzX, 0.8035, 2.74, 0.355, 335, 265, CRYSTAL STRUCTURE OF P38ALPHA Y323R ACTIVE MUTANT
1829, 4tnbA, 0.8034, 2.42, 0.274, 529, 263, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 5 IN COMPLEX WITH SANGIVAMYCIN
1830, 3a8xA, 0.8034, 2.29, 0.280, 334, 261, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1831, 4nttB, 0.8033, 2.33, 0.269, 339, 260, STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE BOUND TO ADP AND ONE MAGNESIUM ION
1832, 3g33C, 0.8032, 3.06, 0.474, 291, 270, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
1833, 4c2vA, 0.8031, 2.24, 0.302, 270, 258, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
1834, 3lfdA, 0.8030, 2.61, 0.361, 331, 266, HUMAN P38 MAP KINASE IN COMPLEX WITH RL113
1835, 2y7jB, 0.8030, 2.22, 0.283, 281, 258, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1836, 3mv5A, 0.8028, 2.46, 0.275, 315, 262, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
1837, 2gcdB, 0.8028, 2.39, 0.271, 308, 262, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
1838, 4bbmA, 0.8026, 3.29, 0.384, 314, 276, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
1839, 2yacA, 0.8026, 2.39, 0.252, 290, 262, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH NMS-P937
1840, 1u5qB, 0.8025, 2.39, 0.271, 308, 262, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
1841, 2fsmX, 0.8024, 2.34, 0.372, 326, 261, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327S) ACTIVATING MUTANT FORM-B
1842, 2v5qB, 0.8021, 2.48, 0.255, 285, 263, CRYSTAL STRUCTURE OF WILD-TYPE PLK-1 KINASE DOMAIN IN COMPLEX WITH A SELECTIVE DARPIN
1843, 3ow4B, 0.8018, 2.31, 0.285, 317, 260, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1844, 2pmlX, 0.8018, 2.60, 0.208, 340, 264, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH AN ATP ANALOGUE
1845, 3fc2A, 0.8016, 2.39, 0.252, 293, 262, PLK1 IN COMPLEX WITH BI6727
1846, 6c9dB, 0.8014, 2.67, 0.312, 422, 263, CRYSTAL STRUCTURE OF KA1-AUTOINHIBITED MARK1 KINASE 
1847, 4tndA, 0.8014, 2.46, 0.274, 529, 263, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 5 IN COMPLEX WITH AMP-PNP
1848, 3kb7A, 0.8013, 2.42, 0.252, 289, 262, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1849, 4eklA, 0.8012, 2.38, 0.280, 329, 261, AKT1 WITH GDC0068
1850, 5ta6A, 0.8011, 2.40, 0.252, 294, 262, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR.
1851, 2uw9A, 0.8011, 2.38, 0.280, 316, 261, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1852, 4a4lA, 0.8010, 2.41, 0.252, 290, 262, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 5-(2-AMINO-PYRIMIDIN-4-YL)-1H-PYRROLE INHIBITOR
1853, 3rcjA, 0.8009, 2.39, 0.280, 281, 261, RAPID PREPARATION OF TRIAZOLYL SUBSTITUTED NH-HETEROCYCLIC KINASE INHIBITORS VIA ONE-POT SONOGASHIRA COUPLING TMS-DEPROTECTION CUAAC SEQUENCE
1854, 3g33A, 0.8009, 2.95, 0.474, 291, 268, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
1855, 3a8xB, 0.8009, 2.08, 0.287, 329, 258, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1856, 3thbA, 0.8008, 2.41, 0.252, 287, 262, STRUCTURE OF PLK1 KINASE DOMAIN IN COMPLEX WITH A BENZOLACTAM-DERIVED INHIBITOR
1857, 2rkuA, 0.8008, 2.41, 0.252, 294, 262, STRUCTURE OF PLK1 IN COMPLEX WITH BI2536
1858, 5mrdA, 0.8007, 2.46, 0.282, 283, 262, HUMAN PDK1-PKCIOTA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS267 BOUND TO THE PIF-POCKET
1859, 5lcuA, 0.8006, 2.38, 0.273, 350, 260, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A S-METHYL-PIPERAZINE SUBSTITUTED FASUDIL-DERIVATIVE (LIGAND 01)
1860, 5uvcA, 0.8005, 2.53, 0.266, 457, 263, DESIGN SYNTHESIS AND EVALUATION OF THE FIRST SELECTIVE AND POTENT G- PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) INHIBITOR FOR THE POTENTIAL TREATMENT OF HEART FAILURE
1861, 5lcpA, 0.8004, 2.38, 0.273, 350, 260, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH FASUDIL (M77)
1862, 4q9zA, 0.8004, 2.45, 0.287, 331, 261, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
1863, 4ra5A, 0.8003, 2.46, 0.287, 332, 261, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1864, 4qmwA, 0.8003, 2.41, 0.273, 286, 260, MST3 IN COMPLEX WITH PP-121 1-CYCLOPENTYL-3-(1H-PYRROLO[23- B]PYRIDIN-5-YL)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
1865, 2xh5A, 0.8003, 2.39, 0.280, 316, 261, STRUCTURE OF 4-(4-TERT-BUTYLBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDIN-4-AMINE BOUND TO PKB
1866, 4j52A, 0.8002, 2.43, 0.252, 293, 262, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A PYRIMIDODIAZEPINONE INHIBITOR
1867, 4c57B, 0.8002, 2.38, 0.253, 308, 261, STRUCTURE OF GAK KINASE IN COMPLEX WITH A NANOBODY
1868, 4q9zB, 0.8001, 2.50, 0.286, 308, 262, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
1869, 5lvlA, 0.8000, 2.45, 0.272, 285, 261, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND PS653 BOUND TO THE ATP-BINDING SITE
1870, 5f9eB, 0.8000, 2.48, 0.286, 293, 262, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
1871, 4l9iA, 0.8000, 2.49, 0.262, 504, 263, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH PAROXETINE
1872, 3pvwA, 0.8000, 2.53, 0.270, 613, 263, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD103A)
1873, 5lvmA, 0.7999, 2.50, 0.279, 283, 262, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENINE BOUND TO THE ATP- BINDING SITE
1874, 4ekkB, 0.7999, 2.31, 0.285, 318, 260, AKT1 WITH AMP-PNP
1875, 3qklA, 0.7999, 2.42, 0.280, 317, 261, SPIROCHROMANE AKT INHIBITORS
1876, 2v5qA, 0.7999, 2.58, 0.259, 285, 263, CRYSTAL STRUCTURE OF WILD-TYPE PLK-1 KINASE DOMAIN IN COMPLEX WITH A SELECTIVE DARPIN
1877, 5m71A, 0.7998, 2.39, 0.273, 350, 260, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH AN (R)-METHYL SUBSTITUED FASUDIL-DERIVATIVE. 
1878, 2welA, 0.7998, 2.49, 0.299, 304, 261, CRYSTAL STRUCTURE OF SU6656-BOUND CALCIUM/CALMODULIN- DEPENDENT PROTEIN KINASE II DELTA IN COMPLEX WITH CALMODULIN
1879, 2pmnX, 0.7998, 2.58, 0.208, 340, 264, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH AN ATP-SITE INHIBITOR
1880, 5lcrA, 0.7997, 2.40, 0.273, 350, 260, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH OPEN-CHAIN FASUDIL-DERIVATIVE (LIGAND 04)
1881, 4nttA, 0.7997, 2.38, 0.269, 339, 260, STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE BOUND TO ADP AND ONE MAGNESIUM ION
1882, 3a7gB, 0.7997, 2.33, 0.269, 290, 260, HUMAN MST3 KINASE
1883, 4gv1A, 0.7996, 2.34, 0.281, 329, 260, PKB ALPHA IN COMPLEX WITH AZD5363
1884, 2pmoX, 0.7996, 2.64, 0.197, 340, 264, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH HYMENIALDISINE
1885, 4ra4A, 0.7995, 2.46, 0.267, 317, 262, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE C ALPHA IN COMPLEX WITH COMPOUND 28 ((R)-6-((3S4S)-13-DIMETHYL-PIPERIDIN-4-YL)-7-(2-FLUORO- PHENYL)-4-METHYL-210-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1886, 4c57A, 0.7995, 2.39, 0.253, 310, 261, STRUCTURE OF GAK KINASE IN COMPLEX WITH A NANOBODY
1887, 5f9eA, 0.7994, 2.54, 0.286, 334, 262, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
1888, 4a4oA, 0.7994, 2.44, 0.252, 290, 262, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 2- (2-AMINO-PYRIMIDIN-4-YL)-1567-TETRAHYDRO-PYRROLOPYRIDIN- 4-ONE INHIBITOR
1889, 1zysA, 0.7994, 2.60, 0.274, 271, 263, CO-CRYSTAL STRUCTURE OF CHECKPOINT KINASE CHK1 WITH A PYRROLO-PYRIDINE INHIBITOR
1890, 5ml5A, 0.7993, 2.55, 0.383, 326, 264, HUMAN P38ALPHA MAPK IN COMPLEX WITH IMIDAZOLYL PYRIDINE INHIBITOR 11B
1891, 1stcE, 0.7992, 2.37, 0.269, 334, 260, CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH STAUROSPORINE
1892, 3hrfA, 0.7991, 2.49, 0.272, 284, 261, CRYSTAL STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN ALLOSTERIC ACTIVATOR BOUND TO THE PIF-POCKET
1893, 4rqvA, 0.7990, 2.45, 0.272, 288, 261, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS2
1894, 3a7iA, 0.7990, 2.47, 0.272, 286, 261, HUMAN MST3 KINASE IN COMPLEX WITH ADENINE
1895, 2x8dA, 0.7990, 2.61, 0.278, 279, 263, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
1896, 4qmzA, 0.7989, 2.49, 0.272, 286, 261, MST3 IN COMPLEX WITH SUNITINIB
1897, 3iecB, 0.7989, 2.19, 0.312, 313, 256, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1898, 2bajA, 0.7989, 2.50, 0.392, 337, 260, P38ALPHA BOUND TO PYRAZOLOUREA
1899, 2biyA, 0.7988, 2.49, 0.267, 287, 262, STRUCTURE OF PDK1-S241A MUTANT KINASE DOMAIN
1900, 5lvoA, 0.7987, 2.53, 0.279, 285, 262, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PSE10 BOUND TO THE PIF-POCKET
1901, 3o7lD, 0.7987, 2.35, 0.269, 333, 260, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
1902, 1bx6A, 0.7987, 2.40, 0.269, 337, 260, CRYSTAL STRUCTURE OF THE POTENT NATURAL PRODUCT INHIBITOR BALANOL IN COMPLEX WITH THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1903, 3a8wB, 0.7986, 2.21, 0.283, 327, 258, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1904, 2fstX, 0.7986, 2.35, 0.369, 324, 260, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327L) ACTIVATING MUTANT
1905, 4xx9A, 0.7985, 2.52, 0.279, 288, 262, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RF4
1906, 5vedA, 0.7983, 2.53, 0.264, 289, 261, PAK4 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
1907, 5lvnA, 0.7983, 2.53, 0.279, 283, 262, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENOSINE BOUND TO THE ATP- BINDING SITE
1908, 4rqkA, 0.7983, 2.46, 0.272, 285, 261, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS1
1909, 4w8eA, 0.7982, 2.49, 0.272, 290, 261, STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF-06645342)
1910, 4rrvA, 0.7982, 2.53, 0.279, 283, 262, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND PIFTIDE
1911, 4qmxA, 0.7982, 2.49, 0.272, 287, 261, MST3 IN COMPLEX WITH SARACATINIB
1912, 4qmlA, 0.7982, 2.43, 0.273, 280, 260, MST3 IN COMPLEX WITH AMP-PNP
1913, 2y7jD, 0.7981, 2.44, 0.271, 281, 258, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
1914, 4a06A, 0.7980, 2.40, 0.273, 282, 260, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS114 BOUND TO THE PIF-POCKET
1915, 3fi3A, 0.7980, 2.45, 0.364, 328, 261, CRYSTAL STRUCTURE OF JNK3 WITH INDAZOLE INHIBITOR SR-3737
1916, 3a7hB, 0.7980, 2.34, 0.273, 290, 260, HUMAN MST3 KINASE IN COMPLEX WITH ATP
1917, 4ct1A, 0.7979, 2.52, 0.282, 283, 262, HUMAN PDK1-PKCZETA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS315 BOUND TO THE PIF-POCKET
1918, 4nw6A, 0.7978, 2.40, 0.298, 302, 262, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 27
1919, 4b8mA, 0.7978, 2.32, 0.302, 270, 258, AURORA B KINASE IN COMPLEX WITH VX-680
1920, 4ysmB, 0.7977, 2.60, 0.284, 475, 261, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA
1921, 5ta8A, 0.7976, 2.50, 0.256, 294, 262, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR
1922, 5kbqA, 0.7976, 2.56, 0.276, 289, 261, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
1923, 4ra5B, 0.7976, 2.37, 0.288, 310, 260, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1924, 4ysmA, 0.7975, 2.49, 0.285, 475, 260, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA
1925, 4o0rA, 0.7975, 2.53, 0.276, 293, 261, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1926, 2fsoX, 0.7975, 2.35, 0.377, 325, 260, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A) ACTIVATING MUTANT
1927, 3qkkA, 0.7974, 2.38, 0.281, 326, 260, SPIROCHROMANE AKT INHIBITORS
1928, 3d5uA, 0.7974, 2.43, 0.267, 288, 262, CRYSTAL STRUCTURE OF A WILDTYPE POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
1929, 2vrxA, 0.7973, 2.33, 0.302, 268, 258, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
1930, 1cmkE, 0.7973, 2.41, 0.273, 348, 260, CRYSTAL STRUCTURES OF THE MYRISTYLATED CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE REVEAL OPEN AND CLOSED CONFORMATIONS
1931, 4nw5A, 0.7972, 2.40, 0.298, 302, 262, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 8
1932, 3hrcA, 0.7972, 2.50, 0.276, 279, 261, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ATP
1933, 3cquA, 0.7972, 2.46, 0.276, 318, 261, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
1934, 3a8wA, 0.7972, 2.08, 0.284, 326, 257, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1935, 2i0eA, 0.7972, 2.42, 0.252, 326, 262, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
1936, 3pvuA, 0.7971, 2.58, 0.270, 609, 263, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD101)
1937, 2ydiA, 0.7970, 2.63, 0.278, 279, 263, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
1938, 2vgoA, 0.7970, 2.33, 0.302, 268, 258, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
1939, 5xvfA, 0.7969, 2.55, 0.264, 289, 261, CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INHIBITOR CZH062
1940, 3ztxA, 0.7969, 2.35, 0.302, 269, 258, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
1941, 5lctA, 0.7967, 2.44, 0.273, 350, 260, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A R-METHYL-PIPERAZINE SUBSTITUTED FASUDIL-DERIVATIVE (LIGAND 02)
1942, 4qmtA, 0.7967, 2.47, 0.273, 284, 260, MST3 IN COMPLEX WITH HESPERADIN
1943, 4qmnA, 0.7967, 2.45, 0.273, 283, 260, MST3 IN COMPLEX WITH BOSUTINIB
1944, 5m6yA, 0.7966, 2.33, 0.274, 350, 259, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A METHYLISOQUINOLINE FASUDIL-DERIVATIVE 
1945, 5uuuA, 0.7965, 2.61, 0.266, 414, 263, DESIGN SYNTHESIS AND EVALUATION OF THE FIRST SELECTIVE AND POTENT G- PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) INHIBITOR FOR THE POTENTIAL TREATMENT OF HEART FAILURE
1946, 5ok3A, 0.7965, 2.39, 0.274, 349, 259, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP241 AND FASUDIL 
1947, 4b6lA, 0.7965, 2.55, 0.270, 281, 263, DISCOVERY OF ORAL POLO-LIKE KINASE (PLK) INHIBITORS WITH ENHANCED SELECTIVITY PROFILE USING RESIDUE TARGETED DRUG DESIGN
1948, 5o0eA, 0.7964, 2.39, 0.274, 349, 259, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP120 AND FASUDIL 
1949, 2bfxA, 0.7964, 2.35, 0.302, 269, 258, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
1950, 4figA, 0.7963, 2.51, 0.264, 292, 261, CATALYTIC DOMAIN OF HUMAN PAK4
1951, 3pfqA, 0.7963, 2.42, 0.257, 520, 261, CRYSTAL STRUCTURE AND ALLOSTERIC ACTIVATION OF PROTEIN KINASE C BETA II
1952, 1h1wA, 0.7963, 2.45, 0.273, 284, 260, HIGH RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PDK1 CATALYTIC DOMAIN
1953, 5ackA, 0.7962, 2.59, 0.279, 286, 262, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND 7 BOUND TO THE PIF-POCKET
1954, 4qmyA, 0.7962, 2.51, 0.268, 287, 261, MST3 IN COMPLEX WITH STAUROSPORINE
1955, 4figB, 0.7962, 2.51, 0.264, 292, 261, CATALYTIC DOMAIN OF HUMAN PAK4
1956, 2f57B, 0.7962, 2.64, 0.279, 299, 262, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
1957, 1ctpE, 0.7962, 2.43, 0.273, 332, 260, STRUCTURE OF THE MAMMALIAN CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND AN INHIBITOR PEPTIDE DISPLAYS AN OPEN CONFORMATION
1958, 6c9dA, 0.7961, 2.67, 0.313, 425, 262, CRYSTAL STRUCTURE OF KA1-AUTOINHIBITED MARK1 KINASE 
1959, 2jdrA, 0.7961, 2.39, 0.281, 316, 260, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A- 443654
1960, 4yzbA, 0.7960, 2.35, 0.279, 466, 258, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1521
1961, 4qnaA, 0.7959, 2.45, 0.273, 284, 260, MST3 IN COMPLEX WITH 2-(46-DIAMINO-135-TRIAZIN-2-YL)PHENOL
1962, 3orxC, 0.7959, 2.45, 0.271, 283, 262, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1963, 5m6vA, 0.7958, 2.36, 0.274, 350, 259, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A DOUBLE METHYLATED FASUDIL-DERIVATIVE 
1964, 4c35A, 0.7958, 2.41, 0.278, 337, 259, PKA-S6K1 CHIMERA WITH COMPOUND 1 (NU1085) BOUND
1965, 4a07A, 0.7958, 2.44, 0.273, 282, 260, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS171 BOUND TO THE PIF-POCKET
1966, 3orxD, 0.7958, 2.45, 0.271, 282, 262, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1967, 4rerA, 0.7957, 2.27, 0.306, 458, 258, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED HUMAN ALPHA1 BETA2 GAMMA1 HOLO-AMPK COMPLEX BOUND TO AMP AND CYCLODEXTRIN
1968, 1zrzA, 0.7957, 2.42, 0.284, 310, 261, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF ATYPICAL PROTEIN KINASE C-IOTA
1969, 3orxA, 0.7956, 2.45, 0.271, 283, 262, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1970, 4o0tA, 0.7955, 2.58, 0.294, 292, 262, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
1971, 3krwA, 0.7955, 2.63, 0.266, 618, 263, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (SOAK)
1972, 3kk8A, 0.7955, 2.71, 0.308, 283, 263, CAMKII SUBSTRATE COMPLEX A
1973, 3iecA, 0.7955, 2.15, 0.311, 311, 254, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1974, 4aaaA, 0.7954, 3.16, 0.374, 295, 273, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN
1975, 1uvrA, 0.7954, 2.41, 0.277, 284, 260, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-8
1976, 5vibA, 0.7953, 2.47, 0.269, 308, 260, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITORS
1977, 3d5wA, 0.7953, 2.29, 0.270, 284, 259, CRYSTAL STRUCTURE OF A PHOSPHORYLATED POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH ADP.
1978, 2wtkC, 0.7953, 2.73, 0.266, 285, 263, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
1979, 2f57A, 0.7953, 2.56, 0.264, 297, 261, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
1980, 4qmuA, 0.7951, 2.48, 0.273, 286, 260, MST3 IN COMPLEX WITH JNJ-7706621 4-({5-AMINO-1-[(26-DIFLUOROPHENYL) CARBONYL]-1H-124-TRIAZOL-3-YL}AMINO)BENZENESULFONAMIDE
1981, 3l9mA, 0.7951, 2.40, 0.274, 338, 259, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
1982, 1ql6A, 0.7951, 2.40, 0.282, 281, 259, THE CATALYTIC MECHANISM OF PHOSPHORYLASE KINASE PROBED BY MUTATIONAL STUDIES
1983, 5m75A, 0.7950, 2.37, 0.274, 350, 259, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A (S)-METHYL SUBSTITUED FASUDIL-DERIVATIVE 
1984, 4qmsA, 0.7950, 2.52, 0.268, 283, 261, MST3 IN COMPLEX WITH DASATINIB
1985, 4c2wA, 0.7949, 2.37, 0.302, 268, 258, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
1986, 4hyiA, 0.7948, 2.53, 0.276, 269, 261, X-RAY CRYSTAL STRUCTURE OF COMPOUND 40 BOUND TO HUMAN CHK1 KINASE DOMAIN
1987, 5ntjA, 0.7946, 2.35, 0.278, 346, 259, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUND RKP032 
1988, 5l2sA, 0.7946, 2.38, 0.498, 263, 259, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND ABEMACICLIB.
1989, 3rwqA, 0.7945, 2.47, 0.273, 283, 260, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
1990, 4qfgA, 0.7944, 2.31, 0.302, 365, 258, STRUCTURE OF AMPK IN COMPLEX WITH STAUROSPORINE INHIBITOR AND IN THE ABSENCE OF A SYNTHETIC ACTIVATOR
1991, 3qkmA, 0.7943, 2.51, 0.280, 329, 261, SPIROCYCLIC SULFONAMIDES AS AKT INHIBITORS
1992, 3orxB, 0.7943, 2.49, 0.271, 280, 262, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1993, 1smhA, 0.7943, 2.40, 0.274, 348, 259, PROTEIN KINASE A VARIANT COMPLEX WITH COMPLETELY ORDERED N- TERMINAL HELIX
1994, 4xbrA, 0.7942, 2.54, 0.264, 315, 261, IN CELLULO CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INKA
1995, 5li9A, 0.7941, 2.38, 0.286, 329, 259, STRUCTURE OF A NUCLEOTIDE-BOUND FORM OF PKCIOTA CORE KINASE DOMAIN
1996, 5bmsA, 0.7940, 2.60, 0.264, 290, 261, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 4 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
1997, 1ia8A, 0.7940, 2.63, 0.280, 272, 261, THE 1.7 A CRYSTAL STRUCTURE OF HUMAN CELL CYCLE CHECKPOINT KINASE CHK1
1998, 4uakA, 0.7939, 2.87, 0.250, 404, 268, MRCK BETA IN COMPLEX WITH ADP
1999, 4fieB, 0.7939, 2.55, 0.264, 300, 261, FULL-LENGTH HUMAN PAK4
2000, 4fieA, 0.7939, 2.55, 0.264, 300, 261, FULL-LENGTH HUMAN PAK4
2001, 3krxA, 0.7939, 2.64, 0.266, 618, 263, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (CO-CRYSTAL)
2002, 3iecC, 0.7939, 2.20, 0.311, 311, 254, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2003, 2x4zA, 0.7939, 2.57, 0.250, 290, 260, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH PF-03758309
2004, 4qmmA, 0.7938, 2.53, 0.268, 288, 261, MST3 IN COMPLEX WITH AT-9283 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]- 1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
2005, 5nw8A, 0.7937, 2.33, 0.275, 337, 258, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP032 AND FASUDIL 
2006, 3ckxA, 0.7937, 2.31, 0.267, 276, 258, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24) IN COMPLEX WITH STAUROSPORINE
2007, 2bfyA, 0.7937, 2.43, 0.298, 270, 258, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
2008, 4fifB, 0.7936, 2.56, 0.264, 292, 261, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
2009, 3db6A, 0.7936, 2.45, 0.264, 287, 261, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 902
2010, 4yzbB, 0.7935, 2.49, 0.279, 464, 258, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1521
2011, 4c34A, 0.7935, 2.46, 0.278, 336, 259, PKA-S6K1 CHIMERA WITH STAUROSPORINE BOUND
2012, 3nuxA, 0.7934, 2.35, 0.492, 261, 258, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
2013, 4fifA, 0.7933, 2.57, 0.264, 293, 261, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
2014, 5uplA, 0.7932, 2.57, 0.264, 290, 261, CDC42 BINDS PAK4 VIA AN EXTENDED GTPASE-EFFECTOR INTEFACE - 2 PEPTIDE: PAK4FL CDC42 - UNREFINED
2015, 5k3yA, 0.7932, 2.40, 0.302, 267, 258, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
2016, 2bcjA, 0.7932, 2.69, 0.270, 624, 263, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GALPHA-Q AND GBETAGAMMA SUBUNITS
2017, 6aywB, 0.7930, 2.72, 0.294, 293, 262, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2018, 4jdiA, 0.7930, 2.64, 0.264, 289, 261, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
2019, 1xhaA, 0.7930, 2.41, 0.274, 348, 259, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2020, 1xh8A, 0.7930, 2.41, 0.270, 337, 259, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2021, 5n1dA, 0.7929, 2.41, 0.274, 348, 259, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-METHYL-1-(5-PYRIDIN-3-YLOXYFURAN-2-YL) METHANAMINE
2022, 4qmvA, 0.7929, 2.48, 0.269, 288, 260, MST3 IN COMPLEX WITH PF-03814735 N-{2-[(1S4R)-6-{[4- (CYCLOBUTYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}-1234- TETRAHYDRO-14-EPIMINONAPHTHALEN-9-YL]-2-OXOETHYL}ACETAMIDE
2023, 3mfuA, 0.7929, 2.96, 0.297, 302, 263, CASK-4M CAM KINASE DOMAIN AMPPNP-MN2+
2024, 1rejA, 0.7929, 2.43, 0.270, 333, 259, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 1
2025, 4ntsB, 0.7927, 2.44, 0.269, 341, 260, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
2026, 4jdhA, 0.7927, 2.66, 0.264, 289, 261, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
2027, 4crsA, 0.7927, 2.40, 0.293, 331, 259, HUMAN PROTEIN KINASE N2 (PKN2 PRKCL2) IN COMPLEX WITH ATPGAMMAS
2028, 2uw7A, 0.7926, 2.46, 0.266, 335, 259, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
2029, 2ghgA, 0.7925, 2.60, 0.276, 269, 261, H-CHK1 COMPLEXED WITH A431994
2030, 2e9oA, 0.7925, 2.52, 0.277, 269, 260, STRUCTURE OF H-CHK1 COMPLEXED WITH AA582939
2031, 1xh5A, 0.7924, 2.38, 0.264, 335, 258, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2032, 1szmA, 0.7924, 2.42, 0.270, 317, 259, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
2033, 4cfhA, 0.7923, 2.33, 0.302, 401, 258, STRUCTURE OF AN ACTIVE FORM OF MAMMALIAN AMPK
2034, 4aw0A, 0.7923, 2.59, 0.280, 283, 261, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS182 BOUND TO THE PIF-POCKET
2035, 2ywpA, 0.7923, 2.61, 0.276, 269, 261, CRYSTAL STRUCTURE OF CHK1 WITH A UREA INHIBITOR
2036, 2br1A, 0.7922, 2.65, 0.280, 272, 261, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2037, 4w8dA, 0.7921, 2.56, 0.268, 289, 261, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06454589).
2038, 4o0vA, 0.7921, 2.62, 0.264, 290, 261, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2039, 1okyA, 0.7921, 2.37, 0.275, 281, 258, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2040, 4ks8A, 0.7920, 2.66, 0.280, 286, 261, PAK6 KINASE DOMAIN IN COMPLEX WITH SUNITINIB
2041, 3l9lA, 0.7920, 2.45, 0.274, 338, 259, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
2042, 1svhA, 0.7920, 2.39, 0.264, 335, 258, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 8
2043, 2brbA, 0.7919, 2.57, 0.281, 272, 260, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2044, 6b2eA, 0.7918, 2.34, 0.291, 442, 258, STRUCTURE OF FULL LENGTH HUMAN AMPK (A2B2G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4. 
2045, 4o27B, 0.7918, 2.59, 0.268, 281, 261, CRYSTAL STRUCTURE OF MST3-MO25 COMPLEX WITH WIF MOTIF
2046, 3iecD, 0.7918, 2.25, 0.311, 311, 254, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2047, 3dbeA, 0.7917, 2.41, 0.266, 284, 259, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 557
2048, 2vgoB, 0.7917, 2.41, 0.292, 277, 257, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
2049, 3mfsA, 0.7916, 2.90, 0.298, 303, 262, CASK-4M CAM KINASE DOMAIN AMPPNP
2050, 3l9mB, 0.7914, 2.39, 0.264, 336, 258, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
2051, 2e9nA, 0.7914, 2.54, 0.277, 269, 260, STRUCTURE OF H-CHK1 COMPLEXED WITH A767085
2052, 3otuA, 0.7912, 2.52, 0.271, 276, 258, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR JS30
2053, 1phkA, 0.7912, 2.48, 0.282, 277, 259, TWO STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHORYLASE KINASE: AN ACTIVE PROTEIN KINASE COMPLEXED WITH NUCLEOTIDE SUBSTRATE-ANALOGUE AND PRODUCT
2054, 5dh3B, 0.7911, 2.53, 0.284, 283, 261, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
2055, 4zy4A, 0.7911, 2.31, 0.277, 288, 256, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
2056, 3e87B, 0.7911, 2.45, 0.281, 321, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2057, 3e87A, 0.7911, 2.45, 0.281, 321, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2058, 3a7jA, 0.7911, 2.59, 0.273, 286, 260, HUMAN MST3 KINASE IN COMPLEX WITH MNADP
2059, 2hxqA, 0.7911, 2.56, 0.281, 272, 260, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2
2060, 2hxlA, 0.7911, 2.57, 0.281, 272, 260, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1
2061, 2cgxA, 0.7910, 2.54, 0.281, 265, 260, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
2062, 4i6hA, 0.7909, 2.56, 0.240, 285, 263, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE ALPHA-SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2063, 3kk9A, 0.7909, 2.52, 0.313, 275, 259, CAMKII SUBSTRATE COMPLEX B
2064, 2uztA, 0.7909, 2.48, 0.263, 336, 259, PKA STRUCTURES OF AKT INDAZOLE-PYRIDINE INHIBITORS
2065, 2bujA, 0.7909, 2.35, 0.241, 291, 257, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
2066, 1bkxA, 0.7909, 2.37, 0.264, 337, 258, A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND ADENOSINE FURTHER DEFINES CONFORMATIONAL FLEXIBILITY
2067, 4otgA, 0.7907, 2.50, 0.288, 322, 260, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH LESTAURTINIB
2068, 3c0hB, 0.7907, 2.98, 0.289, 300, 263, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
2069, 1zltA, 0.7907, 2.55, 0.277, 272, 260, CRYSTAL STRUCTURE OF CHK1 COMPLEXED WITH A HYMENALDISINE ANALOG
2070, 5vloB, 0.7906, 2.74, 0.294, 293, 262, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2071, 4otdA, 0.7906, 2.57, 0.291, 334, 261, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN
2072, 4nusA, 0.7906, 2.73, 0.282, 301, 262, RSK2 N-TERMINAL KINASE IN COMPLEX WITH LJH685
2073, 4i6fA, 0.7906, 2.57, 0.240, 285, 263, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2074, 2jdvA, 0.7906, 2.50, 0.270, 334, 259, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH A-443654
2075, 4u8zA, 0.7905, 2.55, 0.268, 289, 261, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06447475)
2076, 1xjdA, 0.7905, 2.45, 0.287, 280, 258, CRYSTAL STRUCTURE OF PKC-THETA COMPLEXED WITH STAUROSPORINE AT 2A RESOLUTION
2077, 1j3hA, 0.7904, 2.43, 0.270, 329, 259, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
2078, 2aypA, 0.7903, 2.50, 0.277, 268, 260, CRYSTAL STRUCTURE OF CHK1 WITH AN INDOL INHIBITOR
2079, 1xh9A, 0.7903, 2.42, 0.264, 336, 258, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2080, 1o6kA, 0.7903, 2.44, 0.281, 317, 260, STRUCTURE OF ACTIVATED FORM OF PKB KINASE DOMAIN S474D WITH GSK3 PEPTIDE AND AMP-PNP
2081, 5l2tA, 0.7902, 2.28, 0.488, 261, 256, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND RIBOCICLIB.
2082, 4qo9B, 0.7902, 2.59, 0.273, 285, 260, MST3 IN COMPLEX WITH DANUSERTIB
2083, 2vo0A, 0.7902, 2.45, 0.260, 340, 258, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
2084, 2e9uA, 0.7902, 2.55, 0.277, 269, 260, STRUCTURE OF H-CHK1 COMPLEXED WITH A780125
2085, 1o6lA, 0.7902, 2.56, 0.280, 316, 261, CRYSTAL STRUCTURE OF AN ACTIVATED AKT/PROTEIN KINASE B (PKB-PIF CHIMERA) TERNARY COMPLEX WITH AMP-PNP AND GSK3 PEPTIDE
2086, 5dzcA, 0.7901, 2.56, 0.264, 816, 261, CRYSTAL STRUCTURE OF PVX_084705 IN COMPLEX WITH AMP-PNP
2087, 4qmoA, 0.7901, 2.55, 0.268, 288, 261, MST3 IN COMPLEX WITH IMIDAZOLO-OXINDOLE PKR INHIBITOR C16
2088, 4i5pA, 0.7901, 2.58, 0.240, 284, 263, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2089, 2cgvA, 0.7901, 2.49, 0.282, 264, 259, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
2090, 3ag9B, 0.7900, 2.47, 0.274, 317, 259, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
2091, 6babD, 0.7899, 2.76, 0.294, 291, 262, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2092, 4o0xA, 0.7899, 2.66, 0.264, 290, 261, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2093, 4i6bA, 0.7899, 2.60, 0.240, 285, 263, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
2094, 3pscA, 0.7899, 2.52, 0.272, 614, 261, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
2095, 3e88B, 0.7899, 2.46, 0.281, 319, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2096, 3e88A, 0.7899, 2.46, 0.281, 319, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2097, 5f0aA, 0.7898, 2.57, 0.268, 811, 261, CRYSTAL STRUCTURE OF PVX_084705 WITH BOUND 1-TERT-BUTYL-3-(3- CHLOROPHENOXY)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE INHIBITOR
2098, 4aw2A, 0.7898, 2.84, 0.255, 398, 267, CRYSTAL STRUCTURE OF CDC42 BINDING PROTEIN KINASE ALPHA (MRCK ALPHA)
2099, 2uw0A, 0.7898, 2.47, 0.271, 334, 258, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  6-(4-(4-(4- CHLORO-PHENYL)-PIPERIDIN-4-YL)-PHENYL)-9H-PURINE
2100, 5h9bA, 0.7897, 2.57, 0.320, 269, 259, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/AMPPN
2101, 4o0yA, 0.7897, 2.66, 0.264, 290, 261, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2102, 3c0iA, 0.7897, 2.99, 0.293, 298, 263, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P212121 FORM
2103, 2uw6A, 0.7897, 2.47, 0.267, 334, 258, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (S)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
2104, 1q8wA, 0.7897, 2.50, 0.270, 334, 259, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR FASUDIL (HA-1077)
2105, 5isoC, 0.7896, 2.45, 0.290, 429, 259, STRUCTURE OF FULL LENGTH HUMAN AMPK (NON-PHOSPHORYLATED AT T-LOOP) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
2106, 5dh3A, 0.7896, 2.58, 0.284, 287, 261, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
2107, 1rekA, 0.7896, 2.46, 0.270, 336, 259, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 8
2108, 1j3hB, 0.7896, 2.44, 0.270, 327, 259, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
2109, 5vefA, 0.7895, 2.71, 0.264, 289, 261, PAK4 KINASE DOMAIN IN COMPLEX WITH FASUDIL
2110, 4ct2A, 0.7895, 2.25, 0.281, 277, 256, HUMAN PDK1-PKCZETA KINASE CHIMERA
2111, 2vnwA, 0.7895, 2.47, 0.267, 334, 258, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)METHANAMINE
2112, 5upkB, 0.7894, 2.65, 0.264, 288, 261, CDC42 BINDS PAK4 VIA AN EXTENDED GTPASE-EFFECTOR INTERFACE - 3 PEPTIDE: PAK4CAT PAK4-N45 CDC42
2113, 2jdtA, 0.7894, 2.44, 0.260, 334, 258, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
2114, 5li1A, 0.7893, 2.50, 0.288, 331, 260, STRUCTURE OF A PAR3-INHIBITORY PEPTIDE BOUND TO PKCIOTA CORE KINASE DOMAIN
2115, 3v8sD, 0.7893, 2.79, 0.249, 397, 265, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
2116, 5k3yB, 0.7892, 2.53, 0.295, 277, 258, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
2117, 5he1A, 0.7892, 2.55, 0.268, 618, 261, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224062
2118, 3l9lB, 0.7891, 2.43, 0.264, 337, 258, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
2119, 4fijA, 0.7890, 2.73, 0.264, 291, 261, CATALYTIC DOMAIN OF HUMAN PAK4
2120, 4fihA, 0.7890, 2.72, 0.264, 291, 261, CATALYTIC DOMAIN OF HUMAN PAK4 WITH QKFTGLPRQW PEPTIDE
2121, 3e8dB, 0.7890, 2.49, 0.285, 317, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2122, 3e8dA, 0.7890, 2.49, 0.281, 315, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2123, 2i0eB, 0.7890, 2.52, 0.252, 300, 262, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
2124, 5oteA, 0.7889, 2.88, 0.254, 407, 268, MRCK BETA IN COMPLEX WITH BDP-00008900
2125, 5lcqA, 0.7889, 2.42, 0.264, 350, 258, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH LONG-CHAIN FASUDIL-DERIVATIVE (LIGAND 05)
2126, 4z84A, 0.7889, 2.45, 0.260, 335, 258, PKAB3 IN COMPLEX WITH PYRROLIDINE INHIBITOR 34A
2127, 4ks7A, 0.7889, 2.65, 0.280, 286, 261, PAK6 KINASE DOMAIN IN COMPLEX WITH PF-3758309
2128, 2brnA, 0.7889, 2.62, 0.277, 268, 260, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2129, 5he0A, 0.7888, 2.56, 0.268, 621, 261, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG215022
2130, 4jdkA, 0.7888, 2.66, 0.265, 288, 260, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
2131, 5he2A, 0.7886, 2.55, 0.268, 628, 261, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224406
2132, 3l9nA, 0.7886, 2.41, 0.264, 332, 258, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 27
2133, 3ambA, 0.7886, 2.45, 0.267, 340, 258, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR VX- 680
2134, 2i6lB, 0.7885, 2.88, 0.331, 269, 260, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
2135, 2cguA, 0.7885, 2.52, 0.282, 263, 259, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
2136, 2vo3A, 0.7884, 2.43, 0.261, 334, 257, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
2137, 2vn9B, 0.7884, 2.61, 0.295, 301, 261, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
2138, 1fotA, 0.7884, 2.46, 0.263, 299, 259, STRUCTURE OF THE UNLIGANDED CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT FROM SACCHAROMYCES CEREVISIAE
2139, 4pnkA, 0.7883, 2.54, 0.272, 625, 261, G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GSK180736A
2140, 3v8sB, 0.7883, 2.81, 0.249, 397, 265, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
2141, 3d0eB, 0.7883, 2.51, 0.281, 322, 260, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
2142, 3d0eA, 0.7883, 2.51, 0.281, 322, 260, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
2143, 6aywA, 0.7882, 2.59, 0.300, 293, 260, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2144, 5m0bA, 0.7882, 2.43, 0.264, 350, 258, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A SHORT-CHAINED N-(2-AMINOETHYL)ISOQUINOLINE-5-SULFONAMIDE) FASUDIL-DERIVATIVE (LIGAND 03) 
2145, 4fiiA, 0.7882, 2.74, 0.264, 291, 261, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
2146, 2bfyB, 0.7882, 2.43, 0.281, 278, 256, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
2147, 5eykB, 0.7881, 2.52, 0.280, 275, 257, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
2148, 2uw3A, 0.7881, 2.49, 0.267, 334, 258, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 5-METHYL-4- PHENYL-1H-PYRAZOLE
2149, 2broA, 0.7881, 2.73, 0.280, 272, 261, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2150, 3tv7D, 0.7880, 2.79, 0.253, 397, 265, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
2151, 2vnyA, 0.7880, 2.43, 0.257, 334, 257, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)AMINE
2152, 2vn9A, 0.7880, 2.66, 0.303, 301, 261, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
2153, 4jdjA, 0.7879, 2.67, 0.265, 288, 260, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
2154, 3mfrA, 0.7879, 3.01, 0.297, 302, 263, CASK-4M CAM KINASE DOMAIN NATIVE
2155, 3cikA, 0.7879, 2.77, 0.270, 619, 263, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
2156, 2gnlA, 0.7879, 2.48, 0.275, 338, 258, PKA THREEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR H- 1152P
2157, 1uu7A, 0.7879, 2.47, 0.271, 280, 258, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-2
2158, 4qmqA, 0.7878, 2.59, 0.268, 289, 261, MST3 IN COMPLEX WITH CP-673451
2159, 4axaA, 0.7878, 2.38, 0.261, 335, 257, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1S)-2-AMINO-1-( 4-CHLOROPHENYL)-1-(4-(1H-PYRAZOL-4-YL)PHENYL)ETHAN-1-OL
2160, 3c0hA, 0.7878, 2.82, 0.291, 300, 261, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
2161, 2xckA, 0.7878, 2.39, 0.270, 275, 256, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2162, 2ojfE, 0.7878, 2.50, 0.263, 336, 259, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
2163, 5otfA, 0.7877, 2.91, 0.254, 411, 268, MRCK BETA IN COMPLEX WITH BDP-00009066
2164, 3pwyA, 0.7877, 2.44, 0.276, 281, 257, CRYSTAL STRUCTURE OF AN EXTENDER (SPD28345)-MODIFIED HUMAN PDK1 COMPLEX 2
2165, 1xh6A, 0.7877, 2.46, 0.260, 331, 258, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2166, 4ie9A, 0.7876, 2.48, 0.264, 335, 258, BOVINE PKA C-ALPHA IN COMPLEX WITH 3-PYRIDYLMETHYL-5-METHYL-1H- PYRAZOLE-3-CARBOXYLATE
2167, 3amaA, 0.7876, 2.49, 0.267, 342, 258, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR JNJ- 7706621
2168, 2uvyA, 0.7876, 2.45, 0.261, 333, 257, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH METHYL-(4-(9H- PURIN-6-YL)-BENZYL)-AMINE
2169, 5t5tA, 0.7875, 2.47, 0.302, 368, 258, AMPK BOUND TO ALLOSTERIC ACTIVATOR
2170, 5ig1A, 0.7875, 2.66, 0.277, 300, 260, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
2171, 5dykA, 0.7875, 2.43, 0.266, 809, 259, CRYSTAL STRUCTURE OF PF3D7_1436600
2172, 3tv7B, 0.7875, 2.83, 0.244, 397, 266, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
2173, 2xikA, 0.7875, 2.56, 0.278, 288, 259, STRUCTURE OF HUMAN YSK1 (YEAST SPS1-STE20-RELATED KINASE 1)
2174, 4qmpA, 0.7874, 2.62, 0.268, 289, 261, MST3 IN COMPLEX WITH CDK1/2 INHIBITOR III 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
2175, 5o5mA, 0.7873, 2.43, 0.275, 336, 258, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP120 AND RKP117 
2176, 6b1uA, 0.7872, 2.46, 0.291, 441, 258, STRUCTURE OF FULL-LENGTH HUMAN AMPK (A2B1G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4 
2177, 6b16A, 0.7872, 2.33, 0.298, 285, 255, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
2178, 4ae6A, 0.7872, 2.51, 0.273, 319, 260, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
2179, 3hkoA, 0.7872, 2.75, 0.280, 319, 261, CRYSTAL STRUCTURE OF A CDPK KINASE DOMAIN FROM CRYPTOSPORIDIUM PARVUM CGD7_40
2180, 1q61A, 0.7872, 2.48, 0.264, 335, 258, PKA TRIPLE MUTANT MODEL OF PKB
2181, 5lvpA, 0.7871, 2.34, 0.285, 275, 256, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
2182, 3agmA, 0.7871, 2.51, 0.278, 337, 259, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-670
2183, 1xh4A, 0.7871, 2.43, 0.265, 334, 257, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2184, 4z83E, 0.7870, 2.54, 0.270, 335, 259, PKAB3 IN COMPLEX WITH PYRROLIDINE INHIBITOR 47A
2185, 4ntsA, 0.7870, 2.51, 0.259, 341, 259, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
2186, 3c4yB, 0.7870, 2.37, 0.257, 466, 257, CRYSTAL STRUCTURE OF APO FORM OF G PROTEIN COUPLED RECEPTOR KINASE 1 AT 7.51A
2187, 2c3kA, 0.7870, 2.51, 0.275, 262, 258, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
2188, 1xh7A, 0.7870, 2.43, 0.265, 337, 257, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2189, 5lvpB, 0.7869, 2.36, 0.285, 276, 256, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
2190, 4ij9A, 0.7869, 2.48, 0.264, 335, 258, BOVINE PKA C-ALPHA IN COMPLEX WITH 2-[[5-(4-PYRIDYL)-1H-124-TRIAZOL- 3-YL]SULFANYL]-1-(2-THIOPHENYL)ETHANONE
2191, 4c2vB, 0.7869, 2.56, 0.288, 280, 257, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
2192, 2vgpA, 0.7869, 2.23, 0.303, 265, 254, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
2193, 6c0uA, 0.7868, 2.56, 0.277, 338, 260, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CALPHA SUBUNIT BOUND WITH N46 
2194, 5ho7A, 0.7868, 2.40, 0.273, 280, 256, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2195, 3dneA, 0.7868, 2.47, 0.264, 336, 258, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
2196, 4uj2A, 0.7867, 2.50, 0.264, 335, 258, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
2197, 4rewA, 0.7867, 2.53, 0.301, 411, 259, CRYSTAL STRUCTURE OF THE NON-PHOSPHORYLATED HUMAN ALPHA1 BETA2 GAMMA1 HOLO-AMPK COMPLEX
2198, 3nayB, 0.7867, 2.37, 0.277, 278, 256, PDK1 IN COMPLEX WITH INHIBITOR MP6
2199, 2wtkB, 0.7867, 2.53, 0.238, 311, 260, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
2200, 5n23A, 0.7866, 2.52, 0.279, 333, 258, PROTEIN KINASE A MUTANTS AS SURROGATE MODEL FOR AURORA B WITH AT9283 INHIBITOR
2201, 4xw4A, 0.7866, 2.39, 0.265, 334, 257, X-RAY STRUCTURE OF PKAC WITH AMPPNP SP20 CALCIUM IONS
2202, 1sveA, 0.7866, 2.47, 0.260, 341, 258, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 1
2203, 6e4uA, 0.7865, 2.47, 0.302, 365, 258, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
2204, 2xchA, 0.7865, 2.41, 0.273, 278, 256, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2205, 2q0nA, 0.7865, 2.66, 0.264, 293, 261, STRUCTURE OF HUMAN P21 ACTIVATING KINASE 4 (PAK4) IN COMPLEX WITH A CONSENSUS PEPTIDE
2206, 2c1bA, 0.7865, 2.49, 0.260, 335, 258, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ( 4R2S)-5 -(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2- YLMETHANESULFONYL)ISOQUINOLINE
2207, 5ezvA, 0.7864, 2.48, 0.291, 441, 258, X-RAY CRYSTAL STRUCTURE OF AMP-ACTIVATED PROTEIN KINASE ALPHA-2/ALPHA- 1 RIM CHIMAERA (ALPHA-2(1-347)/ALPHA-1(349-401)/ALPHA-2(397-END) BETA-1 GAMMA-1) CO-CRYSTALLIZED WITH C2 (5-(5-HYDROXYL-ISOXAZOL-3- YL)-FURAN-2-PHOSPHONIC ACID)
2208, 2uw5A, 0.7864, 2.54, 0.271, 333, 258, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (R)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
2209, 2f7zE, 0.7864, 2.53, 0.263, 336, 259, PROTEIN KINASE A BOUND TO (R)-1-(1H-INDOL-3-YLMETHYL)-2-(2- PYRIDIN-4-YL-[17]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
2210, 3pooA, 0.7863, 2.40, 0.265, 331, 257, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2211, 2uvxA, 0.7863, 2.56, 0.266, 335, 259, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 7-AZAINDOLE
2212, 2f7eE, 0.7863, 2.52, 0.263, 336, 259, PKA COMPLEXED WITH (S)-2-(1H-INDOL-3-YL)-1-(5-ISOQUINOLIN-6- YL-PYRIDIN-3-YLOXYMETHYL-ETYLAMINE
2213, 2e9vA, 0.7863, 2.59, 0.277, 268, 260, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
2214, 2bfxB, 0.7863, 2.44, 0.290, 275, 255, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
2215, 1ym7D, 0.7863, 2.77, 0.270, 599, 263, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
2216, 1ym7C, 0.7863, 2.77, 0.270, 607, 263, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
2217, 1q62A, 0.7863, 2.51, 0.260, 336, 258, PKA DOUBLE MUTANT MODEL OF PKB
2218, 5vhbA, 0.7862, 2.50, 0.275, 325, 258, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITOR
2219, 4c2wB, 0.7862, 2.56, 0.288, 277, 257, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
2220, 4b8mB, 0.7861, 2.66, 0.291, 279, 258, AURORA B KINASE IN COMPLEX WITH VX-680
2221, 2w99B, 0.7861, 3.11, 0.463, 291, 268, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
2222, 1svgA, 0.7861, 2.47, 0.264, 338, 258, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 4
2223, 1omwA, 0.7861, 2.65, 0.271, 614, 262, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN G PROTEIN-COUPLED RECEPTOR KINASE 2 AND HETEROTRIMERIC G PROTEIN BETA 1 AND GAMMA 2 SUBUNITS
2224, 2c1aA, 0.7860, 2.48, 0.260, 335, 258, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE
2225, 5l2iA, 0.7859, 2.47, 0.490, 260, 257, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND PALBOCICLIB.
2226, 4ujbA, 0.7859, 2.49, 0.264, 344, 258, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
2227, 4yr8F, 0.7858, 2.33, 0.354, 300, 254, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
2228, 3dndA, 0.7858, 2.48, 0.264, 334, 258, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
2229, 4yxsA, 0.7857, 2.49, 0.264, 335, 258, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
2230, 4ualA, 0.7857, 2.91, 0.255, 403, 267, MRCK BETA IN COMPLEX WITH BDP00005290
2231, 4o22A, 0.7857, 2.40, 0.265, 336, 257, BINARY COMPLEX OF METAL-FREE PKAC WITH SP20.
2232, 3sc1A, 0.7857, 2.41, 0.273, 278, 256, NOVEL ISOQUINOLONE PDK1 INHIBITORS DISCOVERED THROUGH FRAGMENT-BASED LEAD DISCOVERY
2233, 2vo6A, 0.7857, 2.43, 0.272, 335, 257, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4- CHLOROBENZYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YLAMINE
2234, 2vd5A, 0.7857, 2.68, 0.259, 390, 263, STRUCTURE OF HUMAN MYOTONIC DYSTROPHY PROTEIN KINASE IN COMPLEX WITH THE BISINDOYLMALEIDE INHIBITOR BIM VIII
2235, 2f7xE, 0.7857, 2.57, 0.269, 336, 260, PROTEIN KINASE A BOUND TO (S)-2-(1H-INDOL-3-YL)-1-[5-((E)-2- PYRIDIN-4-YL-VINYL)-PYRIDIN-3-YLOXYMETHYL]-ETHYLAMINE
2236, 2e9vB, 0.7857, 2.60, 0.277, 268, 260, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
2237, 6e4wA, 0.7856, 2.50, 0.302, 361, 258, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
2238, 3c0gB, 0.7856, 2.99, 0.286, 320, 262, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
2239, 2oh0E, 0.7856, 2.57, 0.269, 336, 260, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
2240, 2cgwA, 0.7856, 2.52, 0.279, 262, 258, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
2241, 4qyeA, 0.7855, 2.55, 0.280, 271, 257, CHK1 KINASE DOMAIN IN COMPLEX WITH DIARYLPYRAZINE COMPOUND 1
2242, 2uw4A, 0.7855, 2.51, 0.267, 334, 258, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-(5-METHYL- 1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
2243, 2gdoA, 0.7855, 2.55, 0.282, 269, 259, 4-(AMINOALKYLAMINO)-3-BENZIMIDAZOLE-QUINOLINONES AS POTENT CHK1 INHIBITORS
2244, 1ym7B, 0.7855, 2.68, 0.271, 608, 262, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
2245, 5ufuA, 0.7854, 2.54, 0.314, 368, 258, STRUCTURE OF AMPK BOUND TO ACTIVATOR
2246, 5lvpC, 0.7854, 2.39, 0.285, 275, 256, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
2247, 3mftA, 0.7854, 2.92, 0.298, 302, 262, CASK-4M CAM KINASE DOMAIN MN2+
2248, 1ym7A, 0.7854, 2.68, 0.271, 608, 262, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
2249, 1vebA, 0.7854, 2.54, 0.274, 338, 259, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 5
2250, 4zhxA, 0.7853, 2.49, 0.291, 408, 258, NOVEL BINDING SITE FOR ALLOSTERIC ACTIVATION OF AMPK
2251, 3ovvA, 0.7853, 2.52, 0.264, 335, 258, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2252, 1re8A, 0.7853, 2.53, 0.270, 337, 259, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 2
2253, 5uzkA, 0.7852, 2.50, 0.264, 335, 258, CRYSTAL STRUCTURE OF PKA BOUND TO AN PYRROLO PYRIDINE INHIBITOR
2254, 4qfsA, 0.7852, 2.49, 0.302, 361, 258, STRUCTURE OF AMPK IN COMPLEX WITH BR2-A769662CORE ACTIVATOR AND STAUROSPORINE INHIBITOR
2255, 2uzwE, 0.7852, 2.53, 0.263, 336, 259, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
2256, 6e4tA, 0.7851, 2.50, 0.302, 361, 258, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
2257, 4ujaA, 0.7851, 2.51, 0.264, 336, 258, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
2258, 4rvkA, 0.7851, 2.44, 0.281, 264, 256, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 8: N-[3-(6-CYANO-9H- PYRROLO[23-B:54-C ]DIPYRIDIN-3-YL)PHENYL]ACETAMIDE
2259, 4qfrA, 0.7851, 2.49, 0.302, 361, 258, STRUCTURE OF AMPK IN COMPLEX WITH CL-A769662 ACTIVATOR AND STAUROSPORINE INHIBITOR
2260, 3oogA, 0.7851, 2.51, 0.264, 333, 258, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH A SMALL FRAGMENT
2261, 2vo7A, 0.7851, 2.51, 0.264, 335, 258, STRUCTURE OF PKA COMPLEXED WITH 4-(4-CHLOROBENZYL)-1-(7H- PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN-4-YLAMINE
2262, 2uzuE, 0.7851, 2.58, 0.273, 336, 260, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
2263, 4yxrA, 0.7850, 2.51, 0.264, 334, 258, CRYSTAL STRUCTURE OF PKA IN COMPLEX WITH INHIBITOR.
2264, 3x2wA, 0.7850, 2.42, 0.265, 336, 257, MICHAELIS COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
2265, 2vgpB, 0.7850, 2.58, 0.288, 277, 257, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
2266, 2erzE, 0.7850, 2.50, 0.260, 334, 258, CRYSTAL STRUCTURE OF C-AMP DEPENDENT KINASE (PKA) BOUND TO HYDROXYFASUDIL
2267, 5lvpD, 0.7849, 2.39, 0.285, 276, 256, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
2268, 3x2uA, 0.7849, 2.46, 0.265, 336, 257, MICHAELIS-LIKE INITIAL COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT.
2269, 6c2yA, 0.7848, 2.50, 0.270, 617, 259, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG257142 
2270, 5ukmA, 0.7848, 2.61, 0.272, 621, 261, BOVINE GRK2 IN COMPLEX WITH HUMAN GBETAGAMMA SUBUNITS AND CCG258208 (14AS)
2271, 2uvzA, 0.7848, 2.49, 0.257, 334, 257, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH C-PHENYL-C-(4-( 9H-PURIN-6-YL)-PHENYL)-METHYLAMINE
2272, 1ydsE, 0.7848, 2.50, 0.264, 334, 258, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H8 PROTEIN KINASE INHIBITOR [N-(2-METHYLAMINO)ETHYL]-5- ISOQUINOLINESULFONAMIDE
2273, 5x3fB, 0.7847, 2.54, 0.259, 348, 259, CRYSTAL STRUCTURE OF THE YGJG-PROTEIN A-ZPA963-PKA CATALYTIC DOMAIN
2274, 5wngD, 0.7847, 2.90, 0.249, 396, 265, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2275, 5oq5A, 0.7847, 2.52, 0.279, 265, 258, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
2276, 4zy6A, 0.7847, 2.32, 0.299, 284, 254, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
2277, 3j4rE, 0.7846, 2.63, 0.268, 325, 261, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A LINEAR CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
2278, 3j4rD, 0.7846, 2.63, 0.268, 325, 261, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A LINEAR CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
2279, 3j4qE, 0.7846, 2.63, 0.268, 325, 261, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A BENT CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
2280, 3j4qD, 0.7846, 2.63, 0.268, 325, 261, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A BENT CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
2281, 5fg8A, 0.7845, 2.65, 0.320, 269, 259, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
2282, 5bx6A, 0.7845, 2.52, 0.267, 343, 258, PKA IN COMPLEX WITH A HALOGENATED PHTHALAZINONE FRAGMENT COMPOUND.
2283, 4qyfA, 0.7845, 2.46, 0.281, 269, 256, CHK1 KINASE DOMAIN IN COMPLEX WITH AMINOPYRAZINE COMPOUND 13
2284, 2uzvA, 0.7845, 2.52, 0.270, 336, 259, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
2285, 5ezrA, 0.7844, 2.62, 0.264, 803, 261, CRYSTAL STRUCTURE OF PVX_084705 BOUND TO COMPOUND
2286, 4l6qB, 0.7844, 2.97, 0.256, 388, 266, ROCK2 IN COMPLEX WITH BENZOXABOROLE
2287, 1ydrE, 0.7844, 2.56, 0.270, 334, 259, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H7 PROTEIN KINASE INHIBITOR 1-(5- ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE
2288, 4uj1A, 0.7843, 2.52, 0.264, 335, 258, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
2289, 3zo4A, 0.7843, 2.52, 0.264, 335, 258, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
2290, 3c0gA, 0.7843, 2.96, 0.290, 309, 262, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
2291, 2gu8A, 0.7843, 2.42, 0.265, 335, 257, DISCOVERY OF 2-PYRIMIDYL-5-AMIDOTHIOPHENES AS NOVEL AND POTENT INHIBITORS FOR AKT: SYNTHESIS AND SAR STUDIES
2292, 5kq5A, 0.7842, 2.51, 0.302, 362, 258, AMPK BOUND TO ALLOSTERIC ACTIVATOR
2293, 4qo9A, 0.7842, 2.59, 0.270, 280, 259, MST3 IN COMPLEX WITH DANUSERTIB
2294, 3owpA, 0.7842, 2.53, 0.264, 334, 258, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2295, 3eqrB, 0.7842, 2.43, 0.253, 271, 257, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
2296, 2brmA, 0.7842, 2.58, 0.283, 263, 258, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2297, 4xw5A, 0.7841, 2.54, 0.271, 334, 258, X-RAY STRUCTURE OF PKAC WITH ATP CP20 CALCIUM IONS
2298, 4l6qA, 0.7841, 2.94, 0.245, 388, 265, ROCK2 IN COMPLEX WITH BENZOXABOROLE
2299, 4aw1A, 0.7841, 2.51, 0.272, 283, 257, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS210 BOUND TO THE PIF-POCKET
2300, 3a7gA, 0.7841, 2.63, 0.269, 289, 260, HUMAN MST3 KINASE
2301, 2gnhA, 0.7841, 2.50, 0.279, 338, 258, PKA FIVE FOLD MUTANT MODEL OF RHO-KINASE WITH H1152P
2302, 4l67A, 0.7840, 2.76, 0.264, 289, 261, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF PAK4
2303, 3zo2A, 0.7839, 2.53, 0.275, 340, 258, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
2304, 3zo1A, 0.7839, 2.54, 0.275, 339, 258, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
2305, 2wtkE, 0.7839, 2.58, 0.238, 308, 260, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
2306, 4appA, 0.7838, 2.79, 0.264, 291, 261, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH (S)-N-(5-(3-BENZYL-1-METHYLPIPERAZINE-4- CARBONYL)-66-DIMETHYL-1456-TETRAHYDROPYRROLO(34-C) PYRAZOL-3-YL)-3-PHENOXYBENZAMIDE
2307, 3tacA, 0.7838, 2.82, 0.290, 324, 262, CRYSTAL STRUCTURE OF THE LIPRIN-ALPHA/CASK COMPLEX
2308, 3aglB, 0.7838, 2.51, 0.267, 335, 258, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
2309, 2gnjA, 0.7838, 2.53, 0.275, 335, 258, PKA THREE FOLD MUTANT MODEL OF RHO-KINASE WITH Y-27632
2310, 5he3A, 0.7837, 2.65, 0.268, 623, 261, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224411
2311, 4uj9A, 0.7837, 2.53, 0.264, 339, 258, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
2312, 4iakA, 0.7837, 2.44, 0.261, 334, 257, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH SR2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2313, 3p0mA, 0.7837, 2.52, 0.264, 335, 258, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2314, 4zy5A, 0.7835, 2.28, 0.281, 283, 253, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
2315, 4ez5A, 0.7835, 2.38, 0.482, 258, 255, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
2316, 3vqhA, 0.7835, 2.53, 0.264, 344, 258, BROMINE SAD PARTIALLY RESOLVES MULTIPLE BINDING MODES FOR PKA INHIBITOR H-89
2317, 2gnfA, 0.7835, 2.51, 0.279, 339, 258, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH Y- 27632
2318, 4hptE, 0.7834, 2.52, 0.264, 335, 258, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE DISPLAYING COMPLETE PHOSPHORYL TRANSFER OF AMP-PNP ONTO A SUBSTRATE PEPTIDE
2319, 4ae9A, 0.7834, 2.51, 0.270, 321, 259, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
2320, 1q8uA, 0.7834, 2.52, 0.264, 341, 258, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR H-1152P
2321, 1nvsA, 0.7834, 2.47, 0.281, 264, 256, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/SB218078
2322, 5vi9A, 0.7833, 2.59, 0.268, 306, 257, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITORS
2323, 5bx7A, 0.7833, 2.53, 0.267, 343, 258, PKA IN COMPLEX WITH A BENZOTHIOPHENE FRAGMENT COMPOUND.
2324, 2f2uA, 0.7833, 2.93, 0.244, 386, 266, CRYSTAL STRUCTURE OF THE RHO-KINASE KINASE DOMAIN
2325, 1nvrA, 0.7832, 2.47, 0.281, 264, 256, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/STAUROSPORINE
2326, 2vrxB, 0.7831, 2.45, 0.291, 274, 254, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
2327, 5wneD, 0.7830, 2.92, 0.253, 396, 265, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2328, 5jznB, 0.7830, 2.19, 0.299, 266, 251, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
2329, 4iazA, 0.7830, 2.50, 0.265, 334, 257, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH BA2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2330, 3oxtA, 0.7830, 2.49, 0.268, 335, 257, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2331, 3f3zA, 0.7830, 2.69, 0.274, 271, 259, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840 IN PRESENCE OF INDIRUBIN E804
2332, 4ftiA, 0.7829, 2.48, 0.281, 270, 256, CRYSTAL STRUCTURE OF THE CHK1
2333, 1nvqA, 0.7829, 2.48, 0.281, 264, 256, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/UCN-01
2334, 4iayA, 0.7828, 2.49, 0.265, 333, 257, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH SR2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2335, 5hngA, 0.7827, 2.46, 0.273, 280, 256, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2336, 2hy0A, 0.7827, 2.49, 0.281, 272, 256, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 22
2337, 2bdwB, 0.7827, 2.68, 0.310, 309, 261, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
2338, 4fsnA, 0.7826, 2.42, 0.278, 270, 255, CRYSTAL STRUCTURE OF THE CHK1
2339, 3tkiA, 0.7826, 2.59, 0.280, 272, 257, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S25
2340, 3nayA, 0.7826, 2.43, 0.277, 278, 256, PDK1 IN COMPLEX WITH INHIBITOR MP6
2341, 3a7hA, 0.7826, 2.66, 0.273, 289, 260, HUMAN MST3 KINASE IN COMPLEX WITH ATP
2342, 1ydtE, 0.7826, 2.53, 0.264, 334, 258, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H89 PROTEIN KINASE INHIBITOR N-[2- (4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE
2343, 1q8tA, 0.7826, 2.53, 0.264, 338, 258, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH RHO-KINASE INHIBITOR Y-27632
2344, 2uw8A, 0.7825, 2.51, 0.257, 334, 257, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-CHLORO- PHENYL)-2-PHENYL-ETHYLAMINE
2345, 2gngA, 0.7824, 2.57, 0.286, 338, 259, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE
2346, 5oorA, 0.7823, 2.42, 0.278, 273, 255, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH STAUROSPORINE
2347, 4mk0A, 0.7823, 2.65, 0.272, 631, 261, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH A A RATIONALLY DESIGNED PAROXETINE DERIVATIVE
2348, 2hogA, 0.7823, 2.47, 0.285, 272, 256, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 20
2349, 4rvmA, 0.7822, 2.48, 0.281, 264, 256, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 19
2350, 3tnqB, 0.7822, 2.58, 0.271, 331, 258, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
2351, 4wbbB, 0.7821, 2.57, 0.271, 334, 258, SINGLE TURNOVER AUTOPHOSPHORYLATION CYCLE OF THE PKA RIIB HOLOENZYME
2352, 4ftuA, 0.7821, 2.54, 0.285, 270, 256, CRYSTAL STRUCTURE OF THE CHK1
2353, 2f2uB, 0.7821, 2.93, 0.248, 383, 266, CRYSTAL STRUCTURE OF THE RHO-KINASE KINASE DOMAIN
2354, 5wg4A, 0.7820, 2.57, 0.274, 621, 259, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG257284
2355, 3ag9A, 0.7820, 2.49, 0.257, 323, 257, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
2356, 6fd3A, 0.7819, 2.84, 0.303, 296, 261, THIOPHOSPHORYLATED PAK3 KINASE DOMAIN
2357, 3e5aA, 0.7819, 2.66, 0.300, 264, 257, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH VX-680 AND TPX2
2358, 2qvsE, 0.7818, 2.63, 0.269, 323, 260, CRYSTAL STRUCTURE OF TYPE IIA HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
2359, 1okzA, 0.7818, 2.30, 0.280, 276, 254, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH UCN-01
2360, 5hvuA, 0.7817, 2.97, 0.244, 394, 266, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH A PYRIDINE THIAZOLE PIPERIDINE INHIBITOR
2361, 5eykA, 0.7817, 2.42, 0.299, 263, 254, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
2362, 3nusA, 0.7817, 2.35, 0.276, 276, 254, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT8
2363, 3iopA, 0.7817, 2.43, 0.275, 275, 255, PDK-1 IN COMPLEX WITH THE INHIBITOR COMPOUND-8I
2364, 2etkA, 0.7817, 2.92, 0.245, 400, 265, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO HYDROXYFASUDIL
2365, 2c3lA, 0.7817, 2.52, 0.281, 265, 256, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
2366, 5j5xA, 0.7816, 2.55, 0.271, 340, 258, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1416
2367, 5isoA, 0.7816, 2.57, 0.286, 453, 259, STRUCTURE OF FULL LENGTH HUMAN AMPK (NON-PHOSPHORYLATED AT T-LOOP) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
2368, 4cfeC, 0.7816, 2.55, 0.287, 403, 258, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
2369, 3h9oA, 0.7816, 2.44, 0.275, 275, 255, PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK-1) IN COMPLEX WITH COMPOUND 9
2370, 3gniB, 0.7816, 2.43, 0.242, 304, 256, STRUCTURE OF STRAD AND MO25
2371, 2cdzA, 0.7816, 2.69, 0.266, 289, 259, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH CGP74514A
2372, 3rwpA, 0.7815, 2.46, 0.275, 277, 255, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
2373, 3nuuA, 0.7815, 2.34, 0.276, 276, 254, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT11
2374, 3idbA, 0.7815, 2.55, 0.260, 341, 258, CRYSTAL STRUCTURE OF (108-268)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
2375, 3e8eI, 0.7815, 2.52, 0.264, 345, 258, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2376, 1jluE, 0.7815, 2.54, 0.260, 337, 258, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PHOSPHORYLATED SUBSTRATE PEPTIDE AND DETERGENT
2377, 5m0cA, 0.7814, 2.56, 0.267, 336, 258, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH THE FASUDIL-FRAGMENT ISOQUINOLINE-5-SULFONAMIDE 
2378, 4c0tA, 0.7814, 2.96, 0.255, 290, 263, CANDIDA ALBICANS PKH KINASE DOMAIN
2379, 3zo3A, 0.7814, 2.58, 0.275, 337, 258, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
2380, 2v7oA, 0.7814, 2.74, 0.300, 305, 260, CRYSTAL STRUCTURE OF HUMAN CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE II GAMMA
2381, 5dylA, 0.7813, 2.36, 0.270, 802, 256, CRYSTAL STRUCTURE OF PVX_084705
2382, 4ft7A, 0.7813, 2.46, 0.282, 270, 255, CRYSTAL STRUCTURE OF THE CHK1
2383, 3w2qA, 0.7813, 2.73, 0.211, 307, 261, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH HKI-272
2384, 3ow3A, 0.7813, 2.46, 0.265, 334, 257, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
2385, 3mvjE, 0.7813, 2.58, 0.278, 334, 259, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
2386, 3e8cF, 0.7813, 2.54, 0.267, 341, 258, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2387, 5i0bA, 0.7812, 2.58, 0.267, 288, 258, STRUCTURE OF PAK4
2388, 3nuyA, 0.7811, 2.36, 0.276, 276, 254, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT17
2389, 5u7qC, 0.7810, 3.01, 0.241, 390, 266, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2390, 4ewhB, 0.7810, 2.53, 0.252, 273, 258, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
2391, 2r2pA, 0.7810, 2.42, 0.218, 283, 257, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 5 (EPHA5)
2392, 5oopA, 0.7809, 2.47, 0.281, 261, 256, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMP-PNP
2393, 3e8cD, 0.7809, 2.60, 0.274, 344, 259, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2394, 5vloA, 0.7807, 2.58, 0.296, 290, 257, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2395, 5ho8A, 0.7807, 2.35, 0.276, 278, 254, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2396, 3e8cB, 0.7807, 2.61, 0.274, 344, 259, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2397, 3e8cA, 0.7807, 2.61, 0.274, 341, 259, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2398, 3d9vA, 0.7807, 2.90, 0.250, 400, 264, CRYSTAL STRUCTURE OF ROCK I BOUND TO H-1152P A DI- METHYLATED VARIANT OF FASUDIL
2399, 2esmA, 0.7807, 2.92, 0.249, 400, 265, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO FASUDIL
2400, 5m0uA, 0.7806, 2.46, 0.263, 346, 255, APOSTRUCTURE STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) FROM CHO CELLS WITH A PEPTIDIC INHIBITOR FRAGMENT 
2401, 4iacA, 0.7806, 2.47, 0.265, 333, 257, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION AMP-PCP AND PSEUDO-SUBSTRATE PEPTIDE SP20
2402, 4cffA, 0.7806, 2.57, 0.287, 424, 258, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A THIENOPYRIDONE DERIVATIVE (A-769662)
2403, 3ndmD, 0.7806, 2.92, 0.249, 396, 265, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
2404, 3e8cE, 0.7806, 2.61, 0.274, 336, 259, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2405, 3e8cC, 0.7806, 2.61, 0.274, 341, 259, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2406, 4ewhA, 0.7805, 2.55, 0.252, 274, 258, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
2407, 3x2vA, 0.7805, 2.50, 0.261, 331, 257, MICHAELIS-LIKE COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
2408, 4c37A, 0.7804, 2.59, 0.283, 335, 258, PKA-S6K1 CHIMERA WITH COMPOUND 21A (CCT196539) BOUND
2409, 3w2oA, 0.7804, 2.74, 0.211, 305, 261, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH TAK-285
2410, 3nunA, 0.7804, 2.38, 0.276, 278, 254, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH LEAD COMPOUND
2411, 3d5xA, 0.7804, 2.35, 0.267, 279, 255, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH WORTMANNIN.
2412, 5wg3A, 0.7803, 2.61, 0.270, 618, 259, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG258748
2413, 4qyhB, 0.7803, 2.50, 0.281, 264, 256, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
2414, 5uklA, 0.7802, 2.71, 0.272, 630, 261, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG222886 (14BD)
2415, 4xbuA, 0.7802, 2.82, 0.264, 292, 261, IN VITRO CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INKA PEPTIDE
2416, 4j7bA, 0.7802, 2.38, 0.272, 284, 254, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
2417, 4c38A, 0.7802, 2.59, 0.279, 334, 258, PKA-S6K1 CHIMERA WITH COMPOUND 21E (CCT239066) BOUND
2418, 3v5wA, 0.7802, 2.70, 0.272, 623, 261, HUMAN G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH SOLUBLE GBETAGAMMA SUBUNITS AND PAROXETINE
2419, 2jdsA, 0.7802, 2.53, 0.265, 334, 257, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A- 443654
2420, 1jbpE, 0.7802, 2.55, 0.264, 339, 258, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE COMPLEXED WITH A SUBSTRATE PEPTIDE ADP AND DETERGENT
2421, 4qygB, 0.7801, 2.50, 0.281, 264, 256, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
2422, 3orzB, 0.7801, 2.54, 0.273, 278, 256, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2423, 2gniA, 0.7801, 2.56, 0.279, 338, 258, PKA FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR FASUDIL (HA1077)
2424, 4cffC, 0.7800, 2.57, 0.287, 422, 258, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A THIENOPYRIDONE DERIVATIVE (A-769662)
2425, 3qcqA, 0.7800, 2.39, 0.276, 276, 254, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-(3- AMINO-1H-INDAZOL-6-YL)-N4-ETHYL-24-PYRIMIDINEDIAMINE
2426, 3orzD, 0.7800, 2.54, 0.273, 278, 256, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2427, 4hyhA, 0.7799, 2.51, 0.281, 263, 256, X-RAY CRYSTAL STRUCTURE OF COMPOUND 39 BOUND TO HUMAN CHK1 KINASE DOMAIN
2428, 3qd3A, 0.7799, 2.39, 0.276, 278, 254, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL {(3R6S)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-6-METHYL-3-PIPERIDINYL}CARBAMATE
2429, 1uu8A, 0.7799, 2.43, 0.275, 277, 255, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-1
2430, 4qygA, 0.7798, 2.53, 0.281, 264, 256, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
2431, 2gfcA, 0.7798, 2.59, 0.264, 335, 258, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
2432, 5izfA, 0.7797, 2.63, 0.278, 336, 259, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1408
2433, 4r3pA, 0.7797, 2.74, 0.207, 310, 261, CRYSTAL STRUCTURES OF EGFR IN COMPLEX WITH MIG6
2434, 4qyhA, 0.7797, 2.54, 0.281, 264, 256, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
2435, 4j7bD, 0.7797, 2.36, 0.273, 281, 253, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
2436, 4iebA, 0.7797, 2.71, 0.280, 472, 257, CRYSTAL STRUCTURE OF A GLY128MET MUTANT OF THE TOXOPLASMA CDPK TGME49_101440
2437, 4ft0A, 0.7797, 2.43, 0.283, 266, 254, CRYSTAL STRUCTURE OF THE CHK1
2438, 5u7qB, 0.7796, 3.00, 0.241, 385, 266, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2439, 5jznA, 0.7796, 2.30, 0.294, 268, 252, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
2440, 5jzjA, 0.7796, 2.23, 0.300, 271, 250, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
2441, 4dg2E, 0.7796, 2.52, 0.265, 347, 257, CRYSTAL STRUCTURE OF MYRISTOYLATED WT CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20
2442, 3ztxB, 0.7796, 2.47, 0.285, 272, 253, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
2443, 2etrA, 0.7796, 2.95, 0.245, 400, 265, CRYSTAL STRUCTURE OF ROCK I BOUND TO Y-27632
2444, 5n3qA, 0.7795, 2.59, 0.275, 336, 258, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINOBENZAMIDE
2445, 5n3pA, 0.7795, 2.59, 0.275, 336, 258, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 1H-INDOL-5-OL
2446, 4iafA, 0.7795, 2.54, 0.265, 333, 257, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2447, 4ft3A, 0.7794, 2.38, 0.283, 269, 254, CRYSTAL STRUCTURE OF THE CHK1
2448, 4dh5A, 0.7794, 2.54, 0.261, 333, 257, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ ADP PHOSPHATE AND IP20
2449, 3nx8A, 0.7794, 2.64, 0.274, 333, 259, HUMAN CAMP DEPENDENT PROTEIN KINASE IN COMPLEX WITH PHENOL
2450, 3kkvA, 0.7794, 2.52, 0.261, 335, 257, STRUCTURE OF PKA WITH A PROTEIN KINASE B-SELECTIVE INHIBITOR.
2451, 3e8eP, 0.7794, 2.58, 0.264, 341, 258, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2452, 4njdA, 0.7793, 2.81, 0.264, 290, 261, STRUCTURE OF P21-ACTIVATED KINASE 4 WITH A NOVEL INHIBITOR KY-04031
2453, 3qcsA, 0.7793, 2.40, 0.276, 276, 254, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-[2- AMINO-6-(4-MORPHOLINYL)-4-PYRIMIDINYL]-1H-INDAZOL-3-AMINE
2454, 5n3jA, 0.7792, 2.60, 0.279, 337, 258, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-NITROBENZOIC ACID
2455, 5wnhD, 0.7791, 3.01, 0.248, 397, 266, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2456, 3qcxA, 0.7791, 2.40, 0.276, 276, 254, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-{2- AMINO-6-[(3R)-3-METHYL-4-MORPHOLINYL]-4-PYRIMIDINYL}-1H-INDAZOL-3- AMINE
2457, 2qurA, 0.7790, 2.56, 0.260, 338, 258, CRYSTAL STRUCTURE OF F327A/K285P MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
2458, 1q24A, 0.7790, 2.61, 0.256, 335, 258, PKA DOUBLE MUTANT MODEL OF PKB IN COMPLEX WITH MGATP
2459, 1eh4B, 0.7790, 2.62, 0.176, 293, 261, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
2460, 5xdkA, 0.7789, 2.70, 0.208, 307, 260, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH CO-1686
2461, 5cziA, 0.7789, 2.76, 0.211, 310, 261, EGFR L858R MUTANT IN COMPLEX WITH A SHC PEPTIDE SUBSTRATE
2462, 4cfeA, 0.7789, 2.58, 0.287, 425, 258, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
2463, 3orxE, 0.7789, 2.39, 0.278, 274, 255, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2464, 2r7bA, 0.7789, 2.38, 0.280, 274, 254, CRYSTAL STRUCTURE OF THE PHOSPHOINOSITIDE-DEPENDENT KINASE- 1 (PDK-1)CATALYTIC DOMAIN BOUND TO A DIBENZONAPHTHYRIDINE INHIBITOR
2465, 3twjA, 0.7788, 3.02, 0.259, 396, 266, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
2466, 3ha6A, 0.7788, 2.35, 0.300, 263, 253, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH TPX2 AND COMPOUND 10
2467, 5n3gA, 0.7787, 2.58, 0.275, 337, 258, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (R)-14-OXAZEPAN-6-OL
2468, 4ft9A, 0.7787, 2.45, 0.280, 270, 254, CRYSTAL STRUCTURE OF THE CHK1
2469, 3tkuB, 0.7787, 3.06, 0.243, 395, 267, MRCK BETA IN COMPLEX WITH FASUDIL
2470, 3q5iA, 0.7787, 2.36, 0.304, 470, 253, CRYSTAL STRUCTURE OF PBANKA_031420
2471, 6brcA, 0.7786, 2.55, 0.290, 265, 255, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
2472, 5wnfD, 0.7786, 2.99, 0.249, 396, 265, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2473, 5n3rA, 0.7786, 2.58, 0.279, 336, 258, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-(CARBAMOYLAMINO)-4- METHYLSULFANYLBUTANOIC ACID
2474, 5n3nA, 0.7786, 2.60, 0.275, 337, 258, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE [(2R)-24-DIHYDROXY-4-OXOBUTYL]- TRIMETHYLAZANIUM
2475, 5n1fA, 0.7786, 2.60, 0.275, 337, 258, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-QUINOLIN-5-YLPYRIDINE-3-CARBOXAMIDE
2476, 4o21A, 0.7786, 2.55, 0.268, 333, 257, PRODUCT COMPLEX OF METAL-FREE PKAC ATP-GAMMA-S AND SP20.
2477, 3ionA, 0.7786, 2.44, 0.276, 274, 254, PDK1 IN COMPLEX WITH COMPOUND 8H
2478, 4dfzE, 0.7785, 2.53, 0.265, 347, 257, CRYSTAL STRUCTURE OF MYRISTOYLATED K7C CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20
2479, 4auaA, 0.7785, 2.20, 0.474, 256, 251, LIGANDED X-RAY CRYSTAL STRUCTURE OF CYCLIN DEPENDENT KINASE 6 (CDK6)
2480, 5n3tA, 0.7784, 2.60, 0.279, 337, 258, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 5-CHLOROTHIOPHENE-2-SULFONAMIDE
2481, 3nlbA, 0.7784, 2.55, 0.277, 261, 256, NOVEL KINASE PROFILE HIGHLIGHTS THE TEMPORAL BASIS OF CONTEXT DEPENDENT CHECKPOINT PATHWAYS TO CELL DEATH
2482, 5wg5A, 0.7783, 2.55, 0.271, 617, 258, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224061
2483, 5n3kA, 0.7783, 2.60, 0.275, 337, 258, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE O-GUANIDINO-L-HOMOSERINE
2484, 5g1xA, 0.7783, 2.33, 0.296, 262, 253, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH N-MYC
2485, 2e9pA, 0.7783, 2.77, 0.278, 269, 259, STRUCTURE OF H-CHK1 COMPLEXED WITH A771129
2486, 5op7A, 0.7782, 2.44, 0.275, 261, 255, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
2487, 2vd5B, 0.7782, 2.72, 0.261, 380, 261, STRUCTURE OF HUMAN MYOTONIC DYSTROPHY PROTEIN KINASE IN COMPLEX WITH THE BISINDOYLMALEIDE INHIBITOR BIM VIII
2488, 1uu3A, 0.7782, 2.43, 0.276, 276, 254, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH LY333531
2489, 5u7rB, 0.7781, 2.92, 0.255, 387, 263, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2490, 5n1hA, 0.7781, 2.61, 0.275, 337, 258, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE METHYL 4-(AMINOMETHYL)BENZOATE
2491, 4dc2A, 0.7781, 2.55, 0.286, 328, 259, STRUCTURE OF PKC IN COMPLEX WITH A SUBSTRATE PEPTIDE FROM PAR-3
2492, 3w2pA, 0.7781, 2.76, 0.211, 308, 261, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 2
2493, 3orxG, 0.7781, 2.34, 0.280, 274, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2494, 5n3hA, 0.7780, 2.61, 0.275, 337, 258, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE PYRIDINE-3-CARBOXAMIDE
2495, 5kksA, 0.7780, 2.90, 0.254, 395, 264, ROCK 1 BOUND TO AZAINDOLE THIOZOLE INHIBITOR
2496, 3ot3A, 0.7780, 2.49, 0.280, 259, 254, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22K BOUND TO HUMAN CHK1 KINASE DOMAIN
2497, 3orxF, 0.7780, 2.35, 0.280, 274, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2498, 3c4eB, 0.7780, 2.41, 0.256, 273, 254, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2499, 6b1uC, 0.7779, 2.61, 0.287, 459, 258, STRUCTURE OF FULL-LENGTH HUMAN AMPK (A2B1G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4 
2500, 5n3oA, 0.7779, 2.62, 0.279, 335, 258, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-(13-OXAZOL-5-YL)ANILINE
2501, 5m0lA, 0.7778, 2.60, 0.264, 338, 258, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH THE METHYLATED FASUDIL-DERIVED FRAGMENT N-METHYLISOQUINOLINE-5- SULFONAMIDE (LIGAND 02) 
2502, 4rz7A, 0.7778, 2.38, 0.262, 801, 256, CRYSTAL STRUCTURE OF PVX_084705 WITH BOUND PCI32765
2503, 4dfxE, 0.7778, 2.55, 0.265, 347, 257, CRYSTAL STRUCTURE OF MYRISTOYLATED K7C CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20 AND AMP-PNP
2504, 3ndmB, 0.7778, 2.97, 0.249, 396, 265, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
2505, 3e8eA, 0.7778, 2.61, 0.267, 341, 258, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2506, 5u7qA, 0.7777, 2.94, 0.255, 388, 263, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2507, 5n3sA, 0.7777, 2.62, 0.279, 337, 258, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-HYDROXYBENZAMIDE
2508, 5n1gA, 0.7777, 2.61, 0.275, 337, 258, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-(2-AMINO-13-THIAZOL-4-YL)-1- OXASPIRO[4.5]DECAN-2-ONE
2509, 5e8xA, 0.7777, 2.47, 0.217, 304, 254, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F) IN COMPLEX WITH STAUROSPORINE
2510, 5czhA, 0.7777, 2.78, 0.211, 311, 261, EGFR L858R MUTANT IN COMPLEX WITH AN OPTIMAL PEPTIDE SUBSTRATE
2511, 4xw6A, 0.7777, 2.58, 0.265, 334, 257, X-RAY STRUCTURE OF PKAC WITH ADP FREE PHOSPHATE ION CP20 MAGNESIUM IONS
2512, 3tkuA, 0.7777, 3.12, 0.250, 395, 268, MRCK BETA IN COMPLEX WITH FASUDIL
2513, 3orxH, 0.7777, 2.35, 0.280, 274, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2514, 3e8eE, 0.7777, 2.58, 0.267, 341, 258, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2515, 6fckA, 0.7776, 2.64, 0.274, 269, 259, CHK1 KINASE IN COMPLEX WITH COMPOUND 13
2516, 4yveA, 0.7776, 2.83, 0.252, 390, 262, ROCK 1 BOUND TO METHOXYPHENYL THIAZOLE INHIBITOR
2517, 4ib3A, 0.7776, 2.57, 0.265, 336, 257, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH ADP PHOSPHORYLATED PEPTIDE PSP20 AND NO METAL
2518, 4c33A, 0.7776, 2.56, 0.272, 335, 257, PKA-S6K1 CHIMERA APO
2519, 3qcyA, 0.7776, 2.34, 0.281, 275, 253, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 4-[2- AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-N-PHENYL-2- MORPHOLINECARBOXAMIDE
2520, 3orzC, 0.7776, 2.54, 0.275, 276, 255, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2521, 3c4eA, 0.7776, 2.41, 0.256, 273, 254, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2522, 5n3lA, 0.7775, 2.62, 0.279, 337, 258, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-[(1R)-2-AMINO-1-HYDROXYETHYL]BENZENE-1 2-DIOL
2523, 5n3iA, 0.7775, 2.61, 0.279, 337, 258, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE METHYL (2S)-2-AMINO-3-PHENYLPROPANOATE
2524, 3orzA, 0.7775, 2.55, 0.275, 276, 255, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2525, 3fjqE, 0.7775, 2.63, 0.264, 334, 258, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA IN COMPLEX WITH PEPTIDE INHIBITOR PKI ALPHA (6-25)
2526, 2pe2A, 0.7775, 2.46, 0.276, 275, 254, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 3-{5-[2-OXO-5-UREIDO-12-DIHYDRO-INDOL-(3Z)-YLIDENEMETHYL]-1H- PYRROL-3-YL}-N-(2-PIPERIDIN-1-YL-ETHYL)-BENZAMIDE COMPLEX
2527, 5ezvC, 0.7774, 2.61, 0.287, 440, 258, X-RAY CRYSTAL STRUCTURE OF AMP-ACTIVATED PROTEIN KINASE ALPHA-2/ALPHA- 1 RIM CHIMAERA (ALPHA-2(1-347)/ALPHA-1(349-401)/ALPHA-2(397-END) BETA-1 GAMMA-1) CO-CRYSTALLIZED WITH C2 (5-(5-HYDROXYL-ISOXAZOL-3- YL)-FURAN-2-PHOSPHONIC ACID)
2528, 1apmE, 0.7774, 2.60, 0.264, 338, 258, 2.0 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PEPTIDE INHIBITOR AND DETERGENT
2529, 5uyjA, 0.7773, 2.66, 0.284, 281, 257, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
2530, 5u7rC, 0.7773, 2.92, 0.251, 387, 263, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2531, 5opvA, 0.7773, 2.46, 0.276, 261, 254, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
2532, 3e8eB, 0.7773, 2.60, 0.267, 337, 258, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2533, 2pe0A, 0.7773, 2.46, 0.276, 275, 254, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 5-HYDROXY-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-13-DIHYDRO- INDOL-2-ONE COMPLEX
2534, 1uu9A, 0.7773, 2.42, 0.276, 276, 254, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-3
2535, 5hvkA, 0.7772, 2.62, 0.243, 297, 255, CRYSTAL STRUCTURE OF LIMK1 MUTANT D460N IN COMPLEX WITH FULL-LENGTH COFILIN-1
2536, 4dg0E, 0.7772, 2.57, 0.265, 338, 257, CRYSTAL STRUCTURE OF MYRISTOYLATED WT CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20 AND AMP-PNP
2537, 5ootA, 0.7770, 2.43, 0.276, 260, 254, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
2538, 3gu5A, 0.7770, 2.56, 0.265, 280, 257, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP-MG2+
2539, 3c51B, 0.7770, 2.25, 0.261, 461, 249, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 3.55A
2540, 3a7fA, 0.7769, 2.48, 0.275, 283, 255, HUMAN MST3 KINASE
2541, 1z5mA, 0.7769, 2.47, 0.276, 275, 254, CRYSTAL STRUCTURE OF N1-[3-[[5-BROMO-2-[[3-[(1-PYRROLIDINYLCARBONYL) AMINO]PHENYL]AMINO]-4-PYRIMIDINYL]AMINO]PROPYL]-22- DIMETHYLPROPANEDIAMIDE COMPLEXED WITH HUMAN PDK1
2542, 1fmoE, 0.7769, 2.61, 0.264, 336, 258, CRYSTAL STRUCTURE OF A POLYHISTIDINE-TAGGED RECOMBINANT CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH THE PEPTIDE INHIBITOR PKI(5-24) AND ADENOSINE
2543, 5hkmA, 0.7768, 2.37, 0.277, 272, 253, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2544, 5dlsA, 0.7768, 2.45, 0.281, 257, 253, IDENTIFICATION OF NOVEL IN VIVO ACTIVE CHK1 INHIBITORS UTILIZING STRUCTURE GUIDED DRUG DESIGN
2545, 4hpuE, 0.7768, 2.58, 0.265, 336, 257, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE DISPLAYING PARTIAL PHOSPHORYL TRANSFER OF AMP-PNP ONTO A SUBSTRATE PEPTIDE
2546, 3tkhA, 0.7766, 2.54, 0.283, 269, 254, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S01
2547, 3qamE, 0.7766, 2.63, 0.260, 348, 258, CRYSTAL STRUCTURE OF GLU208ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
2548, 3comA, 0.7766, 2.44, 0.278, 264, 255, CRYSTAL STRUCTURE OF MST1 KINASE
2549, 5ukkA, 0.7765, 2.76, 0.264, 613, 261, HUMAN GRK2 IN COMPLEX WITH HUMAN G-BETA-GAMMA SUBUNITS AND CCG211998 (14AK)
2550, 2brgA, 0.7765, 2.38, 0.281, 257, 253, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2551, 3e8eL, 0.7764, 2.60, 0.267, 336, 258, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2552, 3comB, 0.7764, 2.50, 0.280, 279, 257, CRYSTAL STRUCTURE OF MST1 KINASE
2553, 2zm3B, 0.7764, 2.62, 0.205, 296, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2554, 2cpkE, 0.7764, 2.59, 0.265, 333, 257, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE MONOPHOSPHATE-DEPENDENT PROTEIN KINASE
2555, 1xwsA, 0.7764, 2.30, 0.257, 273, 253, CRYSTAL STRUCTURE OF THE HUMAN PIM1 KINASE DOMAIN
2556, 1sykA, 0.7764, 2.62, 0.256, 348, 258, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
2557, 4fsrA, 0.7763, 2.49, 0.280, 269, 254, CRYSTAL STRUCTURE OF THE CHK1
2558, 1atpE, 0.7763, 2.63, 0.264, 334, 258, 2.2 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH MNATP AND A PEPTIDE INHIBITOR
2559, 4dh8A, 0.7761, 2.60, 0.261, 333, 257, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ AMP-PNP AND IP20
2560, 1sykB, 0.7761, 2.62, 0.256, 323, 258, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
2561, 4j96B, 0.7760, 2.67, 0.245, 305, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
2562, 4ib1A, 0.7760, 2.59, 0.265, 335, 257, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH K+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2563, 5n3mA, 0.7759, 2.63, 0.279, 337, 258, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE D-ARGININE
2564, 4c36A, 0.7759, 2.58, 0.272, 335, 257, PKA-S6K1 CHIMERA WITH COMPOUND 15E (CCT147581) BOUND
2565, 1rdqE, 0.7759, 2.56, 0.261, 340, 257, HYDROLYSIS OF ATP IN THE CRYSTAL OF Y204A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
2566, 1jkkA, 0.7759, 2.57, 0.265, 277, 257, 2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG.
2567, 6fc8A, 0.7758, 2.76, 0.273, 269, 260, CHK1 KINASE IN COMPLEX WITH COMPOUND 13
2568, 5w4wB, 0.7758, 2.68, 0.192, 291, 260, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2569, 5ugbA, 0.7758, 2.70, 0.205, 307, 259, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN IN COMPLEX WITH 4-(4-{[2- {[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9-(PROPAN-2-YL)-9H-PURIN-6- YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
2570, 4zhxC, 0.7758, 2.64, 0.287, 452, 258, NOVEL BINDING SITE FOR ALLOSTERIC ACTIVATION OF AMPK
2571, 2c30A, 0.7758, 2.84, 0.251, 289, 259, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 6
2572, 3uztA, 0.7757, 2.49, 0.276, 586, 254, STRUCTURE OF THE C13.18 RNA APTAMER IN COMPLEX WITH G PROTEIN-COUPLED RECEPTOR KINASE 2
2573, 3o7lB, 0.7757, 2.49, 0.251, 326, 255, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
2574, 3lijA, 0.7757, 2.44, 0.328, 465, 253, CRYSTAL STRUCTURE OF FULL LENGTH CPCDPK3 (CGD5_820) IN COMPLEX WITH CA2+ AND AMPPNP
2575, 2x7fC, 0.7757, 2.27, 0.263, 285, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2576, 5ui0B, 0.7755, 2.67, 0.241, 304, 257, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
2577, 4ll5A, 0.7755, 2.33, 0.257, 268, 253, CRYSTAL STRUCTURE OF PIM-1 IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
2578, 4iadA, 0.7755, 2.61, 0.265, 334, 257, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2579, 2w9zB, 0.7755, 3.15, 0.466, 287, 266, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
2580, 5n50A, 0.7754, 2.32, 0.257, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 2-(4-CHLOROPHENYL) SULFANYLACETOHYDRAZIDE
2581, 5fetA, 0.7754, 2.50, 0.258, 802, 256, CRYSTAL STRUCTURE OF PVX_084705 IN PRESENCE OF COMPOUND 2
2582, 4wb5A, 0.7754, 2.52, 0.270, 335, 256, CRYSTAL STRUCTURE OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2583, 3dlsA, 0.7754, 2.68, 0.258, 285, 256, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2584, 3c4eC, 0.7753, 2.46, 0.256, 272, 254, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2585, 5jzjB, 0.7752, 2.16, 0.298, 261, 248, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
2586, 4fsuA, 0.7752, 2.54, 0.280, 260, 254, CRYSTAL STRUCTURE OF THE CHK1
2587, 5lxmA, 0.7751, 2.36, 0.296, 266, 253, CRYSTAL STRUCTURE OF AURORA-A BOUND TO A HYDROCARBON-STAPLED PROTEOMIMETIC OF TPX2
2588, 4wnpB, 0.7751, 2.50, 0.295, 272, 254, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2589, 3soaA, 0.7751, 2.76, 0.297, 436, 259, FULL-LENGTH HUMAN CAMKII
2590, 3nczD, 0.7751, 2.84, 0.248, 397, 262, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
2591, 3gu4A, 0.7751, 2.58, 0.265, 280, 257, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP
2592, 5em8A, 0.7750, 2.78, 0.205, 303, 259, EGFR KINASE DOMAIN WITH PYRIDONE COMPOUND 13: 4-[(2-METHOXYPHENYL) AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2-OXIDANYLIDENE-1~{H}- PYRIDINE-3-CARBOXAMIDE
2593, 2pe1A, 0.7750, 2.49, 0.276, 275, 254, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) {2-OXO-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-23-DIHYDRO-1H- INDOL-5-YL}-UREA {BX-517} COMPLEX
2594, 5w4wA, 0.7749, 2.69, 0.192, 291, 260, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2595, 5u7rA, 0.7749, 2.92, 0.250, 387, 264, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2596, 4x6rA, 0.7749, 2.65, 0.275, 347, 258, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
2597, 4ib0A, 0.7749, 2.61, 0.261, 334, 257, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH NA+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2598, 4iaiA, 0.7749, 2.60, 0.265, 333, 257, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH CA2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2599, 3mvjB, 0.7749, 2.63, 0.264, 320, 258, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
2600, 3hx4A, 0.7749, 2.62, 0.280, 467, 254, CRYSTAL STRUCTURE OF CDPK1 OF TOXOPLASMA GONDII TGME49_101440 IN PRESENCE OF CALCIUM
2601, 3bhhB, 0.7749, 2.63, 0.312, 289, 256, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2602, 2x7fB, 0.7749, 2.44, 0.261, 288, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2603, 5kktA, 0.7748, 2.68, 0.254, 389, 260, ROCK 1 BOUND TO AZAINDOLE THIOZOLE PIPERAZINE INHIBITOR
2604, 4yvcA, 0.7748, 2.79, 0.244, 388, 262, ROCK 1 BOUND TO THIAZOLE INHIBITOR
2605, 4wnpA, 0.7748, 2.61, 0.294, 273, 255, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2606, 2etkB, 0.7748, 2.99, 0.242, 398, 265, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO HYDROXYFASUDIL
2607, 1yxsA, 0.7748, 2.47, 0.256, 274, 254, CRYSTAL STRUCTURE OF KINASE PIM1 WITH P123M MUTATION
2608, 1ig1A, 0.7748, 2.58, 0.265, 280, 257, 1.8A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MN.
2609, 5ig1B, 0.7747, 2.80, 0.278, 304, 259, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
2610, 5wneA, 0.7746, 3.06, 0.248, 384, 266, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2611, 5telA, 0.7746, 2.38, 0.257, 273, 253, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2612, 3gu7A, 0.7746, 2.59, 0.265, 280, 257, CRYSTAL STRUCTURE OF DAPKQ23V-ADP-MG2+
2613, 2yexA, 0.7746, 2.87, 0.272, 269, 261, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
2614, 2j2iB, 0.7746, 2.33, 0.257, 273, 253, CRYSTAL STRUCTURE OF THE HUMAB PIM1 IN COMPLEX WITH LY333531
2615, 2j0lA, 0.7746, 2.46, 0.255, 274, 255, CRYSTAL STRUCTURE OF A THE ACTIVE CONFORMATION OF THE KINASE DOMAIN OF FOCAL ADHESION KINASE WITH A PHOSPHORYLATED ACTIVATION LOOP.
2616, 2bzhB, 0.7746, 2.32, 0.253, 275, 253, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
2617, 5wngA, 0.7745, 2.90, 0.255, 395, 263, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2618, 4zy4B, 0.7745, 2.64, 0.311, 292, 254, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
2619, 3d9vB, 0.7745, 3.04, 0.252, 398, 266, CRYSTAL STRUCTURE OF ROCK I BOUND TO H-1152P A DI- METHYLATED VARIANT OF FASUDIL
2620, 1jksA, 0.7745, 2.59, 0.265, 280, 257, 1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2621, 5vcwB, 0.7744, 2.40, 0.280, 285, 254, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PELITINIB
2622, 5c1qB, 0.7744, 2.33, 0.257, 273, 253, SERINE/THREONINE-PROTEIN KINASE PIM-1
2623, 4k1bA, 0.7744, 2.34, 0.257, 273, 253, STRUCTURE OF PIM-1 KINASE BOUND TO N-(5-(2-FLUOROPHENYL)-1H-PYRROLO[2 3-B]PYRIDIN-3-YL)-5-((((3R4R)-3-FLUOROPIPERIDIN-4-YL)METHYL)AMINO) PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2624, 4dh3A, 0.7744, 2.63, 0.265, 333, 257, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ ATP AND IP20
2625, 3vbyA, 0.7744, 2.38, 0.257, 267, 253, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2626, 3v8sC, 0.7743, 2.91, 0.251, 395, 263, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
2627, 5kktB, 0.7742, 3.06, 0.244, 394, 266, ROCK 1 BOUND TO AZAINDOLE THIOZOLE PIPERAZINE INHIBITOR
2628, 1jklA, 0.7742, 2.60, 0.265, 280, 257, 1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE
2629, 5uy6A, 0.7741, 2.59, 0.286, 282, 255, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
2630, 5mjbB, 0.7741, 2.64, 0.229, 278, 258, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
2631, 4j99B, 0.7741, 2.71, 0.241, 291, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
2632, 3qalE, 0.7741, 2.57, 0.261, 339, 257, CRYSTAL STRUCTURE OF ARG280ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
2633, 2phkA, 0.7741, 2.75, 0.282, 277, 259, THE CRYSTAL STRUCTURE OF A PHOSPHORYLASE KINASE PEPTIDE SUBSTRATE COMPLEX: KINASE SUBSTRATE RECOGNITION
2634, 2bilB, 0.7741, 2.33, 0.257, 274, 253, THE HUMAN PROTEIN KINASE PIM1 IN COMPLEX WITH ITS CONSENSUS PEPTIDE PIMTIDE
2635, 5u7rD, 0.7740, 2.74, 0.255, 382, 259, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2636, 5l8kA, 0.7740, 2.62, 0.302, 266, 255, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 2)
2637, 3odyX, 0.7740, 2.88, 0.374, 321, 257, CRYSTAL STRUCTURE OF P38ALPHA Y323Q ACTIVE MUTANT
2638, 3dfcB, 0.7740, 2.59, 0.265, 280, 257, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH AMPPNP
2639, 2oi4X, 0.7740, 2.33, 0.257, 275, 253, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH FLUORINATED RUTHENIUM PYRIDOCARBAZOLE
2640, 2bzjA, 0.7740, 2.36, 0.257, 273, 253, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU3
2641, 1ywvA, 0.7740, 2.36, 0.257, 274, 253, CRYSTAL STRUCTURES OF PROTO-ONCOGENE KINASE PIM1: A TARGET OF ABERRANT SOMATIC HYPERMUTATIONS IN DIFFUSE LARGE CELL LYMPHOMA
2642, 6babB, 0.7739, 2.75, 0.301, 285, 256, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2643, 5vjaC, 0.7739, 2.48, 0.258, 265, 256, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
2644, 5bmlA, 0.7739, 3.00, 0.242, 393, 264, ROCK 1 BOUND TO A PYRIDINE THIAZOLE INHIBITOR
2645, 4zy5B, 0.7739, 2.66, 0.311, 287, 254, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
2646, 3vbtA, 0.7739, 2.39, 0.257, 267, 253, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2647, 2qcsA, 0.7739, 2.63, 0.265, 335, 257, A COMPLEX STRUCTURE BETWEEN THE CATALYTIC AND REGULATORY SUBUNIT OF PROTEIN KINASE A THAT REPRESENTS THE INHIBITED STATE
2648, 2bikB, 0.7739, 2.41, 0.257, 272, 253, HUMAN PIM1 PHOSPHORYLATED ON SER261
2649, 3v8sA, 0.7738, 2.91, 0.255, 395, 263, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
2650, 3q4zA, 0.7738, 2.31, 0.271, 282, 251, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
2651, 5n4nA, 0.7737, 2.35, 0.257, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 34-DIMETHYL-5-(1H-124-TRIAZOL- 3-YL)THIOPHENE-2-CARBONITRILE
2652, 4mbiA, 0.7737, 2.50, 0.256, 274, 254, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
2653, 4dh7A, 0.7737, 2.53, 0.266, 333, 256, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ AMP-PNP AND IP20 
2654, 4b4lA, 0.7737, 2.72, 0.263, 299, 259, CRYSTAL STRUCTURE OF AN ARD DAP-KINASE 1 MUTANT
2655, 3we8A, 0.7737, 2.38, 0.257, 273, 253, PIM-1 KINASE IN COMPLEX WITH RUTHENIUM-BASED INHIBITOR
2656, 1rqqB, 0.7737, 2.93, 0.204, 294, 260, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
2657, 5n7pA, 0.7736, 2.59, 0.265, 350, 257, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINO-5-(PYRROLIDIN-1-YL)-1H-PYRAZOLE- 4-CARBONITRILE
2658, 4tksA, 0.7736, 2.71, 0.205, 307, 258, NATIVE-SAD PHASING FOR HUMAN EGFR KINASE DOMAIN.
2659, 4dh1A, 0.7736, 2.63, 0.265, 333, 257, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH LOW MG2+ ATP AND IP20
2660, 4bbmB, 0.7736, 2.92, 0.398, 292, 259, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
2661, 3qd4A, 0.7736, 2.39, 0.274, 276, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL{(3R5R)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-5-METHYL-3-PIPERIDINYL}CARBAMATE
2662, 2j0iA, 0.7736, 2.71, 0.268, 289, 257, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
2663, 2etrB, 0.7736, 2.85, 0.256, 398, 262, CRYSTAL STRUCTURE OF ROCK I BOUND TO Y-27632
2664, 2c3jA, 0.7736, 2.48, 0.273, 257, 253, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
2665, 4wotC, 0.7735, 2.91, 0.247, 392, 263, ROCK2 IN COMPLEX WITH 1426382-07-1
2666, 4rpvA, 0.7735, 2.35, 0.257, 273, 253, CO-CRYSTAL STRUCTURE OF PIM1 WITH COMPOUND 3
2667, 4j96A, 0.7735, 2.71, 0.245, 302, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
2668, 3dgkA, 0.7735, 2.61, 0.265, 278, 257, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN
2669, 5ui0A, 0.7734, 2.71, 0.241, 301, 257, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
2670, 5n4zA, 0.7734, 2.34, 0.253, 272, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE (E)-4-(4-HYDROXYPHENYL)BUT-3-EN-2- ONE
2671, 4j95B, 0.7734, 2.66, 0.242, 282, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
2672, 2itwA, 0.7734, 2.61, 0.214, 300, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AFN941
2673, 6bqqA, 0.7733, 2.44, 0.285, 271, 253, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH BI2526
2674, 5b2lA, 0.7733, 2.53, 0.235, 288, 255, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
2675, 4yuqA, 0.7733, 2.63, 0.286, 462, 255, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1354
2676, 4medA, 0.7733, 2.32, 0.262, 272, 252, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE DERIVATIVES
2677, 4ae6B, 0.7733, 2.63, 0.258, 321, 256, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
2678, 3zh8C, 0.7733, 2.72, 0.288, 312, 260, A NOVEL SMALL MOLECULE APKC INHIBITOR
2679, 3vbxA, 0.7733, 2.40, 0.257, 268, 253, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2680, 3qfvA, 0.7733, 3.11, 0.243, 395, 267, MRCK BETA IN COMPLEX WITH TPCA-1
2681, 3eqrA, 0.7733, 2.60, 0.255, 270, 255, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
2682, 2gs2A, 0.7733, 2.69, 0.205, 305, 258, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN
2683, 2brhA, 0.7733, 2.50, 0.285, 257, 253, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2684, 1yxuB, 0.7733, 2.50, 0.256, 273, 254, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2685, 1u59A, 0.7733, 2.70, 0.224, 282, 259, CRYSTAL STRUCTURE OF THE ZAP-70 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2686, 5xvgA, 0.7732, 2.95, 0.264, 292, 261, CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INHIBITOR CZH226
2687, 5xvaA, 0.7732, 2.95, 0.264, 292, 261, CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INHIBITOR CZH216
2688, 4wb7A, 0.7732, 2.64, 0.265, 402, 257, CRYSTAL STRUCTURE OF A CHIMERIC FUSION OF HUMAN DNAJ (HSP40) AND CAMP- DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2689, 4r3rA, 0.7732, 2.78, 0.208, 309, 260, CRYSTAL STRUCTURES OF EGFR IN COMPLEX WITH MIG6
2690, 3pvbA, 0.7732, 2.65, 0.265, 341, 257, CRYSTAL STRUCTURE OF (73-244)RIA:C HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
2691, 3mvjA, 0.7732, 2.67, 0.264, 334, 258, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
2692, 2gs6A, 0.7732, 2.66, 0.202, 311, 258, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AN ATP ANALOG-PEPTIDE CONJUGATE
2693, 6cd6D, 0.7731, 2.48, 0.268, 267, 254, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
2694, 5w4wC, 0.7731, 2.70, 0.188, 284, 260, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
2695, 5vjaA, 0.7731, 2.56, 0.253, 266, 257, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
2696, 5texA, 0.7731, 2.52, 0.256, 274, 254, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2697, 5l2qA, 0.7731, 2.57, 0.191, 293, 257, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
2698, 4fszA, 0.7731, 2.48, 0.281, 268, 253, CRYSTAL STRUCTURE OF THE CHK1
2699, 4as0A, 0.7731, 2.35, 0.257, 273, 253, CYCLOMETALATED PHTHALIMIDES AS PROTEIN KINASE INHIBITORS
2700, 3cblA, 0.7731, 2.78, 0.240, 356, 258, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES) IN COMPLEX WITH STAUROSPORINE AND A CONSENSUS PEPTIDE
2701, 2esmB, 0.7731, 2.85, 0.256, 398, 262, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO FASUDIL
2702, 5vjaB, 0.7730, 2.56, 0.253, 266, 257, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
2703, 5n4yA, 0.7730, 2.36, 0.253, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 25-DIHYDRO-1H-ISOTHIOCHROMENO[3 4-D]PYRAZOL-3-ONE
2704, 5kgkA, 0.7730, 2.36, 0.257, 273, 253, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 3-(4-METHOXYPHENYL)-1~{H}- PYRAZOL-5-AMINE
2705, 5hvkC, 0.7730, 2.69, 0.243, 291, 255, CRYSTAL STRUCTURE OF LIMK1 MUTANT D460N IN COMPLEX WITH FULL-LENGTH COFILIN-1
2706, 4wb7B, 0.7730, 2.65, 0.265, 402, 257, CRYSTAL STRUCTURE OF A CHIMERIC FUSION OF HUMAN DNAJ (HSP40) AND CAMP- DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2707, 3nupA, 0.7730, 2.23, 0.470, 252, 249, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
2708, 3jxwA, 0.7730, 2.39, 0.257, 274, 253, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2709, 3gu6A, 0.7730, 2.62, 0.265, 280, 257, CRYSTAL STRUCTURE OF DAPKQ23V-ADP
2710, 3fhiA, 0.7730, 2.58, 0.265, 336, 257, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE CATALYTIC AND REGULATORY (RI{ALPHA}) SUBUNITS OF PKA
2711, 2xuuA, 0.7730, 2.79, 0.250, 301, 260, CRYSTAL STRUCTURE OF A DAP-KINASE 1 MUTANT
2712, 1yxuA, 0.7730, 2.36, 0.253, 273, 253, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2713, 6brcB, 0.7729, 2.44, 0.294, 260, 252, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
2714, 5kksB, 0.7729, 2.92, 0.255, 395, 263, ROCK 1 BOUND TO AZAINDOLE THIOZOLE INHIBITOR
2715, 5dgzA, 0.7729, 2.37, 0.257, 273, 253, DISCOVERY OF 35-SUBSTITUTED 6-AZAINDAZOLES AS POTENT PAN-PIM INHIBITORS
2716, 4wt6A, 0.7729, 2.48, 0.252, 273, 254, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIADIAZOLAMINE-INDOLE INHIBITOR.
2717, 3bwjA, 0.7729, 2.54, 0.262, 338, 256, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR LEAD COMPOUND ARC-1034
2718, 2z8cA, 0.7729, 2.80, 0.202, 297, 258, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN-2- YL]AMINO}PHENYL)ACETIC ACID
2719, 1m14A, 0.7729, 2.63, 0.214, 307, 257, TYROSINE KINASE DOMAIN FROM EPIDERMAL GROWTH FACTOR RECEPTOR
2720, 1cdkB, 0.7729, 2.70, 0.267, 342, 258, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
2721, 4j98B, 0.7728, 2.66, 0.242, 304, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
2722, 3zh8A, 0.7728, 2.73, 0.288, 318, 260, A NOVEL SMALL MOLECULE APKC INHIBITOR
2723, 3qfvB, 0.7728, 3.12, 0.247, 396, 267, MRCK BETA IN COMPLEX WITH TPCA-1
2724, 3bu6A, 0.7728, 2.79, 0.202, 294, 257, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PHOSPHOPEPTIDE
2725, 1m17A, 0.7728, 2.81, 0.212, 312, 259, EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE DOMAIN WITH 4-ANILINOQUINAZOLINE INHIBITOR ERLOTINIB
2726, 6cd6B, 0.7727, 2.51, 0.268, 266, 254, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
2727, 5wnfA, 0.7727, 2.98, 0.246, 395, 264, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2728, 5op4A, 0.7727, 2.39, 0.278, 259, 252, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDINE LRRK2 INHIBITOR
2729, 5kgeA, 0.7727, 2.38, 0.257, 273, 253, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 5-(34-DICHLOROPHENYL)- 1~{H}-PYRAZOL-3-AMINE
2730, 4yznA, 0.7727, 2.43, 0.228, 269, 250, HUMANIZED ROCO4 BOUND TO COMPOUND 19
2731, 2x8eA, 0.7727, 2.59, 0.275, 259, 255, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
2732, 1yxvA, 0.7727, 2.38, 0.253, 274, 253, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH 34-DIHYDROXY-1- METHYLQUINOLIN-2(1H)-ONE
2733, 6aydA, 0.7726, 2.40, 0.257, 272, 253, PIM1 COMPLEXED WITH N-(6-(4-HYDROXYPHENYL)-1H-INDAZOL-3-YL) CYCLOPROPANECARBOXAMIDE
2734, 5kgdA, 0.7726, 2.37, 0.253, 273, 253, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-PYRIDIN-3-YL-1~{H}- BENZIMIDAZOLE
2735, 5auyA, 0.7726, 2.56, 0.266, 275, 256, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH MORIN.
2736, 4xh6A, 0.7726, 2.36, 0.253, 273, 253, CRYSTAL STRUCTURE OF PROTO-ONCOGENE KINASE PIM1 BOUND TO HISPIDULIN
2737, 4pf4A, 0.7726, 2.62, 0.265, 278, 257, 1.1A X-RAY STRUCTURE OF THE APO CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 1 AA 1-277
2738, 2zm3A, 0.7726, 2.72, 0.212, 300, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2739, 2yerA, 0.7726, 2.82, 0.273, 268, 260, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
2740, 2v7aB, 0.7726, 2.60, 0.242, 268, 256, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
2741, 5eg3A, 0.7725, 2.74, 0.236, 301, 258, CRYSTAL STRUCTURE OF THE ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH THE CSH2 DOMAIN OF PHOSPHOLIPASE C GAMMA (PLCGAMMA)
2742, 4wsyA, 0.7725, 2.37, 0.253, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIAZOLAMINE-INDAZOLE INHIBITOR.
2743, 3ehaA, 0.7725, 2.63, 0.261, 279, 257, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH AMPPNP
2744, 1yxuC, 0.7725, 2.39, 0.257, 272, 253, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
2745, 6bkuA, 0.7724, 2.60, 0.283, 267, 254, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO GSK650394
2746, 5vioD, 0.7724, 2.71, 0.281, 271, 256, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
2747, 5uzjA, 0.7724, 2.83, 0.248, 387, 262, CRYSTAL STRUCTURE OF ROCK1 BOUND TO AN AMINOPYRIDINE INHIBITOR
2748, 5op5A, 0.7724, 2.45, 0.277, 259, 253, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
2749, 5ndtA, 0.7724, 2.36, 0.257, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE (E)-3-(2-(THIOPHEN-2-YL)VINYL)-3; 4-DIHYDROQUINOXALIN-2(1H)-ONE 
2750, 5n4rA, 0.7724, 2.37, 0.253, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 2-(AZEPAN-1-YL)-1-(1H-INDOL-3-YL) PROPAN-1-ONE
2751, 5kgiA, 0.7724, 2.37, 0.253, 273, 253, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR 2-[34-BIS(CHLORANYL) PHENOXY]ETHANAMINE
2752, 4jq8A, 0.7724, 2.65, 0.214, 303, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4B
2753, 2w4jA, 0.7724, 2.63, 0.265, 276, 257, X-RAY STRUCTURE OF A DAP-KINASE 2-277
2754, 5oq6A, 0.7723, 2.42, 0.274, 257, 252, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
2755, 5jr7A, 0.7723, 2.68, 0.275, 335, 258, CRYSTAL STRUCTURE OF AN ACRDYS HETERODIMER [RIA(92-365):C] OF PKA
2756, 4wrsA, 0.7723, 2.38, 0.253, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AZASPIRO PYRAZINYL-INDAZOLE INHIBITOR.
2757, 3tv7C, 0.7723, 2.94, 0.251, 394, 263, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
2758, 3tv7A, 0.7723, 2.95, 0.247, 394, 263, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
2759, 3r01A, 0.7723, 2.39, 0.253, 274, 253, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2760, 2j5eA, 0.7723, 2.97, 0.206, 309, 262, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 13-JAB
2761, 5f4nA, 0.7722, 2.53, 0.285, 258, 253, MULTI-PARAMETER LEAD OPTIMIZATION TO GIVE AN ORAL CHK1 INHIBITOR CLINICAL CANDIDATE: (R)-5-((4-((MORPHOLIN-2-YLMETHYL)AMINO)-5- (TRIFLUOROMETHYL)PYRIDIN-2-YL)AMINO)PYRAZINE-2-CARBONITRILE (CCT245737)
2762, 4j98A, 0.7722, 2.78, 0.241, 304, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
2763, 4dg3E, 0.7722, 2.66, 0.265, 335, 257, CRYSTAL STRUCTURE OF R336A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED TURN MOTIF.
2764, 3vbvA, 0.7722, 2.40, 0.253, 268, 253, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2765, 3jyaA, 0.7722, 2.40, 0.253, 274, 253, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2766, 3gu8A, 0.7722, 2.61, 0.265, 278, 257, CRYSTAL STRUCTURE OF DAPKL93G WITH N6-CYCLOPENTYLADENOSINE
2767, 2v55C, 0.7722, 3.07, 0.244, 396, 266, MECHANISM OF MULTI-SITE PHOSPHORYLATION FROM A ROCK-I:RHOE COMPLEX STRUCTURE
2768, 2v55A, 0.7722, 3.07, 0.244, 393, 266, MECHANISM OF MULTI-SITE PHOSPHORYLATION FROM A ROCK-I:RHOE COMPLEX STRUCTURE
2769, 2qhmA, 0.7722, 2.46, 0.274, 268, 252, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2A
2770, 5n37A, 0.7721, 2.62, 0.276, 347, 257, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-(13-BENZODIOXOL-5-YLMETHYL) CYCLOPENTANAMINE
2771, 5n1kA, 0.7721, 2.57, 0.262, 341, 256, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-AMINO-1-(4-FLUOROPHENYL)ETHANOL
2772, 5n1eA, 0.7721, 2.60, 0.265, 347, 257, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-(13-BENZODIOXOL-5-YL)-2-PIPERIDIN-1- YLACETAMIDE
2773, 5g15A, 0.7721, 2.64, 0.298, 265, 255, STRUCTURE AURORA A (122-403) BOUND TO ACTIVATING MONOBODY MB1 AND AMPPCP
2774, 4fsyA, 0.7721, 2.45, 0.286, 267, 252, CRYSTAL STRUCTURE OF THE CHK1
2775, 3jpvA, 0.7721, 2.37, 0.253, 273, 253, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A PYRROLO[23- A]CARBAZOLE LIGAND
2776, 3cxwA, 0.7721, 2.38, 0.257, 272, 253, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A BETA CARBOLINE LIGAND I
2777, 5u7qD, 0.7720, 3.08, 0.242, 383, 265, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2778, 5turA, 0.7720, 2.50, 0.252, 270, 254, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2779, 5n4uA, 0.7720, 2.37, 0.253, 272, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE 5-(2-AMINO-13-THIAZOL-4- YL)-13-DIHYDROBENZIMIDAZOL-2-ONE
2780, 4uxlA, 0.7720, 2.43, 0.237, 288, 253, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH PF-06463922
2781, 2v7aA, 0.7720, 2.65, 0.234, 269, 256, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
2782, 5vioA, 0.7719, 2.81, 0.277, 271, 256, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
2783, 5v80A, 0.7719, 2.37, 0.253, 273, 253, PIM1 KINASE IN COMPLEX WITH CPD1 (1-METHYL-4-(3-(6-(PIPERAZIN-1-YL) PYRIDIN-2-YL)-1H-PYRAZOLO[3;4-C]PYRIDIN-5-YL)PIPERAZIN-2-ONE) 
2784, 4k18A, 0.7719, 2.37, 0.261, 277, 253, STRUCTURE OF PIM-1 KINASE BOUND TO 5-(4-CYANOBENZYL)-N-(4- FLUOROPHENYL)-7-HYDROXYPYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2785, 3zh8B, 0.7719, 2.74, 0.288, 317, 260, A NOVEL SMALL MOLECULE APKC INHIBITOR
2786, 3qd0A, 0.7719, 2.42, 0.274, 274, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH (2R5S)- 1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-6-METHYL-N- PHENYL-3-PIPERIDINECARBOXAMIDE
2787, 2r0uA, 0.7719, 2.50, 0.281, 269, 253, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 54
2788, 2o64A, 0.7719, 2.51, 0.252, 274, 254, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETAGETIN
2789, 6babA, 0.7718, 2.96, 0.295, 290, 261, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2790, 5n4xA, 0.7718, 2.39, 0.253, 272, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE 45-DIBROMOTHIOPHENE-2- CARBOHYDRAZIDE
2791, 5l6wL, 0.7718, 2.66, 0.247, 290, 255, STRUCTURE OF THE LIMK1-ATPGAMMAS-CFL1 COMPLEX
2792, 4wotB, 0.7718, 2.80, 0.257, 394, 261, ROCK2 IN COMPLEX WITH 1426382-07-1
2793, 4wnpD, 0.7718, 2.58, 0.295, 272, 254, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2794, 3pa3A, 0.7718, 2.58, 0.283, 259, 254, X-RAY CRYSTAL STRUCTURE OF COMPOUND 70 BOUND TO HUMAN CHK1 KINASE DOMAIN
2795, 2o3pA, 0.7718, 2.52, 0.256, 274, 254, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETIN
2796, 5jr7C, 0.7717, 2.68, 0.275, 335, 258, CRYSTAL STRUCTURE OF AN ACRDYS HETERODIMER [RIA(92-365):C] OF PKA
2797, 4wb8A, 0.7717, 2.57, 0.270, 334, 256, CRYSTAL STRUCTURE OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT) EXON 1 DELETION
2798, 4jq7A, 0.7717, 2.67, 0.214, 303, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 2A
2799, 2eb2A, 0.7717, 2.67, 0.202, 305, 257, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (G719S)
2800, 2bziB, 0.7717, 2.35, 0.258, 272, 252, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU2
2801, 1l3rE, 0.7717, 2.57, 0.266, 338, 256, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
2802, 6cd6C, 0.7716, 2.65, 0.278, 265, 255, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
2803, 5n5mA, 0.7716, 2.33, 0.258, 272, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND (R)-3-(2-((ISOQUINOLIN-5-YLMETHYL)(METHYL) CARBAMOYL)PHENYL)PYRROLIDIN-1-IUM
2804, 3r04A, 0.7716, 2.39, 0.253, 271, 253, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2805, 1eh4A, 0.7716, 2.70, 0.180, 293, 261, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
2806, 6cmjA, 0.7715, 2.73, 0.292, 285, 257, HUMAN CAMKK2 WITH GSK650393
2807, 5ugxA, 0.7715, 2.78, 0.237, 297, 257, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
2808, 5oktA, 0.7715, 2.73, 0.188, 285, 260, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
2809, 5kcxA, 0.7715, 2.52, 0.252, 272, 254, PIM-1 KINASE IN COMPLEX WITH A SELECTIVE N-SUBSTITUTED 7-AZAINDOLE INHIBITOR
2810, 4yuqB, 0.7715, 2.59, 0.287, 462, 254, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1354
2811, 4mblA, 0.7715, 2.39, 0.253, 274, 253, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
2812, 4ftrA, 0.7715, 2.33, 0.280, 258, 250, CRYSTAL STRUCTURE OF THE CHK1
2813, 4ftjA, 0.7715, 2.47, 0.286, 266, 252, CRYSTAL STRUCTURE OF THE CHK1
2814, 4a7cA, 0.7715, 2.43, 0.257, 273, 253, CRYSTAL STRUCTURE OF PIM1 KINASE WITH ETP46546
2815, 3nczA, 0.7715, 2.94, 0.250, 399, 264, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
2816, 3bwfA, 0.7715, 2.41, 0.257, 273, 253, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AN OSMIUM COMPOUND
2817, 3bu3A, 0.7715, 2.82, 0.202, 294, 257, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE
2818, 2qhnA, 0.7715, 2.47, 0.274, 268, 252, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1A
2819, 1yxxA, 0.7715, 2.40, 0.253, 274, 253, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH (3E)-3-[(4- HYDROXYPHENYL)IMINO]-1H-INDOL-2(3H)-ONE
2820, 5xgnA, 0.7714, 2.64, 0.214, 302, 257, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
2821, 5toeA, 0.7714, 2.54, 0.256, 272, 254, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2822, 5av3A, 0.7714, 2.59, 0.266, 275, 256, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF IODIDE IONS.
2823, 4gw8A, 0.7714, 2.38, 0.253, 273, 253, HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND LEUCETTINE L41
2824, 3uzpA, 0.7714, 2.72, 0.188, 292, 260, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
2825, 3lvpC, 0.7714, 2.81, 0.208, 293, 260, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
2826, 2w1cA, 0.7714, 2.47, 0.300, 261, 253, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2827, 5flfC, 0.7713, 2.88, 0.240, 283, 258, DISEASE LINKED MUTATION IN FGFR
2828, 5dhjA, 0.7713, 2.38, 0.253, 273, 253, PIM1 IN COMPLEX WITH CPD4 (3-METHYL-5-(PYRIDIN-3-YL)-1H-PYRAZOLO[34- C]PYRIDINE)
2829, 4trlA, 0.7713, 2.39, 0.213, 268, 253, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
2830, 4gh2A, 0.7713, 2.28, 0.288, 266, 250, CRYSTAL STRUCTURE OF THE CHK1
2831, 2itqA, 0.7713, 2.66, 0.210, 300, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AFN941
2832, 5wnhA, 0.7712, 2.96, 0.255, 394, 263, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2833, 5n7uA, 0.7712, 2.61, 0.265, 350, 257, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-BROMO-35-DIMETHYL-1H-PYRAZOLE
2834, 4u44A, 0.7712, 2.57, 0.275, 286, 255, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
2835, 4ty1A, 0.7712, 2.48, 0.252, 273, 254, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AMINOOXADIAZOLE-INDOLE INHIBITOR.
2836, 3tnpF, 0.7712, 2.64, 0.265, 334, 257, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
2837, 3tnpC, 0.7712, 2.64, 0.265, 334, 257, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
2838, 3f5gA, 0.7712, 2.60, 0.266, 279, 256, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH ADP AND MG2+
2839, 2itpA, 0.7712, 2.77, 0.209, 305, 258, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AEE788
2840, 4x6qC, 0.7711, 2.65, 0.265, 334, 257, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
2841, 4wihA, 0.7711, 2.60, 0.265, 350, 257, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS
2842, 4f1oA, 0.7711, 2.60, 0.229, 276, 253, CRYSTAL STRUCTURE OF THE L1180T MUTANT ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO APPCP
2843, 3r00A, 0.7711, 2.40, 0.253, 274, 253, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2844, 3b2tA, 0.7711, 2.75, 0.241, 288, 257, STRUCTURE OF PHOSPHOTRANSFERASE
2845, 6cmjB, 0.7710, 2.74, 0.292, 284, 257, HUMAN CAMKK2 WITH GSK650393
2846, 4wd5A, 0.7710, 2.69, 0.214, 307, 257, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH QL-X138
2847, 4jr3A, 0.7710, 2.69, 0.214, 303, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 3G
2848, 4aluA, 0.7710, 2.40, 0.253, 274, 253, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2849, 3kulB, 0.7710, 2.55, 0.207, 271, 256, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
2850, 3f5uA, 0.7710, 2.59, 0.262, 279, 256, CRYSTAL STRUCTURE OF THE DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH AMPPNP AND MG2+
2851, 2o65A, 0.7710, 2.53, 0.260, 274, 254, CRYSTAL STRUCTURE OF PIM1 WITH PENTAHYDROXYFLAVONE
2852, 5n3aA, 0.7709, 2.57, 0.266, 349, 256, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-METHYL-5-(1-METHYLIMIDAZOL-2-YL)-13- THIAZOL-2-AMINE
2853, 4ysjB, 0.7709, 2.64, 0.289, 462, 253, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA IN COMPLEX WITH ADP
2854, 4hnfA, 0.7709, 2.59, 0.191, 289, 257, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
2855, 2bujB, 0.7709, 2.61, 0.247, 286, 255, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
2856, 1k3aA, 0.7709, 2.85, 0.212, 288, 259, STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR KINASE
2857, 5vilD, 0.7708, 2.81, 0.277, 271, 256, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
2858, 5opuA, 0.7708, 2.54, 0.280, 261, 254, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
2859, 4yveB, 0.7708, 2.96, 0.255, 393, 263, ROCK 1 BOUND TO METHOXYPHENYL THIAZOLE INHIBITOR
2860, 4j99C, 0.7708, 2.79, 0.241, 291, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
2861, 3dlsD, 0.7708, 2.58, 0.260, 284, 254, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2862, 2qg5B, 0.7708, 2.62, 0.263, 280, 255, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
2863, 6bskA, 0.7707, 2.40, 0.253, 273, 253, HUMAN PIM1 KINASE IN COMPLEX WITH COMPOUND 12B
2864, 4lm5A, 0.7707, 2.37, 0.258, 264, 252, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH 2-{4-[(3-AMINOPROPYL) AMINO]QUINAZOLIN-2-YL}PHENOL (RESULTING FROM DISPLACEMENT OF SKF86002)
2865, 4hnfB, 0.7707, 2.70, 0.185, 290, 260, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
2866, 3vc4A, 0.7707, 2.41, 0.253, 274, 253, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2867, 3lcdA, 0.7707, 2.55, 0.220, 290, 255, INHIBITOR BOUND TO A DFG-IN STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
2868, 3eh9A, 0.7707, 2.60, 0.266, 278, 256, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH ADP
2869, 2o63A, 0.7707, 2.54, 0.256, 274, 254, CRYSTAL STRUCTURE OF PIM1 WITH MYRICETIN
2870, 1ir3A, 0.7707, 2.91, 0.205, 300, 259, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH PEPTIDE SUBSTRATE AND ATP ANALOG
2871, 5vilA, 0.7706, 2.83, 0.277, 271, 256, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
2872, 5kggA, 0.7706, 2.41, 0.253, 273, 253, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-(5-CHLORANYL-1~{H}-INDOL- 3-YL)ETHANAMINE
2873, 5cavA, 0.7706, 2.66, 0.214, 306, 257, EGFR KINASE DOMAIN WITH COMPOUND 41A
2874, 5av2A, 0.7706, 2.61, 0.266, 275, 256, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2875, 5av1A, 0.7706, 2.60, 0.266, 275, 256, CRYSTAL STRUCTURE OF DAPK1 IN THE PRESENCE OF BROMIDE IONS.
2876, 4tw9B, 0.7706, 2.72, 0.188, 289, 260, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
2877, 4i41A, 0.7706, 2.37, 0.262, 272, 252, CRYSTAL STRUCTURE OF HUMAN SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE
2878, 5n4vA, 0.7705, 2.39, 0.253, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE 2-CYCLOPROPYL-45- DIMETHYLTHIENO[54-D]PYRIMIDINE-6-CARBOXYLIC ACID
2879, 4ysjA, 0.7705, 2.56, 0.286, 459, 252, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA IN COMPLEX WITH ADP
2880, 2yakA, 0.7705, 2.68, 0.260, 277, 258, STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 (DAPK1) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OSV)
2881, 1ol5A, 0.7705, 2.42, 0.302, 263, 252, STRUCTURE OF AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288 AND BOUND TO TPX2 1-43
2882, 5wngC, 0.7704, 2.84, 0.250, 387, 260, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2883, 5vd1A, 0.7704, 2.51, 0.286, 295, 252, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
2884, 4w7pB, 0.7704, 2.80, 0.257, 387, 261, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
2885, 4jx7A, 0.7704, 2.41, 0.253, 274, 253, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR 2-[(TRANS- 4-AMINOCYCLOHEXYL)AMINO]-4-{[3-(TRIFLUOROMETHYL) PHENYL]AMINO}PYRIDO[43-D]PYRIMIDIN-5(6H)-ONE
2886, 2zm3D, 0.7704, 2.69, 0.214, 293, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2887, 5auvA, 0.7703, 2.61, 0.266, 275, 256, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH APIGENIN.
2888, 4n6yA, 0.7703, 2.34, 0.258, 273, 252, PIM1 COMPLEXED WITH A PHENYLCARBOXAMIDE
2889, 4kbkB, 0.7703, 2.71, 0.188, 289, 260, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
2890, 4f0fA, 0.7703, 2.67, 0.236, 276, 254, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM
2891, 3ikaA, 0.7703, 2.64, 0.215, 310, 256, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
2892, 5mjbA, 0.7702, 2.50, 0.231, 276, 255, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
2893, 4yo4A, 0.7702, 2.66, 0.265, 280, 257, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT PHTHALAZINE
2894, 4twcB, 0.7702, 2.73, 0.188, 292, 260, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
2895, 4alvA, 0.7702, 2.41, 0.253, 274, 253, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2896, 6bqlA, 0.7701, 2.63, 0.287, 278, 254, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH TAE-226
2897, 5x18A, 0.7701, 2.74, 0.212, 294, 260, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
2898, 5vioC, 0.7701, 2.82, 0.281, 271, 256, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
2899, 5vilC, 0.7701, 2.85, 0.277, 271, 256, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
2900, 5n3eA, 0.7701, 2.59, 0.266, 348, 256, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 6-DIMETHYLAMINOPYRIDINE-3-CARBOXYLIC ACID
2901, 4f1mA, 0.7701, 2.61, 0.225, 278, 253, CRYSTAL STRUCTURE OF THE G1179S ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM.
2902, 3uytB, 0.7701, 2.66, 0.186, 286, 258, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
2903, 5flfB, 0.7700, 2.91, 0.236, 292, 258, DISEASE LINKED MUTATION IN FGFR
2904, 5av0A, 0.7700, 2.61, 0.266, 275, 256, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH 73 4 - TRIHYDROXYISOFLAVONE.
2905, 4u45A, 0.7700, 2.59, 0.275, 289, 255, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
2906, 4id7A, 0.7700, 2.41, 0.257, 268, 253, ACK1 KINASE IN COMPLEX WITH THE INHIBITOR CIS-3-[8-AMINO-1-(4- PHENOXYPHENYL)IMIDAZO[15-A]PYRAZIN-3-YL]CYCLOBUTANOL
2907, 4fttA, 0.7700, 2.45, 0.279, 266, 251, CRYSTAL STRUCTURE OF THE CHK1
2908, 3r02A, 0.7700, 2.42, 0.253, 271, 253, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2909, 3qf9A, 0.7700, 2.41, 0.253, 274, 253, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A FURAN- THIAZOLIDINEDIONE LIGAND
2910, 3idcA, 0.7700, 2.69, 0.260, 341, 258, CRYSTAL STRUCTURE OF (102-265)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
2911, 6b16B, 0.7699, 2.42, 0.300, 281, 250, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
2912, 5ipjA, 0.7699, 2.42, 0.253, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A QUINAZOLINONE-PYRROLOPYRROLONE INHIBITOR.
2913, 3cy2A, 0.7699, 2.42, 0.253, 271, 253, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A BETA CARBOLINE LIGAND II
2914, 2j6mA, 0.7699, 2.68, 0.214, 306, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AEE788
2915, 6d8eA, 0.7698, 2.69, 0.207, 304, 256, DISCOVERY OF A HIGHLY POTENT AND BROADLY EFFECTIVE EGFR AND HER2 EXON 20 INSERTION MUTANT INHIBITOR 
2916, 6cd6A, 0.7698, 2.67, 0.271, 264, 255, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
2917, 5u6bB, 0.7698, 2.71, 0.216, 291, 259, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
2918, 5ng0B, 0.7698, 2.76, 0.228, 282, 259, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
2919, 5n3cA, 0.7698, 2.65, 0.276, 348, 257, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE THIOPHENE-3-CARBOXIMIDAMIDE
2920, 4yvcB, 0.7698, 2.88, 0.256, 392, 262, ROCK 1 BOUND TO THIAZOLE INHIBITOR
2921, 4jx3A, 0.7698, 2.41, 0.261, 274, 253, CRYSTAL STRUCTURE OF PIM1 KINASE
2922, 5n5lA, 0.7697, 2.37, 0.258, 271, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND [2-OXO-2-(1H-PYRROL-2-YL)ETHYL] 5-BROMO-1H- INDOLE-3-CARBOXYLATE
2923, 4rc4A, 0.7697, 2.37, 0.258, 272, 252, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2924, 4mtaA, 0.7697, 2.42, 0.253, 273, 253, CRYSTAL STRUCTURE OF PIM-1 KINASE DOMAIN IN COMPLEX WITH 2-METHYL-5- PHENYLFURAN-3-CARBOXYLIC ACID
2925, 3uytA, 0.7697, 2.61, 0.191, 287, 257, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
2926, 3u9nA, 0.7697, 2.56, 0.281, 257, 253, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
2927, 3nczC, 0.7697, 2.90, 0.248, 389, 262, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
2928, 3aglA, 0.7697, 2.69, 0.264, 338, 258, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
2929, 2h9vA, 0.7697, 3.05, 0.257, 383, 265, STRUCTURAL BASIS FOR INDUCED-FIT BINDING OF RHO-KINASE TO THE INHIBITOR Y27632
2930, 5hibA, 0.7696, 2.89, 0.201, 314, 259, EGFR KINASE DOMAIN MUTANT TMLR WITH A PYRAZOLOPYRIMIDINE INHIBITOR
2931, 4dtkA, 0.7696, 2.42, 0.253, 273, 253, NOVEL AND SELECTIVE PAN-PIM KINASE INHIBITOR
2932, 1zwsB, 0.7696, 2.69, 0.260, 278, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2933, 5y9tA, 0.7695, 2.55, 0.216, 300, 255, CRYSTAL STRUCTURE OF EGFR T790M MUTANT IN COMPLEX WITH NAQUOTINIB 
2934, 5v82A, 0.7695, 2.41, 0.257, 273, 253, PIM1 KINASE IN COMPLEX WITH CPD17 (1-(6-(44-DIFLUOROPIPERIDIN-3-YL) PYRIDIN-2-YL)-6-(6-METHYLPYRAZIN-2-YL)-1H-PYRAZOLO[43-C]PYRIDINE)
2935, 5n1lA, 0.7695, 2.70, 0.265, 347, 257, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 25-DIMETHYL-N-PYRIDIN-4-YLFURAN-3- CARBOXAMIDE
2936, 5hu3A, 0.7695, 2.72, 0.320, 266, 256, DROSOPHILA CAMKII-D136N IN COMPLEX WITH A PHOSPHORYLATED FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
2937, 4rc2A, 0.7695, 2.38, 0.258, 272, 252, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2938, 4k0yA, 0.7695, 2.41, 0.253, 274, 253, STRUCTURE OF PIM-1 KINASE BOUND TO N-(4-FLUOROPHENYL)-7-HYDROXY-5- (PIPERIDIN-4-YL)PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
2939, 4i23A, 0.7695, 2.66, 0.203, 304, 256, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH DACOMITINIB (SOAKED)
2940, 3up2A, 0.7695, 2.50, 0.295, 266, 254, AURORA A IN COMPLEX WITH RPM1686
2941, 2itxA, 0.7695, 2.78, 0.209, 307, 258, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AMP- PNP
2942, 1gagA, 0.7695, 2.92, 0.205, 300, 259, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR
2943, 5wnfC, 0.7694, 2.85, 0.254, 386, 260, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2944, 5wneC, 0.7694, 2.86, 0.254, 384, 260, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2945, 5u6bD, 0.7694, 2.71, 0.216, 291, 259, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
2946, 5n36A, 0.7694, 2.70, 0.265, 347, 257, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3H-ISOINDOL-2-IUM-1-AMINE
2947, 5autA, 0.7694, 2.56, 0.267, 274, 255, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH ANS.
2948, 4iaaA, 0.7694, 2.37, 0.262, 272, 252, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE
2949, 2xiyA, 0.7694, 2.39, 0.258, 273, 252, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-2 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2950, 1xqzA, 0.7694, 2.43, 0.261, 277, 253, CRYSTAL STRUCTURE OF HPIM-1 KINASE AT 2.1 A RESOLUTION
2951, 5auxA, 0.7693, 2.62, 0.266, 275, 256, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH KAEMPFEROL.
2952, 4ypdA, 0.7693, 2.68, 0.265, 281, 257, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT 4-METHYLPYRIDAZINE
2953, 5y90A, 0.7692, 2.64, 0.234, 304, 256, MAP2K7 MUTANT -C218S
2954, 5uhnA, 0.7692, 2.89, 0.241, 282, 257, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
2955, 5bmlB, 0.7692, 2.97, 0.247, 395, 263, ROCK 1 BOUND TO A PYRIDINE THIAZOLE INHIBITOR
2956, 4xlvA, 0.7692, 2.85, 0.209, 307, 258, CRYSTAL STRUCTURE OF THE ACTIVATED INSULIN RECEPTOR TYROSINE KINASE DIMER
2957, 4kikB, 0.7692, 3.08, 0.277, 648, 264, HUMAN IKB KINASE BETA
2958, 2zm3C, 0.7692, 2.86, 0.208, 296, 260, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2959, 5uglA, 0.7691, 2.88, 0.233, 285, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
2960, 5oprA, 0.7691, 2.47, 0.278, 258, 252, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIDINE LRRK2 INHIBITOR
2961, 5l2qB, 0.7691, 2.76, 0.194, 282, 258, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
2962, 4xhgA, 0.7691, 2.76, 0.181, 357, 260, STRUCTURE OF C. GLABRATA HRR25 BOUND TO ADP (FORMATE CONDITION)
2963, 4rc3A, 0.7691, 2.34, 0.263, 271, 251, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2964, 4fzaB, 0.7691, 2.74, 0.261, 281, 257, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX
2965, 3dcvA, 0.7691, 2.50, 0.257, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM1 KINASE COMPLEXED WITH 4-(4- HYDROXY-3-METHYL-PHENYL)-6-PHENYLPYRIMIDIN-2(1H)-ONE
2966, 3c4eD, 0.7691, 2.43, 0.253, 273, 253, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
2967, 5n33A, 0.7689, 2.70, 0.265, 347, 257, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINO-5-(TRIFLUOROMETHYL)-1H-PYRIDIN-2- ONE
2968, 5n1nA, 0.7689, 2.60, 0.266, 348, 256, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-CHLORO-9-PROPAN-2-YLPURINE
2969, 3utoB, 0.7689, 2.84, 0.255, 566, 259, TWITCHIN KINASE REGION FROM C.ELEGANS (FN31-NL-KIN-CRD-IG26)
2970, 1zwsG, 0.7689, 2.68, 0.260, 278, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2971, 5n3bA, 0.7688, 2.60, 0.266, 342, 256, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-(PYRIDIN-3-YL)ETHANAMINE
2972, 5n32A, 0.7688, 2.71, 0.261, 345, 257, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-CHLOROBENZYL CARBAMIMIDOTHIOATE
2973, 5diaA, 0.7688, 2.43, 0.253, 273, 253, PIM1 IN COMPLEX WITH CPD36 ((1S3S)-N1-(6-(5-(PYRIDIN-3-YL)-1H- PYRAZOLO[34-C]PYRIDIN-3-YL)PYRIDIN-2-YL)CYCLOHEXANE-13-DIAMINE)
2974, 4wnoA, 0.7688, 2.71, 0.294, 272, 255, STRUCTURE OF ULK1 BOUND TO AN INHIBITOR
2975, 3zewA, 0.7688, 2.32, 0.227, 269, 251, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
2976, 1zwsF, 0.7688, 2.67, 0.260, 278, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2977, 1rqqA, 0.7688, 2.87, 0.209, 294, 258, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
2978, 5vc5A, 0.7687, 2.36, 0.236, 261, 250, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PD- 166285
2979, 5mhiA, 0.7687, 2.65, 0.265, 348, 257, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (5-CHLORO-2-METHOXYPHENYL)METHANAMINE
2980, 3ue4B, 0.7686, 2.50, 0.229, 268, 253, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
2981, 3ue4A, 0.7686, 2.57, 0.239, 270, 255, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
2982, 3pa4A, 0.7686, 2.59, 0.281, 257, 253, X-RAY CRYSTAL STRUCTURE OF COMPOUND 2A BOUND TO HUMAN CHK1 KINASE DOMAIN
2983, 3dlsE, 0.7686, 2.61, 0.265, 282, 253, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2984, 3bhhA, 0.7686, 2.67, 0.314, 289, 255, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2985, 1szmB, 0.7686, 2.65, 0.259, 320, 255, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
2986, 5n1mA, 0.7685, 2.61, 0.266, 347, 256, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (5-CHLORO-2-METHOXYPHENYL)METHANAMINE
2987, 4wb6B, 0.7685, 2.67, 0.272, 340, 257, CRYSTAL STRUCTURE OF A L205R MUTANT OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2988, 3qc4A, 0.7685, 2.70, 0.265, 276, 257, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
2989, 3bgpA, 0.7685, 2.39, 0.258, 272, 252, HUMAN PIM-1 COMPLEXED WITH A BENZOISOXAZOLE INHIBITOR VX1
2990, 2ydkA, 0.7685, 2.61, 0.278, 263, 255, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
2991, 2xj0A, 0.7685, 2.45, 0.253, 274, 253, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-4 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
2992, 2wmrA, 0.7685, 2.39, 0.280, 254, 250, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
2993, 1cdkA, 0.7685, 2.65, 0.268, 342, 257, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
2994, 6ccfB, 0.7684, 2.59, 0.280, 262, 254, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH HESPERADIN
2995, 5vuaB, 0.7684, 2.38, 0.254, 270, 252, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
2996, 4rblA, 0.7684, 2.34, 0.263, 271, 251, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2997, 4nfmA, 0.7684, 2.73, 0.184, 293, 261, HUMAN TAU TUBULIN KINASE 1 (TTBK1)
2998, 3uodA, 0.7684, 2.39, 0.302, 266, 252, AURORA A IN COMPLEX WITH RPM1693
2999, 3f5pC, 0.7684, 2.75, 0.212, 301, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3000, 3eqpB, 0.7684, 2.71, 0.255, 270, 255, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
3001, 6bl8B, 0.7683, 2.88, 0.219, 268, 256, PREDICTING THE CONFORMATIONAL VARIABILITY OF ABL TYROSINE KINASE USING MOLECULAR DYNAMICS SIMULATIONS AND MARKOV STATE MODELS
3002, 5opsA, 0.7683, 2.42, 0.279, 258, 251, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
3003, 5iisA, 0.7683, 2.52, 0.257, 273, 253, DESIGN SYNTHESIS AND STRUCTURE ACTIVITY RELATIONSHIP OF POTENT PAN- PIM KINASE INHIBITORS DERIVED FROM THE PYRIDYL-AMIDE SCAFFOLD
3004, 5eolA, 0.7683, 2.44, 0.253, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A MACROCYCLIC QUINOXALINE-PYRROLODIHYDROPIPERIDINONE INHIBITOR
3005, 4riwD, 0.7683, 2.66, 0.211, 297, 256, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
3006, 5n4oA, 0.7682, 2.33, 0.255, 271, 251, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE (E)-3-(P-TOLYL)ACRYLIC ACID
3007, 4umpD, 0.7682, 2.66, 0.320, 321, 253, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3008, 3dlsF, 0.7682, 2.63, 0.265, 281, 253, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3009, 1zwsD, 0.7682, 2.69, 0.260, 278, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3010, 1yxuD, 0.7682, 2.43, 0.253, 273, 253, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
3011, 1yi4A, 0.7682, 2.36, 0.259, 267, 251, STRUCTURE OF PIM-1 BOUND TO ADENOSINE
3012, 5wnhC, 0.7681, 2.88, 0.250, 388, 260, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
3013, 5lihB, 0.7681, 2.33, 0.298, 318, 252, STRUCTURE OF A PEPTIDE-SUBSTRATE BOUND TO PKCIOTA CORE KINASE DOMAIN
3014, 5es1A, 0.7681, 2.31, 0.329, 304, 246, CRYSTAL STRUCTURE OF MICROTUBULE AFFINITY-REGULATING KINASE 4 CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
3015, 4riyD, 0.7681, 2.59, 0.212, 297, 255, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
3016, 3f5pD, 0.7681, 2.76, 0.212, 297, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3017, 3cy3A, 0.7681, 2.39, 0.258, 270, 252, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND THE JNK INHIBITOR V
3018, 2pwlB, 0.7681, 2.87, 0.245, 286, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
3019, 2objA, 0.7681, 2.39, 0.258, 272, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH INHIBITOR
3020, 2f4jA, 0.7681, 2.93, 0.239, 287, 259, STRUCTURE OF THE KINASE DOMAIN OF AN IMATINIB-RESISTANT ABL MUTANT IN COMPLEX WITH THE AURORA KINASE INHIBITOR VX-680
3021, 1xr1A, 0.7681, 2.55, 0.261, 277, 253, CRYSTAL STRUCTURE OF HPIM-1 KINASE IN COMPLEX WITH AMP-PNP AT 2.1 A RESOLUTION
3022, 5vcvA, 0.7680, 2.66, 0.289, 287, 253, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH DASATINIB
3023, 4xliA, 0.7680, 2.40, 0.239, 264, 251, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
3024, 3f5pA, 0.7680, 2.76, 0.212, 299, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3025, 3dlsC, 0.7680, 2.56, 0.262, 281, 252, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3026, 5e8wA, 0.7679, 2.63, 0.213, 303, 254, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE
3027, 3vbqA, 0.7679, 2.45, 0.253, 271, 253, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3028, 3f5pH, 0.7679, 2.76, 0.212, 299, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3029, 4wb6A, 0.7678, 2.63, 0.273, 336, 256, CRYSTAL STRUCTURE OF A L205R MUTANT OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
3030, 4jiaA, 0.7678, 2.94, 0.262, 298, 260, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 9
3031, 4gmyA, 0.7678, 2.80, 0.257, 298, 257, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH 26-DICHLORO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
3032, 3ri1A, 0.7678, 2.91, 0.244, 285, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
3033, 3gubA, 0.7678, 2.68, 0.265, 278, 257, CRYSTAL STRUCTURE OF DAPKL93G COMPLEXED WITH N6-(2- PHENYLETHYL)ADENOSINE
3034, 2xizA, 0.7678, 2.41, 0.258, 273, 252, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-3 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3035, 1wvxA, 0.7678, 2.68, 0.261, 275, 257, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
3036, 5vd4A, 0.7677, 2.48, 0.227, 261, 251, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 016 A MK1775 ANALOUGUE
3037, 5n3dA, 0.7677, 2.62, 0.266, 346, 256, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-(TRIFLUOROMETHYL)BENZENECARBOXIMIDAMIDE
3038, 5mjaB, 0.7677, 2.53, 0.231, 274, 255, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
3039, 3sxsA, 0.7677, 2.51, 0.213, 264, 253, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEXED WITH PP2
3040, 3jvrA, 0.7677, 2.37, 0.273, 258, 249, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
3041, 5auuA, 0.7676, 2.60, 0.267, 274, 255, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH LUTEOLIN.
3042, 4x2nA, 0.7676, 2.61, 0.213, 303, 254, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3043, 4wotD, 0.7676, 2.97, 0.247, 389, 263, ROCK2 IN COMPLEX WITH 1426382-07-1
3044, 4tl0A, 0.7676, 2.90, 0.262, 300, 260, CRYSTAL STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 WITH A CRUCIAL PHOSPHOMIMICKING MUTATION
3045, 4lmuA, 0.7676, 2.45, 0.266, 265, 252, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH THE INHIBITOR QUERCETIN (RESULTING FROM DISPLACEMENT OF SKF86002)
3046, 3f5pT, 0.7676, 2.73, 0.213, 295, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3047, 3f5pG, 0.7676, 2.76, 0.212, 299, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3048, 2pvfA, 0.7676, 2.84, 0.236, 285, 258, CRYSTAL STRUCTURE OF TYROSINE PHOSPHORYLATED ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH ATP ANALOG AND SUBSTRATE PEPTIDE
3049, 5av4A, 0.7675, 2.60, 0.267, 274, 255, CRYSTAL STRUCTURE OF DAPK1-GENISTEIN COMPLEX IN THE PRESENCE OF BROMIDE IONS.
3050, 4txcA, 0.7675, 2.74, 0.260, 276, 258, CRYSTAL STRUCTURE OF DAPK1 KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
3051, 4jrvA, 0.7675, 2.57, 0.209, 300, 254, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4C
3052, 4fswA, 0.7675, 2.56, 0.283, 265, 251, CRYSTAL STRUCTURE OF THE CHK1
3053, 3uysC, 0.7675, 2.72, 0.185, 286, 259, CRYSTAL STRUCTURE OF APO HUMAN CK1D
3054, 3kxxA, 0.7675, 2.85, 0.240, 305, 258, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
3055, 3kl8G, 0.7675, 2.39, 0.311, 259, 251, CAMKIINTIDE INHIBITOR COMPLEX
3056, 3bgzA, 0.7675, 2.41, 0.258, 267, 252, HUMAN PIM-1 KINASE IN COMPLEX WITH DIPHENYL INDOLE INHIBITOR VX3
3057, 2ym6A, 0.7675, 2.36, 0.281, 253, 249, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3058, 1yhsA, 0.7675, 2.36, 0.259, 267, 251, CRYSTAL STRUCTURE OF PIM-1 BOUND TO STAUROSPORINE
3059, 4alwA, 0.7674, 2.48, 0.253, 273, 253, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
3060, 3cd3A, 0.7674, 2.43, 0.238, 352, 252, CRYSTAL STRUCTURE OF PHOSPHORYLATED HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V-FES) IN COMPLEX WITH STAUROSPORINE AND A CONSENSUS PEPTIDE
3061, 5n39A, 0.7673, 2.62, 0.266, 347, 256, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-(23-DIHYDROBENZO[B][14]DIOXIN-6-YL) PYRROLIDINE
3062, 5auzA, 0.7673, 2.60, 0.267, 274, 255, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH GENISTEIN.
3063, 4xhkB, 0.7673, 2.39, 0.258, 269, 252, PIM1 KINASE IN COMPLEX WITH COMPOUND 1S
3064, 4deaA, 0.7673, 2.39, 0.298, 266, 252, AURORA A IN COMPLEX WITH YL1-038-18
3065, 4ae9B, 0.7673, 2.61, 0.259, 321, 255, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
3066, 3uytC, 0.7673, 2.73, 0.192, 286, 260, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
3067, 5auwA, 0.7672, 2.61, 0.267, 274, 255, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH QUERCETIN.
3068, 4ft5A, 0.7672, 2.56, 0.271, 265, 251, CRYSTAL STRUCTURE OF THE CHK1
3069, 3f5pB, 0.7672, 2.77, 0.212, 298, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3070, 3f2aA, 0.7672, 2.40, 0.258, 276, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 IN COMPLEX WITH DAPPA
3071, 2xynC, 0.7672, 2.62, 0.240, 262, 254, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
3072, 2qg5A, 0.7672, 2.73, 0.266, 284, 256, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
3073, 5n1oA, 0.7671, 2.63, 0.262, 335, 256, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-CHLORO-4-(CHLOROMETHYL)-5- HYDROXYPHENYL)ETHAN-1-ONE
3074, 5ci7A, 0.7671, 2.71, 0.295, 276, 254, STRUCTURE OF ULK1 BOUND TO A SELECTIVE INHIBITOR
3075, 4o0sA, 0.7671, 2.57, 0.296, 265, 253, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3076, 4gfgA, 0.7671, 2.66, 0.198, 277, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R9021
3077, 4bznA, 0.7671, 2.42, 0.254, 272, 252, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO(12-A) PYRAZINONE INHIBITOR
3078, 3jy0A, 0.7671, 2.43, 0.254, 275, 252, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
3079, 1wvwA, 0.7671, 2.67, 0.265, 275, 257, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
3080, 5vjaD, 0.7670, 2.49, 0.256, 261, 254, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
3081, 2xj1A, 0.7670, 2.41, 0.258, 273, 252, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INIBITOR
3082, 5ghvB, 0.7669, 2.39, 0.202, 265, 252, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3083, 5ghvA, 0.7669, 2.38, 0.202, 265, 252, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3084, 5e8uA, 0.7669, 2.57, 0.217, 306, 254, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F)
3085, 5dwrA, 0.7669, 2.41, 0.258, 273, 252, IDENTIFICATION OF N-(4-((1R3S5S)-3-AMINO-5-METHYLCYCLOHEXYL)PYRIDIN- 3-YL)-6-(26-DIFLUOROPHENYL)-5-FLUOROPICOLINAMIDE (PIM447) A POTENT AND SELECTIVE PROVIRAL INSERTION SITE OF MOLONEY MURINE LEUKEMIA (PIM) 12 AND 3 KINASE INHIBITOR IN CLINICAL TRIALS FOR HEMATOLOGICAL MALIGNANCIES
3086, 5vioB, 0.7668, 2.87, 0.282, 271, 255, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
3087, 5fqdF, 0.7668, 2.80, 0.196, 294, 260, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
3088, 4w7pC, 0.7668, 2.86, 0.257, 383, 261, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
3089, 3uo5A, 0.7668, 2.53, 0.304, 267, 253, AURORA A IN COMPLEX WITH YL1-038-31
3090, 2yabB, 0.7668, 2.86, 0.259, 299, 259, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
3091, 5vczA, 0.7667, 2.66, 0.287, 294, 254, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB ISOMER
3092, 4rixD, 0.7667, 2.72, 0.214, 297, 257, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
3093, 3f5pF, 0.7667, 2.77, 0.212, 299, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3094, 1oecA, 0.7667, 2.75, 0.247, 280, 255, FGFR2 KINASE DOMAIN
3095, 5flfA, 0.7666, 2.95, 0.240, 296, 258, DISEASE LINKED MUTATION IN FGFR
3096, 4wotA, 0.7666, 2.96, 0.256, 389, 262, ROCK2 IN COMPLEX WITH 1426382-07-1
3097, 4bzoA, 0.7666, 2.42, 0.258, 272, 252, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO- PYRAZINONE INHIBITOR
3098, 1zwsH, 0.7666, 2.72, 0.260, 278, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3099, 5lihA, 0.7665, 2.53, 0.294, 324, 255, STRUCTURE OF A PEPTIDE-SUBSTRATE BOUND TO PKCIOTA CORE KINASE DOMAIN
3100, 4x2kA, 0.7665, 2.88, 0.214, 303, 257, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3101, 4x2jA, 0.7665, 2.88, 0.214, 303, 257, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3102, 4tn6B, 0.7665, 2.73, 0.189, 285, 259, CK1D IN COMPLEX WITH INHIBITOR
3103, 4rvlA, 0.7665, 2.44, 0.272, 258, 250, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 7: 3-(2- HYDROXYPHENYL)-9H-PYRROLO[23-B:54-C ]DIPYRIDINE-6-CARBONITRILE
3104, 4j99D, 0.7665, 2.80, 0.243, 281, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
3105, 3ppzA, 0.7665, 2.25, 0.258, 264, 248, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
3106, 3f5pE, 0.7665, 2.78, 0.212, 299, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3107, 1gjoA, 0.7665, 2.77, 0.243, 280, 255, THE FGFR2 TYROSINE KINASE DOMAIN
3108, 5te0A, 0.7664, 2.70, 0.245, 316, 253, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH BIBF 1120
3109, 4umpB, 0.7664, 2.58, 0.315, 324, 251, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3110, 3bgqA, 0.7664, 2.55, 0.257, 272, 253, HUMAN PIM-1 KINASE IN COMPLEX WITH AN TRIAZOLO PYRIDAZINE INHIBITOR VX2
3111, 2vz6A, 0.7664, 3.01, 0.297, 291, 259, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
3112, 2ckeC, 0.7664, 2.95, 0.254, 300, 260, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
3113, 2c3iB, 0.7664, 2.37, 0.259, 266, 251, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH IMIDAZOPYRIDAZIN I
3114, 2bdwA, 0.7664, 2.77, 0.304, 309, 260, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
3115, 5vilB, 0.7663, 2.89, 0.275, 271, 255, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
3116, 5d9kB, 0.7663, 2.53, 0.292, 280, 253, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
3117, 3eqpA, 0.7663, 2.57, 0.257, 268, 253, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
3118, 2wotA, 0.7663, 2.73, 0.213, 303, 254, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
3119, 2ivsA, 0.7663, 2.79, 0.246, 284, 256, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
3120, 1yi3A, 0.7663, 2.36, 0.259, 267, 251, CRYSTAL STRUCTURE OF PIM-1 BOUND TO LY294002
3121, 5oktB, 0.7662, 2.75, 0.189, 281, 259, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
3122, 4n70A, 0.7662, 2.43, 0.258, 274, 252, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
3123, 4ftcA, 0.7662, 2.46, 0.276, 266, 250, CRYSTAL STRUCTURE OF THE CHK1
3124, 2psqA, 0.7662, 2.95, 0.236, 287, 258, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
3125, 2ckeB, 0.7662, 2.89, 0.255, 300, 259, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
3126, 4x2gA, 0.7661, 2.87, 0.214, 303, 257, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3127, 3a99A, 0.7661, 2.57, 0.257, 273, 253, STRUCTURE OF PIM-1 KINASE CRYSTALLIZED IN THE PRESENCE OF P27KIP1 CARBOXY-TERMINAL PEPTIDE
3128, 5vubB, 0.7660, 2.37, 0.255, 269, 251, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
3129, 4j95C, 0.7660, 2.68, 0.248, 281, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
3130, 4iw0A, 0.7660, 3.27, 0.236, 647, 267, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
3131, 5tvtA, 0.7659, 2.36, 0.328, 321, 247, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
3132, 5j9yA, 0.7659, 2.69, 0.211, 300, 256, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1B
3133, 5cxhA, 0.7659, 2.71, 0.202, 277, 257, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT ORALLY BIOAVAILABLE THIAZOLE INHIBITOR
3134, 4j99A, 0.7659, 2.86, 0.246, 280, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
3135, 4fsmA, 0.7659, 2.45, 0.280, 265, 250, CRYSTAL STRUCTURE OF THE CHK1
3136, 3utoA, 0.7659, 2.84, 0.259, 559, 259, TWITCHIN KINASE REGION FROM C.ELEGANS (FN31-NL-KIN-CRD-IG26)
3137, 3dlsB, 0.7659, 2.58, 0.267, 280, 251, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3138, 2xj2A, 0.7659, 2.43, 0.258, 273, 252, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3139, 5e90A, 0.7658, 2.55, 0.218, 303, 252, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249F S280T Y282FS287NA350CL352F) IN COMPLEX WITH 3-AMINO-6- [4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2- CARBOXAMIDE
3140, 5c26A, 0.7658, 2.71, 0.202, 272, 257, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 1
3141, 3uixA, 0.7658, 2.38, 0.255, 266, 251, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3142, 3kl8A, 0.7658, 2.47, 0.303, 256, 251, CAMKIINTIDE INHIBITOR COMPLEX
3143, 2csnA, 0.7658, 2.78, 0.185, 293, 260, BINARY COMPLEX OF CASEIN KINASE-1 WITH CKI7
3144, 1yxtA, 0.7658, 2.63, 0.252, 274, 254, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMPPNP
3145, 5vd7A, 0.7657, 2.52, 0.227, 261, 251, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 098 A MK1775 ANALOGUE
3146, 5jebA, 0.7657, 2.88, 0.202, 299, 258, CRYSTAL STRUCTURE OF EGFR TYROSINE KINASE DOMAIN WITH NOVEL INHIBITOR OF ACTIVE STATE OF HER2
3147, 4zy6B, 0.7657, 2.46, 0.305, 280, 249, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
3148, 4uv0A, 0.7657, 2.89, 0.250, 300, 260, STRUCTURE OF A SEMISYNTHETIC PHOSPHORYLATED DAPK
3149, 3bkbA, 0.7657, 2.76, 0.238, 373, 256, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES)
3150, 2ckeD, 0.7657, 2.94, 0.254, 300, 260, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
3151, 1zwsC, 0.7657, 2.75, 0.260, 278, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3152, 6b8yA, 0.7656, 2.67, 0.213, 304, 254, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-(3- FLUOROPYRIDIN-4-YL)-2-[6-(TRIFLUOROMETHYL)PYRIDIN-2-YL]-7H-PYRROLO[2 3-D]PYRIMIDIN-4-AMINE
3153, 3uo4A, 0.7656, 2.45, 0.292, 266, 253, AURORA A IN COMPLEX WITH RPM1680
3154, 6fekA, 0.7655, 2.80, 0.246, 294, 256, ONCOGENIC POINT MUTATION OF RET RECEPTOR TYROSINE KINASE
3155, 5l3aA, 0.7655, 2.76, 0.258, 290, 256, FRAGMENT-BASED DISCOVERY OF 6-ARYLINDAZOLE JAK INHIBITORS
3156, 4iwdA, 0.7655, 2.98, 0.219, 299, 260, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-8033 ANALOG
3157, 3f5pM, 0.7655, 2.77, 0.212, 295, 259, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3158, 2ckeA, 0.7655, 2.88, 0.255, 301, 259, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
3159, 5o13A, 0.7654, 2.42, 0.263, 270, 251, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
3160, 5flfD, 0.7654, 2.81, 0.246, 290, 256, DISEASE LINKED MUTATION IN FGFR
3161, 4x2fA, 0.7654, 2.89, 0.214, 303, 257, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3162, 4fzfB, 0.7654, 2.68, 0.259, 279, 255, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX WITH DKI
3163, 3f5pI, 0.7654, 2.75, 0.213, 294, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3164, 1kobA, 0.7654, 2.82, 0.248, 352, 258, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
3165, 5x2kA, 0.7653, 2.71, 0.208, 314, 255, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH WZ4003
3166, 5w4wD, 0.7653, 2.64, 0.187, 287, 256, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
3167, 5vcyA, 0.7653, 2.66, 0.287, 296, 254, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
3168, 4x0mA, 0.7653, 2.87, 0.214, 303, 257, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
3169, 4wnpC, 0.7653, 2.60, 0.300, 271, 253, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
3170, 4rixB, 0.7653, 2.62, 0.217, 293, 254, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
3171, 3kxxB, 0.7653, 2.93, 0.248, 305, 258, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
3172, 3f5pS, 0.7653, 2.75, 0.213, 295, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3173, 5fqdC, 0.7652, 2.83, 0.196, 294, 260, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
3174, 5e8zA, 0.7652, 2.56, 0.218, 303, 252, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3- AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3- YL]PYRAZINE-2-CARBOXAMIDE
3175, 4n6zA, 0.7652, 2.45, 0.258, 272, 252, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
3176, 2z2wA, 0.7652, 2.57, 0.227, 260, 251, HUMAND WEE1 KINASE COMPLEXED WITH INHIBITOR PF0335770
3177, 2pwlA, 0.7652, 2.94, 0.241, 284, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
3178, 5ax9C, 0.7651, 2.46, 0.269, 282, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
3179, 2xixA, 0.7651, 2.41, 0.259, 272, 251, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-1 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
3180, 2chlA, 0.7651, 2.77, 0.208, 298, 259, STRUCTURE OF CASEIN KINASE 1 GAMMA 3
3181, 1zwsA, 0.7651, 2.75, 0.264, 278, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3182, 1tkiB, 0.7651, 2.92, 0.238, 321, 260, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
3183, 1tkiA, 0.7651, 2.92, 0.238, 321, 260, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
3184, 3vjnA, 0.7650, 2.54, 0.202, 297, 253, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH AMPPNP.
3185, 3naxA, 0.7650, 2.75, 0.256, 278, 258, PDK1 IN COMPLEX WITH INHIBITOR MP7
3186, 2gqgB, 0.7650, 2.84, 0.234, 276, 256, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
3187, 1m52B, 0.7650, 2.68, 0.227, 272, 255, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
3188, 1koaA, 0.7650, 2.86, 0.248, 447, 258, TWITCHIN KINASE FRAGMENT (C.ELEGANS) AUTOREGULATED PROTEIN KINASE AND IMMUNOGLOBULIN DOMAINS
3189, 6bl8A, 0.7649, 2.84, 0.234, 270, 256, PREDICTING THE CONFORMATIONAL VARIABILITY OF ABL TYROSINE KINASE USING MOLECULAR DYNAMICS SIMULATIONS AND MARKOV STATE MODELS
3190, 5o0yA, 0.7649, 2.69, 0.245, 288, 257, TLK2 KINASE DOMAIN FROM HUMAN 
3191, 5gtzA, 0.7649, 2.92, 0.205, 317, 258, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH JTS-1-39
3192, 5e8yA, 0.7649, 2.76, 0.232, 298, 254, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH STAUROSPORINE
3193, 5dt3A, 0.7649, 2.61, 0.303, 263, 254, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
3194, 4zogB, 0.7649, 2.78, 0.223, 268, 256, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
3195, 4y83B, 0.7649, 2.10, 0.233, 302, 245, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(2-AMINO-5- (QUINOLIN-3-YL)PYRIDIN-3-YL)-134-OXADIAZOLE-2(3H)-THIONE
3196, 4w9wA, 0.7649, 2.75, 0.265, 306, 253, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH SMALL MOLECULE AZD-7762
3197, 4twpB, 0.7649, 2.68, 0.243, 271, 255, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
3198, 4riwB, 0.7649, 2.64, 0.213, 293, 254, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
3199, 4gvjA, 0.7649, 2.87, 0.233, 290, 257, TYK2 (JH1) IN COMPLEX WITH ADENOSINE DI-PHOSPHATE
3200, 3vjoA, 0.7649, 2.60, 0.206, 298, 253, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH AMPPNP.
3201, 5l8lA, 0.7648, 2.61, 0.299, 263, 254, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 1)
3202, 4xg6A, 0.7648, 2.64, 0.199, 271, 256, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3203, 4hokI, 0.7648, 2.70, 0.195, 291, 257, CRYSTAL STRUCTURE OF APO CK1E
3204, 3r7oA, 0.7648, 3.03, 0.219, 299, 260, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG
3205, 2yaaB, 0.7648, 2.88, 0.259, 299, 259, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
3206, 2jiuA, 0.7648, 2.87, 0.208, 303, 259, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
3207, 5vd5A, 0.7647, 2.54, 0.227, 260, 251, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 050 A MK1775 ANALOUGUE
3208, 4utdA, 0.7647, 2.65, 0.307, 266, 254, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION
3209, 2yabA, 0.7647, 2.77, 0.260, 299, 258, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
3210, 2hz4A, 0.7647, 2.51, 0.231, 262, 251, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
3211, 1kobB, 0.7647, 2.87, 0.255, 352, 259, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
3212, 5hg5A, 0.7646, 3.21, 0.199, 302, 261, EGFR (L858R T790M V948R) IN COMPLEX WITH N-{3-[(2-{[4-(4- METHYLPIPERAZIN-1-YL)PHENYL]AMINO}-7H-PYRROLO[23-D]PYRIMIDIN-4-YL) OXY]PHENYL}PROP-2-ENAMIDE
3213, 4tw9A, 0.7646, 2.81, 0.188, 290, 260, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
3214, 4j97A, 0.7646, 2.65, 0.241, 282, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
3215, 4debA, 0.7646, 2.44, 0.298, 264, 252, AURORA A IN COMPLEX WITH RK2-17-01
3216, 5x17A, 0.7645, 2.80, 0.188, 290, 260, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
3217, 5lmaA, 0.7645, 2.68, 0.191, 267, 256, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
3218, 4fl1A, 0.7645, 2.45, 0.206, 268, 252, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
3219, 3kl8C, 0.7645, 2.31, 0.315, 256, 248, CAMKIINTIDE INHIBITOR COMPLEX
3220, 5d9kA, 0.7644, 2.44, 0.299, 280, 251, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
3221, 4xliB, 0.7644, 2.55, 0.234, 264, 252, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
3222, 4j8nC, 0.7644, 2.64, 0.307, 266, 254, AURORA A KINASE APO
3223, 3twjC, 0.7644, 3.01, 0.251, 396, 263, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
3224, 1zwsE, 0.7644, 2.74, 0.264, 278, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3225, 4xg3B, 0.7643, 2.61, 0.200, 267, 255, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3226, 4j8nD, 0.7643, 2.64, 0.307, 265, 254, AURORA A KINASE APO
3227, 3bhhD, 0.7643, 2.69, 0.310, 286, 255, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
3228, 2a2aC, 0.7643, 2.97, 0.242, 303, 260, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
3229, 5vucB, 0.7642, 2.40, 0.255, 269, 251, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
3230, 5u8lA, 0.7642, 3.09, 0.208, 289, 259, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH A SULFONYL FLUORIDE PROBE XO44
3231, 4li5A, 0.7642, 2.84, 0.207, 306, 256, EGFR-K IN COMPLEX WITH N-[3-[[5-CHLORO-4-(1H-INDOL-3-YL)PYRIMIDIN-2- YL]AMINO]-4-METHOXY-PHENYL] PROP-2-ENAMIDE
3232, 4j97B, 0.7642, 2.77, 0.240, 283, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
3233, 4j8nB, 0.7642, 2.64, 0.307, 266, 254, AURORA A KINASE APO
3234, 3wf9A, 0.7642, 2.59, 0.310, 287, 252, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 1-OXO-1-[(4-SULFAMOYLPHENYL)AMINO]PROPAN-2-YL-2-METHYL-1 234-TETRAHYDROACRIDINE-9-CARBOXYLATE
3235, 3bi6A, 0.7642, 2.49, 0.228, 258, 250, WEE1 KINASE COMPLEX WITH INHIBITOR PD352396
3236, 2gqgA, 0.7642, 2.88, 0.237, 277, 257, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
3237, 5oktC, 0.7641, 2.59, 0.181, 285, 254, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
3238, 3q6wA, 0.7641, 3.01, 0.219, 297, 260, STRUCTURE OF DUALLY-PHOSPHORYLATED MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG WITH SPECIFICITY FOR THE ACTIVATED RECEPTOR
3239, 2w4kA, 0.7641, 2.94, 0.250, 301, 260, X-RAY STRUCTURE OF A DAP-KINASE 2-302
3240, 5vd8A, 0.7640, 2.55, 0.227, 260, 251, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 099 A MK1775 ANALOGUE
3241, 5kziA, 0.7640, 2.49, 0.253, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN IMIDAZOPYRIDAZINE INHIBITOR.
3242, 5hg8A, 0.7640, 3.08, 0.205, 300, 259, EGFR (L858R T790M V948R) IN COMPLEX WITH N-[3-({2-[(1-METHYL-1H- PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY)PHENYL]PROP- 2-ENAMIDE
3243, 4jnwB, 0.7640, 2.86, 0.239, 321, 259, BACTERIALLY EXPRESSED TITIN KINASE
3244, 4i5mA, 0.7640, 2.54, 0.245, 273, 253, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3245, 3lm5A, 0.7640, 2.52, 0.247, 274, 251, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B) IN COMPLEX WITH QUERCETIN
3246, 5e8sA, 0.7639, 2.48, 0.219, 301, 251, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT)
3247, 4jikA, 0.7639, 2.45, 0.281, 256, 249, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22A (R)-2-(4-CHLOROPHENYL)-8- (PIPERIDIN-3-YLAMINO)IMIDAZO[12-C]PYRIMIDINE-5-CARBOXAMIDE BOUND TO HUMAN CHK1 KINASE DOMAIN
3248, 4j8nA, 0.7639, 2.65, 0.307, 266, 254, AURORA A KINASE APO
3249, 2a2aD, 0.7639, 2.95, 0.242, 303, 260, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
3250, 4tn6A, 0.7638, 2.84, 0.188, 292, 260, CK1D IN COMPLEX WITH INHIBITOR
3251, 4ftaA, 0.7638, 2.56, 0.280, 264, 250, CRYSTAL STRUCTURE OF THE CHK1
3252, 4btjB, 0.7638, 2.81, 0.184, 293, 261, TTBK1 IN COMPLEX WITH ATP
3253, 5imeA, 0.7637, 2.34, 0.281, 280, 249, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
3254, 3s95A, 0.7637, 2.64, 0.251, 290, 251, CRYSTAL STRUCTURE OF THE HUMAN LIMK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
3255, 2xeyA, 0.7637, 2.35, 0.274, 252, 248, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3256, 2vz6B, 0.7637, 3.01, 0.296, 294, 260, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
3257, 6ccfA, 0.7636, 2.55, 0.282, 260, 252, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH HESPERADIN
3258, 4y85A, 0.7636, 2.17, 0.240, 307, 246, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(5-(1H-INDOL- 3-YL)-1H-PYRROLO[23-B]PYRIDIN-3-YL)-134-OXADIAZOL-2-AMINE
3259, 4d2pD, 0.7636, 2.73, 0.320, 317, 253, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3260, 3cqeA, 0.7636, 2.59, 0.227, 258, 251, WEE1 KINASE COMPLEX WITH INHIBITOR PD074291
3261, 2xynB, 0.7636, 2.68, 0.244, 264, 254, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
3262, 2hk5A, 0.7636, 2.59, 0.250, 269, 252, HCK KINASE IN COMPLEX WITH LCK TARGETTED INHIBITOR PG-1009247
3263, 1csnA, 0.7636, 2.83, 0.185, 293, 260, BINARY COMPLEX OF CASEIN KINASE-1 WITH MGATP
3264, 5usqA, 0.7635, 2.49, 0.219, 299, 251, ALK-5 KINASE INHIBITOR COMPLEX
3265, 4nfnA, 0.7635, 2.79, 0.184, 293, 261, HUMAN TAU TUBULIN KINASE 1 (TTBK1) COMPLEXED WITH 3-({5-[(4-AMINO-4- METHYLPIPERIDIN-1-YL)METHYL]PYRROLO[21-F][124]TRIAZIN-4-YL}AMINO)- 5-BROMOPHENOL
3266, 4bbeB, 0.7635, 2.79, 0.258, 288, 256, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3267, 3gqiA, 0.7635, 2.84, 0.241, 304, 257, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
3268, 3bceC, 0.7635, 2.76, 0.212, 286, 255, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
3269, 5x18B, 0.7634, 2.94, 0.205, 294, 263, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
3270, 5dnrA, 0.7634, 2.58, 0.300, 264, 253, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P41212
3271, 4zs0A, 0.7634, 2.33, 0.301, 257, 249, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO SB-6-OH
3272, 4enxA, 0.7634, 2.42, 0.255, 266, 251, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH INHIBITOR (2E5Z)-2- (2-CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-NITROBENZYLIDENE)THIAZOLIDIN-4- ONE
3273, 4bbeC, 0.7634, 2.79, 0.254, 288, 256, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3274, 3vbwA, 0.7634, 2.36, 0.257, 264, 249, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
3275, 3umwA, 0.7634, 2.43, 0.263, 264, 251, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDAZOL-3-YL)METHYLENE]-6-METHOXY-7-(PIPERAZIN-1-YLMETHYL)BENZOFURAN- 3(2H)-ONE
3276, 1yrpB, 0.7634, 2.67, 0.254, 275, 256, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
3277, 1yrpA, 0.7634, 2.67, 0.254, 275, 256, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
3278, 5op2A, 0.7633, 2.67, 0.273, 263, 256, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3279, 5n3fA, 0.7633, 2.60, 0.264, 318, 254, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-[3-(AMINOMETHYL)PHENYL]ACETAMIDE
3280, 4lgdB, 0.7633, 2.86, 0.284, 350, 257, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3281, 4d2tD, 0.7633, 2.70, 0.321, 319, 252, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3282, 4btkA, 0.7633, 2.69, 0.178, 287, 258, TTBK1 IN COMPLEX WITH INHIBITOR
3283, 4bbeD, 0.7633, 2.91, 0.263, 288, 259, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3284, 4bbeA, 0.7633, 2.91, 0.263, 288, 259, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3285, 2wtkF, 0.7633, 2.56, 0.280, 268, 250, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
3286, 6bleA, 0.7632, 2.69, 0.287, 265, 254, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CP673451
3287, 4yjoA, 0.7632, 2.69, 0.191, 267, 256, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000222
3288, 4l3lA, 0.7632, 2.66, 0.308, 291, 253, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN (ZINC ANOMALOUS)
3289, 4deeA, 0.7632, 2.64, 0.299, 271, 254, AURORA A IN COMPLEX WITH ADP
3290, 3wf8A, 0.7632, 2.60, 0.310, 287, 252, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 2-OXO-2-[(4-SULFAMOYLPHENYL)AMINO]ETHYL 78910- TETRAHYDRO-6H-CYCLOHEPTA[B]QUINOLINE-11-CARBOXYLATE
3291, 3t9iA, 0.7632, 2.41, 0.259, 273, 251, PIM1 COMPLEXED WITH A NOVEL 36-DISUBSTITUTED INDOLE AT 2.6 ANG RESOLUTION
3292, 3f9nA, 0.7632, 2.44, 0.273, 253, 249, CRYSTAL STRUCTURE OF CHK1 KINASE IN COMPLEX WITH INHIBITOR 38
3293, 3bu5A, 0.7632, 2.73, 0.202, 291, 253, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE AND ATP
3294, 2yaaA, 0.7632, 2.89, 0.259, 300, 259, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
3295, 2psqB, 0.7632, 3.00, 0.240, 286, 258, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
3296, 5vd9A, 0.7631, 2.58, 0.227, 261, 251, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 097 A MK1775 ANALOGUE
3297, 5vc4A, 0.7631, 2.55, 0.227, 261, 251, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB-ISOMER
3298, 5dn3A, 0.7631, 2.50, 0.298, 264, 252, AURORA A IN COMPLEX WITH ATP AND AA35.
3299, 5uzjB, 0.7630, 3.06, 0.252, 386, 262, CRYSTAL STRUCTURE OF ROCK1 BOUND TO AN AMINOPYRIDINE INHIBITOR
3300, 5deyB, 0.7630, 2.47, 0.305, 281, 249, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
3301, 4lg4F, 0.7630, 2.20, 0.289, 276, 246, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3302, 4j97C, 0.7630, 2.67, 0.237, 283, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
3303, 4hokM, 0.7630, 2.90, 0.196, 291, 260, CRYSTAL STRUCTURE OF APO CK1E
3304, 4bbfB, 0.7630, 2.92, 0.263, 288, 259, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3305, 3ri1B, 0.7630, 2.97, 0.230, 283, 257, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
3306, 3kl8E, 0.7630, 2.36, 0.313, 256, 249, CAMKIINTIDE INHIBITOR COMPLEX
3307, 3bhyA, 0.7630, 2.53, 0.259, 268, 251, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH A BETA-CARBOLINE LIGAND
3308, 2izuA, 0.7630, 2.73, 0.210, 297, 257, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3309, 1m52A, 0.7630, 2.72, 0.235, 271, 255, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
3310, 6groA, 0.7629, 2.81, 0.212, 293, 259, HUMAN CSNK1G3 BOUND TO SB-223133 
3311, 4riyB, 0.7629, 2.69, 0.213, 293, 254, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
3312, 3fxxA, 0.7629, 2.59, 0.217, 288, 253, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BOUND TO SUBSTRATE KQWDNYE[PTYR]IW
3313, 3f5pK, 0.7629, 2.74, 0.214, 293, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3314, 2xynA, 0.7629, 2.61, 0.225, 264, 253, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
3315, 4bbfC, 0.7628, 2.93, 0.255, 288, 259, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3316, 2bvaB, 0.7628, 2.30, 0.257, 274, 249, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
3317, 4jnwA, 0.7627, 2.87, 0.239, 320, 259, BACTERIALLY EXPRESSED TITIN KINASE
3318, 4gihA, 0.7627, 2.85, 0.230, 288, 256, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}BENZAMIDE
3319, 3f5pR, 0.7627, 2.78, 0.213, 294, 258, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3320, 5vc6A, 0.7626, 2.55, 0.228, 259, 250, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
3321, 5t68B, 0.7626, 2.43, 0.203, 264, 251, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
3322, 4l46A, 0.7626, 2.53, 0.311, 317, 251, CRYSTAL STRUCTURES OF HUMAN P70S6K1-WT
3323, 3f5pL, 0.7626, 2.75, 0.214, 293, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3324, 4hokO, 0.7625, 2.71, 0.191, 290, 256, CRYSTAL STRUCTURE OF APO CK1E
3325, 4gj3A, 0.7625, 2.85, 0.230, 288, 256, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
3326, 4d2pB, 0.7625, 2.59, 0.316, 323, 250, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3327, 3lm0A, 0.7625, 2.60, 0.246, 278, 252, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B)
3328, 2xzsA, 0.7625, 3.00, 0.250, 301, 260, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
3329, 2of4A, 0.7625, 2.63, 0.229, 271, 253, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 1 BOUND TO LCK
3330, 2a2aA, 0.7625, 2.99, 0.242, 304, 260, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
3331, 1z9xB, 0.7625, 2.92, 0.255, 303, 259, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
3332, 5walA, 0.7624, 2.72, 0.231, 286, 255, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
3333, 5t68A, 0.7624, 2.43, 0.203, 266, 251, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
3334, 5l2qD, 0.7624, 2.74, 0.195, 294, 256, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
3335, 4xg4A, 0.7624, 2.42, 0.203, 264, 251, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3336, 4asxA, 0.7624, 2.77, 0.232, 310, 254, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
3337, 3cr0A, 0.7624, 2.57, 0.228, 257, 250, WEE1 KINASE COMPLEX WITH INHIBITOR PD259_809
3338, 5v5yA, 0.7623, 2.60, 0.236, 259, 250, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH MK1775
3339, 4l45A, 0.7623, 2.45, 0.313, 317, 249, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389E
3340, 4dedA, 0.7623, 2.55, 0.300, 265, 253, AURORA A IN COMPLEX WITH YL1-038-21
3341, 3kmmA, 0.7623, 2.63, 0.225, 270, 253, STRUCTURE OF HUMAN LCK KINASE WITH A SMALL MOLECULE INHIBITOR
3342, 2x8iA, 0.7623, 2.49, 0.278, 261, 252, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
3343, 2of2A, 0.7623, 2.63, 0.229, 271, 253, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 8 BOUND TO LCK
3344, 2clqA, 0.7623, 2.58, 0.284, 263, 250, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
3345, 1x8bA, 0.7623, 2.46, 0.229, 259, 249, STRUCTURE OF HUMAN WEE1A KINASE: KINASE DOMAIN COMPLEXED WITH INHIBITOR PD0407824
3346, 5ax9A, 0.7622, 2.41, 0.267, 282, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
3347, 4twcA, 0.7622, 2.84, 0.192, 293, 260, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
3348, 4k33A, 0.7622, 2.79, 0.238, 293, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 3 (FGFR3) KINASE DOMAIN HARBORING THE K650E MUTATION A GAIN-OF-FUNCTION MUTATION RESPONSIBLE FOR THANATOPHORIC DYSPLASIA TYPE II AND SPERMATOCYTIC SEMINOMA
3349, 4gj2A, 0.7622, 2.86, 0.230, 288, 256, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
3350, 4btmB, 0.7622, 2.82, 0.184, 293, 261, TTBK1 IN COMPLEX WITH INHIBITOR
3351, 4btjA, 0.7622, 2.88, 0.192, 292, 261, TTBK1 IN COMPLEX WITH ATP
3352, 2y0aA, 0.7622, 2.95, 0.250, 300, 260, STRUCTURE OF DAPK1 CONSTRUCT RESIDUES 1-304
3353, 1z9xA, 0.7622, 2.92, 0.255, 303, 259, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
3354, 5d7aC, 0.7621, 2.59, 0.257, 286, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
3355, 5vcwA, 0.7620, 2.64, 0.286, 285, 252, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PELITINIB
3356, 4w7pD, 0.7620, 3.08, 0.268, 387, 265, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
3357, 4f1tA, 0.7620, 2.67, 0.230, 269, 252, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO THE ROCK INHIBITOR H1152
3358, 2wtwA, 0.7620, 2.47, 0.308, 256, 250, AURORA-A INHIBITOR STRUCTURE (2ND CRYSTAL FORM)
3359, 2iztA, 0.7620, 2.73, 0.206, 296, 257, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3360, 5vd0A, 0.7619, 2.66, 0.289, 293, 253, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH MK1775
3361, 5d7aB, 0.7619, 2.66, 0.256, 286, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
3362, 4y83A, 0.7619, 2.18, 0.233, 299, 245, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(2-AMINO-5- (QUINOLIN-3-YL)PYRIDIN-3-YL)-134-OXADIAZOLE-2(3H)-THIONE
3363, 4wa9B, 0.7619, 2.76, 0.224, 276, 255, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
3364, 4fzdB, 0.7619, 2.70, 0.260, 275, 254, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX WITH WSF MOTIF
3365, 4enyA, 0.7619, 2.38, 0.256, 261, 250, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH (2E5Z)-2-(2- CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-METHOXYBENZYLIDENE)THIAZOLIDIN-4- ONE
3366, 1xbcA, 0.7619, 2.44, 0.203, 268, 251, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH STAUROSPORIN
3367, 5x28A, 0.7618, 2.83, 0.207, 310, 256, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(6)
3368, 5mzlA, 0.7618, 2.33, 0.253, 269, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE N-QUINOLIN-5-YLPYRIDINE- 3-CARBOXAMIDE
3369, 4lgdD, 0.7618, 2.86, 0.284, 338, 257, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3370, 4hokW, 0.7618, 2.75, 0.191, 289, 256, CRYSTAL STRUCTURE OF APO CK1E
3371, 4giiA, 0.7618, 2.86, 0.230, 289, 256, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
3372, 3up7A, 0.7618, 2.48, 0.298, 264, 252, AURORA A IN COMPLEX WITH YL1-038-09
3373, 2qg5D, 0.7618, 2.76, 0.262, 283, 256, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
3374, 4dinA, 0.7617, 2.79, 0.264, 340, 258, NOVEL LOCALIZATION AND QUATERNARY STRUCTURE OF THE PKA RI BETA HOLOENZYME
3375, 3p1aA, 0.7617, 2.40, 0.285, 281, 249, STRUCTURE OF HUMAN MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE- SPECIFIC CDC2-INHIBITORY KINASE MYT1 (PKMYT1)
3376, 2wmvA, 0.7617, 2.35, 0.271, 251, 247, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3377, 5usyB, 0.7616, 2.82, 0.254, 287, 256, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
3378, 5u6yK, 0.7616, 3.05, 0.297, 459, 259, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3379, 5u6yC, 0.7616, 3.05, 0.297, 459, 259, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3380, 5d7aA, 0.7616, 2.65, 0.260, 289, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
3381, 2dq7X, 0.7616, 2.49, 0.240, 262, 250, CRYSTAL STRUCTURE OF FYN KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
3382, 6gttA, 0.7615, 2.44, 0.337, 282, 249, HUMAN STK10 BOUND TO BIRB-796 
3383, 5n51A, 0.7615, 2.30, 0.254, 268, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 34-DIBROMOTHIOPHENE-2-CARBOXYLIC ACID
3384, 4rx7A, 0.7615, 2.61, 0.201, 272, 254, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR
3385, 1iasB, 0.7615, 2.76, 0.213, 324, 254, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3386, 5wevA, 0.7614, 2.78, 0.256, 293, 254, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
3387, 5i3oB, 0.7614, 2.75, 0.260, 302, 254, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3388, 4y85B, 0.7614, 2.20, 0.240, 306, 246, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(5-(1H-INDOL- 3-YL)-1H-PYRROLO[23-B]PYRIDIN-3-YL)-134-OXADIAZOL-2-AMINE
3389, 4ftmA, 0.7614, 2.44, 0.274, 263, 248, CRYSTAL STRUCTURE OF THE CHK1
3390, 3bceA, 0.7614, 2.76, 0.220, 285, 255, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
3391, 2a2aB, 0.7614, 3.02, 0.242, 303, 260, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
3392, 6bqpA, 0.7613, 2.72, 0.287, 263, 254, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CRENOLANIB
3393, 4obpA, 0.7613, 2.81, 0.275, 285, 255, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
3394, 3kulA, 0.7613, 2.66, 0.205, 267, 254, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
3395, 2x7fA, 0.7613, 2.38, 0.266, 276, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
3396, 2g2hB, 0.7613, 2.88, 0.219, 272, 256, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
3397, 5vcxA, 0.7612, 2.63, 0.295, 287, 251, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (UNTREATED) IN COMPLEX WITH SARACATINIB
3398, 5oryA, 0.7612, 2.73, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3399, 3faaB, 0.7612, 2.80, 0.213, 324, 254, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
3400, 3f5pJ, 0.7612, 2.77, 0.214, 293, 257, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3401, 3dqwB, 0.7612, 2.70, 0.244, 278, 254, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
3402, 3b2tB, 0.7612, 2.86, 0.232, 287, 254, STRUCTURE OF PHOSPHOTRANSFERASE
3403, 2wouA, 0.7612, 2.45, 0.220, 299, 250, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
3404, 5mjaA, 0.7611, 2.46, 0.239, 271, 251, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
3405, 5ih6A, 0.7611, 2.83, 0.188, 286, 260, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A DERIVATIVE
3406, 5ih5A, 0.7611, 2.82, 0.192, 286, 260, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A
3407, 4btmA, 0.7611, 2.87, 0.188, 292, 261, TTBK1 IN COMPLEX WITH INHIBITOR
3408, 5hvuB, 0.7610, 3.04, 0.253, 394, 261, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH A PYRIDINE THIAZOLE PIPERIDINE INHIBITOR
3409, 5gmpA, 0.7610, 2.69, 0.217, 305, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH XTF-262
3410, 5e8tA, 0.7610, 2.61, 0.218, 302, 252, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D)
3411, 4xeyA, 0.7610, 2.53, 0.223, 269, 251, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
3412, 4hokU, 0.7610, 2.73, 0.195, 289, 256, CRYSTAL STRUCTURE OF APO CK1E
3413, 1jktA, 0.7610, 2.87, 0.260, 276, 258, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
3414, 5oq7B, 0.7609, 2.46, 0.275, 256, 251, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3415, 3ppzB, 0.7609, 2.41, 0.242, 264, 248, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
3416, 3ndmA, 0.7609, 2.93, 0.248, 383, 258, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
3417, 5uoxA, 0.7608, 2.64, 0.288, 263, 250, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3418, 4j95A, 0.7608, 2.66, 0.246, 279, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
3419, 4idtB, 0.7608, 2.54, 0.250, 335, 252, CRYSTAL STRUCTURE OF NIK WITH 11-BROMO-5678-TETRAHYDROPYRIMIDO[4  5 :34]CYCLOHEPTA[12-B]INDOL-2-AMINE (T28)
3420, 4ftkA, 0.7608, 2.45, 0.274, 263, 248, CRYSTAL STRUCTURE OF THE CHK1
3421, 4euuB, 0.7608, 3.20, 0.242, 307, 265, STRUCTURE OF BX-795 COMPLEXED WITH HUMAN TBK1 KINASE DOMAIN PHOSPHORYLATED ON SER172
3422, 3s95B, 0.7608, 2.68, 0.251, 290, 251, CRYSTAL STRUCTURE OF THE HUMAN LIMK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
3423, 1bi8C, 0.7608, 2.40, 0.463, 264, 246, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURES CDK6-P19INK4D INHIBITOR COMPLEX
3424, 1bi8A, 0.7608, 2.40, 0.463, 264, 246, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURES CDK6-P19INK4D INHIBITOR COMPLEX
3425, 5v24B, 0.7607, 2.66, 0.284, 263, 250, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3426, 5u6yL, 0.7607, 2.98, 0.298, 459, 258, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3427, 5u6yJ, 0.7607, 2.98, 0.298, 459, 258, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3428, 5u6yI, 0.7607, 2.98, 0.298, 459, 258, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3429, 5u6yH, 0.7607, 2.98, 0.298, 459, 258, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3430, 5u6yG, 0.7607, 2.98, 0.298, 459, 258, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3431, 5u6yF, 0.7607, 2.98, 0.298, 459, 258, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3432, 5u6yE, 0.7607, 2.98, 0.298, 459, 258, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3433, 5u6yD, 0.7607, 2.98, 0.298, 459, 258, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3434, 5u6yB, 0.7607, 2.98, 0.298, 459, 258, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3435, 5u6yA, 0.7607, 2.98, 0.298, 459, 258, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
3436, 4py1A, 0.7607, 2.83, 0.238, 289, 256, CRYSTAL STRUCTURE OF TYK2 IN COMPLEX WITH COMPOUND 15 6-((25- DIMETHOXYPHENYL)THIO)-3-(1-METHYL-1H-PYRAZOL-4-YL)-[124]TRIAZOLO[4 3-B]PYRIDAZINE
3437, 4kb8B, 0.7607, 2.64, 0.189, 285, 254, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
3438, 4hokA, 0.7607, 2.72, 0.191, 290, 256, CRYSTAL STRUCTURE OF APO CK1E
3439, 3nrmA, 0.7607, 2.52, 0.294, 263, 252, IMIDAZO[12-A]PYRAZINE-BASED AURORA KINASE INHIBITORS
3440, 2g2fA, 0.7607, 2.82, 0.235, 275, 255, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
3441, 2a27D, 0.7607, 2.98, 0.254, 304, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3442, 6babC, 0.7606, 2.81, 0.295, 284, 254, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
3443, 5usyA, 0.7606, 2.87, 0.254, 287, 256, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
3444, 5nkeA, 0.7606, 2.81, 0.211, 292, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3A
3445, 5i3rB, 0.7606, 2.83, 0.260, 302, 254, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3446, 5cxzA, 0.7606, 2.49, 0.202, 269, 252, SYK CATALYTIC DOMAIN COMPLEXED WITH NAPHTHYRIDINE INHIBITOR
3447, 5c27A, 0.7606, 2.73, 0.203, 272, 256, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 2
3448, 3tzmA, 0.7606, 2.49, 0.216, 295, 250, TGF-BETA RECEPTOR TYPE 1 IN COMPLEX WITH SB431542
3449, 3jvsA, 0.7606, 2.39, 0.275, 256, 247, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
3450, 3eyhA, 0.7606, 2.78, 0.252, 285, 254, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
3451, 5vd3A, 0.7605, 2.67, 0.282, 293, 252, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (DE-PHOSPHORYLATED) IN COMPLEX WITH SARACATINIB
3452, 5o11A, 0.7605, 2.35, 0.257, 268, 249, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
3453, 5n52A, 0.7605, 2.32, 0.254, 268, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE (E)-3-(23-DIMETHOXYPHENYL)ACRYLIC ACID
3454, 5dr2A, 0.7605, 2.63, 0.300, 264, 253, AURORA A KINASE IN COMPLEX WITH AA30 AND ATP IN SPACE GROUP P6122
3455, 4xh0A, 0.7605, 2.70, 0.176, 350, 255, STRUCTURE OF C. GLABRATA HRR25 BOUND TO ADP (SO4 CONDITION)
3456, 3fy2A, 0.7605, 2.45, 0.215, 285, 251, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BOUND TO SUBSTRATE KQWDNYEFIW
3457, 2x7oA, 0.7605, 2.63, 0.218, 330, 252, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
3458, 1vjyA, 0.7605, 2.67, 0.217, 299, 253, CRYSTAL STRUCTURE OF A NAPHTHYRIDINE INHIBITOR OF HUMAN TGF- BETA TYPE I RECEPTOR
3459, 5x26A, 0.7604, 2.80, 0.204, 302, 255, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(3)
3460, 4lgdA, 0.7604, 2.88, 0.284, 350, 257, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3461, 4idtA, 0.7604, 2.54, 0.250, 334, 252, CRYSTAL STRUCTURE OF NIK WITH 11-BROMO-5678-TETRAHYDROPYRIMIDO[4  5 :34]CYCLOHEPTA[12-B]INDOL-2-AMINE (T28)
3462, 3bymA, 0.7604, 2.66, 0.225, 271, 253, X-RAY CO-CRYSTAL STRUCTURE AMINOBENZIMIDAZOLE TRIAZINE 1 BOUND TO LCK
3463, 5objA, 0.7603, 2.54, 0.307, 260, 251, AURORA A KINASE IN COMPLEX WITH 2-(3-FLUOROPHENYL)QUINOLINE-4- CARBOXYLIC ACID AND ATP
3464, 4r5sA, 0.7603, 2.86, 0.211, 299, 256, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH FIIN-3
3465, 4lg4A, 0.7603, 2.67, 0.277, 289, 253, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3466, 4euuA, 0.7602, 3.10, 0.243, 307, 263, STRUCTURE OF BX-795 COMPLEXED WITH HUMAN TBK1 KINASE DOMAIN PHOSPHORYLATED ON SER172
3467, 4dhfB, 0.7602, 2.66, 0.298, 258, 252, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
3468, 4d0xA, 0.7602, 2.83, 0.253, 291, 257, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
3469, 3socB, 0.7602, 2.81, 0.232, 309, 254, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
3470, 4w7pA, 0.7601, 3.05, 0.261, 388, 264, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
3471, 4dhfA, 0.7601, 2.44, 0.304, 258, 250, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
3472, 3bhhC, 0.7601, 2.71, 0.299, 285, 254, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
3473, 2ya9A, 0.7601, 2.86, 0.264, 299, 258, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
3474, 4rssA, 0.7600, 2.68, 0.200, 269, 255, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE SYK WITH AN INHIBITOR
3475, 3dqwA, 0.7600, 2.72, 0.244, 278, 254, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
3476, 5opbA, 0.7599, 2.72, 0.273, 262, 256, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH INDAZOLE LRRK2 INHIBITOR
3477, 5friA, 0.7599, 2.53, 0.219, 301, 251, ALK5 IN COMPLEX WITHA AN N-(4-ANILINO-2-PYRIDYL)ACETAMIDE INHIBITOR.
3478, 4u6rA, 0.7599, 2.50, 0.284, 403, 250, CRYSTAL STRUCTURE OF HUMAN IRE1 CYTOPLASMIC DOMAINS IN COMPLEX WITH A SULFONAMIDE INHIBITOR.
3479, 4kbaB, 0.7599, 2.66, 0.180, 285, 255, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
3480, 2ydjA, 0.7599, 2.31, 0.283, 252, 247, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
3481, 2itoA, 0.7599, 2.98, 0.203, 303, 256, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH IRESSA
3482, 2a27B, 0.7599, 2.91, 0.263, 303, 259, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3483, 1ol7A, 0.7599, 2.55, 0.290, 261, 252, STRUCTURE OF HUMAN AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288
3484, 5oq8A, 0.7598, 2.71, 0.275, 261, 255, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3485, 4bn1A, 0.7598, 2.77, 0.295, 261, 254, CRYSTAL STRUCTURE OF V174M MUTANT OF AURORA-A KINASE
3486, 3kckA, 0.7598, 2.70, 0.256, 285, 254, A NOVEL CHEMOTYPE OF KINASE INHIBITORS
3487, 1u4dB, 0.7598, 2.30, 0.263, 262, 247, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
3488, 1qpdA, 0.7597, 2.69, 0.225, 270, 253, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
3489, 1pkgA, 0.7597, 2.85, 0.224, 290, 255, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
3490, 5orwA, 0.7596, 2.76, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3491, 5orpA, 0.7596, 2.76, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3492, 5kz8A, 0.7596, 2.40, 0.324, 302, 244, MARK2 COMPLEX WITH 7-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-55-DIMETHYL-2-(3- PYRIDYLAMINO)PYRROLO[23-D]PYRIMIDIN-6-ONE
3493, 4ythA, 0.7596, 2.78, 0.258, 287, 256, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
3494, 4lg4C, 0.7596, 2.73, 0.285, 288, 253, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3495, 4jajA, 0.7596, 2.59, 0.290, 265, 252, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH BENZO[C][1 8]NAPHTHYRIDIN-6(5H)-ONE
3496, 4ckiA, 0.7596, 2.91, 0.246, 293, 256, CRYSTAL STRUCTURE OF ONCOGENIC RET TYROSINE KINASE M918T BOUND TO ADENOSINE
3497, 3ug2A, 0.7596, 2.61, 0.210, 299, 252, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH GEFITINIB
3498, 3faaE, 0.7596, 2.59, 0.219, 330, 251, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
3499, 2x7oD, 0.7596, 2.64, 0.218, 330, 252, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
3500, 2ivtA, 0.7596, 2.92, 0.246, 288, 256, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
3501, 2a27H, 0.7596, 2.98, 0.258, 304, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3502, 1ckiA, 0.7596, 2.83, 0.185, 292, 260, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
3503, 5vdaA, 0.7595, 2.59, 0.228, 259, 250, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 101 A MK1775 ANALOGUE
3504, 5eakA, 0.7595, 2.54, 0.321, 305, 246, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
3505, 4kbkC, 0.7595, 2.69, 0.184, 280, 256, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
3506, 3we4A, 0.7595, 2.67, 0.306, 286, 252, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRIMIDINE DERIVATIVE PF-4708671 2-{[4-(5-ETHYLPYRIMIDIN-4-YL)PIPERAZIN-1- YL]METHYL}-5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOLE
3507, 2a27F, 0.7595, 2.99, 0.258, 303, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3508, 5x27A, 0.7594, 2.81, 0.208, 302, 255, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(5)
3509, 4wnmA, 0.7594, 2.56, 0.206, 273, 253, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT TRIAZOLOPYRIDINE INHIBITOR
3510, 4hgsA, 0.7594, 2.87, 0.212, 302, 259, CRYSTAL STRUCTURE OF CK1GS WITH COMPOUND 13
3511, 4d1sA, 0.7594, 2.66, 0.262, 280, 252, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
3512, 4ckjA, 0.7594, 2.93, 0.246, 292, 256, CRYSTAL STRUCTURE OF RET TYROSINE KINASE DOMAIN BOUND TO ADENOSINE
3513, 3q4tB, 0.7594, 2.82, 0.232, 308, 254, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
3514, 3lxpA, 0.7594, 3.08, 0.230, 285, 257, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
3515, 3bceB, 0.7594, 2.71, 0.217, 286, 253, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
3516, 2zybA, 0.7594, 2.74, 0.228, 270, 254, CRYSTAL STRUCTURE OF PHENYLIMIDAZO PYRAZIN 2 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3517, 1wmkF, 0.7594, 3.00, 0.242, 303, 260, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3518, 5ax9B, 0.7593, 2.32, 0.262, 274, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
3519, 4ftlA, 0.7593, 2.48, 0.270, 263, 248, CRYSTAL STRUCTURE OF THE CHK1
3520, 2x7oE, 0.7593, 2.65, 0.218, 330, 252, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
3521, 2a27G, 0.7593, 2.99, 0.258, 303, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3522, 2a27C, 0.7593, 2.94, 0.247, 303, 259, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3523, 1wmkC, 0.7593, 2.99, 0.246, 303, 260, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3524, 5oseA, 0.7592, 2.77, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3525, 5orzA, 0.7592, 2.76, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3526, 5nkhA, 0.7592, 2.90, 0.211, 295, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3E
3527, 5i9vA, 0.7592, 2.44, 0.217, 279, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH AGS
3528, 4g16A, 0.7592, 2.88, 0.208, 302, 259, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-{[3-(TRIFLUOROMETHYL)PYRIDIN2- YL]OXY}PHENYL)AMINO]-1H-BENZIMIDAZOLE-6-CARBONITRILE
3529, 3umxA, 0.7592, 2.42, 0.269, 261, 249, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDOL-3-YL)METHYLENE]-7-(AZEPAN-1-YLMETHYL)-6-HYDROXYBENZOFURAN- 3(2H)-ONE
3530, 3sxrA, 0.7592, 2.49, 0.208, 260, 250, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
3531, 3byoA, 0.7592, 2.66, 0.225, 270, 253, X-RAY CO-CRYSTAL STRUCTURE OF 2-AMINO-6-PHENYLPYRIMIDO[5  4 :56]PYRIMIDO[12-A]BENZIMIDAZOL-5(6H)-ONE 25 BOUND TO LCK
3532, 2zm1A, 0.7592, 2.74, 0.228, 270, 254, CRYSTAL STRUCTURE OF IMIDAZO PYRAZIN 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3533, 2g2iA, 0.7592, 2.53, 0.239, 271, 251, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
3534, 1wmkE, 0.7592, 3.00, 0.242, 313, 260, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3535, 1wmkD, 0.7592, 3.00, 0.242, 314, 260, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3536, 1wmkA, 0.7592, 3.00, 0.242, 303, 260, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3537, 5osfA, 0.7591, 2.77, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3538, 5osdA, 0.7591, 2.56, 0.294, 266, 252, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3539, 5os5A, 0.7591, 2.66, 0.304, 267, 253, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3540, 4fsqA, 0.7591, 2.47, 0.278, 263, 248, CRYSTAL STRUCTURE OF THE CHK1
3541, 3fqsA, 0.7591, 2.48, 0.203, 268, 251, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R406
3542, 3ac5A, 0.7591, 2.68, 0.225, 270, 253, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3543, 2x2kA, 0.7591, 2.94, 0.246, 289, 256, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
3544, 2izsA, 0.7591, 2.80, 0.186, 298, 258, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3545, 2bzkB, 0.7591, 2.35, 0.254, 268, 248, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AMPPNP AND PIMTIDE
3546, 2auhA, 0.7591, 2.99, 0.209, 297, 258, CRYSTAL STRUCTURE OF THE GRB14 BPS REGION IN COMPLEX WITH THE INSULIN RECEPTOR TYROSINE KINASE
3547, 2a27A, 0.7591, 2.87, 0.252, 304, 258, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3548, 1wmkB, 0.7591, 3.00, 0.242, 314, 260, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3549, 1qpcA, 0.7591, 2.68, 0.225, 270, 253, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
3550, 5os3A, 0.7590, 2.77, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3551, 4bicB, 0.7590, 2.42, 0.289, 259, 246, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3552, 3kf4B, 0.7590, 2.70, 0.230, 270, 252, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
3553, 3ac1A, 0.7590, 2.68, 0.225, 270, 253, CRYSTAL STRUCTURE OF PYRAZIN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3554, 2g2hA, 0.7590, 2.87, 0.224, 272, 255, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
3555, 1wmkH, 0.7590, 3.00, 0.242, 304, 260, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3556, 1wmkG, 0.7590, 3.00, 0.242, 313, 260, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3557, 5orrA, 0.7589, 2.76, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3558, 4l42A, 0.7589, 2.63, 0.310, 299, 252, CRYSTAL STRUCTURES OF HUMAN P70S6K1-PIF
3559, 3lckA, 0.7589, 2.76, 0.228, 270, 254, THE KINASE DOMAIN OF HUMAN LYMPHOCYTE KINASE (LCK) ACTIVATED FORM (AUTO-PHOSPHORYLATED ON TYR394)
3560, 3ac2A, 0.7589, 2.64, 0.230, 270, 252, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3561, 2ya9B, 0.7589, 2.86, 0.260, 299, 258, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
3562, 2a27E, 0.7589, 2.95, 0.247, 303, 259, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3563, 5oroA, 0.7588, 2.77, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3564, 5ornA, 0.7588, 2.56, 0.294, 264, 252, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3565, 4wsqA, 0.7588, 2.79, 0.245, 317, 253, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3566, 4lrmB, 0.7588, 2.78, 0.207, 293, 256, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
3567, 3lxnA, 0.7588, 2.98, 0.233, 287, 257, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
3568, 3acjA, 0.7588, 2.70, 0.233, 270, 253, CRYSTAL STRUCTURE OF IMIDAZO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3569, 1qpjA, 0.7588, 2.66, 0.230, 265, 252, CRYSTAL STRUCTURE OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH STAUROSPORINE.
3570, 4zogA, 0.7587, 2.82, 0.228, 269, 254, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
3571, 3ma3A, 0.7587, 2.36, 0.254, 266, 248, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A NAPHTHO-DIFURAN LIGAND
3572, 5os1A, 0.7586, 2.78, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3573, 5e91A, 0.7586, 2.85, 0.233, 297, 253, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH 3-AMINO-6-[4-(2- HYDROXYETHYL)PHENYL]-N-[4- (MORPHOLIN-4-YL)PYRIDIN-3-YL] PYRAZINE-2-CARBOXAMIDE
3574, 4z16B, 0.7586, 2.72, 0.257, 276, 253, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3575, 4y85C, 0.7586, 2.26, 0.240, 303, 246, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(5-(1H-INDOL- 3-YL)-1H-PYRROLO[23-B]PYRIDIN-3-YL)-134-OXADIAZOL-2-AMINE
3576, 1y57A, 0.7586, 2.63, 0.238, 452, 252, STRUCTURE OF UNPHOSPHORYLATED C-SRC IN COMPLEX WITH AN INHIBITOR
3577, 5orxA, 0.7585, 2.77, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3578, 5orvA, 0.7585, 2.78, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3579, 5os0A, 0.7584, 2.78, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3580, 5oq7A, 0.7584, 2.64, 0.280, 259, 254, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
3581, 4zk5A, 0.7584, 2.84, 0.271, 286, 255, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
3582, 4zimB, 0.7584, 2.91, 0.253, 294, 257, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
3583, 4gfmA, 0.7584, 2.82, 0.258, 289, 256, JAK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
3584, 3ug1A, 0.7584, 2.47, 0.205, 296, 249, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN THE APO FORM
3585, 3ad5A, 0.7584, 2.69, 0.225, 270, 253, CRYSTAL STRUCTURE OF TRIAZOLONE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3586, 2x7oC, 0.7584, 2.66, 0.218, 330, 252, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
3587, 2x2mA, 0.7584, 2.80, 0.241, 286, 253, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
3588, 2qocA, 0.7584, 2.43, 0.216, 283, 250, HUMAN EPHA3 KINASE DOMAIN PHOSPHORYLATED AMP-PNP BOUND STRUCTURE
3589, 1qpeA, 0.7584, 2.75, 0.228, 270, 254, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
3590, 1ckjA, 0.7584, 2.84, 0.185, 296, 260, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
3591, 6drwA, 0.7583, 2.90, 0.247, 289, 255, JAK2 JH1 IN COMPLEX WITH JNJ-7706621 (CRYSTAL FORM 2) 
3592, 5ukfA, 0.7583, 3.05, 0.152, 322, 263, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
3593, 5dosA, 0.7583, 2.51, 0.304, 259, 250, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
3594, 4j97D, 0.7583, 2.66, 0.235, 285, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
3595, 4hokE, 0.7583, 2.80, 0.195, 291, 257, CRYSTAL STRUCTURE OF APO CK1E
3596, 3sv0A, 0.7583, 2.92, 0.200, 294, 260, CRYSTAL STRUCTURE OF CASEIN KINASE-1 LIKE PROTEIN IN PLANT
3597, 3pa5A, 0.7583, 2.53, 0.282, 255, 248, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
3598, 3ad6A, 0.7583, 2.68, 0.225, 272, 253, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3599, 1rw8A, 0.7583, 2.89, 0.213, 301, 254, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH ATP SITE INHIBITOR
3600, 6g4zB, 0.7582, 2.70, 0.236, 325, 254, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 2F 
3601, 5ugaA, 0.7582, 2.95, 0.212, 283, 255, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH 4-(4-{[2-{[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9- (PROPAN-2-YL)-9H-PURIN-6-YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
3602, 5o12A, 0.7582, 2.33, 0.255, 264, 247, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
3603, 4kbcA, 0.7582, 2.75, 0.184, 288, 256, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
3604, 3e62A, 0.7582, 2.87, 0.253, 291, 257, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
3605, 2py3B, 0.7582, 2.78, 0.234, 284, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
3606, 2j4zB, 0.7582, 2.58, 0.315, 269, 248, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
3607, 6g4yB, 0.7581, 2.69, 0.236, 328, 254, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 1A 
3608, 4hokG, 0.7581, 2.75, 0.191, 290, 256, CRYSTAL STRUCTURE OF APO CK1E
3609, 4hokC, 0.7581, 2.73, 0.191, 289, 256, CRYSTAL STRUCTURE OF APO CK1E
3610, 4dfnA, 0.7581, 2.53, 0.206, 269, 252, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH AN ADAMANTYLPYRAZINE INHIBITOR
3611, 3nz0A, 0.7581, 2.81, 0.228, 285, 254, NON-PHOSPHORYLATED TYK2 KINASE WITH CMP6
3612, 3lvpB, 0.7581, 2.99, 0.213, 295, 258, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
3613, 3e64A, 0.7581, 2.87, 0.261, 291, 257, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
3614, 2x2lA, 0.7581, 2.97, 0.246, 287, 256, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
3615, 2py3A, 0.7581, 2.85, 0.225, 282, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
3616, 2ofuA, 0.7581, 2.68, 0.225, 272, 253, X-RAY CRYSTAL STRUCTURE OF 2-AMINOPYRIMIDINE CARBAMATE 43 BOUND TO LCK
3617, 5orsA, 0.7580, 2.78, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3618, 4xhhA, 0.7580, 2.72, 0.176, 358, 255, STRUCTURE OF C. GLABRATA HRR25 APO STATE
3619, 4hglA, 0.7580, 2.82, 0.190, 302, 258, CRYSTAL STRUCTURE OF CK1G3 WITH COMPOUND 1
3620, 3faaC, 0.7580, 3.07, 0.214, 330, 257, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
3621, 3e63A, 0.7580, 2.88, 0.261, 290, 257, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
3622, 2x0gA, 0.7580, 2.97, 0.251, 318, 259, X-RAY STRUCTURE OF A DAP-KINASE CALMODULIN COMPLEX
3623, 5amnA, 0.7579, 2.93, 0.246, 287, 256, THE DISCOVERY OF 2-SUBSTITUTED PHENOL QUINAZOLINES AS POTENT AND SELECTIVE RET KINASE INHIBITORS
3624, 4g17A, 0.7579, 2.90, 0.208, 302, 259, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-TERT-BUTYLPHENYL)AMINO]-1H- BENZIMIDAZOLE-6-CARBONITRILE
3625, 3kl8I, 0.7579, 2.27, 0.317, 254, 246, CAMKIINTIDE INHIBITOR COMPLEX
3626, 3ad4A, 0.7579, 2.69, 0.225, 270, 253, CRYSTAL STRUCTURE OF METHOXY BENZOFURAN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3627, 3ackA, 0.7579, 2.76, 0.228, 270, 254, CRYSTAL STRUCTURE OF PYRROLO PYRAZINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3628, 2xzsB, 0.7579, 2.94, 0.252, 293, 258, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
3629, 2ituA, 0.7579, 2.78, 0.213, 304, 254, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AFN941
3630, 2in6A, 0.7579, 2.44, 0.231, 256, 247, WEE1 KINASE COMPLEX WITH INHIBITOR PD311839
3631, 5ih4A, 0.7578, 2.87, 0.188, 286, 260, HUMAN CASEIN KINASE 1 ISOFORM DELTA APO (KINASE DOMAIN)
3632, 4d2vD, 0.7578, 2.68, 0.323, 318, 251, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3633, 3ac4A, 0.7578, 2.75, 0.228, 270, 254, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3634, 3ac3A, 0.7578, 2.76, 0.228, 270, 254, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3635, 5ortA, 0.7577, 2.57, 0.294, 264, 252, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3636, 2x7oB, 0.7577, 2.67, 0.218, 330, 252, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
3637, 5tr6A, 0.7576, 2.49, 0.207, 272, 251, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
3638, 5t8oB, 0.7576, 2.69, 0.232, 328, 254, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO IMIDAZOBENZOXEPIN COMPOUND 3
3639, 4ftqA, 0.7576, 2.36, 0.285, 254, 246, CRYSTAL STRUCTURE OF THE CHK1
3640, 3ac8A, 0.7576, 2.77, 0.228, 270, 254, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3641, 2zm4A, 0.7576, 2.76, 0.228, 270, 254, CRYSTAL STRUCTURE OF IMIDAZO QUINOXALINE 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK ACTIVATED FORM (AUTO- PHOSPHORYLATED ON TYR394)
3642, 2qnjA, 0.7576, 2.52, 0.319, 318, 248, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
3643, 1mq4A, 0.7576, 2.61, 0.286, 261, 252, CRYSTAL STRUCTURE OF AURORA-A PROTEIN KINASE
3644, 4rx8A, 0.7575, 2.55, 0.202, 269, 252, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR2
3645, 4w9xA, 0.7574, 2.68, 0.267, 300, 251, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH BARICITINIB
3646, 4idvC, 0.7574, 2.70, 0.236, 335, 254, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
3647, 4e4mD, 0.7574, 2.88, 0.262, 296, 256, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3648, 2x6dA, 0.7574, 2.46, 0.293, 255, 249, AURORA-A BOUND TO AN INHIBITOR
3649, 4l43A, 0.7573, 2.55, 0.313, 316, 249, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM I)
3650, 3kf4A, 0.7573, 2.76, 0.234, 281, 252, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
3651, 5dt4A, 0.7572, 2.52, 0.308, 259, 250, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
3652, 4e4mB, 0.7572, 2.89, 0.262, 296, 256, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3653, 4d0wA, 0.7572, 2.79, 0.255, 289, 255, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
3654, 6fdyU, 0.7571, 2.80, 0.321, 261, 252, UNC-51-LIKE KINASE 3 (ULK3) IN COMPLEX WITH BOSUTINIB 
3655, 5os4A, 0.7571, 2.80, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3656, 4l44A, 0.7571, 2.63, 0.311, 321, 251, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM II)
3657, 4e20A, 0.7571, 2.87, 0.228, 282, 254, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
3658, 4d2tB, 0.7571, 2.67, 0.317, 323, 249, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3659, 2itnA, 0.7571, 2.91, 0.212, 304, 255, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AMP-PNP
3660, 6bu6A, 0.7570, 3.08, 0.152, 322, 263, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3661, 5e92A, 0.7570, 2.94, 0.232, 298, 254, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH AMPPNP
3662, 2izrA, 0.7570, 2.79, 0.183, 298, 257, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
3663, 5vdkA, 0.7569, 2.67, 0.264, 260, 250, CRYSTAL STRUCTURE OF HUMAN WEE2 KINASE DOMAIN IN COMPLEX WITH MK1775
3664, 5uorB, 0.7569, 2.66, 0.285, 262, 249, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3665, 5os6A, 0.7569, 2.80, 0.295, 264, 254, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3666, 5aepA, 0.7569, 2.77, 0.263, 287, 255, NOVEL PYRROLE CARBOXAMIDE INHIBITORS OF JAK2 AS POTENTIAL TREATMENT OF MYELOPROLIFERATIVE DISORDERS
3667, 4ytiA, 0.7569, 2.77, 0.259, 284, 255, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
3668, 4idvB, 0.7569, 2.69, 0.240, 335, 254, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
3669, 4e4mE, 0.7569, 2.97, 0.261, 296, 257, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3670, 4e4mA, 0.7569, 2.97, 0.261, 296, 257, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3671, 6fnhB, 0.7568, 2.82, 0.213, 271, 254, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
3672, 6fcfA, 0.7568, 2.29, 0.289, 251, 246, CHK1 KINASE IN COMPLEX WITH COMPOUND 44
3673, 6cqhB, 0.7568, 3.08, 0.156, 316, 263, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- PROPYNYL-N-ETHYL-DIHYDROPTERIDINE INHIBITOR
3674, 5j79A, 0.7568, 2.68, 0.225, 283, 253, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
3675, 5dewB, 0.7568, 2.56, 0.301, 281, 249, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
3676, 4xg9B, 0.7568, 2.54, 0.202, 265, 252, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3677, 3vf9A, 0.7568, 2.51, 0.207, 265, 251, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 027
3678, 3uysD, 0.7568, 2.61, 0.182, 284, 253, CRYSTAL STRUCTURE OF APO HUMAN CK1D
3679, 3iokA, 0.7568, 2.75, 0.256, 285, 254, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
3680, 2ittA, 0.7568, 2.81, 0.213, 302, 254, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AEE788
3681, 4cegA, 0.7567, 2.59, 0.298, 264, 252, CRYSTAL STRUCTURE OF AURORA A 122-403 C290A C393A BOUND TO ADP
3682, 4bbfD, 0.7567, 2.87, 0.258, 288, 256, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3683, 3vf8A, 0.7567, 2.51, 0.207, 265, 251, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH PYRAZOLYLBENZIMIDAZOLE INHIBITOR 416
3684, 2c47D, 0.7567, 2.67, 0.209, 290, 254, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
3685, 1xbbA, 0.7567, 2.52, 0.203, 268, 251, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH GLEEVEC
3686, 1oplB, 0.7567, 2.88, 0.227, 365, 255, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
3687, 5i9uA, 0.7566, 2.49, 0.217, 281, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
3688, 4ytfA, 0.7566, 2.76, 0.256, 283, 254, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
3689, 4nt4A, 0.7566, 2.80, 0.213, 300, 258, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF GILGAMESH ISOFORM I FROM DROSOPHILA MELANOGASTER
3690, 3kcfB, 0.7566, 2.86, 0.213, 324, 254, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3691, 3faaD, 0.7566, 2.86, 0.213, 330, 254, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
3692, 2clqB, 0.7566, 2.43, 0.289, 259, 246, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
3693, 6eqiC, 0.7565, 2.96, 0.250, 392, 256, STRUCTURE OF PINK1 BOUND TO UBIQUITIN
3694, 5t8oA, 0.7565, 2.61, 0.234, 324, 252, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO IMIDAZOBENZOXEPIN COMPOUND 3
3695, 4jboA, 0.7565, 2.71, 0.296, 266, 253, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3696, 4d2vB, 0.7565, 2.68, 0.312, 322, 250, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3697, 5ar3A, 0.7564, 2.67, 0.229, 279, 253, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH AMP-PCP
3698, 2ivuA, 0.7564, 2.92, 0.247, 288, 255, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR ZD6474
3699, 1xbaA, 0.7564, 2.51, 0.207, 266, 251, CRYSTAL STRUCTURE OF APO SYK TYROSINE KINASE DOMAIN
3700, 5cf5B, 0.7563, 2.93, 0.257, 294, 257, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3701, 4bbfA, 0.7563, 2.89, 0.254, 288, 256, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3702, 3op5A, 0.7563, 3.03, 0.153, 320, 262, HUMAN VACCINIA-RELATED KINASE 1
3703, 2qohA, 0.7563, 2.70, 0.226, 271, 252, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
3704, 3faaA, 0.7562, 3.03, 0.215, 328, 256, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
3705, 2b4sB, 0.7562, 2.98, 0.207, 294, 256, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
3706, 5hvjA, 0.7561, 2.77, 0.244, 283, 250, CRYSTAL STRUCTURE OF LIMK1 D460N MUTANT IN COMPLEX WITH AMP-PNP
3707, 5czoB, 0.7561, 2.83, 0.176, 365, 256, STRUCTURE OF S. CEREVISIAE HRR25:MAM1 COMPLEX FORM 2
3708, 4l3jA, 0.7561, 2.69, 0.306, 291, 252, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN
3709, 5mqvC, 0.7560, 2.89, 0.193, 288, 259, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3710, 5imeB, 0.7560, 2.41, 0.302, 280, 245, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
3711, 4idvA, 0.7560, 2.72, 0.240, 335, 254, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
3712, 4bibB, 0.7560, 2.43, 0.290, 258, 245, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3713, 3kxzA, 0.7560, 2.81, 0.228, 263, 254, THE COMPLEX CRYSTAL STRUCTURE OF LCK WITH A PROBE MOLECULE W259
3714, 6cpfA, 0.7559, 2.46, 0.298, 259, 248, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION 
3715, 5cy3A, 0.7559, 2.79, 0.200, 276, 255, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT AND ORALLY BIOAVAILABLE BENZISOTHIAZOLE INHIBITOR
3716, 5cf4B, 0.7559, 2.94, 0.257, 291, 257, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3717, 4yjpA, 0.7559, 2.66, 0.194, 263, 253, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000223
3718, 3pp0B, 0.7559, 2.76, 0.199, 296, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
3719, 5x17B, 0.7558, 2.92, 0.185, 289, 260, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
3720, 5u94A, 0.7558, 2.56, 0.264, 263, 250, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PASTA KINASE PKNB IN COMPLEX WITH THE POTENTIAL THERAPUTIC KINASE INHIBITOR GSK690693.
3721, 5kz8B, 0.7557, 2.26, 0.326, 300, 242, MARK2 COMPLEX WITH 7-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-55-DIMETHYL-2-(3- PYRIDYLAMINO)PYRROLO[23-D]PYRIMIDIN-6-ONE
3722, 6gl9A, 0.7556, 2.87, 0.253, 292, 257, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 10 (FM475) 
3723, 5lmbB, 0.7556, 2.60, 0.194, 261, 252, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
3724, 4kbkA, 0.7556, 2.62, 0.190, 283, 252, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
3725, 4fstA, 0.7556, 2.35, 0.278, 253, 245, CRYSTAL STRUCTURE OF THE CHK1
3726, 3kxxD, 0.7556, 2.87, 0.249, 288, 253, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
3727, 2w1iA, 0.7556, 2.97, 0.254, 284, 256, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3728, 1py5A, 0.7556, 3.03, 0.224, 301, 255, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH INHIBITOR
3729, 1oplA, 0.7556, 2.96, 0.231, 451, 255, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
3730, 1iasE, 0.7556, 2.88, 0.213, 330, 254, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3731, 6glbB, 0.7555, 2.89, 0.249, 288, 257, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 20 (FM484) 
3732, 6glbA, 0.7555, 2.89, 0.249, 288, 257, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 20 (FM484) 
3733, 5twlA, 0.7555, 2.44, 0.327, 319, 245, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
3734, 4px6A, 0.7555, 2.54, 0.203, 262, 251, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT PYRIDOPYRIMIDINONE INHIBITOR
3735, 4fynA, 0.7555, 2.48, 0.200, 267, 250, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 3-(8-{4- [ETHYL-(2-HYDROXY-ETHYL)-AMINO]-PHENYLAMINO}-IMIDAZO[12-A]PYRAZIN-5- YL)-PHENOL
3736, 4bicA, 0.7555, 2.56, 0.291, 260, 247, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3737, 2w1iB, 0.7555, 2.97, 0.258, 284, 256, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3738, 2q0bB, 0.7555, 2.83, 0.234, 282, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
3739, 2ivvA, 0.7555, 2.84, 0.249, 282, 253, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR PP1
3740, 2pvyD, 0.7554, 2.77, 0.231, 283, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
3741, 5feqA, 0.7553, 2.58, 0.216, 290, 250, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE
3742, 5eakB, 0.7553, 2.34, 0.325, 300, 243, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
3743, 4yjtA, 0.7553, 2.80, 0.196, 268, 255, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000233
3744, 4rioA, 0.7553, 2.80, 0.251, 285, 255, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE CARBOXAMIDE INHIBITOR
3745, 4puzA, 0.7553, 2.66, 0.194, 263, 252, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
3746, 2q0bA, 0.7553, 2.83, 0.230, 280, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
3747, 2kulA, 0.7553, 3.11, 0.155, 360, 264, SOLUTION STRUCTURE OF HUMAN VACCINIA RELATED KINASE 1(VRK1)
3748, 2b4sD, 0.7553, 2.99, 0.207, 294, 256, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
3749, 1opkA, 0.7553, 2.90, 0.228, 449, 254, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
3750, 5m57A, 0.7552, 2.39, 0.285, 261, 246, NEK2 BOUND TO ARYLAMINOPURINE 6
3751, 5lmbA, 0.7552, 2.53, 0.207, 264, 251, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
3752, 5e8vA, 0.7552, 2.82, 0.234, 296, 252, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A)
3753, 4yc8B, 0.7552, 2.53, 0.225, 264, 249, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
3754, 5tozA, 0.7551, 2.76, 0.252, 278, 254, JAK3 WITH COVALENT INHIBITOR PF-06651600
3755, 4hokQ, 0.7551, 2.80, 0.195, 290, 256, CRYSTAL STRUCTURE OF APO CK1E
3756, 3uzsA, 0.7551, 2.35, 0.280, 609, 246, STRUCTURE OF THE C13.28 RNA APTAMER BOUND TO THE G PROTEIN-COUPLED RECEPTOR KINASE 2-HETEROTRIMERIC G PROTEIN BETA 1 AND GAMMA 2 SUBUNIT COMPLEX
3757, 3krrA, 0.7551, 2.92, 0.261, 291, 257, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT QUINOXALINE ATP SITE INHIBITOR
3758, 2z60A, 0.7551, 2.75, 0.229, 281, 253, CRYSTAL STRUCTURE OF THE T315I MUTANT OF ABL KINASE BOUND WITH PPY-A
3759, 5hznC, 0.7550, 2.94, 0.217, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3760, 4hokK, 0.7550, 2.81, 0.191, 290, 256, CRYSTAL STRUCTURE OF APO CK1E
3761, 4d2wD, 0.7550, 2.76, 0.307, 326, 251, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3762, 3srvB, 0.7550, 2.57, 0.195, 263, 251, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
3763, 2j5fA, 0.7550, 3.00, 0.207, 308, 256, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 34-JAB
3764, 6gl9B, 0.7549, 2.89, 0.253, 291, 257, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 10 (FM475) 
3765, 5orlA, 0.7549, 2.61, 0.294, 264, 252, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3766, 5hznG, 0.7549, 2.94, 0.213, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3767, 4kb8C, 0.7549, 2.80, 0.195, 277, 256, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
3768, 4hzrA, 0.7549, 2.34, 0.256, 261, 246, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
3769, 2xezA, 0.7549, 2.37, 0.269, 249, 245, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3770, 5dpvA, 0.7548, 2.44, 0.306, 257, 248, AURORA A KINASE IN COMPLEX WITH AA35 AND JNJ-7706621 IN SPACE GROUP P6122
3771, 4wkqA, 0.7548, 2.53, 0.209, 296, 249, 1.85 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN WITH GEFITINIB
3772, 4kbaC, 0.7548, 2.80, 0.195, 277, 256, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
3773, 3qc4B, 0.7548, 2.56, 0.284, 278, 250, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
3774, 3dqwD, 0.7548, 2.77, 0.241, 276, 253, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
3775, 2itvA, 0.7548, 2.85, 0.209, 303, 254, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AMP-PNP
3776, 1u54B, 0.7548, 2.34, 0.260, 261, 246, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
3777, 1u4dA, 0.7548, 2.40, 0.259, 258, 247, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
3778, 5t8qB, 0.7547, 2.74, 0.236, 328, 254, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO ARYL PYRROLE FRAGMENT 17
3779, 5nk5A, 0.7547, 2.78, 0.209, 287, 253, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1M
3780, 5dt0A, 0.7547, 2.59, 0.300, 259, 250, AURORA A KINASE IN COMPLEX WITH JNJ-7706621 IN SPACE GROUP P6122
3781, 5y5uA, 0.7546, 2.60, 0.206, 266, 252, CRYSTAL STRUCTURES OF SPLEEN TYROSINE KINASE IN COMPLEX WITH A NOVEL INHIBITOR 
3782, 5ng2B, 0.7546, 2.88, 0.224, 278, 255, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
3783, 3kxxC, 0.7546, 2.82, 0.250, 286, 252, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
3784, 3kcfE, 0.7546, 2.90, 0.213, 330, 254, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3785, 2ydjB, 0.7546, 2.34, 0.285, 251, 246, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
3786, 2wmxA, 0.7546, 2.30, 0.270, 248, 244, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3787, 6glaB, 0.7545, 2.90, 0.249, 286, 257, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 11 (FM481) 
3788, 6glaA, 0.7545, 2.91, 0.249, 288, 257, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 11 (FM481) 
3789, 4bidB, 0.7545, 2.44, 0.290, 258, 245, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3790, 3dqwC, 0.7545, 2.77, 0.241, 275, 253, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
3791, 1iasD, 0.7545, 3.10, 0.214, 330, 257, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3792, 5lwmA, 0.7544, 2.90, 0.253, 290, 257, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 4 (FM381)
3793, 5hznD, 0.7544, 2.92, 0.213, 304, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3794, 5d9lA, 0.7544, 2.53, 0.309, 299, 249, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BIS-PHENOL PYRAZOLE
3795, 3kcfC, 0.7544, 2.91, 0.213, 330, 254, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3796, 1u54A, 0.7544, 2.38, 0.259, 262, 247, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
3797, 5lwnA, 0.7543, 2.90, 0.253, 290, 257, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 5 (FM409)
3798, 5hznH, 0.7543, 2.92, 0.213, 303, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3799, 5dr9A, 0.7543, 2.48, 0.310, 257, 248, AURORA A KINASE IN COMPLEX WITH AA29 AND JNJ-7706621 IN SPACE GROUP P6122
3800, 5cf5A, 0.7543, 2.90, 0.258, 287, 256, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3801, 4pv0A, 0.7543, 2.49, 0.204, 268, 250, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH AN IMIDAZOPYRAZINE INHIBITOR
3802, 4gk4A, 0.7543, 2.42, 0.218, 275, 248, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 90
3803, 3q32A, 0.7543, 2.92, 0.265, 291, 257, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
3804, 2pvyA, 0.7543, 2.67, 0.232, 288, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
3805, 2c47B, 0.7543, 2.68, 0.202, 289, 253, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
3806, 1ckiB, 0.7543, 2.89, 0.185, 286, 260, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
3807, 6bruA, 0.7542, 3.13, 0.152, 322, 263, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3808, 5tt7A, 0.7542, 2.49, 0.200, 274, 250, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
3809, 4e6qA, 0.7542, 2.93, 0.261, 296, 257, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
3810, 2g2fB, 0.7542, 2.81, 0.206, 264, 252, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
3811, 1iasC, 0.7542, 3.11, 0.214, 330, 257, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3812, 5ebzE, 0.7541, 3.37, 0.260, 655, 265, CRYSTAL STRUCTURE OF HUMAN IKK1
3813, 3sxrB, 0.7541, 2.47, 0.206, 258, 248, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
3814, 2ityA, 0.7541, 2.80, 0.217, 300, 253, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH IRESSA
3815, 2hziA, 0.7541, 2.92, 0.228, 268, 254, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
3816, 2hz4C, 0.7541, 2.53, 0.230, 259, 248, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
3817, 6cpeA, 0.7540, 2.40, 0.300, 256, 247, STRUCTURE OF APO; DEPHOSPHORYLATED AURORA A (122-403) IN AN ACTIVE CONFORMATION 
3818, 6cnxA, 0.7540, 3.08, 0.153, 322, 262, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 (VRK1) BOUND TO AN N-PROPYNYL-N-ISOPENTYL-DIHYDROPTERIDIN INHIBITOR
3819, 4jjrA, 0.7540, 2.77, 0.187, 284, 256, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
3820, 1ckjB, 0.7540, 2.90, 0.185, 293, 260, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
3821, 5oatE, 0.7539, 3.01, 0.266, 359, 256, PINK1 STRUCTURE
3822, 5ebzK, 0.7539, 3.47, 0.259, 655, 266, CRYSTAL STRUCTURE OF HUMAN IKK1
3823, 3eygA, 0.7539, 2.69, 0.255, 280, 251, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
3824, 2pz5B, 0.7539, 2.82, 0.231, 280, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
3825, 5oatB, 0.7538, 3.01, 0.262, 359, 256, PINK1 STRUCTURE
3826, 5cwzB, 0.7538, 2.66, 0.254, 284, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
3827, 4i0sA, 0.7538, 2.54, 0.204, 267, 250, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(6- CHLORO-1-METHYL-1H-INDAZOL-3-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID ISOPROPYLAMIDE
3828, 4hokS, 0.7538, 2.78, 0.192, 286, 255, CRYSTAL STRUCTURE OF APO CK1E
3829, 3lxlA, 0.7538, 2.81, 0.252, 281, 254, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
3830, 3lvpA, 0.7538, 2.97, 0.212, 289, 255, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
3831, 3fqeA, 0.7538, 2.64, 0.202, 269, 252, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH YM193306
3832, 4g3eB, 0.7537, 2.74, 0.240, 325, 254, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO A 6-ALKYNYLINDOLINE (CMP1)
3833, 2ym5A, 0.7537, 2.33, 0.266, 248, 244, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3834, 2w1gA, 0.7537, 2.42, 0.309, 254, 246, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3835, 2qnjB, 0.7537, 2.56, 0.320, 322, 247, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
3836, 5vt1A, 0.7536, 2.73, 0.292, 265, 253, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO A BENZAMIDE INHIBITOR
3837, 5oatF, 0.7536, 3.01, 0.262, 359, 256, PINK1 STRUCTURE
3838, 5hznE, 0.7536, 2.96, 0.217, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3839, 4z16A, 0.7536, 2.66, 0.260, 271, 250, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3840, 2bvaA, 0.7536, 2.18, 0.254, 272, 244, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
3841, 5oatD, 0.7535, 3.02, 0.262, 359, 256, PINK1 STRUCTURE
3842, 4z16C, 0.7535, 2.67, 0.260, 271, 250, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3843, 4puzB, 0.7535, 2.64, 0.202, 265, 252, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
3844, 4lqmA, 0.7535, 2.94, 0.196, 305, 255, EGFR L858R IN COMPLEX WITH PD168393
3845, 2qo9A, 0.7535, 2.42, 0.218, 277, 248, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION PHOSPHORYLATED AMP-PNP BOUND
3846, 2fo0A, 0.7535, 2.94, 0.231, 465, 255, ORGANIZATION OF THE SH3-SH2 UNIT IN ACTIVE AND INACTIVE FORMS OF THE C-ABL TYROSINE KINASE
3847, 5hznA, 0.7534, 2.99, 0.216, 296, 255, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3848, 5ar2B, 0.7534, 2.93, 0.223, 285, 256, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
3849, 2j4zA, 0.7534, 2.53, 0.308, 263, 247, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
3850, 1mqbB, 0.7534, 2.46, 0.218, 265, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
3851, 5drdA, 0.7533, 2.61, 0.300, 259, 250, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
3852, 4gl9B, 0.7533, 2.80, 0.252, 280, 254, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
3853, 4f09A, 0.7533, 2.95, 0.257, 288, 257, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
3854, 4aqcB, 0.7533, 2.99, 0.257, 295, 257, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
3855, 2itzA, 0.7533, 2.96, 0.204, 302, 255, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH IRESSA
3856, 5os2A, 0.7532, 2.77, 0.298, 261, 252, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3857, 5oktD, 0.7532, 2.55, 0.184, 282, 250, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
3858, 5cf6A, 0.7532, 2.85, 0.267, 285, 255, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3859, 4u42A, 0.7532, 2.69, 0.259, 282, 251, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
3860, 3ot8A, 0.7532, 2.41, 0.282, 251, 245, X-RAY CRYSTAL STRUCTURE OF COMPOUND 17R BOUND TO HUMAN CHK1 KINASE DOMAIN
3861, 3op5B, 0.7532, 3.03, 0.149, 319, 261, HUMAN VACCINIA-RELATED KINASE 1
3862, 1k2pA, 0.7532, 2.63, 0.199, 258, 251, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
3863, 4gk3A, 0.7531, 2.40, 0.219, 275, 247, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 87
3864, 3q32B, 0.7531, 3.00, 0.253, 294, 257, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
3865, 2w5bA, 0.7531, 2.69, 0.277, 271, 249, HUMAN NEK2 KINASE ATPGAMMAS-BOUND
3866, 5oatC, 0.7530, 3.02, 0.262, 359, 256, PINK1 STRUCTURE
3867, 5oatA, 0.7530, 3.03, 0.266, 359, 256, PINK1 STRUCTURE
3868, 5ebzD, 0.7530, 3.47, 0.251, 655, 267, CRYSTAL STRUCTURE OF HUMAN IKK1
3869, 4lrmA, 0.7530, 3.02, 0.200, 307, 260, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
3870, 4hvgA, 0.7530, 2.77, 0.252, 281, 254, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-2-HYDROXY-12-DIMETHYL-PROPYL)- AMIDE
3871, 3io7A, 0.7530, 2.75, 0.261, 282, 253, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
3872, 1yvjA, 0.7530, 2.83, 0.254, 288, 256, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN IN COMPLEX WITH A STAUROSPORINE ANALOGUE
3873, 5mqvF, 0.7529, 2.88, 0.194, 286, 258, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3874, 4ftnA, 0.7529, 2.42, 0.278, 253, 245, CRYSTAL STRUCTURE OF THE CHK1
3875, 4d55A, 0.7529, 2.36, 0.264, 260, 246, FOCAL ADHESION KINASE CATALYTIC DOMAIN
3876, 2pzpB, 0.7529, 2.83, 0.235, 282, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
3877, 2dwbA, 0.7529, 2.50, 0.309, 259, 249, AURORA-A KINASE COMPLEXED WITH AMPPNP
3878, 3jy9A, 0.7528, 2.75, 0.257, 282, 253, JANUS KINASE 2 INHIBITORS
3879, 5tq3B, 0.7527, 2.93, 0.262, 285, 256, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3880, 4o0rB, 0.7527, 2.41, 0.311, 282, 244, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3881, 2w5aA, 0.7527, 2.71, 0.269, 267, 249, HUMAN NEK2 KINASE ADP-BOUND
3882, 5ikwA, 0.7526, 2.79, 0.266, 297, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3883, 5hznB, 0.7526, 3.02, 0.216, 296, 255, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3884, 5dr6A, 0.7526, 2.52, 0.310, 257, 248, AURORA A KINASE IN COMPLEX WITH AA30 AND JNJ-7706621 IN SPACE GROUP P6122
3885, 5ar5A, 0.7526, 2.94, 0.230, 284, 256, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
3886, 4rx9A, 0.7526, 2.53, 0.200, 268, 250, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT PYRIMIDINE INHIBITOR
3887, 4jjrB, 0.7526, 2.79, 0.152, 283, 256, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
3888, 2pzpA, 0.7526, 2.84, 0.231, 280, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
3889, 2pz5A, 0.7526, 2.84, 0.231, 280, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
3890, 5v19B, 0.7525, 2.58, 0.296, 260, 247, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3891, 5hznF, 0.7525, 3.02, 0.216, 296, 255, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3892, 5ebzJ, 0.7525, 3.46, 0.256, 655, 266, CRYSTAL STRUCTURE OF HUMAN IKK1
3893, 4yjuA, 0.7525, 2.80, 0.193, 262, 254, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000249
3894, 4bieB, 0.7525, 2.38, 0.299, 257, 244, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3895, 4z16D, 0.7524, 2.70, 0.260, 271, 250, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3896, 4ytcA, 0.7524, 2.86, 0.251, 284, 255, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
3897, 2xf0A, 0.7524, 2.40, 0.269, 251, 245, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3898, 5up3A, 0.7523, 2.51, 0.290, 258, 245, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3899, 5ei8A, 0.7523, 2.44, 0.306, 261, 245, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3900, 4twpA, 0.7523, 2.64, 0.240, 266, 250, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
3901, 4idvD, 0.7523, 2.77, 0.240, 335, 254, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
3902, 4gl9C, 0.7523, 2.82, 0.256, 282, 254, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
3903, 4g5pA, 0.7523, 2.73, 0.212, 299, 255, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
3904, 3fe3B, 0.7523, 2.61, 0.315, 317, 248, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
3905, 2ym4A, 0.7523, 2.45, 0.286, 251, 245, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3906, 4fyoA, 0.7522, 2.55, 0.204, 267, 250, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH N-{(S)-1- [7-(34-DIMETHOXY-PHENYLAMINO)-THIAZOLO[54-D]PYRIMIDIN-5-YL]- PYRROLIDIN-3-YL}-TEREPHTHALAMIC ACID
3907, 3zosA, 0.7522, 2.95, 0.224, 301, 254, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
3908, 5m51A, 0.7521, 2.46, 0.280, 260, 246, NEK2 BOUND TO ARYLAMINOPURINE COMPOUND 8
3909, 4gl9A, 0.7521, 2.83, 0.252, 282, 254, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
3910, 4d2tA, 0.7521, 2.32, 0.333, 316, 243, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3911, 3zbfA, 0.7521, 2.46, 0.240, 281, 246, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH CRIZOTINIB
3912, 5j95A, 0.7520, 2.89, 0.265, 284, 253, MAP4K4 IN COMPLEX WITH INHIBITOR
3913, 4kb8D, 0.7520, 2.60, 0.188, 278, 250, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
3914, 2g2iB, 0.7520, 2.60, 0.236, 265, 250, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
3915, 5y5tA, 0.7519, 2.42, 0.198, 263, 248, CRYSTAL STRUCTURES OF SPLEEN TYROSINE KINASE IN COMPLEX WITH A NOVEL INHIBITOR 
3916, 4d2wB, 0.7519, 2.72, 0.297, 323, 249, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3917, 4d2vC, 0.7519, 2.30, 0.329, 316, 243, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3918, 3ohtB, 0.7519, 3.06, 0.324, 331, 259, CRYSTAL STRUCTURE OF SALMO SALAR P38ALPHA
3919, 3ohtA, 0.7519, 3.07, 0.324, 331, 259, CRYSTAL STRUCTURE OF SALMO SALAR P38ALPHA
3920, 2hziB, 0.7519, 2.77, 0.227, 264, 251, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
3921, 2cmwA, 0.7519, 2.89, 0.207, 294, 256, STRUCTURE OF HUMAN CASEIN KINASE 1 GAMMA-1 IN COMPLEX WITH 2-(2-HYDROXYETHYLAMINO)-6-(3-CHLOROANILINO)-9- ISOPROPYLPURINE (CASP TARGET)
3922, 4e6qB, 0.7518, 2.96, 0.261, 296, 257, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
3923, 4dflA, 0.7518, 2.43, 0.206, 263, 248, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A SULFONAMIDOPYRAZINE PIPERIDINE INHIBITOR
3924, 3uysA, 0.7518, 2.57, 0.184, 281, 250, CRYSTAL STRUCTURE OF APO HUMAN CK1D
3925, 3clyA, 0.7518, 3.18, 0.244, 289, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAINS TRAPPED IN TRANS-PHOSPHORYLATION REACTION
3926, 2pzrA, 0.7518, 2.82, 0.231, 280, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
3927, 5tkxA, 0.7517, 3.16, 0.163, 315, 263, CRYSTAL STRUCTURE OF HUMAN VACCINIA-RELATED KINASE 2 (VRK-2) BOUND TO BI-D1870
3928, 5ebzC, 0.7517, 3.52, 0.256, 655, 266, CRYSTAL STRUCTURE OF HUMAN IKK1
3929, 4g3dA, 0.7517, 2.67, 0.246, 324, 252, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK)
3930, 2jitA, 0.7517, 2.83, 0.180, 299, 256, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
3931, 5uu1A, 0.7516, 3.16, 0.160, 315, 263, CRYSTAL STRUCTURE OF HUMAN VACCINIA-RELATED KINASE 2 (VRK-2) BOUND TO BI-D1870
3932, 4p90A, 0.7516, 2.18, 0.306, 272, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
3933, 2c47A, 0.7516, 2.66, 0.198, 288, 252, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
3934, 5ng0A, 0.7515, 2.73, 0.226, 274, 252, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
3935, 2hz4B, 0.7515, 2.59, 0.220, 261, 250, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
3936, 2wtvB, 0.7514, 2.62, 0.308, 261, 247, AURORA-A INHIBITOR STRUCTURE
3937, 2qohB, 0.7514, 2.81, 0.229, 281, 253, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
3938, 2np8A, 0.7514, 2.48, 0.294, 256, 248, STRUCTURAL BASIS FOR THE INHIBITION OF AURORA A KINASE BY A NOVEL CLASS OF HIGH AFFINITY DISUBSTITUTED PYRIMIDINE INHIBITORS
3939, 6cmmA, 0.7513, 3.08, 0.146, 318, 261, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A NN- DIPROPYNYL-DIHYDROPTERIDINE INHIBITOR
3940, 5tq8A, 0.7513, 3.00, 0.253, 291, 257, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3941, 5hg7A, 0.7513, 2.93, 0.209, 280, 253, EGFR (L858R T790M V948R) IN COMPLEX WITH 1-{(3R4R)-3-[5-CHLORO-2- (1-METHYL-1H-PYRAZOL-4-YLAMINO)-7H-PYRROLO[23-D]PYRIMIDIN-4- YLOXYMETHYL]-4-METHOXY-PYRROLIDIN-1-YL}PROPENONE (PF-06459988)
3942, 5ebzB, 0.7513, 3.41, 0.257, 655, 265, CRYSTAL STRUCTURE OF HUMAN IKK1
3943, 4asxB, 0.7513, 2.94, 0.224, 307, 254, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
3944, 3zepD, 0.7513, 2.84, 0.262, 272, 252, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3945, 2zvaA, 0.7513, 2.82, 0.243, 261, 251, LYN TYROSINE KINASE DOMAIN-DASATINIB COMPLEX
3946, 1p4fA, 0.7513, 2.65, 0.267, 269, 251, DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH BOUND INHIBITOR FRAGMENT
3947, 1iasA, 0.7513, 3.14, 0.214, 330, 257, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
3948, 5k00A, 0.7512, 2.44, 0.328, 311, 244, MELK IN COMPLEX WITH NVS-MELK5
3949, 5ebzG, 0.7512, 3.41, 0.264, 655, 265, CRYSTAL STRUCTURE OF HUMAN IKK1
3950, 4kbcB, 0.7512, 2.88, 0.187, 277, 256, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
3951, 2wtvC, 0.7512, 2.63, 0.308, 261, 247, AURORA-A INHIBITOR STRUCTURE
3952, 5t8pA, 0.7511, 2.78, 0.240, 327, 254, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO BENZOXEPIN COMPOUND 2
3953, 5ek7B, 0.7511, 2.51, 0.222, 286, 248, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
3954, 5ebzA, 0.7511, 3.45, 0.252, 655, 266, CRYSTAL STRUCTURE OF HUMAN IKK1
3955, 4wsqB, 0.7511, 2.80, 0.250, 310, 252, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3956, 3emgA, 0.7511, 2.46, 0.202, 255, 248, DISCOVERY AND SAR OF NOVEL 4-THIAZOLYL-2- PHENYLAMINOPYRIMIDINES AS POTENT INHIBITORS OF SPLEEN TYROSINE KINASE (SYK)
3957, 2wmwA, 0.7511, 2.30, 0.272, 247, 243, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3958, 5vd2A, 0.7510, 2.70, 0.228, 258, 250, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PF- 03814735
3959, 5tq3A, 0.7510, 2.97, 0.258, 282, 256, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3960, 5fedA, 0.7510, 2.50, 0.206, 288, 247, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
3961, 5ei6A, 0.7510, 2.25, 0.305, 264, 243, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
3962, 4xg2A, 0.7510, 2.40, 0.198, 259, 247, CRYSTAL STRUCTURE OF LIGAND-FREE SYK
3963, 4lrmC, 0.7510, 2.87, 0.199, 293, 256, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
3964, 2pzrB, 0.7510, 2.85, 0.227, 282, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
3965, 6cqhA, 0.7509, 3.10, 0.149, 316, 261, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- PROPYNYL-N-ETHYL-DIHYDROPTERIDINE INHIBITOR
3966, 5twuA, 0.7509, 2.28, 0.322, 318, 242, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
3967, 5i3oA, 0.7509, 2.82, 0.262, 302, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3968, 4ivaA, 0.7509, 3.01, 0.257, 290, 257, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-[(8AS)- 2-[(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(8AH)- YL]CYCLOHEXANECARBONITRILE
3969, 2ym3A, 0.7509, 2.34, 0.267, 247, 243, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3970, 1z9xC, 0.7509, 3.02, 0.269, 303, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
3971, 5tq5A, 0.7508, 3.01, 0.253, 291, 257, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3972, 3kcfD, 0.7508, 2.94, 0.213, 330, 254, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3973, 5ugxB, 0.7507, 2.77, 0.244, 282, 250, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
3974, 4aqcA, 0.7507, 3.00, 0.257, 289, 257, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
3975, 3lvpD, 0.7507, 2.58, 0.217, 282, 249, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
3976, 2x2mB, 0.7507, 2.73, 0.245, 279, 249, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
3977, 6g4yA, 0.7506, 2.62, 0.240, 322, 250, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 1A 
3978, 4f08B, 0.7506, 3.01, 0.257, 288, 257, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
3979, 3rvgA, 0.7506, 2.91, 0.256, 285, 254, CRYSTALS STRUCTURE OF JAK2 WITH A 1-AMINO-5H-PYRIDO[43-B]INDOL-4- CARBOXAMIDE INHIBITOR
3980, 4kbkD, 0.7505, 2.60, 0.188, 281, 250, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
3981, 3pjcA, 0.7505, 2.86, 0.256, 286, 254, CRYSTAL STRUCTURE OF JAK3 COMPLEXED WITH A POTENT ATP SITE INHIBITOR SHOWING HIGH SELECTIVITY WITHIN THE JANUS KINASE FAMILY
3982, 2wmtA, 0.7505, 2.39, 0.266, 248, 244, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3983, 4zauA, 0.7504, 2.44, 0.211, 283, 246, AZD9291 COMPLEX WITH WILD TYPE EGFR
3984, 4xg7A, 0.7504, 2.63, 0.199, 266, 251, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3985, 2r0iA, 0.7504, 2.48, 0.321, 300, 243, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
3986, 4f08A, 0.7503, 3.01, 0.257, 288, 257, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
3987, 3kcfA, 0.7503, 3.12, 0.215, 328, 256, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
3988, 6g4zA, 0.7502, 2.65, 0.244, 322, 250, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 2F 
3989, 5cf6B, 0.7502, 2.94, 0.255, 290, 255, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3990, 4ji9B, 0.7502, 2.95, 0.259, 288, 255, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
3991, 5t8qA, 0.7501, 2.67, 0.239, 323, 251, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO ARYL PYRROLE FRAGMENT 17
3992, 5cwzA, 0.7501, 2.62, 0.259, 284, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
3993, 4ixpA, 0.7501, 2.94, 0.303, 334, 254, CRYSTAL STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK)
3994, 5ttvA, 0.7500, 2.82, 0.253, 280, 253, JAK3 WITH COVALENT INHIBITOR 6
3995, 5mqvA, 0.7500, 2.88, 0.195, 286, 257, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
3996, 5ebzL, 0.7500, 3.47, 0.252, 655, 266, CRYSTAL STRUCTURE OF HUMAN IKK1
3997, 5ebzI, 0.7500, 3.56, 0.263, 655, 266, CRYSTAL STRUCTURE OF HUMAN IKK1
3998, 4fz6A, 0.7500, 2.52, 0.201, 266, 249, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH [6-((S)-2- METHYL-PYRROLIDIN-1-YL)-PYRIDIN-2-YL]-(6-PHENYL-IMIDAZO[12- B]PYRIDAZIN-8-YL)-AMINE
3999, 3lctA, 0.7500, 2.90, 0.201, 308, 254, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
4000, 3cekA, 0.7499, 2.56, 0.301, 256, 246, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK)
4001, 4j8mA, 0.7498, 2.55, 0.314, 265, 245, AURORA A IN COMPLEX WITH CD532
4002, 5vc3A, 0.7497, 2.78, 0.223, 260, 251, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
4003, 4zimA, 0.7497, 2.92, 0.263, 285, 255, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
4004, 4g2fA, 0.7497, 2.40, 0.220, 275, 246, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 7
4005, 5ug9A, 0.7496, 2.91, 0.210, 280, 252, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH A COVALENT INHIBITOR N-[(3R4R)-4-FLUORO-1-{6-[(3- METHOXY-1-METHYL-1H-PYRAZOL-4-YL)AMINO]-9-(PROPAN-2-YL)-9H-PURIN-2- YL}PYRROLIDIN-3-YL]PROPANAMIDE
4006, 4o0tB, 0.7496, 2.59, 0.304, 280, 247, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
4007, 4gl9D, 0.7496, 2.94, 0.251, 282, 255, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
4008, 2c6eA, 0.7495, 2.42, 0.314, 251, 245, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
4009, 5ebzF, 0.7494, 3.58, 0.258, 655, 267, CRYSTAL STRUCTURE OF HUMAN IKK1
4010, 3lcsA, 0.7494, 2.93, 0.201, 304, 254, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
4011, 3dk3B, 0.7494, 2.98, 0.213, 269, 253, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
4012, 5t8pB, 0.7493, 2.80, 0.240, 328, 254, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO BENZOXEPIN COMPOUND 2
4013, 5nkgA, 0.7493, 2.62, 0.217, 292, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3D
4014, 5nkfA, 0.7493, 2.63, 0.217, 291, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3B
4015, 5fm3A, 0.7493, 3.04, 0.242, 276, 252, CRYSTAL STRUCTURE OF HYPER-PHOSPHORYLATED RET KINASE DOMAIN WITH (PROXIMAL) JUXTAMEMBRANE SEGMENT
4016, 5ek7A, 0.7493, 2.53, 0.222, 286, 248, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
4017, 2r0iB, 0.7493, 2.39, 0.322, 300, 242, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
4018, 5i3rA, 0.7492, 2.84, 0.262, 302, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
4019, 5ehlA, 0.7492, 2.43, 0.291, 258, 244, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4020, 4bhnB, 0.7492, 2.46, 0.295, 257, 244, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4021, 3dk7B, 0.7492, 3.08, 0.220, 268, 254, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
4022, 5mqvB, 0.7491, 2.91, 0.195, 287, 257, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4023, 4dn5B, 0.7491, 2.52, 0.254, 330, 248, CRYSTAL STRUCTURE OF NF-KB-INDUCING KINASE (NIK)
4024, 1b6cF, 0.7491, 3.13, 0.220, 326, 255, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
4025, 5ia2A, 0.7490, 2.63, 0.217, 287, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 66
4026, 4jbqA, 0.7490, 2.48, 0.297, 257, 246, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
4027, 1u46A, 0.7490, 2.36, 0.258, 255, 244, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
4028, 5ukfC, 0.7489, 3.01, 0.151, 317, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
4029, 4xhlA, 0.7489, 2.85, 0.161, 330, 255, STRUCTURE OF S. CEREVISIAE HRR25 1-394 (K38R MUTANT)
4030, 4lrmE, 0.7489, 2.90, 0.199, 290, 256, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
4031, 4i0tA, 0.7489, 2.57, 0.205, 266, 249, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(5678- TETRAHYDRO-IMIDAZO[15-A]PYRIDIN-1-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID TERT-BUTYLAMIDE
4032, 2ym7A, 0.7489, 2.45, 0.275, 248, 244, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4033, 5ng2A, 0.7488, 2.73, 0.219, 274, 251, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
4034, 5ar5B, 0.7488, 2.71, 0.231, 279, 251, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
4035, 4xg9A, 0.7488, 2.59, 0.197, 259, 249, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4036, 4mkcA, 0.7488, 2.89, 0.202, 303, 253, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE COMPLEXED WITH LDK378
4037, 4dn5A, 0.7488, 2.55, 0.254, 331, 248, CRYSTAL STRUCTURE OF NF-KB-INDUCING KINASE (NIK)
4038, 3hmmA, 0.7488, 2.70, 0.213, 293, 249, STRUCTURE OF ALK5 + GW855857
4039, 5ugcA, 0.7487, 2.96, 0.213, 280, 253, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH A COVALENT INHIBITOR N-[(3R4R)-4-FLUORO-1-{6-[(3- METHOXY-1-METHYL-1H-PYRAZOL-4-YL)AMINO]-9-METHYL-9H-PURIN-2- YL}PYRROLIDIN-3-YL]PROPANAMIDE
4040, 5ug8A, 0.7487, 2.84, 0.211, 280, 251, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH A COVALENT INHIBITOR N-[(3R4R)-4-FLUORO-1-{6-[(1- METHYL-1H-PYRAZOL-4-YL)AMINO]-9-(PROPAN-2-YL)-9H-PURIN-2- YL}PYRROLIDIN-3-YL]PROPANAMIDE
4041, 3srvA, 0.7487, 2.62, 0.200, 262, 250, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
4042, 1k2pB, 0.7487, 2.68, 0.199, 258, 251, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
4043, 5nk6A, 0.7486, 2.59, 0.214, 284, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2D
4044, 5ebzH, 0.7486, 3.65, 0.263, 655, 266, CRYSTAL STRUCTURE OF HUMAN IKK1
4045, 4g3cB, 0.7486, 2.82, 0.240, 327, 254, CRYSTAL STRUCTURE OF APO MURINE NF-KAPPAB INDUCING KINASE (NIK)
4046, 3nyxA, 0.7486, 3.02, 0.203, 287, 256, NON-PHOSPHORYLATED TYK2 JH1 DOMAIN WITH QUINOLINE-THIADIAZOLE- THIOPHENE INHIBITOR
4047, 4byiA, 0.7485, 2.64, 0.306, 254, 248, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
4048, 2zv2A, 0.7485, 2.42, 0.283, 256, 247, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2 BETA CAMKK2 KINASE DOMAIN IN COMPLEX WITH STO-609
4049, 6eimB, 0.7484, 2.69, 0.319, 295, 248, HUMAN STK10 BOUND TO GW683134A
4050, 5hvjB, 0.7484, 2.71, 0.243, 284, 247, CRYSTAL STRUCTURE OF LIMK1 D460N MUTANT IN COMPLEX WITH AMP-PNP
4051, 5caqA, 0.7484, 2.74, 0.201, 301, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 33
4052, 4v0gA, 0.7484, 2.78, 0.264, 267, 250, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
4053, 3zhpD, 0.7484, 2.59, 0.264, 264, 250, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
4054, 2io6A, 0.7484, 2.29, 0.227, 252, 242, WEE1 KINASE COMPLEXED WITH INHIBITOR PD330961
4055, 5hg9A, 0.7483, 2.85, 0.211, 280, 251, EGFR (L858R T790M V948R) IN COMPLEX WITH 1-[(3R4R)-3-[({2-[(1- METHYL-1H-PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY) METHYL]-4-(TRIFLUOROMETHYL)PYRROLIDIN-1-YL]PROP-2-EN-1-ONE
4056, 5ei2A, 0.7483, 2.24, 0.306, 256, 242, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4057, 5ar3B, 0.7483, 2.67, 0.224, 276, 250, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH AMP-PCP
4058, 3zosB, 0.7483, 2.99, 0.224, 303, 254, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
4059, 3zepC, 0.7483, 2.88, 0.250, 276, 252, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
4060, 5mqvD, 0.7482, 2.93, 0.195, 287, 257, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4061, 5j79B, 0.7482, 2.67, 0.224, 277, 250, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
4062, 5cf8B, 0.7482, 2.92, 0.260, 288, 254, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
4063, 4xg3A, 0.7482, 2.48, 0.202, 262, 248, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4064, 4lg4B, 0.7482, 2.63, 0.280, 284, 246, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4065, 2j0jA, 0.7482, 2.68, 0.274, 611, 248, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
4066, 5xp5B, 0.7481, 2.60, 0.247, 267, 247, C-SRC IN COMPLEX WITH ATP-CHF
4067, 5c8mA, 0.7481, 2.76, 0.201, 302, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 17
4068, 4qt1A, 0.7481, 2.75, 0.254, 277, 252, JAK3 KINASE DOMAIN IN COMPLEX WITH 1-[(3S)-1-ISOBUTYLSULFONYL-3- PIPERIDYL]-3-(5H-PYRROLO[23-B]PYRAZIN-2-YL)UREA
4069, 3q4tA, 0.7481, 2.78, 0.227, 305, 251, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
4070, 2pvyC, 0.7481, 2.68, 0.234, 285, 248, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
4071, 4u5jB, 0.7480, 2.57, 0.248, 267, 246, C-SRC IN COMPLEX WITH RUXOLITINIB
4072, 4ftoA, 0.7480, 2.45, 0.279, 252, 244, CRYSTAL STRUCTURE OF THE CHK1
4073, 3l9pA, 0.7480, 2.92, 0.201, 303, 254, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
4074, 2qluA, 0.7480, 3.02, 0.222, 297, 252, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE II KINASE DOMAIN FROM HUMAN
4075, 2c47C, 0.7480, 2.61, 0.200, 282, 250, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
4076, 6fnhA, 0.7479, 2.64, 0.221, 277, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
4077, 5ih9A, 0.7479, 2.32, 0.335, 308, 242, MELK IN COMPLEX WITH NVS-MELK8A
4078, 4y83C, 0.7479, 2.02, 0.238, 293, 239, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(2-AMINO-5- (QUINOLIN-3-YL)PYRIDIN-3-YL)-134-OXADIAZOLE-2(3H)-THIONE
4079, 4bieA, 0.7479, 2.56, 0.291, 257, 244, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4080, 3socA, 0.7479, 3.01, 0.228, 307, 254, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
4081, 3nczB, 0.7479, 2.88, 0.248, 379, 254, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
4082, 3h10A, 0.7479, 2.66, 0.316, 268, 247, AURORA A INHIBITOR COMPLEX
4083, 2w1fA, 0.7479, 2.33, 0.311, 253, 244, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
4084, 1o6yA, 0.7479, 2.55, 0.259, 260, 247, CATALYTIC DOMAIN OF PKNB KINASE FROM MYCOBACTERIUM TUBERCULOSIS
4085, 5nkbA, 0.7478, 2.62, 0.214, 285, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4A
4086, 3eknA, 0.7478, 3.00, 0.205, 297, 254, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
4087, 2ktyA, 0.7478, 3.18, 0.159, 360, 264, SOLUTION STRUCTURE OF HUMAN VACCINIA RELATED KINASE-1
4088, 5nk2A, 0.7477, 2.62, 0.214, 290, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2B
4089, 5ia0B, 0.7477, 2.49, 0.219, 266, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
4090, 5di1A, 0.7477, 2.87, 0.254, 285, 252, MAP4K4 IN COMPLEX WITH AN INHIBITOR
4091, 4yjqA, 0.7477, 2.82, 0.194, 264, 252, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000224
4092, 4umqA, 0.7477, 2.57, 0.327, 314, 245, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4093, 4nzwB, 0.7477, 2.44, 0.273, 266, 245, CRYSTAL STRUCTURE OF STK25-MO25 COMPLEX
4094, 4hvdA, 0.7477, 2.77, 0.254, 276, 252, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-122-TRIMETHYL-PROPYL)-AMIDE
4095, 4at3A, 0.7477, 2.68, 0.228, 289, 250, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH CPD5N
4096, 3zepA, 0.7477, 2.87, 0.259, 274, 251, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
4097, 3hgkC, 0.7477, 3.34, 0.205, 284, 259, CRYSTAL STRUCTURE OF EFFECT PROTEIN AVRPTOB COMPLEXED WITH KINASE PTO
4098, 2x4fB, 0.7477, 2.75, 0.270, 288, 252, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
4099, 2eb3A, 0.7477, 2.72, 0.209, 294, 249, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (L858R) IN COMPLEX WITH AMPPNP
4100, 5hgiA, 0.7476, 2.49, 0.293, 395, 246, CRYSTAL STRUCTURE OF APO HUMAN IRE1 ALPHA
4101, 5cf8A, 0.7476, 2.93, 0.260, 285, 254, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
4102, 4kbaD, 0.7476, 2.62, 0.189, 274, 249, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4103, 4hvhA, 0.7476, 2.76, 0.254, 278, 252, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-2-HYDROXY-12-DIMETHYL-PROPYL
4104, 4fz7A, 0.7476, 2.52, 0.202, 265, 248, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 6-((1R2S)- 2-AMINO-CYCLOHEXYLAMINO)-4-(6-ETHYL-PYRIDIN-2-YLAMINO)-PYRIDAZINE-3- CARBOXYLIC ACID AMIDE
4105, 3lxkA, 0.7476, 2.89, 0.252, 279, 254, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
4106, 3hgkD, 0.7476, 3.35, 0.205, 286, 259, CRYSTAL STRUCTURE OF EFFECT PROTEIN AVRPTOB COMPLEXED WITH KINASE PTO
4107, 2b7aA, 0.7476, 2.98, 0.259, 284, 255, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
4108, 5o49A, 0.7475, 2.86, 0.250, 289, 252, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
4109, 4j95D, 0.7475, 2.69, 0.251, 271, 247, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
4110, 2zmcA, 0.7475, 2.36, 0.303, 260, 244, CRYSTAL STRUCTURE OF HUMAN MITOTIC CHECKPOINT KINASE MPS1 CATALYTIC DOMAIN APO FORM
4111, 5nttA, 0.7474, 2.52, 0.302, 276, 245, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) C604Y MUTANT IN COMPLEX WITH NMS-P715
4112, 5khwA, 0.7474, 2.63, 0.257, 276, 249, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
4113, 4lrmD, 0.7474, 2.94, 0.211, 289, 256, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
4114, 3uysB, 0.7474, 2.54, 0.181, 279, 248, CRYSTAL STRUCTURE OF APO HUMAN CK1D
4115, 3r21A, 0.7474, 2.63, 0.308, 254, 247, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
4116, 3fe3A, 0.7474, 2.57, 0.320, 317, 247, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
4117, 2ym8A, 0.7474, 2.23, 0.270, 246, 241, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4118, 6cswC, 0.7473, 3.11, 0.149, 319, 261, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- METHYL-N-PROPYL-DIHYDROPTERIDINE INHIBITOR
4119, 5w86C, 0.7473, 2.67, 0.262, 273, 248, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
4120, 3tjcB, 0.7473, 2.90, 0.260, 287, 254, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
4121, 5oneA, 0.7472, 2.62, 0.314, 257, 245, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH FMF-03-145-1 (COMPOUND 2)
4122, 5nk1A, 0.7472, 2.65, 0.218, 284, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1K
4123, 5kz7B, 0.7472, 2.36, 0.318, 296, 239, MARK2 COMPLEX WITH 7-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-55-DIMETHYL-2-(3- PYRIDYLAMINO)PYRROLO[23-D]PYRIMIDIN-6-ONE
4124, 4uzdB, 0.7472, 2.51, 0.310, 258, 248, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
4125, 3bizA, 0.7472, 2.42, 0.222, 250, 243, WEE1 KINASE COMPLEX WITH INHIBITOR PD331618
4126, 2xngA, 0.7472, 2.37, 0.303, 253, 244, STRUCTURE OF AURORA-A BOUND TO A SELECTIVE IMIDAZOPYRAZINE INHIBITOR
4127, 2wtvD, 0.7472, 2.53, 0.318, 262, 245, AURORA-A INHIBITOR STRUCTURE
4128, 1b6cD, 0.7472, 3.18, 0.220, 326, 255, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
4129, 4zegA, 0.7471, 2.38, 0.305, 260, 243, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
4130, 4ji9A, 0.7471, 2.99, 0.263, 284, 255, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
4131, 4equB, 0.7471, 2.33, 0.324, 282, 241, HUMAN STK-10 (LOK) KINASE DOMAIN IN DFG-OUT CONFORMATION WITH INHIBITOR DSA-7
4132, 3zhpC, 0.7471, 2.63, 0.264, 272, 250, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
4133, 5nk9A, 0.7470, 2.63, 0.214, 285, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2E
4134, 5n87A, 0.7470, 2.39, 0.300, 255, 243, TTK KINASE DOMAIN IN COMPLEX WITH NTRC 0066-0
4135, 5i9xA, 0.7470, 2.63, 0.218, 284, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH BOSUTINIB (SKI-606)
4136, 4o0wA, 0.7470, 2.46, 0.305, 259, 246, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
4137, 4d2wA, 0.7470, 2.27, 0.324, 314, 241, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4138, 5obrA, 0.7469, 2.57, 0.313, 255, 246, AURORA A KINASE IN COMPLEX WITH 2-(3-CHLORO-5-FLUOROPHENYL)QUINOLINE- 4-CARBOXYLIC ACID AND JNJ-7706621
4139, 5kz7A, 0.7469, 2.35, 0.318, 296, 239, MARK2 COMPLEX WITH 7-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-55-DIMETHYL-2-(3- PYRIDYLAMINO)PYRROLO[23-D]PYRIMIDIN-6-ONE
4140, 5fm2A, 0.7469, 3.08, 0.242, 273, 252, CRYSTAL STRUCTURE OF HYPER-PHOSPHORYLATED RET KINASE DOMAIN WITH (PROXIMAL) JUXTAMEMBRANE SEGMENT
4141, 3hgkA, 0.7469, 3.25, 0.205, 286, 258, CRYSTAL STRUCTURE OF EFFECT PROTEIN AVRPTOB COMPLEXED WITH KINASE PTO
4142, 2wtvA, 0.7469, 2.54, 0.318, 262, 245, AURORA-A INHIBITOR STRUCTURE
4143, 5canA, 0.7468, 2.77, 0.201, 301, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 27
4144, 4p7eB, 0.7468, 3.00, 0.259, 285, 255, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
4145, 4e26A, 0.7468, 2.72, 0.204, 270, 250, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
4146, 3zfxA, 0.7468, 2.56, 0.227, 267, 247, CRYSTAL STRUCTURE OF EPHB1
4147, 3tt0A, 0.7468, 3.17, 0.243, 305, 255, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
4148, 2qobA, 0.7468, 2.55, 0.210, 279, 248, HUMAN EPHA3 KINASE DOMAIN BASE STRUCTURE
4149, 5mahA, 0.7467, 2.55, 0.324, 316, 244, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
4150, 4d2pC, 0.7467, 2.29, 0.326, 316, 242, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4151, 2wmqA, 0.7467, 2.32, 0.285, 246, 242, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4152, 6bu6D, 0.7466, 3.12, 0.153, 318, 261, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4153, 5cf4A, 0.7466, 2.92, 0.264, 283, 254, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
4154, 5casA, 0.7466, 2.72, 0.202, 299, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41A
4155, 5nkcA, 0.7465, 2.66, 0.214, 286, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2H
4156, 5ew8A, 0.7465, 3.05, 0.244, 291, 254, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
4157, 5ttsA, 0.7464, 2.69, 0.256, 274, 250, JAK3 WITH COVALENT INHIBITOR 4
4158, 4bc6A, 0.7464, 2.74, 0.324, 285, 247, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO NOVEL BOSUTINIB ISOFORM 1 PREVIOUSLY THOUGHT TO BE BOSUTINIB
4159, 3qd2B, 0.7464, 2.74, 0.278, 271, 248, CRSYTAL STRUCTURE OF MOUSE PERK KINASE DOMAIN
4160, 3dk3A, 0.7464, 2.92, 0.214, 266, 252, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
4161, 3a4oX, 0.7464, 2.70, 0.238, 259, 248, LYN KINASE DOMAIN
4162, 4g3dB, 0.7463, 2.78, 0.251, 318, 251, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK)
4163, 4d2wC, 0.7463, 2.24, 0.325, 313, 240, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4164, 3zfxD, 0.7463, 2.58, 0.227, 265, 247, CRYSTAL STRUCTURE OF EPHB1
4165, 5nk7A, 0.7462, 2.66, 0.218, 284, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2A
4166, 4i6qA, 0.7462, 2.81, 0.254, 277, 252, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-PHENOXY-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-1-CYCLOPROPYL-ETHYL)-AMIDE
4167, 4g5jA, 0.7462, 2.43, 0.208, 307, 245, CRYSTAL STRUCTURE OF EGFR KINASE IN COMPLEX WITH BIBW2992
4168, 4d2pA, 0.7462, 2.25, 0.333, 313, 240, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4169, 3gfwA, 0.7462, 2.30, 0.302, 253, 242, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYROLO-PYRIDIN LIGAND
4170, 3dk6A, 0.7462, 2.83, 0.220, 262, 250, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
4171, 5odtA, 0.7461, 2.57, 0.317, 258, 246, AURORA-A IN COMPLEX WITH TACC3
4172, 5czoA, 0.7461, 2.94, 0.173, 365, 255, STRUCTURE OF S. CEREVISIAE HRR25:MAM1 COMPLEX FORM 2
4173, 5c8nA, 0.7461, 2.71, 0.202, 300, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 23
4174, 4z55A, 0.7461, 2.93, 0.202, 294, 252, ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE DERIVATIVE OF LDK378
4175, 3r22A, 0.7461, 2.62, 0.296, 255, 247, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
4176, 5uvfB, 0.7460, 3.01, 0.147, 316, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4177, 5mqvE, 0.7460, 2.95, 0.195, 287, 257, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
4178, 5eh0A, 0.7460, 2.41, 0.305, 258, 243, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4179, 5cyzA, 0.7460, 2.92, 0.153, 353, 255, STRUCTURE OF S. CEREVISIAE HRR25:MAM1 COMPLEX FORM 1
4180, 5ap6A, 0.7460, 2.27, 0.306, 262, 242, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4181, 3zfxH, 0.7460, 2.58, 0.227, 266, 247, CRYSTAL STRUCTURE OF EPHB1
4182, 3lpbB, 0.7460, 2.94, 0.257, 284, 253, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
4183, 4v0gB, 0.7459, 2.77, 0.261, 272, 249, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
4184, 4cqgA, 0.7459, 2.49, 0.321, 313, 243, THE CRYSTAL STRUCTURE OF MPK38 IN COMPLEX WITH OTSSP167 AN ORALLY-ADMINISTRATIVE MELK SELECTIVE INHIBITOR
4185, 3fqhA, 0.7459, 2.53, 0.198, 262, 248, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
4186, 5nk3A, 0.7458, 2.65, 0.218, 281, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1L
4187, 4twoA, 0.7458, 2.45, 0.220, 278, 246, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 164
4188, 4bfmA, 0.7458, 2.49, 0.321, 313, 243, THE CRYSTAL STRUCTURE OF MOUSE PK38
4189, 3hmpA, 0.7458, 2.39, 0.309, 258, 243, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH A QUINAZOLIN LIGAND COMPOUND 4
4190, 3dk7A, 0.7458, 2.93, 0.226, 265, 252, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
4191, 5n84A, 0.7457, 2.50, 0.307, 256, 244, TTK KINASE DOMAIN IN COMPLEX WITH MPS-BAY2B
4192, 5m5aA, 0.7457, 2.50, 0.333, 315, 243, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
4193, 2w1eA, 0.7457, 2.32, 0.313, 252, 243, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
4194, 5em7A, 0.7456, 2.74, 0.202, 300, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 13: 4-[(2- METHOXYPHENYL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
4195, 4xg8A, 0.7456, 2.59, 0.201, 258, 249, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4196, 4i0rA, 0.7456, 2.55, 0.202, 264, 248, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(345- TRIMETHOXY-PHENYL)-5H-PYRROLO[23-B]PYRAZINE-7-CARBOXYLIC ACID ISOPROPYLAMIDE
4197, 4hgtA, 0.7456, 2.81, 0.193, 283, 254, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
4198, 2wmuA, 0.7456, 2.37, 0.269, 246, 242, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4199, 1wvyA, 0.7456, 2.93, 0.270, 273, 256, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
4200, 6btwA, 0.7455, 3.03, 0.155, 317, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4201, 4uzdA, 0.7455, 2.41, 0.313, 254, 246, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
4202, 4d2tC, 0.7455, 2.27, 0.325, 313, 240, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4203, 3rhxA, 0.7455, 3.05, 0.244, 289, 254, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
4204, 5o91A, 0.7454, 2.45, 0.311, 266, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) C604W MUTANT IN COMPLEX WITH CPD-5
4205, 4uwcB, 0.7454, 2.95, 0.245, 301, 253, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
4206, 4qpsA, 0.7454, 2.47, 0.265, 270, 245, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
4207, 4c02A, 0.7454, 3.06, 0.237, 313, 253, CRYSTAL STRUCTURE OF HUMAN ACVR1 (ALK2) IN COMPLEX WITH FKBP12.6 AND DORSOMORPHIN
4208, 3fqhB, 0.7454, 2.45, 0.199, 258, 246, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
4209, 3fbvC, 0.7454, 2.91, 0.287, 415, 251, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4210, 2pvyB, 0.7454, 2.67, 0.235, 286, 247, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
4211, 5uvfA, 0.7453, 3.04, 0.147, 317, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4212, 4xeyB, 0.7453, 2.54, 0.215, 359, 246, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
4213, 4ueuA, 0.7453, 2.64, 0.247, 256, 247, TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL
4214, 4hgeB, 0.7453, 3.03, 0.259, 288, 255, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
4215, 2b7aB, 0.7453, 3.02, 0.259, 287, 255, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
4216, 6dd4B, 0.7452, 3.17, 0.153, 309, 261, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N;N- DIPROPYL-DIHYDROPTERIDINE INHIBITOR 
4217, 5tiuA, 0.7452, 2.49, 0.202, 266, 247, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH INHIBITOR
4218, 4e1zA, 0.7452, 2.93, 0.225, 288, 253, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
4219, 4aotA, 0.7452, 2.64, 0.336, 278, 247, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
4220, 5j5tA, 0.7451, 2.99, 0.288, 297, 250, GLK CO-CRYSTAL STRUCTURE WITH AMINOPYRROLOPYRIMIDINE INHIBITOR
4221, 4p5qA, 0.7451, 2.41, 0.220, 275, 245, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
4222, 4hzrB, 0.7451, 2.40, 0.258, 258, 244, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
4223, 3wyxA, 0.7451, 2.53, 0.307, 258, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 6- ((3-(CYANOMETHOXY)-4-(1-METHYL-1H-PYRAZOL-4-YL)PHENYL)AMINO)-2- (CYCLOHEXYLAMINO)NICOTINONITRILE
4224, 3uytD, 0.7451, 2.72, 0.194, 268, 252, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
4225, 3d15A, 0.7451, 2.55, 0.287, 256, 247, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-(3-CHLORO-PHENYL)-3-{5-[2-(THIENO[32- D]PYRIMIDIN-4-YLAMINO)- ETHYL]-THIAZOL-2-YL}-UREA [SNS-314]
4226, 5y5uB, 0.7450, 2.53, 0.198, 257, 247, CRYSTAL STRUCTURES OF SPLEEN TYROSINE KINASE IN COMPLEX WITH A NOVEL INHIBITOR 
4227, 5w86D, 0.7450, 2.62, 0.263, 272, 247, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
4228, 5magA, 0.7450, 2.35, 0.328, 314, 241, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
4229, 2fumB, 0.7450, 2.65, 0.265, 262, 249, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
4230, 2fumA, 0.7450, 2.73, 0.264, 263, 250, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
4231, 1jktB, 0.7450, 3.08, 0.260, 276, 258, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
4232, 4rwiA, 0.7449, 2.98, 0.250, 305, 252, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
4233, 3fbvE, 0.7449, 2.91, 0.287, 415, 251, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4234, 6bu6B, 0.7448, 3.10, 0.151, 307, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4235, 5xdlA, 0.7448, 2.66, 0.202, 292, 247, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH CO-1686
4236, 5c8kA, 0.7448, 2.75, 0.202, 300, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 1
4237, 4uynA, 0.7448, 2.35, 0.320, 249, 241, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
4238, 4c4jA, 0.7448, 2.28, 0.302, 261, 242, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4239, 3sdmG, 0.7448, 2.82, 0.288, 415, 250, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4240, 3sdmF, 0.7448, 2.82, 0.288, 415, 250, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4241, 3sdmE, 0.7448, 2.82, 0.288, 415, 250, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4242, 3sdmD, 0.7448, 2.82, 0.288, 415, 250, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4243, 3sdmC, 0.7448, 2.82, 0.288, 415, 250, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4244, 3sdmB, 0.7448, 2.82, 0.288, 415, 250, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4245, 3sdmA, 0.7448, 2.82, 0.288, 415, 250, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
4246, 3fbvB, 0.7448, 2.82, 0.288, 415, 250, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4247, 2w5hA, 0.7448, 2.75, 0.287, 265, 247, HUMAN NEK2 KINASE APO
4248, 2qokA, 0.7448, 2.45, 0.224, 281, 246, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:S768A TRIPLE MUTANT
4249, 1zmwA, 0.7448, 2.54, 0.314, 302, 242, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
4250, 1lufA, 0.7448, 2.49, 0.237, 275, 245, CRYSTAL STRUCTURE OF THE MUSK TYROSINE KINASE: INSIGHTS INTO RECEPTOR AUTOREGULATION
4251, 4yjvA, 0.7447, 2.80, 0.195, 263, 251, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000250
4252, 4jrnA, 0.7447, 2.77, 0.216, 349, 250, ROP18 KINASE DOMAIN IN COMPLEX WITH AMP-PNP AND SUCROSE
4253, 4ix4A, 0.7447, 3.66, 0.206, 346, 262, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH ADP
4254, 3fbvG, 0.7447, 2.82, 0.288, 415, 250, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4255, 3fbvA, 0.7447, 2.82, 0.288, 415, 250, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4256, 2etmB, 0.7447, 2.47, 0.265, 263, 245, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
4257, 1u46B, 0.7447, 2.28, 0.269, 257, 242, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
4258, 5nkdA, 0.7446, 2.63, 0.215, 287, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2I
4259, 5nk4A, 0.7446, 2.60, 0.219, 290, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2C
4260, 5n7vA, 0.7446, 2.44, 0.305, 260, 243, TTK KINASE DOMAIN IN COMPLEX WITH MPI-0479605
4261, 5ehoA, 0.7446, 2.27, 0.307, 258, 241, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4262, 4rj4A, 0.7446, 2.74, 0.202, 299, 248, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 6
4263, 3fbvN, 0.7446, 2.82, 0.288, 415, 250, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4264, 3fbvF, 0.7446, 2.83, 0.288, 415, 250, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4265, 1mruA, 0.7446, 2.60, 0.267, 269, 247, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
4266, 5i9yA, 0.7445, 2.72, 0.218, 287, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DASATINIB
4267, 5capA, 0.7445, 2.89, 0.208, 303, 250, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 30
4268, 4yjrA, 0.7445, 2.82, 0.191, 263, 251, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000225
4269, 4uwbB, 0.7445, 2.82, 0.247, 299, 251, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
4270, 4rwkA, 0.7445, 2.95, 0.247, 308, 251, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
4271, 4ix5A, 0.7445, 3.66, 0.202, 346, 262, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH AMP-PNP
4272, 4f4pA, 0.7445, 2.55, 0.210, 262, 248, SYK IN COMPLEX WITH LIGAND LASW836
4273, 3js2B, 0.7445, 2.98, 0.245, 291, 253, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
4274, 3hgkB, 0.7445, 3.25, 0.205, 286, 258, CRYSTAL STRUCTURE OF EFFECT PROTEIN AVRPTOB COMPLEXED WITH KINASE PTO
4275, 3fbvL, 0.7445, 2.83, 0.288, 415, 250, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4276, 3fbvK, 0.7445, 2.83, 0.288, 422, 250, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4277, 3fbvH, 0.7445, 2.83, 0.288, 415, 250, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4278, 2vx0A, 0.7445, 2.76, 0.220, 273, 250, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4279, 2dylA, 0.7445, 2.39, 0.230, 272, 243, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 7 ACTIVATED MUTANT (S287D T291D)
4280, 1b6cB, 0.7445, 3.35, 0.218, 326, 257, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
4281, 6dd4C, 0.7444, 3.06, 0.151, 317, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N;N- DIPROPYL-DIHYDROPTERIDINE INHIBITOR 
4282, 6cswB, 0.7444, 3.21, 0.153, 308, 261, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- METHYL-N-PROPYL-DIHYDROPTERIDINE INHIBITOR
4283, 5ar4B, 0.7444, 2.72, 0.220, 279, 250, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
4284, 5ap0A, 0.7444, 2.41, 0.302, 254, 242, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4285, 5a46B, 0.7444, 3.18, 0.243, 297, 255, FGFR1 IN COMPLEX WITH DOVITINIB
4286, 4umpA, 0.7444, 2.25, 0.329, 313, 240, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4287, 4bi0A, 0.7444, 2.31, 0.307, 254, 241, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4288, 3sdjC, 0.7444, 2.92, 0.287, 415, 251, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4289, 3h9fA, 0.7444, 2.39, 0.305, 260, 243, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYRIMIDO-DIAZEPIN LIGAND
4290, 3fbvM, 0.7444, 2.83, 0.288, 415, 250, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4291, 6cmmC, 0.7443, 3.03, 0.147, 316, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A NN- DIPROPYNYL-DIHYDROPTERIDINE INHIBITOR
4292, 3sdjF, 0.7443, 2.93, 0.287, 415, 251, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4293, 3sdjB, 0.7443, 2.93, 0.287, 415, 251, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4294, 3sdjA, 0.7443, 2.92, 0.287, 415, 251, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4295, 3k5uA, 0.7443, 2.44, 0.306, 260, 245, IDENTIFICATION SAR STUDIES AND X-RAY COCRYSTAL ANALYSIS OF A NOVEL FURANO-PYRIMIDINE AURORA KINASE A INHIBITOR
4296, 6cfmA, 0.7442, 3.04, 0.147, 316, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PROPYNYL-PTERIDINONE INHIBITOR
4297, 5w5qA, 0.7442, 2.93, 0.267, 291, 255, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
4298, 4wrgA, 0.7442, 2.52, 0.216, 289, 245, 1.9 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN
4299, 4hviA, 0.7442, 2.74, 0.256, 274, 250, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-1-METHYL-2-OXO-2-PIPERIDIN-1-YL- ETHYL)-AMIDE
4300, 3sdjN, 0.7442, 2.93, 0.287, 415, 251, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4301, 3sdjM, 0.7442, 2.93, 0.287, 415, 251, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4302, 3sdjL, 0.7442, 2.93, 0.287, 415, 251, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4303, 3sdjK, 0.7442, 2.93, 0.287, 422, 251, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4304, 3sdjG, 0.7442, 2.93, 0.287, 415, 251, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4305, 3sdjE, 0.7442, 2.93, 0.287, 415, 251, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4306, 6bp0A, 0.7441, 3.06, 0.151, 317, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4307, 5n9sA, 0.7441, 2.34, 0.306, 259, 242, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1161909
4308, 5ia3A, 0.7441, 2.56, 0.215, 275, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH PD173955
4309, 5f1zA, 0.7441, 2.53, 0.232, 281, 246, STRUCTURE OF TYK2 WITH INHIBITOR 16: 3-AZANYL-5-[(2~{S})-3- METHYLBUTAN-2-YL]-7-[1-METHYL-5-(2-OXIDANYLPROPAN-2-YL)PYRAZOL-3-YL]- 1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
4310, 5ew8B, 0.7441, 3.01, 0.245, 290, 253, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
4311, 4useA, 0.7441, 2.88, 0.319, 286, 248, HUMAN STK10 (LOK) WITH SB-633825
4312, 3sdjH, 0.7441, 2.93, 0.287, 415, 251, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4313, 5iu2B, 0.7440, 2.41, 0.225, 313, 244, DISCOVERY OF IMIDAZOQUINOLINES AS A NOVEL CLASS OF POTENT SELECTIVE AND IN VIVO EFFICACIOUS COT KINASE INHIBITORS
4314, 4c4iA, 0.7440, 2.38, 0.298, 253, 242, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4315, 3sdjD, 0.7440, 2.93, 0.287, 422, 251, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4316, 3h10B, 0.7440, 2.61, 0.317, 267, 246, AURORA A INHIBITOR COMPLEX
4317, 3fbvD, 0.7440, 2.83, 0.288, 422, 250, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4318, 3f6xD, 0.7440, 2.55, 0.249, 267, 245, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4319, 3dj7A, 0.7440, 2.68, 0.297, 257, 249, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 130.
4320, 5feeA, 0.7439, 2.50, 0.204, 287, 245, EGFR KINASE DOMAIN T790M MUTANT IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
4321, 4cvaA, 0.7439, 2.37, 0.298, 254, 242, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4322, 3hmoA, 0.7439, 2.35, 0.310, 257, 242, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH THE INHIBITOR STAUROSPORINE
4323, 3fupB, 0.7439, 3.02, 0.263, 287, 255, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
4324, 2vwyA, 0.7439, 2.76, 0.220, 274, 250, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4325, 5ar2A, 0.7438, 2.68, 0.229, 277, 249, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
4326, 4p7eA, 0.7438, 2.96, 0.264, 281, 254, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
4327, 4fobA, 0.7438, 3.07, 0.198, 295, 253, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 1
4328, 4c4fA, 0.7438, 2.33, 0.299, 254, 241, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4329, 5i9zA, 0.7437, 2.64, 0.224, 273, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DANUSERTIB (PHA739358)
4330, 4uwbA, 0.7437, 3.12, 0.244, 299, 254, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
4331, 4rj8A, 0.7437, 2.72, 0.202, 298, 247, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 8
4332, 3tjcA, 0.7437, 3.05, 0.263, 284, 255, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
4333, 3d2iA, 0.7437, 2.55, 0.296, 255, 247, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH 1-{5-[2-(1-METHYL-1H- PYRAZOLO[43-D]PYRIMIDIN-7-YLAMINO)-ETHYL]-THIAZOL-2-YL}-3- (3-TRIFLUOROMETHYL-PHENYL)-UREA
4334, 5iu2A, 0.7436, 2.42, 0.225, 312, 244, DISCOVERY OF IMIDAZOQUINOLINES AS A NOVEL CLASS OF POTENT SELECTIVE AND IN VIVO EFFICACIOUS COT KINASE INHIBITORS
4335, 4hgeA, 0.7436, 2.97, 0.268, 284, 254, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
4336, 2vx1A, 0.7436, 2.77, 0.220, 274, 250, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4337, 2ivsB, 0.7436, 2.84, 0.254, 277, 248, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
4338, 6dd4A, 0.7435, 3.06, 0.151, 317, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N;N- DIPROPYL-DIHYDROPTERIDINE INHIBITOR 
4339, 5uhnB, 0.7435, 2.77, 0.251, 269, 247, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
4340, 5hcyA, 0.7435, 2.88, 0.200, 302, 250, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-CARBOXAMIDE AZAINDOLE COMPOUND 13
4341, 5gjdA, 0.7435, 2.61, 0.294, 292, 245, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 2
4342, 5ehyA, 0.7435, 2.38, 0.302, 255, 242, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
4343, 5cauA, 0.7435, 2.73, 0.202, 297, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41B
4344, 5a4eC, 0.7435, 1.76, 0.362, 262, 232, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
4345, 1yi6B, 0.7435, 2.84, 0.243, 274, 251, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
4346, 5ftoA, 0.7434, 3.03, 0.198, 298, 253, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH ENTRECTINIB
4347, 4k8aB, 0.7434, 2.46, 0.258, 258, 244, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
4348, 4bi2A, 0.7434, 2.31, 0.307, 253, 241, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4349, 3fupA, 0.7434, 2.99, 0.268, 284, 254, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
4350, 2wzjA, 0.7434, 2.37, 0.315, 310, 241, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4351, 2vwzA, 0.7434, 2.75, 0.228, 274, 250, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4352, 2vwxA, 0.7434, 2.75, 0.228, 274, 250, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4353, 2jfmA, 0.7434, 2.33, 0.277, 287, 242, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE (UNLIGANDED FORM)
4354, 2j0kB, 0.7434, 2.51, 0.269, 612, 245, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
4355, 1jqhA, 0.7434, 2.95, 0.202, 291, 253, IGF-1 RECEPTOR KINASE DOMAIN
4356, 6cmmB, 0.7433, 3.12, 0.151, 310, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A NN- DIPROPYNYL-DIHYDROPTERIDINE INHIBITOR
4357, 5v19A, 0.7433, 2.28, 0.300, 250, 240, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
4358, 4ix6A, 0.7433, 3.66, 0.202, 346, 262, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE SOAKED WITH ATP
4359, 3gxlA, 0.7433, 2.66, 0.211, 285, 247, ALK-5 KINASE COMPLEX WITH GW857175
4360, 4cd0A, 0.7432, 2.96, 0.203, 295, 251, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPANE-12-DIOL
4361, 3lpbA, 0.7432, 2.92, 0.269, 278, 253, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
4362, 3lauA, 0.7432, 2.46, 0.315, 251, 241, CRYSTAL STRUCTURE OF AURORA2 KINASE IN COMPLEX WITH A GSK3BETA INHIBITOR
4363, 4u5jA, 0.7431, 2.68, 0.251, 267, 247, C-SRC IN COMPLEX WITH RUXOLITINIB
4364, 4mneB, 0.7431, 2.74, 0.184, 270, 250, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4365, 1jqhC, 0.7431, 2.97, 0.202, 291, 253, IGF-1 RECEPTOR KINASE DOMAIN
4366, 1bi7A, 0.7431, 2.77, 0.457, 269, 247, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURE OF THE CDK6-P16INK4A TUMOR SUPPRESSOR COMPLEX
4367, 5njzA, 0.7430, 2.51, 0.216, 273, 245, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1G
4368, 5mafA, 0.7430, 2.46, 0.331, 315, 242, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
4369, 4p2kA, 0.7430, 2.56, 0.215, 259, 247, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
4370, 4c7tA, 0.7430, 2.64, 0.264, 259, 246, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
4371, 3etaB, 0.7430, 2.88, 0.205, 292, 249, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
4372, 2j51A, 0.7430, 2.34, 0.277, 288, 242, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 5- AMINO-3-((4-(AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-124-TRIAZOLE-1-CARBOTHIOAMIDE
4373, 5vndB, 0.7429, 2.96, 0.245, 295, 253, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
4374, 5j7hA, 0.7429, 2.70, 0.202, 291, 248, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) BOUND BY BRIGATINIB
4375, 3uzpB, 0.7429, 2.74, 0.183, 284, 252, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
4376, 3tjdA, 0.7429, 3.04, 0.259, 284, 255, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
4377, 3js2A, 0.7429, 3.19, 0.243, 295, 255, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
4378, 2jiiB, 0.7429, 3.02, 0.155, 326, 258, STRUCTURE OF VACCINIA RELATED KINASE 3
4379, 5ih8A, 0.7428, 2.33, 0.329, 306, 240, MELK IN COMPLEX WITH NVS-MELK1
4380, 4zp5A, 0.7428, 2.94, 0.246, 284, 252, MAP4K4 IN COMPLEX WITH INHIBITOR
4381, 4yc8A, 0.7428, 2.53, 0.224, 259, 245, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
4382, 4umrA, 0.7428, 2.46, 0.329, 313, 243, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4383, 4bhnA, 0.7428, 2.55, 0.296, 256, 243, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4384, 4bf2B, 0.7428, 2.35, 0.304, 252, 240, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4385, 3zfxI, 0.7428, 2.52, 0.233, 263, 245, CRYSTAL STRUCTURE OF EPHB1
4386, 6fnmA, 0.7427, 2.70, 0.221, 270, 249, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH DASATINIB 
4387, 5o4aA, 0.7427, 2.93, 0.250, 290, 252, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
4388, 5k5xA, 0.7427, 2.90, 0.207, 345, 251, CRYSTAL STRUCTURE OF HUMAN PDGFRA
4389, 5aafA, 0.7427, 2.47, 0.306, 254, 245, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14A)
4390, 3d14A, 0.7427, 2.70, 0.297, 262, 249, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-{5-[2-(THIENO[32-D]PYRIMIDIN-4-YLAMINO)- ETHYL]- THIAZOL-2-YL}-3-(3-TRIFLUOROMETHYL-PHENYL)-UREA
4391, 2xa4A, 0.7427, 2.82, 0.268, 276, 250, INHIBITORS OF JAK2 KINASE DOMAIN
4392, 1mruB, 0.7427, 2.69, 0.255, 271, 247, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
4393, 5hhwA, 0.7426, 2.83, 0.200, 306, 250, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH CIS-(R)-7-(3-(AZETIDIN-1-YLMETHYL)CYCLOBUTYL)-5-(3-((TETRAHYDRO-2H- PYRAN-2-YL)METHOXY)PHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE.
4394, 4u40A, 0.7426, 3.06, 0.262, 295, 256, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
4395, 4ix3A, 0.7426, 3.69, 0.202, 346, 262, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE
4396, 4c8bB, 0.7426, 2.83, 0.216, 281, 250, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
4397, 3dqxA, 0.7426, 2.69, 0.251, 267, 247, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
4398, 2helA, 0.7426, 2.40, 0.197, 256, 244, CRYSTAL STRUCTURE OF A MUTANT EPHA4 KINASE DOMAIN (Y742A)
4399, 2hakF, 0.7426, 2.60, 0.325, 318, 246, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4400, 5ttuA, 0.7425, 2.72, 0.249, 271, 249, JAK3 WITH COVALENT INHIBITOR 7
4401, 4qrcA, 0.7425, 2.84, 0.256, 297, 250, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 4 IN COMPLEX WITH PONATINIB
4402, 4e26B, 0.7425, 2.68, 0.202, 264, 247, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
4403, 4b8lA, 0.7425, 2.36, 0.307, 249, 241, AURORA B KINASE P353G MUTANT
4404, 3fbvJ, 0.7425, 2.91, 0.288, 413, 250, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4405, 6fnkA, 0.7424, 2.72, 0.221, 274, 249, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
4406, 3hmiA, 0.7424, 3.01, 0.217, 268, 253, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
4407, 3fbvI, 0.7424, 2.91, 0.288, 413, 250, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
4408, 2zmdA, 0.7424, 2.39, 0.298, 259, 242, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN T686A MUTANT IN COMPLEX WITH SP600125 INHIBITOR
4409, 6bu6C, 0.7423, 3.02, 0.148, 315, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4410, 3wf7A, 0.7423, 2.89, 0.311, 288, 251, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PURINE DERIVATIVE 1-(9H-PURIN-6-YL)-N-[3-(TRIFLUOROMETHYL)PHENYL]PIPERIDINE- 4-CARBOXAMIDE
4411, 3vw6A, 0.7423, 2.48, 0.293, 255, 242, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
4412, 3fzrA, 0.7423, 2.66, 0.215, 261, 247, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-431396
4413, 1zmwB, 0.7423, 2.58, 0.314, 302, 242, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
4414, 5uglB, 0.7422, 2.78, 0.255, 271, 247, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
4415, 5ajqB, 0.7422, 2.60, 0.335, 267, 245, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
4416, 5aagA, 0.7422, 2.47, 0.306, 253, 245, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14B)
4417, 3vw6B, 0.7422, 2.40, 0.303, 253, 241, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
4418, 2jflA, 0.7422, 2.35, 0.277, 286, 242, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE ( DIPHOSPHORYLATED FORM) BOUND TO 5- AMINO-3-((4-( AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-12 4-TRIAZOLE-1-CARBOTHIOAMIDE
4419, 4qpsC, 0.7421, 2.90, 0.261, 276, 253, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
4420, 4gu9B, 0.7421, 2.59, 0.257, 255, 245, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
4421, 2j0kA, 0.7421, 2.44, 0.266, 598, 244, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
4422, 5khwB, 0.7420, 2.70, 0.257, 276, 249, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
4423, 3wyyA, 0.7420, 2.59, 0.307, 258, 244, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH (E)- 3-(4-((6-(((3S5S7S)-ADAMANTAN-1-YL)AMINO)-4-AMINO-5-CYANOPYRIDIN-2- YL)AMINO)-2-(CYANOMETHOXY)PHENYL)-N-(2-METHOXYETHYL)ACRYLAMIDE
4424, 3f69B, 0.7420, 3.05, 0.234, 282, 256, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
4425, 2gsfA, 0.7420, 2.45, 0.220, 281, 245, THE HUMAN EPHA3 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
4426, 5calA, 0.7419, 2.79, 0.202, 300, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 24
4427, 2jkmA, 0.7419, 2.49, 0.262, 260, 244, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4428, 4focA, 0.7418, 3.02, 0.198, 296, 252, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 2
4429, 3fdnA, 0.7418, 2.57, 0.297, 261, 246, STRUCTURE-BASED DRUG DESIGN OF NOVEL AURORA KINASE A INHIBITORS: STRUCTURE BASIS FOR POTENCY AND SPECIFICITY
4430, 6cnxC, 0.7417, 3.02, 0.148, 311, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 (VRK1) BOUND TO AN N-PROPYNYL-N-ISOPENTYL-DIHYDROPTERIDIN INHIBITOR
4431, 6bruC, 0.7417, 3.03, 0.148, 315, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4432, 5ap5A, 0.7417, 2.30, 0.299, 252, 241, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4433, 4fodA, 0.7417, 2.98, 0.198, 308, 252, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 36
4434, 3hmnA, 0.7417, 2.39, 0.306, 255, 242, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH ATP
4435, 3dbqA, 0.7417, 2.54, 0.299, 259, 244, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN
4436, 4e6dA, 0.7416, 3.02, 0.268, 286, 254, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
4437, 4c4eA, 0.7416, 2.35, 0.311, 256, 241, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4438, 4at4A, 0.7416, 2.89, 0.234, 292, 252, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH EX429
4439, 3zepB, 0.7416, 2.84, 0.253, 268, 249, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
4440, 3sdjJ, 0.7416, 2.93, 0.288, 413, 250, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4441, 3sdjI, 0.7416, 2.93, 0.288, 413, 250, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
4442, 3g6hA, 0.7416, 2.58, 0.249, 266, 245, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
4443, 4lgdC, 0.7415, 2.70, 0.274, 349, 248, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4444, 3vquA, 0.7415, 2.52, 0.309, 258, 243, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4- [(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2- YL)AMINO]BENZAMIDE
4445, 3et7A, 0.7415, 2.67, 0.211, 261, 247, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-2318841
4446, 1fvrA, 0.7415, 2.76, 0.242, 299, 248, TIE2 KINASE DOMAIN
4447, 4u43A, 0.7414, 2.92, 0.272, 287, 254, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
4448, 6cmmD, 0.7413, 3.13, 0.154, 315, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A NN- DIPROPYNYL-DIHYDROPTERIDINE INHIBITOR
4449, 4o6lA, 0.7413, 2.48, 0.306, 257, 242, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
4450, 4c4gA, 0.7413, 2.26, 0.304, 251, 240, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4451, 6d22A, 0.7412, 2.73, 0.227, 299, 247, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR 
4452, 4hvsA, 0.7412, 2.70, 0.227, 326, 247, CRYSTAL STRUCTURE OF KIT KINASE DOMAIN WITH A SMALL MOLECULE INHIBITOR PLX647
4453, 3tjdB, 0.7412, 2.99, 0.260, 287, 254, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
4454, 2j0mB, 0.7412, 2.34, 0.260, 257, 242, CRYSTAL STRUCTURE A TWO-CHAIN COMPLEX BETWEEN THE FERM AND KINASE DOMAINS OF FOCAL ADHESION KINASE.
4455, 5j7bA, 0.7411, 2.75, 0.224, 277, 250, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
4456, 4o6lB, 0.7411, 2.40, 0.307, 256, 241, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
4457, 4ix5B, 0.7411, 3.69, 0.195, 350, 261, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH AMP-PNP
4458, 4e93A, 0.7411, 2.59, 0.241, 361, 245, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES)IN COMPLEX WITH TAE684
4459, 3pp0A, 0.7411, 2.91, 0.205, 286, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
4460, 3h3cA, 0.7411, 2.46, 0.217, 263, 244, CRYSTAL STRUCTURE OF PYK2 IN COMPLEX WITH SULFOXIMINE- SUBSTITUTED TRIFLUOROMETHYLPYRIMIDINE ANALOG
4461, 3c4fA, 0.7411, 3.15, 0.244, 290, 254, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
4462, 2x4fA, 0.7411, 2.80, 0.264, 289, 250, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
4463, 6bp0C, 0.7410, 3.04, 0.148, 315, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4464, 5mrbA, 0.7410, 2.44, 0.314, 264, 242, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH CPD-5
4465, 5aadA, 0.7410, 2.45, 0.299, 252, 244, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (7A)
4466, 5a46A, 0.7410, 3.05, 0.238, 289, 252, FGFR1 IN COMPLEX WITH DOVITINIB
4467, 4uzhA, 0.7410, 2.40, 0.317, 251, 240, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
4468, 4e6dB, 0.7410, 3.03, 0.264, 286, 254, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
4469, 4c3rA, 0.7410, 2.66, 0.297, 252, 246, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP
4470, 3fzpA, 0.7410, 2.41, 0.214, 259, 243, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH ATPGS
4471, 2xruA, 0.7410, 2.49, 0.299, 253, 244, AURORA-A T288E COMPLEXED WITH PHA-828300
4472, 1b6cH, 0.7410, 3.40, 0.218, 326, 257, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
4473, 5xp5A, 0.7409, 2.75, 0.251, 267, 247, C-SRC IN COMPLEX WITH ATP-CHF
4474, 5em6A, 0.7409, 2.81, 0.202, 301, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 19: 4-[(2- AZANYLPYRIMIDIN-4-YL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]- 2-OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
4475, 5ap3A, 0.7409, 2.28, 0.300, 253, 240, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4476, 3lw0A, 0.7409, 2.81, 0.214, 292, 248, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
4477, 2wzjC, 0.7409, 2.42, 0.315, 310, 241, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4478, 1fvrB, 0.7409, 2.92, 0.236, 300, 250, TIE2 KINASE DOMAIN
4479, 6gwrA, 0.7408, 3.15, 0.227, 300, 256, STRUCTURE OF THE KINASE DOMAIN OF HUMAN DDR1 IN COMPLEX WITH A POTENT AND SELECTIVE INHIBITOR OF DDR1 AND DDR2 
4480, 6btwC, 0.7408, 3.04, 0.148, 315, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4481, 5edpA, 0.7408, 2.69, 0.206, 295, 247, EGFR KINASE (T790M/L858R) APO
4482, 5bvnA, 0.7408, 3.02, 0.229, 278, 253, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
4483, 4rj6A, 0.7408, 2.75, 0.202, 297, 247, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 4
4484, 4js8A, 0.7408, 2.42, 0.302, 259, 242, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401348
4485, 3lw0C, 0.7408, 2.82, 0.214, 292, 248, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
4486, 3ckwA, 0.7408, 2.08, 0.277, 255, 238, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24)
4487, 3c4fB, 0.7408, 3.04, 0.245, 290, 253, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
4488, 2zv8A, 0.7408, 2.62, 0.237, 257, 245, LYN TYROSINE KINASE DOMAIN-AMP-PNP COMPLEX
4489, 1jqhB, 0.7408, 2.97, 0.202, 287, 252, IGF-1 RECEPTOR KINASE DOMAIN
4490, 6dkbA, 0.7407, 2.63, 0.229, 272, 245, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 10B. 
4491, 5ljjA, 0.7407, 2.42, 0.307, 264, 241, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH REVERSINE
4492, 5ap1A, 0.7407, 2.33, 0.298, 268, 242, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4493, 4xcuA, 0.7406, 2.96, 0.244, 288, 250, CRYSTAL STRUCTURE OF FGFR4 WITH AN IRREVERSIBLE INHIBITOR
4494, 4lg4E, 0.7406, 2.48, 0.279, 275, 244, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4495, 4f0iB, 0.7406, 2.55, 0.224, 294, 245, CRYSTAL STRUCTURE OF APO TRKA
4496, 3m11A, 0.7406, 2.47, 0.303, 256, 244, CRYSTAL STRUCTURE OF AURORA A KINASE COMPLEXED WITH INHIBITOR
4497, 3lw0D, 0.7406, 2.82, 0.214, 292, 248, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
4498, 2wzjF, 0.7406, 2.43, 0.315, 310, 241, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4499, 2qkwB, 0.7406, 3.28, 0.206, 290, 257, STRUCTURAL BASIS FOR ACTIVATION OF PLANT IMMUNITY BY BACTERIAL EFFECTOR PROTEIN AVRPTO
4500, 1ol6A, 0.7406, 2.28, 0.304, 245, 240, STRUCTURE OF UNPHOSPHORYLATED D274N MUTANT OF AURORA-A
4501, 6bp0B, 0.7405, 3.05, 0.148, 304, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4502, 5uorA, 0.7405, 2.36, 0.300, 249, 240, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4503, 4ztsA, 0.7405, 2.55, 0.307, 249, 244, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1142
4504, 4ymjA, 0.7405, 2.60, 0.241, 270, 245, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
4505, 4rvtA, 0.7405, 2.85, 0.269, 281, 249, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
4506, 4rj7A, 0.7405, 2.74, 0.203, 295, 246, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 1
4507, 4dfyE, 0.7405, 2.66, 0.271, 312, 251, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
4508, 4cv9A, 0.7405, 2.42, 0.293, 254, 242, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4509, 4bi1A, 0.7405, 2.21, 0.301, 252, 239, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4510, 5o49B, 0.7404, 2.80, 0.241, 286, 249, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
4511, 2w1dA, 0.7404, 2.36, 0.314, 251, 242, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
4512, 1m7nB, 0.7404, 2.78, 0.206, 299, 248, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
4513, 6fu5A, 0.7403, 2.83, 0.220, 282, 250, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE INHIBITOR CSLP18 
4514, 6cfmC, 0.7403, 3.05, 0.152, 316, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PROPYNYL-PTERIDINONE INHIBITOR
4515, 5j7bB, 0.7403, 2.81, 0.220, 281, 250, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
4516, 5hicA, 0.7403, 2.79, 0.202, 302, 248, EGFR KINASE DOMAIN MUTANT TMLR WITH A IMIDAZOPYRIDINYL- AMINOPYRIMIDINE INHIBITOR
4517, 4bl1A, 0.7403, 2.36, 0.333, 312, 240, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK) IN COMPLEX WITH AMP-PNP
4518, 3lw0B, 0.7403, 2.82, 0.214, 292, 248, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
4519, 2i1mA, 0.7403, 2.82, 0.214, 311, 248, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
4520, 2etmA, 0.7403, 2.75, 0.267, 262, 247, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
4521, 1p4oA, 0.7403, 2.83, 0.213, 308, 249, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
4522, 4mxxA, 0.7402, 2.53, 0.242, 266, 244, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4523, 4c62A, 0.7402, 2.80, 0.274, 273, 248, INHIBITORS OF JAK2 KINASE DOMAIN
4524, 1yi6A, 0.7402, 3.05, 0.241, 274, 253, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
4525, 5oy6D, 0.7401, 3.17, 0.237, 292, 253, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
4526, 5a4cB, 0.7401, 2.85, 0.240, 286, 250, FGFR1 LIGAND COMPLEX
4527, 4ix3B, 0.7401, 3.72, 0.195, 350, 261, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE
4528, 3zmmA, 0.7401, 2.79, 0.274, 273, 248, INHIBITORS OF JAK2 KINASE DOMAIN
4529, 3q4zB, 0.7401, 2.55, 0.300, 279, 243, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
4530, 3f6xB, 0.7401, 2.51, 0.251, 267, 243, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
4531, 6dkiA, 0.7400, 2.61, 0.224, 279, 245, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 19. 
4532, 5vndA, 0.7400, 3.04, 0.245, 302, 253, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
4533, 5ia4A, 0.7400, 2.80, 0.221, 269, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH FORETINIB (XL880)
4534, 5hcxA, 0.7400, 2.74, 0.202, 298, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH AZABENZIMIDAZOLE COMPOUND 7
4535, 5ar7B, 0.7400, 2.77, 0.224, 278, 250, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
4536, 5ap2A, 0.7400, 2.36, 0.307, 256, 241, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4537, 4kabB, 0.7400, 2.61, 0.257, 258, 245, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
4538, 4ix6B, 0.7400, 3.71, 0.195, 350, 261, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE SOAKED WITH ATP
4539, 4gu6A, 0.7400, 2.81, 0.263, 271, 247, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
4540, 4cljA, 0.7400, 2.90, 0.200, 295, 250, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
4541, 3w1fA, 0.7400, 2.52, 0.296, 259, 243, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 5-(5- ETHOXY-6-(1-METHYL-1H-PYRAZOL-4-YL)-1H-INDAZOL-3-YL)-2- METHYLBENZENESULFONAMIDE
4542, 2uv2A, 0.7400, 2.29, 0.275, 286, 240, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 4-(4-( 5-CYCLOPROPYL-1H-PYRAZOL-3-YLAMINO)-QUINAZOLIN-2-YLAMINO)- PHENYL)-ACETONITRILE
4543, 1fgiA, 0.7400, 3.00, 0.250, 283, 252, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
4544, 5nkaA, 0.7399, 2.51, 0.213, 271, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2G
4545, 4neuA, 0.7399, 3.10, 0.212, 286, 255, X-RAY STRUCTURE OF RECEPTOR INTERACTING PROTEIN 1 (RIP1)KINASE DOMAIN WITH A 1-AMINOISOQUINOLINE INHIBITOR
4546, 2z7rA, 0.7399, 2.32, 0.315, 265, 241, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO STAUROSPORINE
4547, 5n93A, 0.7398, 2.49, 0.305, 259, 243, TTK KINASE DOMAIN IN COMPLEX WITH TC-MPS1-12
4548, 5e1eA, 0.7398, 2.82, 0.256, 279, 250, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
4549, 4u0iA, 0.7398, 2.69, 0.223, 297, 247, CRYSTAL STRUCTURE OF KIT IN COMPLEX WITH PONATINIB
4550, 2ijmB, 0.7398, 2.47, 0.266, 261, 244, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
4551, 2bdfB, 0.7398, 2.73, 0.251, 265, 247, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
4552, 6eimA, 0.7397, 2.60, 0.313, 286, 243, HUMAN STK10 BOUND TO GW683134A
4553, 5t0pB, 0.7397, 2.47, 0.252, 263, 242, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
4554, 4oliA, 0.7397, 2.61, 0.240, 539, 246, THE PSEUDOKINASE/KINASE PROTEIN FROM JAK-FAMILY MEMBER TYK2
4555, 1t45A, 0.7397, 2.78, 0.230, 331, 248, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C- KIT TYROSINE KINASE
4556, 6d1yA, 0.7396, 2.80, 0.231, 300, 247, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 2;4-DICHLORO-N-(3-METHYL-1-PHENYL-1H-PYRAZOL-5-YL)BENZAMIDE INHIBITOR 
4557, 6cswA, 0.7396, 3.06, 0.152, 316, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- METHYL-N-PROPYL-DIHYDROPTERIDINE INHIBITOR
4558, 6cqhD, 0.7396, 3.11, 0.155, 315, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- PROPYNYL-N-ETHYL-DIHYDROPTERIDINE INHIBITOR
4559, 5vamA, 0.7396, 2.69, 0.198, 269, 248, BRAF IN COMPLEX WITH RAF709
4560, 5grnA, 0.7396, 2.91, 0.208, 285, 250, CRYSTAL STRUCTURE OF PDGFRA IN COMPLEX WITH WQ-C-159
4561, 4zsaA, 0.7396, 3.08, 0.245, 289, 253, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
4562, 4xg8C, 0.7396, 2.51, 0.200, 254, 245, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4563, 4ckrA, 0.7396, 3.04, 0.229, 295, 253, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH DDR1-IN-1
4564, 1m7nA, 0.7396, 2.80, 0.206, 299, 248, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
4565, 2jkqA, 0.7395, 2.46, 0.263, 258, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4566, 1p4oB, 0.7395, 2.84, 0.213, 314, 249, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
4567, 5y25A, 0.7394, 2.62, 0.208, 292, 245, EGFR KINASE DOMAIN MUTANT (T790M/L858R) WITH COVALENT LIGAND NS-062 
4568, 5uoxB, 0.7394, 2.43, 0.296, 252, 240, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4569, 5tq6A, 0.7394, 3.02, 0.265, 274, 253, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4570, 5na0A, 0.7394, 2.42, 0.299, 253, 241, TTK KINASE DOMAIN IN COMPLEX WITH A PEG-LINKED PYRIMIDO-INDOLIZINE
4571, 4zjiB, 0.7394, 2.68, 0.294, 276, 248, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4572, 4jaiA, 0.7394, 2.38, 0.320, 249, 241, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH N-{4-[(6-OXO-56- DIHYDROBENZO[C][18]NAPHTHYRIDIN-1-YL)AMINO]PHENYL}BENZAMIDE
4573, 4h58B, 0.7394, 2.61, 0.204, 262, 245, BRAF IN COMPLEX WITH COMPOUND 3
4574, 3uqgA, 0.7394, 2.46, 0.252, 263, 242, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
4575, 3psdB, 0.7394, 2.63, 0.203, 264, 246, NON-OXIME PYRAZOLE BASED INHIBITORS OF B-RAF KINASE
4576, 3dqxB, 0.7394, 2.81, 0.250, 268, 248, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
4577, 2x9fA, 0.7394, 2.47, 0.221, 265, 244, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4578, 2j7tA, 0.7394, 2.67, 0.325, 285, 243, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO SU11274
4579, 1muoA, 0.7394, 2.65, 0.316, 251, 244, CRYSTAL STRUCTURE OF AURORA-2 AN ONCOGENIC SERINE- THREONINE KINASE
4580, 1k9aE, 0.7394, 2.63, 0.233, 440, 245, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4581, 6d1zA, 0.7393, 2.83, 0.227, 290, 247, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 5-(4-FLUOROPHENYL)THIENO[2;3-D]PYRIMIDIN-4(3H)-ONE INHIBITOR 
4582, 5kbqB, 0.7393, 2.56, 0.293, 273, 242, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
4583, 5ia5A, 0.7393, 2.82, 0.217, 273, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH GOLVATINIB (E7050)
4584, 5edqA, 0.7393, 2.76, 0.210, 298, 248, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 15: ~{N}-(7- CHLORANYL-1~{H}-INDAZOL-3-YL)-77-DIMETHYL-2-(1~{H}-PYRAZOL-4-YL)- 5~{H}-FURO[34-D]PYRIMIDIN-4-AMINE
4585, 4rwjA, 0.7393, 3.07, 0.250, 307, 252, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
4586, 4mxzB, 0.7393, 2.51, 0.251, 264, 243, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4587, 4mxyB, 0.7393, 2.51, 0.251, 264, 243, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4588, 4ix4B, 0.7393, 3.72, 0.199, 350, 261, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH ADP
4589, 4cv8A, 0.7393, 2.50, 0.305, 255, 243, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
4590, 4bkyA, 0.7393, 2.40, 0.333, 311, 240, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK) IN COMPLEX WITH PYRROLOPYRAZOLE INHIBITOR
4591, 3zc6A, 0.7393, 3.04, 0.258, 277, 252, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
4592, 2zv9A, 0.7393, 2.73, 0.236, 256, 246, LYN TYROSINE KINASE DOMAIN-PP2 COMPLEX
4593, 2bdjA, 0.7393, 2.66, 0.250, 254, 244, SRC KINASE IN COMPLEX WITH INHIBITOR AP23464
4594, 1t46A, 0.7393, 2.77, 0.234, 297, 248, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C-KIT TYROSINE KINASE
4595, 5vo6A, 0.7392, 2.82, 0.252, 271, 250, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE INHIBITOR
4596, 5m53A, 0.7392, 2.48, 0.289, 255, 242, NEK2 BOUND TO ARYLAMINOPURINE INHIBITOR 11
4597, 5bvkA, 0.7392, 3.15, 0.229, 278, 253, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
4598, 5ia1A, 0.7391, 2.37, 0.215, 261, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH MLN8054
4599, 4aojC, 0.7391, 2.36, 0.230, 261, 243, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
4600, 2xvdA, 0.7391, 2.68, 0.228, 270, 246, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4601, 2qonA, 0.7391, 2.49, 0.220, 281, 245, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742A TRIPLE MUTANT
4602, 5am7A, 0.7390, 2.89, 0.245, 294, 249, FGFR1 MUTANT WITH AN INHIBITOR
4603, 6dkgA, 0.7389, 2.51, 0.225, 276, 244, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 13B. 
4604, 5tq4A, 0.7389, 3.03, 0.258, 290, 256, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4605, 5kmnA, 0.7389, 2.67, 0.224, 296, 245, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
4606, 5kmlA, 0.7389, 2.67, 0.224, 296, 245, TRKA JM-KINASE WITH 1-(5-METHYL-3-PHENYL-12-OXAZOL-4-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
4607, 5hx8A, 0.7389, 2.92, 0.254, 291, 252, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
4608, 5bvwA, 0.7389, 3.09, 0.230, 274, 252, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
4609, 4uwcA, 0.7389, 3.20, 0.244, 300, 254, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
4610, 4at5A, 0.7389, 2.90, 0.234, 294, 252, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH GW2580
4611, 5ia0C, 0.7388, 2.31, 0.220, 269, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
4612, 5caoA, 0.7388, 2.76, 0.203, 300, 246, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 29
4613, 5ap7A, 0.7388, 2.29, 0.304, 263, 240, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4614, 4g3eA, 0.7388, 2.66, 0.243, 314, 247, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO A 6-ALKYNYLINDOLINE (CMP1)
4615, 3wf6A, 0.7388, 2.38, 0.322, 277, 242, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-INDOL-3-YL)-36- DIHYDROPYRIDIN-1(2H)-YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
4616, 2rsvA, 0.7388, 3.34, 0.144, 403, 263, SOLUTION STRUCTURE OF HUMAN FULL-LENGTH VACCINIA RELATED KINASE 1 (VRK1)
4617, 2hakD, 0.7387, 2.52, 0.328, 309, 244, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4618, 5tq7A, 0.7386, 2.96, 0.262, 275, 252, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4619, 3zfxE, 0.7386, 2.55, 0.234, 262, 244, CRYSTAL STRUCTURE OF EPHB1
4620, 3zc6B, 0.7386, 3.07, 0.258, 276, 252, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
4621, 3wf5A, 0.7386, 2.38, 0.322, 277, 242, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-BENZIMIDAZOL-2-YL)PIPERIDIN-1- YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
4622, 3psbB, 0.7386, 2.64, 0.203, 264, 246, FURO[23-C]PYRIDINE-BASED INDANONE OXIMES AS POTENT AND SELECTIVE B- RAF INHIBITORS
4623, 6fu5B, 0.7385, 2.89, 0.223, 286, 251, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE INHIBITOR CSLP18 
4624, 6dd4D, 0.7385, 3.18, 0.154, 311, 259, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N;N- DIPROPYL-DIHYDROPTERIDINE INHIBITOR 
4625, 5f20A, 0.7385, 2.52, 0.230, 274, 244, STRUCTURE OF TYK2 WITH INHIBITOR 4: 3-AZANYL-5-(2-METHYLPHENYL)-7-(1- METHYLPYRAZOL-3-YL)-1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
4626, 3ky2A, 0.7385, 2.98, 0.244, 307, 250, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
4627, 2xneA, 0.7385, 2.28, 0.303, 246, 241, STRUCTURE OF AURORA-A BOUND TO AN IMIDAZOPYRAZINE INHIBITOR
4628, 6gwrB, 0.7384, 2.94, 0.230, 285, 252, STRUCTURE OF THE KINASE DOMAIN OF HUMAN DDR1 IN COMPLEX WITH A POTENT AND SELECTIVE INHIBITOR OF DDR1 AND DDR2 
4629, 1mqbA, 0.7384, 2.47, 0.217, 263, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
4630, 6gipA, 0.7383, 2.93, 0.236, 296, 250, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH A QUINAZOLINONE BASED ALK2 INHIBITOR WITH A 2; 5-DIMETHYL CORE. 
4631, 4zjiA, 0.7383, 2.89, 0.311, 278, 251, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4632, 4ymjB, 0.7383, 2.68, 0.241, 275, 245, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
4633, 4mneG, 0.7383, 2.65, 0.191, 259, 246, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4634, 4bb4A, 0.7383, 2.48, 0.221, 265, 244, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4635, 3mdyA, 0.7383, 2.98, 0.234, 320, 252, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
4636, 3h10D, 0.7383, 2.45, 0.314, 255, 242, AURORA A INHIBITOR COMPLEX
4637, 3etaA, 0.7383, 2.93, 0.205, 293, 249, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
4638, 3cohB, 0.7383, 2.46, 0.307, 247, 241, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
4639, 5nadA, 0.7382, 2.38, 0.303, 256, 241, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1217389
4640, 5i9wA, 0.7382, 2.44, 0.215, 267, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ANP
4641, 5cwzC, 0.7382, 2.36, 0.256, 271, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
4642, 3priA, 0.7382, 2.74, 0.203, 264, 246, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
4643, 5wr7A, 0.7381, 2.50, 0.230, 301, 244, CRYSTAL STRUCTURE OF TRK-A COMPLEXED WITH A SELECTIVE INHIBITOR CH7057288
4644, 5o4aB, 0.7381, 2.96, 0.240, 291, 250, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
4645, 5edrA, 0.7381, 2.68, 0.207, 299, 246, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 27: ~{N}-(1~{H}- INDAZOL-3-YL)-77-DIMETHYL-2-(2-METHYLPYRAZOL-3-YL)-5~{H}-FURO[34- D]PYRIMIDIN-4-AMINE
4646, 5ap4A, 0.7381, 2.41, 0.307, 257, 241, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
4647, 4mxoA, 0.7381, 2.56, 0.246, 266, 244, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
4648, 4bf2A, 0.7381, 2.52, 0.295, 253, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4649, 2jkkA, 0.7381, 2.57, 0.259, 258, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4650, 2hakE, 0.7381, 2.55, 0.327, 318, 245, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4651, 6bbvA, 0.7380, 3.17, 0.253, 289, 257, CRYSTAL STRUCTURE OF JAK2 IN COMPLEX WITH COMPOUND 25
4652, 5nk0A, 0.7380, 2.49, 0.218, 273, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1J
4653, 5jgaA, 0.7380, 2.67, 0.299, 296, 244, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 11C
4654, 5e1sA, 0.7380, 2.66, 0.192, 284, 245, THE CRYSTAL STRUCTURE OF INSR TYROSINE KINASE IN COMPLEX WITH THE INHIBITOR BI 885578
4655, 4zloB, 0.7380, 2.21, 0.303, 263, 238, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
4656, 4kb8A, 0.7380, 2.75, 0.205, 265, 249, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
4657, 4gu6B, 0.7380, 2.58, 0.257, 258, 245, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
4658, 3priB, 0.7380, 2.74, 0.203, 264, 246, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
4659, 5v5nA, 0.7379, 2.64, 0.300, 294, 243, CRYSTAL STRUCTURE OF TAKINIB BOUND TO TAK1
4660, 4mxoB, 0.7379, 2.53, 0.247, 264, 243, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
4661, 4d2vA, 0.7379, 2.30, 0.326, 313, 239, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4662, 3q4uB, 0.7379, 3.09, 0.238, 300, 252, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
4663, 3ppjB, 0.7379, 2.66, 0.203, 264, 246, HUMAN B-RAF KINASE IN COMPLEX WITH A FUROPYRIDINE INHIBITOR
4664, 3dk6B, 0.7379, 2.86, 0.220, 259, 246, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
4665, 3cohA, 0.7379, 2.47, 0.307, 247, 241, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
4666, 2oiqB, 0.7379, 2.59, 0.254, 265, 244, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
4667, 6cnxB, 0.7378, 3.07, 0.156, 311, 256, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 (VRK1) BOUND TO AN N-PROPYNYL-N-ISOPENTYL-DIHYDROPTERIDIN INHIBITOR
4668, 4ztrA, 0.7378, 2.53, 0.300, 249, 243, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1141
4669, 4umpC, 0.7378, 2.28, 0.328, 311, 238, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4670, 4rwlB, 0.7378, 2.84, 0.229, 285, 249, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
4671, 2wzjE, 0.7378, 2.46, 0.315, 310, 241, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4672, 2jiiA, 0.7378, 3.40, 0.141, 321, 263, STRUCTURE OF VACCINIA RELATED KINASE 3
4673, 1zmvB, 0.7378, 2.36, 0.311, 296, 238, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
4674, 1zmuB, 0.7378, 2.37, 0.315, 296, 238, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
4675, 5w5oM, 0.7377, 2.69, 0.226, 276, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4676, 5hczA, 0.7377, 2.77, 0.202, 300, 247, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-AZETIDINYL AZAINDAZOLE COMPOUND 21
4677, 4c4hA, 0.7377, 2.17, 0.298, 248, 238, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
4678, 2wzjB, 0.7377, 2.50, 0.315, 310, 241, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4679, 5xy1A, 0.7376, 2.63, 0.242, 253, 244, CRYSTAL STRUCTURE OF LYN KINASE DOMAIN IN COMPLEX WITH N-(1H-INDAZOL- 6-YL)-8-(PIPERIDIN-4-YLOXY)-6-PROPYLQUINAZOLIN-2-AMINE
4680, 4aojA, 0.7376, 2.40, 0.226, 260, 243, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
4681, 4c61A, 0.7375, 2.78, 0.271, 272, 247, INHIBITORS OF JAK2 KINASE DOMAIN
4682, 5zv2A, 0.7374, 2.97, 0.251, 284, 251, FGFR-1 IN COMPLEX WITH LIGAND LENVATINIB 
4683, 5kvtA, 0.7374, 2.84, 0.225, 287, 249, THE STRUCTURE OF TRKA KINASE DOMAIN BOUND TO THE INHIBITOR ENTRECTINIB
4684, 5ia0A, 0.7374, 2.40, 0.219, 263, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
4685, 4hniA, 0.7374, 2.87, 0.190, 284, 253, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
4686, 4brxA, 0.7374, 2.75, 0.264, 259, 246, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
4687, 3g0fB, 0.7374, 2.78, 0.231, 293, 247, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
4688, 1i44A, 0.7374, 2.76, 0.206, 282, 247, CRYSTALLOGRAPHIC STUDIES OF AN ACTIVATION LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
4689, 5w86B, 0.7373, 2.64, 0.258, 267, 244, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
4690, 5am6A, 0.7373, 2.82, 0.250, 295, 248, NATIVE FGFR1 WITH AN INHIBITOR
4691, 4yhtB, 0.7373, 2.66, 0.207, 258, 246, BRAF COMPLEXED WITH AN INHIBITOR
4692, 4cmoA, 0.7373, 2.92, 0.201, 295, 249, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 2-((1R)-1-((3-AMINO-6-(2- METHOXYPYRIDIN- -YL)PYRAZIN-2-YL)OXY)ETHYL)-4-FLUORO-N-METHYLBENZAMIDE
4693, 4afeA, 0.7373, 2.66, 0.266, 253, 244, NEK2 BOUND TO HYBRID COMPOUND 21
4694, 3g2fA, 0.7373, 3.08, 0.239, 302, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE II (BMPR2) AT 2.35 A RESOLUTION
4695, 3g0eA, 0.7373, 2.74, 0.235, 332, 247, KIT KINASE DOMAIN IN COMPLEX WITH SUNITINIB
4696, 3beaA, 0.7373, 2.84, 0.214, 310, 248, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH A PYRIMIDINOPYRIDONE INHIBITOR
4697, 5w5oE, 0.7372, 2.75, 0.226, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4698, 5lpzA, 0.7372, 3.07, 0.222, 283, 252, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1196) IN COMPLEX WITH ADP FROM ARABIDOPSIS THALIANA
4699, 4o0uA, 0.7372, 2.63, 0.305, 259, 246, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
4700, 4fk6A, 0.7372, 3.11, 0.248, 285, 254, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
4701, 4c8bA, 0.7372, 2.80, 0.218, 279, 248, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
4702, 3q4cB, 0.7372, 2.59, 0.204, 264, 245, CRYSTAL STRUCTURE OF WILD TYPE BRAF KINASE DOMAIN IN COMPLEX WITH ORGANOMETALLIC INHIBITOR CNS292
4703, 4kikA, 0.7371, 3.42, 0.263, 618, 255, HUMAN IKB KINASE BETA
4704, 4k77A, 0.7371, 2.97, 0.254, 282, 252, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
4705, 4cnhB, 0.7371, 2.94, 0.201, 293, 249, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
4706, 3uojB, 0.7371, 2.57, 0.317, 263, 243, AURORA A IN COMPLEX WITH RPM1715
4707, 3uojA, 0.7371, 2.57, 0.317, 263, 243, AURORA A IN COMPLEX WITH RPM1715
4708, 3g0fA, 0.7371, 2.77, 0.235, 291, 247, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
4709, 5wngB, 0.7370, 2.79, 0.274, 365, 248, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
4710, 5wfjA, 0.7370, 2.75, 0.254, 265, 248, THE JAK3 KINASE DOMAIN IN COMPLEX WITH A COVALENT INHIBITOR
4711, 5aaaA, 0.7370, 2.91, 0.205, 294, 249, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4712, 3ppkB, 0.7370, 2.67, 0.203, 264, 246, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
4713, 6bbuA, 0.7369, 2.95, 0.246, 279, 252, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH COMPOUND 25
4714, 4tyiA, 0.7369, 2.75, 0.247, 277, 247, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4
4715, 3mygA, 0.7369, 2.48, 0.300, 252, 243, AURORA A KINASE COMPLEXED WITH SCH 1473759
4716, 3mdyC, 0.7369, 3.18, 0.232, 320, 254, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
4717, 3gqlB, 0.7369, 2.86, 0.230, 276, 248, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
4718, 1zmuA, 0.7369, 2.45, 0.315, 293, 238, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
4719, 5xp7A, 0.7368, 2.55, 0.251, 265, 243, C-SRC IN COMPLEX WITH ATP-CHCL
4720, 4fk6B, 0.7368, 3.08, 0.248, 284, 254, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
4721, 3nw6A, 0.7368, 2.74, 0.211, 301, 247, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11A)
4722, 6cswD, 0.7367, 3.16, 0.151, 312, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- METHYL-N-PROPYL-DIHYDROPTERIDINE INHIBITOR
4723, 6bruD, 0.7367, 3.12, 0.152, 311, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4724, 5wo4A, 0.7367, 2.96, 0.246, 292, 252, JAK1 COMPLEXED WITH COMPOUND 28
4725, 4nkaB, 0.7367, 2.97, 0.233, 287, 249, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
4726, 3ewhA, 0.7367, 2.93, 0.225, 300, 249, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDYL-PYRIMIDINE BENZIMIDAZOLE INHIBITOR
4727, 6es0A, 0.7366, 3.21, 0.224, 288, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE ACTIVATION LOOP TARGETING INHIBITOR CS-R35
4728, 6c7yA, 0.7366, 2.84, 0.257, 273, 249, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS1 IN COMPLEX WITH JAK1 KINASE DOMAIN 
4729, 5e1eB, 0.7366, 2.90, 0.255, 280, 251, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
4730, 4e4nB, 0.7366, 2.92, 0.255, 280, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
4731, 3wzkA, 0.7366, 2.57, 0.305, 258, 243, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH N- CYCLOPROPYL-4-(8-((THIOPHEN-2-YLMETHYL)AMINO)IMIDAZO[12-A]PYRAZIN-3- YL)BENZAMIDE
4732, 5aaeA, 0.7365, 2.47, 0.300, 252, 243, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14D)
4733, 4mneC, 0.7365, 2.73, 0.178, 260, 247, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4734, 4aszA, 0.7365, 2.94, 0.219, 289, 251, CRYSTAL STRUCTURE OF APO TRKB KINASE DOMAIN
4735, 2zv7A, 0.7365, 2.71, 0.237, 257, 245, LYN TYROSINE KINASE DOMAIN APO FORM
4736, 2ijmA, 0.7365, 2.47, 0.259, 260, 243, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
4737, 6cfmD, 0.7364, 3.16, 0.151, 313, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PROPYNYL-PTERIDINONE INHIBITOR
4738, 5jgdA, 0.7364, 2.71, 0.299, 295, 244, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 12
4739, 5iuiA, 0.7364, 3.08, 0.194, 303, 252, CRYSTAL STRUCTURE OF ANAPLASTIC LYPHOMA KINASE (ALK) IN COMPLEX WITH 4
4740, 4nk9B, 0.7364, 3.12, 0.228, 282, 250, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
4741, 4gk2A, 0.7364, 2.42, 0.219, 265, 242, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 66
4742, 6cnxD, 0.7363, 3.12, 0.152, 312, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 (VRK1) BOUND TO AN N-PROPYNYL-N-ISOPENTYL-DIHYDROPTERIDIN INHIBITOR
4743, 5tq6B, 0.7363, 3.02, 0.266, 271, 252, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4744, 4ibmA, 0.7363, 2.95, 0.200, 301, 250, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
4745, 4dfyA, 0.7363, 2.63, 0.273, 310, 249, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
4746, 3prfA, 0.7363, 2.58, 0.197, 262, 244, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
4747, 5owrA, 0.7362, 2.59, 0.324, 282, 241, HUMAN STK10 BOUND TO DASATINIB
4748, 5kmjA, 0.7362, 2.69, 0.225, 300, 244, TRKA JM-KINASE WITH {N}-(2-PYRIDYLMETHYL)-2-[2-(2-THIENYL)INDOL-1- YL]ACETAMIDE
4749, 5bvoA, 0.7362, 3.04, 0.226, 276, 252, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
4750, 4nk9A, 0.7362, 3.10, 0.228, 281, 250, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
4751, 3uo6A, 0.7362, 2.48, 0.318, 264, 242, AURORA A IN COMPLEX WITH YL5-083
4752, 3d4qA, 0.7362, 2.75, 0.203, 264, 246, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
4753, 2xa4B, 0.7362, 2.75, 0.271, 275, 247, INHIBITORS OF JAK2 KINASE DOMAIN
4754, 6es0B, 0.7361, 2.99, 0.226, 287, 252, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE ACTIVATION LOOP TARGETING INHIBITOR CS-R35
4755, 6eixA, 0.7361, 3.33, 0.239, 312, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE Q207E MUTANT OF ACVR1 (ALK2) IN COMPLEX WITH A 2-AMINOPYRIDINE INHIBITOR K02288
4756, 6b4wA, 0.7361, 2.40, 0.307, 259, 241, TTK IN COMPLEX WITH INHIBITOR
4757, 5am6B, 0.7361, 2.89, 0.246, 280, 248, NATIVE FGFR1 WITH AN INHIBITOR
4758, 3uo6B, 0.7361, 2.49, 0.318, 264, 242, AURORA A IN COMPLEX WITH YL5-083
4759, 5l8jA, 0.7360, 2.54, 0.306, 253, 242, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 S93R
4760, 5kz0A, 0.7360, 2.94, 0.205, 293, 249, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-[(1R)- 1-{[2-AMINO-5-(13-DIMETHYL-1H-PYRAZOL-4-YL)PYRIDIN-3-YL]OXY}ETHYL]- 4-FLUORO-NN-DIMETHYLBENZAMIDE
4761, 5dg5B, 0.7360, 2.89, 0.219, 297, 247, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
4762, 5dg5A, 0.7360, 2.94, 0.218, 297, 248, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
4763, 6d20A, 0.7359, 2.63, 0.224, 296, 245, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 5-(4-FLUOROPHENYL)THIENO[2;3-D]PYRIMIDIN-4(3H)-ONE AND 5-{[2;4- DICHLORO-5-(PYRIDIN-2-YL)BENZENE-1-CARBONYL]AMINO}-N-(2-HYDROXY-2- METHYLPROPYL)-1-PHENYL-1H-PYRAZOLE-3-CARBOXAMIDE INHIBITORS 
4764, 5j9zA, 0.7359, 2.75, 0.220, 291, 246, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1A
4765, 5aa9A, 0.7359, 3.01, 0.208, 295, 250, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
4766, 4ccbA, 0.7359, 2.89, 0.198, 287, 248, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 3-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(5-METHYL-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE
4767, 4bkjB, 0.7359, 3.11, 0.206, 297, 253, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
4768, 3d94A, 0.7359, 2.78, 0.215, 288, 246, CRYSTAL STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE IN COMPLEX WITH PQIP
4769, 3d7tB, 0.7359, 2.64, 0.238, 265, 244, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4770, 2hz0A, 0.7359, 3.11, 0.222, 265, 252, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
4771, 5w5oA, 0.7358, 2.77, 0.226, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4772, 4qqjA, 0.7358, 2.93, 0.245, 282, 249, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN HARBORING THE V550L GATE-KEEPER MUTATION
4773, 3txoA, 0.7358, 2.91, 0.272, 317, 246, PKC ETA KINASE IN COMPLEX WITH A NAPHTHYRIDINE
4774, 1zmvA, 0.7358, 2.35, 0.312, 293, 237, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
4775, 5ar7A, 0.7357, 2.87, 0.228, 278, 250, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
4776, 4jbpA, 0.7357, 2.58, 0.303, 255, 244, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
4777, 4cmuA, 0.7357, 3.02, 0.204, 294, 250, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (10R)-7-AMINO-12-FLUORO-1310 16-TETRAMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(43- H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
4778, 4cliA, 0.7357, 3.03, 0.204, 294, 250, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-21016-TRIMETHYL-15 -OXO-10151617-TETRAHYDRO-2H-84-(METHENO)PYRAZOLO(43-H) (2511)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
4779, 3kfaB, 0.7357, 2.82, 0.244, 284, 246, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
4780, 3kfaA, 0.7357, 2.82, 0.244, 284, 246, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
4781, 2qoqA, 0.7357, 2.46, 0.214, 284, 243, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BASE AMP-PNP BOUND STRUCTURE
4782, 5oxgD, 0.7356, 3.17, 0.237, 293, 253, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
4783, 5fdxA, 0.7356, 3.03, 0.229, 280, 253, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
4784, 4zjjA, 0.7356, 2.82, 0.309, 280, 249, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4785, 3psbA, 0.7356, 2.59, 0.205, 262, 244, FURO[23-C]PYRIDINE-BASED INDANONE OXIMES AS POTENT AND SELECTIVE B- RAF INHIBITORS
4786, 3o23A, 0.7356, 2.80, 0.206, 293, 247, HUMAN UNPHOSPHORYLATED IGF1-R KINASE DOMAIN IN COMPLEX WITH AN HYDANTOIN INHIBITOR
4787, 2yjrA, 0.7356, 2.52, 0.198, 278, 242, STRUCTURE OF F1174L MUTANT ANAPLASTIC LYMPHOMA KINASE
4788, 2wkmA, 0.7356, 2.90, 0.222, 286, 248, X-RAY STRUCTURE OF PHA-00665752 BOUND TO THE KINASE DOMAIN OF C-MET
4789, 5v24A, 0.7355, 2.42, 0.301, 249, 239, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
4790, 4yjsA, 0.7355, 2.57, 0.196, 257, 245, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000226
4791, 3unzB, 0.7355, 2.50, 0.318, 263, 242, AURORA A IN COMPLEX WITH RPM1679
4792, 3unzA, 0.7355, 2.50, 0.318, 263, 242, AURORA A IN COMPLEX WITH RPM1679
4793, 2xb7A, 0.7355, 2.67, 0.200, 286, 245, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH NVP- TAE684
4794, 2wzjD, 0.7355, 2.45, 0.317, 313, 240, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
4795, 4tygA, 0.7354, 3.00, 0.248, 293, 250, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
4796, 3u6jA, 0.7354, 2.83, 0.222, 308, 248, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
4797, 3d4qB, 0.7354, 2.76, 0.203, 264, 246, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
4798, 5twyA, 0.7353, 2.41, 0.331, 313, 239, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
4799, 5twuB, 0.7353, 2.13, 0.322, 315, 236, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
4800, 5ftqA, 0.7353, 3.03, 0.200, 293, 250, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH CMPD 17
4801, 4ivdB, 0.7353, 2.92, 0.255, 280, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
4802, 4aotB, 0.7353, 2.77, 0.336, 279, 247, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
4803, 3uohB, 0.7353, 2.61, 0.317, 264, 243, AURORA A IN COMPLEX WITH RPM1722
4804, 3uohA, 0.7353, 2.61, 0.317, 264, 243, AURORA A IN COMPLEX WITH RPM1722
4805, 3oy3A, 0.7353, 2.96, 0.242, 284, 248, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
4806, 3h0zA, 0.7353, 2.54, 0.310, 248, 242, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4807, 2reiA, 0.7353, 2.43, 0.223, 277, 242, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7)
4808, 6fnhC, 0.7352, 2.46, 0.219, 270, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
4809, 5kmiA, 0.7352, 2.63, 0.226, 300, 243, TRKA JM-KINASE WITH 1-(9{H}-FLUOREN-9-YL)-3-(2-METHYL-4-PHENYL- PYRIMIDIN-5-YL)UREA
4810, 5ajqA, 0.7352, 2.93, 0.337, 280, 249, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
4811, 4k77B, 0.7352, 2.93, 0.255, 280, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
4812, 4gt5A, 0.7352, 2.57, 0.225, 290, 244, CRYSTAL STRUCTURE OF THE INACTIVE TRKA KINASE DOMAIN
4813, 3zzeA, 0.7352, 2.97, 0.218, 286, 248, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH N - ((3Z)-4-CHLORO-7-METHYL-2-OXO-12-DIHYDRO-3H-INDOL-3- YLIDENE)-2-(4-HYDROXYPHENYL)PROPANOHYDRAZIDE
4814, 3oy3B, 0.7352, 3.05, 0.241, 284, 249, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
4815, 2j50B, 0.7352, 2.80, 0.303, 249, 244, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
4816, 2j50A, 0.7352, 2.80, 0.303, 249, 244, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
4817, 6cqhC, 0.7351, 3.09, 0.148, 308, 256, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- PROPYNYL-N-ETHYL-DIHYDROPTERIDINE INHIBITOR
4818, 6bp0D, 0.7351, 3.16, 0.152, 311, 257, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4819, 5w5oO, 0.7351, 2.83, 0.225, 276, 249, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4820, 4v05B, 0.7351, 2.90, 0.241, 286, 249, FGFR1 IN COMPLEX WITH AZD4547.
4821, 3bz3A, 0.7351, 2.62, 0.258, 259, 244, CRYSTAL STRUCTURE ANALYSIS OF FOCAL ADHESION KINASE WITH A METHANESULFONAMIDE DIAMINOPYRIMIDINE INHIBITOR
4822, 2wmsA, 0.7351, 2.39, 0.276, 243, 239, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4823, 5vamB, 0.7350, 2.59, 0.201, 260, 244, BRAF IN COMPLEX WITH RAF709
4824, 5ihaA, 0.7350, 2.29, 0.333, 303, 237, MELK IN COMPLEX WITH NVS-MELK8F
4825, 5uvfC, 0.7349, 3.05, 0.153, 301, 255, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4826, 5lpvA, 0.7349, 3.05, 0.222, 282, 252, CRYSTAL STRUCTURE OF THE BRI1 KINASE DOMAIN (865-1160) IN COMPLEX WITH AMPPNP AND MN FROM ARABIDOPSIS THALIANA
4827, 4v05A, 0.7349, 2.97, 0.248, 287, 250, FGFR1 IN COMPLEX WITH AZD4547.
4828, 4rj5A, 0.7349, 2.75, 0.200, 296, 245, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 5
4829, 4h58A, 0.7349, 2.61, 0.204, 263, 245, BRAF IN COMPLEX WITH COMPOUND 3
4830, 3d7uC, 0.7349, 2.65, 0.238, 257, 244, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4831, 3d7uA, 0.7349, 2.65, 0.238, 257, 244, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4832, 2xirA, 0.7349, 2.91, 0.226, 296, 248, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH PF-00337210 (N2-DIMETHYL-6-(7-(2-MORPHOLINOETHOXY) QUINOLIN-4-YLOXY)BENZOFURAN-3-CARBOXAMIDE)
4833, 4e5wA, 0.7348, 2.97, 0.247, 292, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
4834, 5w5oJ, 0.7347, 2.78, 0.226, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4835, 5twzA, 0.7347, 2.42, 0.326, 313, 239, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
4836, 5jgbA, 0.7347, 2.62, 0.292, 295, 243, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 10
4837, 4ag8A, 0.7347, 2.91, 0.226, 296, 248, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H- INDAZOL-6- YLSULFANYL)-BENZAMIDE)
4838, 3gqlA, 0.7347, 2.98, 0.245, 287, 249, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
4839, 3en4B, 0.7347, 2.66, 0.254, 266, 244, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
4840, 2fb8A, 0.7347, 2.64, 0.208, 259, 245, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
4841, 1k9aA, 0.7347, 2.62, 0.225, 439, 244, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4842, 5w86A, 0.7346, 2.68, 0.258, 269, 244, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
4843, 5kmoA, 0.7346, 2.44, 0.228, 291, 241, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(2- PYRIDYL)UREA
4844, 4usfB, 0.7346, 3.17, 0.282, 285, 252, HUMAN SLK WITH SB-440719
4845, 4k8aA, 0.7346, 2.45, 0.257, 251, 241, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
4846, 4i5cA, 0.7346, 2.89, 0.256, 279, 250, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4847, 2x9eA, 0.7346, 2.58, 0.302, 253, 242, HUMAN MPS1 IN COMPLEX WITH NMS-P715
4848, 4uxqA, 0.7345, 3.01, 0.237, 286, 249, FGFR4 IN COMPLEX WITH PONATINIB
4849, 4e4nA, 0.7345, 2.91, 0.256, 291, 250, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
4850, 4bibA, 0.7345, 2.59, 0.295, 254, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4851, 4bhzA, 0.7345, 2.31, 0.307, 251, 238, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
4852, 4agcA, 0.7345, 2.90, 0.226, 304, 248, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-( 3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL)- BENZAMIDE)
4853, 5am7B, 0.7344, 3.01, 0.236, 287, 250, FGFR1 MUTANT WITH AN INHIBITOR
4854, 4bkjA, 0.7344, 3.13, 0.194, 295, 253, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
4855, 3psdA, 0.7344, 2.61, 0.205, 262, 244, NON-OXIME PYRAZOLE BASED INHIBITORS OF B-RAF KINASE
4856, 3krjA, 0.7344, 2.74, 0.211, 304, 246, CFMS TYROSINE KINASE IN COMPLEX WITH 4-CYANO-1H-IMIDAZOLE-2-CARBOXYLIC ACID (2-CYCLOHEX-1-ENYL-4-PIPERIDIN-4-YL-PHENYL)-AMIDE
4857, 3ik3A, 0.7344, 3.10, 0.237, 280, 249, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
4858, 5jfvA, 0.7343, 2.64, 0.230, 277, 243, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05206283
4859, 4c61B, 0.7343, 2.69, 0.269, 274, 245, INHIBITORS OF JAK2 KINASE DOMAIN
4860, 4asdA, 0.7343, 2.93, 0.226, 305, 248, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SORAFENIB (BAY 43-9006)
4861, 3zmmB, 0.7343, 2.69, 0.273, 274, 245, INHIBITORS OF JAK2 KINASE DOMAIN
4862, 3tudA, 0.7343, 2.69, 0.196, 256, 245, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH N-(4-METHYL-3-(8-METHYL-7- OXO-2-(PHENYLAMINO)-78-DIHYDROPYRIDO[23-D]PYRIMIDIN-6-YL)PHENYL)-3- (TRIFLUOROMETHYL)BENZAMIDE
4863, 3q4cA, 0.7343, 2.64, 0.204, 264, 245, CRYSTAL STRUCTURE OF WILD TYPE BRAF KINASE DOMAIN IN COMPLEX WITH ORGANOMETALLIC INHIBITOR CNS292
4864, 3omvA, 0.7343, 2.75, 0.195, 264, 246, CRYSTAL STRUCTURE OF C-RAF (RAF-1)
4865, 3my0N, 0.7343, 3.05, 0.236, 300, 250, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4866, 3my0L, 0.7343, 3.08, 0.236, 296, 250, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4867, 2c6eB, 0.7343, 2.47, 0.308, 246, 240, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
4868, 5w5oK, 0.7342, 2.79, 0.226, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4869, 5oxgC, 0.7342, 3.19, 0.237, 301, 253, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
4870, 5nkiA, 0.7342, 2.46, 0.216, 268, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4B
4871, 4usdA, 0.7342, 2.69, 0.332, 268, 247, HUMAN STK10 (LOK) WITH SB-633825
4872, 4o91A, 0.7342, 2.51, 0.302, 293, 242, CRYSTAL STRUCTURE OF TYPE II INHIBITOR NG25 BOUND TO TAK1-TAB1
4873, 4f64B, 0.7342, 2.79, 0.248, 272, 246, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
4874, 4b0gA, 0.7342, 2.27, 0.311, 247, 238, COMPLEX OF AURORA-A BOUND TO AN IMIDAZOPYRIDINE-BASED INHIBITOR
4875, 3uokB, 0.7342, 2.51, 0.318, 265, 242, AURORA A IN COMPLEX WITH YL5-81-1
4876, 3uokA, 0.7342, 2.51, 0.318, 265, 242, AURORA A IN COMPLEX WITH YL5-81-1
4877, 2c6dA, 0.7342, 2.60, 0.317, 254, 243, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH ADPNP
4878, 5lpwA, 0.7341, 2.98, 0.225, 280, 249, CRYSTAL STRUCTURE OF THE APO-BRI1 KINASE DOMAIN (865-1160)
4879, 5ihcA, 0.7341, 2.49, 0.326, 305, 239, MELK IN COMPLEX WITH NVS-MELK12B
4880, 4bkzA, 0.7341, 2.26, 0.335, 309, 236, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK) IN COMPLEX WITH A BENZODIPYRAZOLE INHIBITOR
4881, 3vo3A, 0.7341, 2.93, 0.226, 303, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH IMIDAZO[1 2-B]PYRIDAZINE DERIVATIVE
4882, 3ppkA, 0.7341, 2.62, 0.205, 262, 244, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
4883, 5w5oI, 0.7340, 2.71, 0.227, 275, 247, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4884, 5w5oH, 0.7340, 2.71, 0.227, 275, 247, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4885, 5w5oD, 0.7340, 2.79, 0.226, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4886, 4v04B, 0.7340, 2.82, 0.227, 287, 247, FGFR1 IN COMPLEX WITH PONATINIB.
4887, 3vhkA, 0.7340, 2.93, 0.226, 297, 248, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BACK POCKET BINDER
4888, 5w5oG, 0.7339, 2.80, 0.226, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4889, 4bidA, 0.7339, 2.61, 0.295, 254, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4890, 3vntA, 0.7339, 2.93, 0.226, 301, 248, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
4891, 3vheA, 0.7339, 2.92, 0.226, 303, 248, CRYSTAL STRUCTURE OF HUMAN VEGFR2 KINASE DOMAIN WITH A NOVEL PYRROLOPYRIMIDINE INHIBITOR.
4892, 2xnpA, 0.7339, 2.63, 0.263, 253, 243, STRUCTURE OF NEK2 BOUND TO CCT244858
4893, 5zv2B, 0.7338, 3.00, 0.237, 282, 249, FGFR-1 IN COMPLEX WITH LIGAND LENVATINIB 
4894, 5k9iB, 0.7338, 2.57, 0.252, 262, 242, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
4895, 4kbaA, 0.7338, 2.74, 0.202, 263, 248, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
4896, 4g3cA, 0.7338, 2.73, 0.247, 315, 247, CRYSTAL STRUCTURE OF APO MURINE NF-KAPPAB INDUCING KINASE (NIK)
4897, 3q4uD, 0.7338, 3.20, 0.237, 299, 253, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
4898, 3ppjA, 0.7338, 2.63, 0.205, 262, 244, HUMAN B-RAF KINASE IN COMPLEX WITH A FUROPYRIDINE INHIBITOR
4899, 3el8A, 0.7338, 2.56, 0.252, 263, 242, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
4900, 2wgjA, 0.7338, 2.84, 0.211, 289, 246, X-RAY STRUCTURE OF PF-02341066 BOUND TO THE KINASE DOMAIN OF C-MET
4901, 2jkoA, 0.7338, 2.50, 0.252, 256, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4902, 6fnfA, 0.7337, 2.48, 0.219, 267, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH NVP-BHG712 
4903, 5jfsA, 0.7337, 2.66, 0.222, 277, 243, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-00593174
4904, 4r7hA, 0.7337, 2.85, 0.219, 308, 247, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX3397
4905, 4o2pB, 0.7337, 2.57, 0.256, 265, 242, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
4906, 4kaoB, 0.7337, 2.47, 0.260, 254, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
4907, 4a4xA, 0.7337, 2.72, 0.270, 253, 244, NEK2-EDE BOUND TO CCT248662
4908, 3my0B, 0.7337, 3.07, 0.228, 295, 250, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4909, 2bdfA, 0.7337, 2.74, 0.253, 261, 245, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
4910, 1irkA, 0.7337, 2.93, 0.198, 303, 248, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN RECEPTOR
4911, 4qqtA, 0.7336, 2.74, 0.244, 283, 246, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 TYROSINE KINASE DOMAIN
4912, 4mxzA, 0.7336, 2.67, 0.254, 266, 244, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4913, 4mxyA, 0.7336, 2.67, 0.254, 266, 244, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4914, 4aojB, 0.7336, 2.44, 0.224, 258, 241, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
4915, 3lcoA, 0.7336, 2.90, 0.219, 293, 247, INHIBITOR BOUND TO A DFG-OUT STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
4916, 3ik3B, 0.7336, 2.86, 0.240, 286, 246, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
4917, 6bruB, 0.7335, 2.99, 0.154, 301, 253, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4918, 5hx8B, 0.7335, 2.96, 0.247, 279, 251, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
4919, 4mxcA, 0.7335, 2.82, 0.227, 290, 247, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
4920, 4ivcB, 0.7335, 2.95, 0.255, 280, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
4921, 3nw5A, 0.7335, 2.87, 0.210, 302, 248, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11B)
4922, 3cjgA, 0.7335, 2.65, 0.217, 280, 244, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
4923, 4mcvB, 0.7334, 2.64, 0.251, 265, 243, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
4924, 4bggB, 0.7334, 3.15, 0.238, 293, 252, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
4925, 3i81A, 0.7334, 2.86, 0.211, 296, 247, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH BMS-754807 [1-(4-((5-CYCLOPROPYL- 1H-PYRAZOL-3-YL)AMINO)PYRROLO[21-F][124]TRIAZIN-2-YL)-N- (6-FLUORO-3-PYRIDINYL)-2-METHYL-L-PROLINAMIDE]
4926, 2jitB, 0.7334, 3.28, 0.169, 312, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
4927, 5em5A, 0.7333, 2.78, 0.204, 298, 245, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 2: 4-[2-(4- CHLOROPHENYL)ETHYLAMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
4928, 4z7hA, 0.7333, 2.78, 0.298, 385, 245, CRYSTAL STRUCTURE OF HUMAN IRE1 CYTOPLASMIC KINASE-RNASE REGION - COMPLEX WITH IMIDAZOPYRIDINE COMPOUND 3
4929, 4ehzA, 0.7333, 3.00, 0.258, 290, 252, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
4930, 2xnmA, 0.7333, 2.71, 0.287, 258, 244, STRUCTURE OF NEK2 BOUND TO CCT
4931, 1pkgB, 0.7333, 2.98, 0.235, 277, 247, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
4932, 6fnlA, 0.7332, 2.53, 0.218, 262, 243, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE 
4933, 5ar4A, 0.7332, 2.75, 0.223, 274, 247, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
4934, 4bggA, 0.7332, 3.17, 0.238, 296, 252, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
4935, 4aw5A, 0.7332, 2.46, 0.227, 261, 242, COMPLEX OF THE EPHB4 KINASE DOMAIN WITH AN OXINDOLE INHIBITOR
4936, 3b2wA, 0.7332, 2.89, 0.231, 261, 247, CRYSTAL STRUCTURE OF PYRIMIDINE AMIDE 11 BOUND TO LCK
4937, 5x02A, 0.7331, 2.73, 0.224, 305, 246, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR FF- 10101
4938, 4g3fA, 0.7331, 2.79, 0.253, 312, 249, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO A 2-(AMINOTHIAZOLY)PHENOL (CMP2)
4939, 3my0M, 0.7331, 3.32, 0.228, 298, 254, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4940, 3eqfA, 0.7331, 3.02, 0.262, 314, 252, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH K252A AND MG2P
4941, 6b2pA, 0.7330, 2.54, 0.251, 255, 243, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
4942, 5wo4B, 0.7330, 2.97, 0.247, 280, 251, JAK1 COMPLEXED WITH COMPOUND 28
4943, 4r7iA, 0.7330, 2.81, 0.220, 290, 246, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR GLEEVEC
4944, 3zclA, 0.7330, 2.74, 0.216, 289, 245, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-3-(1-(1H-PYRROLO(23-B)PYRIDIN-3-YL)ETHYL)-N-ISOPROPYL-( 124)TRIAZOLO(43-B)PYRIDAZIN-6-AMINE
4945, 2fb8B, 0.7330, 2.50, 0.210, 259, 243, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
4946, 5oxgB, 0.7329, 3.15, 0.238, 296, 252, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
4947, 3wzeA, 0.7329, 2.86, 0.223, 298, 247, KDR IN COMPLEX WITH LIGAND SORAFENIB
4948, 1f3mC, 0.7329, 2.94, 0.312, 287, 250, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
4949, 4pmmA, 0.7328, 2.65, 0.226, 285, 243, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N-(3-CYCLOPROPYL- 1-PHENYL-1H-PYRAZOL-5-YL)-2-{4-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1- YL)PHENYL]-1H-123-TRIAZOL-1-YL}ACETAMIDE
4950, 4ap7A, 0.7328, 2.85, 0.211, 289, 246, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( (6-(4- FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN-3-YL)METHYL) PHENOL
4951, 4an2A, 0.7328, 3.28, 0.262, 282, 256, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
4952, 3q4uC, 0.7328, 3.19, 0.237, 296, 253, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
4953, 3a62A, 0.7328, 2.40, 0.329, 263, 240, CRYSTAL STRUCTURE OF PHOSPHORYLATED P70S6K1
4954, 5t0pA, 0.7327, 2.60, 0.252, 264, 242, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
4955, 5khxA, 0.7327, 2.91, 0.253, 276, 249, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH PF-4950736
4956, 3uolB, 0.7327, 2.66, 0.317, 263, 243, AURORA A IN COMPLEX WITH SO2-162
4957, 3uolA, 0.7327, 2.66, 0.317, 263, 243, AURORA A IN COMPLEX WITH SO2-162
4958, 3qquA, 0.7327, 2.76, 0.207, 285, 246, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
4959, 1agwB, 0.7327, 2.80, 0.248, 272, 246, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
4960, 5w5oP, 0.7326, 2.72, 0.227, 275, 247, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4961, 5w5oL, 0.7326, 2.83, 0.226, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4962, 5w5oC, 0.7326, 2.83, 0.226, 275, 248, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
4963, 4yhtA, 0.7326, 2.60, 0.209, 256, 244, BRAF COMPLEXED WITH AN INHIBITOR
4964, 4pmsA, 0.7326, 2.54, 0.227, 283, 242, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 4-NAPHTHALEN-1-YL- 1-[(5-PHENYL-124-OXADIAZOL-3-YL)METHYL]-1H-PYRROLO[32-C]PYRIDINE- 2-CARBOXYLIC ACID
4965, 4oh4A, 0.7326, 3.01, 0.228, 299, 250, CRYSTAL STRUCTURE OF BRI1 IN COMPLEX WITH BKI1
4966, 4mneF, 0.7326, 2.57, 0.193, 258, 243, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4967, 4g3gA, 0.7326, 2.80, 0.253, 312, 249, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) V408L BOUND TO A 2-(AMINOTHIAZOLYL)PHENOL (CMP3)
4968, 2yiyA, 0.7326, 2.54, 0.298, 293, 242, CRYSTAL STRUCTURE OF COMPOUND 8 BOUND TO TAK1-TAB
4969, 5oxgA, 0.7325, 3.00, 0.229, 293, 249, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
4970, 5htiA, 0.7325, 2.84, 0.223, 290, 247, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH LXM108
4971, 4zjjB, 0.7325, 2.66, 0.282, 277, 245, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4972, 4hw7A, 0.7325, 2.83, 0.220, 289, 246, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX647-OME
4973, 4h1jA, 0.7325, 2.75, 0.194, 263, 248, CRYSTAL STRUCTURE OF PYK2 WITH THE PYRAZOLE 13A
4974, 3rhxB, 0.7325, 2.80, 0.248, 275, 246, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
4975, 2fgiB, 0.7325, 2.79, 0.248, 272, 246, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
4976, 6dkwA, 0.7324, 2.41, 0.228, 284, 241, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 3. 
4977, 5kmmA, 0.7324, 2.66, 0.226, 301, 243, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(1- NAPHTHYL)UREA
4978, 5jfxA, 0.7324, 2.42, 0.224, 277, 241, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-06273340
4979, 4ivbB, 0.7324, 2.96, 0.247, 280, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
4980, 3prfB, 0.7324, 2.65, 0.197, 262, 244, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
4981, 4pdpB, 0.7323, 2.40, 0.328, 265, 238, CRYSTAL STRUCTURE OF RAD53 KINASE DOMAIN AND SCD2
4982, 4mnfA, 0.7323, 2.62, 0.206, 257, 243, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
4983, 2i0vA, 0.7323, 2.84, 0.215, 303, 246, C-FMS TYROSINE KINASE IN COMPLEX WITH A QUINOLONE INHIBITOR
4984, 2evaA, 0.7323, 2.63, 0.292, 295, 243, STRUCTURAL BASIS FOR THE INTERACTION OF TAK1 KINASE WITH ITS ACTIVATING PROTEIN TAB1
4985, 1fgkB, 0.7323, 2.80, 0.248, 272, 246, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
4986, 5jfwA, 0.7322, 2.67, 0.222, 277, 243, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05247452
4987, 4ivcA, 0.7322, 2.94, 0.256, 291, 250, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
4988, 4ei4B, 0.7322, 2.98, 0.255, 280, 251, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
4989, 3omvB, 0.7322, 2.80, 0.195, 264, 246, CRYSTAL STRUCTURE OF C-RAF (RAF-1)
4990, 3my0U, 0.7322, 3.04, 0.237, 285, 249, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4991, 3eqhA, 0.7322, 3.33, 0.262, 314, 256, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH U0126 ADP AND MG2P
4992, 2xkfA, 0.7322, 2.59, 0.275, 250, 240, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 2
4993, 4b9dB, 0.7321, 2.95, 0.252, 295, 250, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
4994, 3wzjA, 0.7321, 2.54, 0.295, 257, 241, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(6- (CYCLOHEXYLAMINO)-8-(((TETRAHYDRO-2H-PYRAN-4-YL)METHYL)AMINO) IMIDAZO[12-B]PYRIDAZIN-3-YL)-N-CYCLOPROPYLBENZAMIDE
4995, 1k9aB, 0.7321, 2.66, 0.234, 441, 244, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4996, 4y95A, 0.7320, 2.81, 0.188, 266, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
4997, 3nw7A, 0.7320, 2.84, 0.211, 297, 247, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (34)
4998, 2ogvA, 0.7320, 2.96, 0.214, 317, 248, CRYSTAL STRUCTURE OF THE AUTOINHIBITED HUMAN C-FMS KINASE DOMAIN
4999, 6b2qB, 0.7319, 2.82, 0.276, 266, 246, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
5000, 4rfyA, 0.7319, 2.80, 0.184, 263, 244, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(MORPHOLINE-4- CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-34- DIHYDROISOQUINOLIN-1-ONE
